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Abstract
Background: Critical examination of the quality and validity of available allergic rhinitis (AR) 
literature is necessary to improve understanding and to appropriately translate this knowledge to 
clinical care of the AR patient. To evaluate the existing AR literature, international 
multidisciplinary experts with an interest in AR have produced the International Consensus 
statement on Allergy and Rhinology: Allergic Rhinitis (ICAR:AR).
Methods: Using previously described methodology, specific topics were developed relating to 
AR. Each topic was assigned a literature review, evidence-based review (EBR), or evidence-based 
review with recommendations (EBRR) format as dictated by available evidence and purpose 
within the ICAR:AR document. Following iterative reviews of each topic, the ICAR:AR document 
was synthesized and reviewed by all authors for consensus.
Results: The ICAR:AR document addresses over 100 individual topics related to AR, including 
diagnosis, pathophysiology, epidemiology, disease burden, risk factors for the development of AR, 
allergy testing modalities, treatment, and other conditions/comorbidities associated with AR.
Conclusion: This critical review of the AR literature has identified several strengths; providers 
can be confident that treatment decisions are supported by rigorous studies. However, there are 
also substantial gaps in the AR literature. These knowledge gaps should be viewed as 
opportunities for improvement, as often the things that we teach and the medicine that we practice 
are not based on the best quality evidence. This document aims to highlight the strengths and 
weaknesses of the AR literature to identify areas for future AR research and improved 
understanding.
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I. Introduction
The available literature on allergic rhinitis (AR) grows more quickly with each passing 
decade. A search of “allergic rhinitis” in the PubMed database yielded 4135 articles 
published between 1945 and 1979. The next 20 years (1980-2000) saw 7064 AR articles 
published. Each subsequent decade has surpassed this number with 8143 AR articles 
published between 2000 and 2010, and 8212 published from 2010 to the present day. Like 
many other areas of medicine, a close look at the available literature demonstrates a wide 
variation in the type and quality of AR publications, ranging from case reports to meta-
analyses, review articles to randomized controlled trials (RCTs), and large prospective 
studies to small retrospective case series. As a medical professional reads the literature or 
hears literature quoted by others, it is important that he/she understand the quality of the 
evidence in order to appropriately translate the findings and recommendations into daily 
clinical care of the AR patient. With such vast AR literature available, developing an 
appropriate understanding of the relevant evidence can be daunting.
This International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis 
(ICAR:AR) was developed to summarize the best external evidence relating to AR, with the 
goal of gathering and critically reviewing the available literature on AR epidemiology, risk 
factors, diagnosis, management, and associated conditions/comorbidities. More than 100 
international authors from various specialties utilized a structured review process to evaluate 
the evidence related to AR. Initial topic development and writing by a primary author or 
team of authors, followed by a stepwise anonymous iterative review process for over 100 AR 
topics held this process to extremely high standards. The resulting document provides a 
strong review of the existing AR literature. The recommendations for AR diagnostic 
modalities and treatment contained herein rely directly on this evidence, with a clear 
delineation of the benefit, harm, and cost considerations that supported each 
recommendation level.
Like the 2016 International Consensus Statement on Allergy and Rhinology: Rhinosinusitis 
(ICAR:RS) by Orlandi et al.,1 this ICAR:AR document places high value on the strength of 
the evidence in making recommendations. Therefore, for example, expert opinion receives 
lower value (Table II.A-1). There are limitations, however. Like ICAR:RS, this document is 
not a clinical practice guideline (CPG) or a meta-analysis. This document summarizes the 
findings of meta-analyses and other systematic reviews when those are identified in the 
literature for a specific AR topic area. However, a meta-analysis was not performed on the 
data included in this document. In addition, much of the available AR literature is not 
appropriate for meta-analysis due to its heterogeneous nature and inconsistent 
methodologies. ICAR:AR is also not a CPG, as the typical steps of a CPG (ie, medical 
specialty society and patient advocate review) were not employed here.
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Throughout this document, certain topic areas have very strong evidence whereas other 
topics demonstrate relatively weak evidence. Many of our common practices in the 
diagnosis and care of the AR patient are based upon weak external evidence. As 
practitioners, academicians, and scientists, we must examine this evidence and strive to 
increase the strength of the evidence in areas where gaps exist.
Within the ICAR:AR document, recommendations are given based on the evidence in a 
specific topic area. However, this document is a compilation of the best AR evidence, not a 
manual for the care of the AR patient. Evidence-based medicine requires that the clinician 
has the best evidence available, but also uses his/her expertise and takes the patient’s values 
and expectations into account.2 Therefore, with a background of evidence-based knowledge, 
the practitioner must approach each patient as an individual to determine the most 
appropriate diagnostic and treatment modalities for that particular patient. Given the 
numerous potential conditions in the AR differential diagnosis, various diagnostic and 
treatment options available, and diverse comorbidities and associated conditions that may 
accompany AR, treatment of the AR patient with an evidence-based approach requires 
careful consideration.
As previously stated by Orlandi et al.,1 the recommendations provided in an ICAR 
document must be interpreted based on the strength of the evidence that forms their 
foundation. The recommendations in this document are evidence-based. They do not define 
the standard of care or medical necessity. Recommendations written in this document, or any 
similar document, do not dictate the specific care of an individual patient. There are 
numerous other factors that enter into the treatment decisions for each individual patient. 
Finally, it is expected that these recommendations will change with time and with new 
evidence. We encourage new research, especially rigorous studies that aim to fill the 
identified knowledge gaps. With new evidence, recommendations will undergo necessary 
revisions and better patient outcomes should result.
II. Methods
II.A. Topic development
In a similar fashion to the 2016 ICAR:RS document by Orlandi et al.,1 this ICAR:AR 
document is formulated with the utmost reliance on published evidence. With the 2011 
Rudmik and Smith3 evidence-based review with recommendations (EBRR) method as its 
foundation, ICAR:AR strives to analyze the existing literature on each AR topic, grading the 
evidence and providing literature-based recommendations where appropriate.
The subject of AR was initially divided into 103 topics or content areas. A senior author 
who is a recognized expert in allergy, rhinology, or the assigned topic was appointed to each 
topic. Authors were initially selected via online literature searches for each ICAR:AR topic. 
Authors of high-quality publications in each topic area were invited as ICAR:AR 
contributors. Other invited authors included experts in the EBRR process, experts in 
teaching/lecturing on specific AR topic areas, and those with knowledge of the systematic 
review process.
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Some of the topics, such as those providing background or definitions, were assigned as 
literature reviews without evidence grades. Certain topics that were not appropriate for 
clinical recommendations were assigned as evidence-based reviews without 
recommendations (EBRs). Topics that had evidence to inform clinical recommendations 
were assigned as EBRRs.
Each topic author received specific instructions to perform a systematic review for the topic 
literature using the Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) standardized guidelines.4 Ovid MEDLINE® (1947-September 2016), EMBASE 
(1974-September 2016), and Cochrane Review databases were included. The search began 
by identifying any previously published systematic reviews or guidelines pertaining to the 
assigned topic. Since clinical recommendations are best supported by high-quality evidence, 
the search focused on identifying RCTs and meta-analyses of RCTs to provide the highest 
level of evidence (LOE). Reference lists of all identified studies were examined to ensure all 
relevant studies were captured. If the authors felt as though a non-English study should be 
included in the review, it was instructed that the paper be appropriately translated to 
minimize the risk of missing important data during the development of recommendations.4
To optimize transparency of the evidence, all included studies in EBR and EBRR topic 
sections are presented in a standardized table format and the quality of each study was 
evaluated to receive a level based on the Oxford LOE (level 1a to 5).5 At the completion of 
the systematic review and research quality evaluation for each clinical topic, an aggregate 
grade of evidence was produced for the topic based on the guidelines from the American 
Academy of Pediatrics Steering Committee on Quality Improvement and Management 
(AAP SCQIM)6 (Table II.A-1).
After providing an aggregate grade of evidence for each EBRR topic (A to D), a 
recommendation using the AAP SCQIM guidelines was produced (Table II.A-2). It is 
important to note that each evidence-based recommendation took into account the aggregate 
grade of evidence along with the balance of benefit, harm, and costs. A summary of the 
EBRR development process is provided in Figure II.A-1.
II.B. Iterative review
Following the development of the initial topic text and any associated evidence tables, 
evidence grades, and recommendations, each section underwent a 2-stage online iterative 
review process using 2 independent reviewers (Fig. II.A-2). The purpose of the topic 
iterative review process was to evaluate the completeness of the identified literature and 
ensure that any EBRR recommendations were appropriate. The content of the first draft 
from each topic section was reviewed by a first reviewer, and all changes were agreed upon 
by the initial author and this first reviewer. The revised topic section was then subsequently 
reviewed by a second reviewer. Initial authors of the topic and both assigned reviewers 
agreed upon all changes before each section was considered appropriate to proceed into the 
final ICAR statement stage.
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II.C. ICAR statement development
After the content of each of topic was reviewed and consensus reached among the initial 
author and 2 iterative reviewers, the principal editor (S.K.W.) compiled all topics into a 
single ICAR:AR statement. The first draft of each large ICAR:AR portion (ie, Evaluation 
and Diagnosis, Pharmacotherapy, Immunotherapy, etc.) then underwent additional reviews 
for consistency and understanding using a group of 6 to 8 authors. Finally, the draft 
ICAR:AR was circulated to all authors. The final ICAR:AR manuscript was produced when 
all authors agreed upon the literature and final recommendations. External peer review, with 
20 reviewers, was also undertaken for the final ICAR:AR document (Fig. II.A-3).
II.D. Limitations of methods and data presentation
It should be noted that because each topic author individually performed the literature search 
for his/her assigned topic, search results may demonstrate some inherent variability despite 
specific and detailed search instructions. Furthermore, while aiming to be as comprehensive 
as possible, this document may not present every study published on every topic. For certain 
topics, the literature is extensive and only high-quality studies or systematic reviews are 
listed. If the aggregate evidence on a topic reached a high evidence grade with only high-
level studies, an exhaustive list of lower level studies (or all studies ever performed) is not 
provided.
III. Definition and differential diagnosis
III.A. Allergic rhinitis definition
AR is an immunoglobulin E (IgE)-mediated inflammatory nasal condition resulting from 
allergen introduction in a sensitized individual.7 AR was defined in 1929 as a process which 
included 3 cardinal symptoms: sneezing, nasal obstruction, and mucus discharge.8 
Symptoms occur with allergen exposure in the allergic patient. AR is a widely prevalent 
condition that can result in significant physical sequelae and recurrent or persistent 
morbidities.7
The prevalence of AR is approximately 10% to 40%, depending on geographic location,9 
with the highest incidence occurring in children.10 However, AR is nearly absent in infants, 
typically not manifesting until the second year of life at the earliest. When AR presents in 
children, this is likely secondary to the rapidly evolving immune system. AR often results 
from an overactive response of T helper (Th) 2 lymphocytes that can initiate a systemic, IgE-
driven reaction which may dominate child’s immune system until it is completely mature. 
During this time, a skin-prick test (SPT) or in vitro antigen-specific IgE (sIgE) test can be 
used to confirm the diagnosis of AR.
In the atopic individual, exposure to indoor and outdoor allergens may prompt antigen-
specific IgE production. Reintroduction of the allergen triggers early-stage and late-stage 
reactions, leading to the clinical manifestations of AR. The early-stage reaction occurs 
within minutes after reintroduction of the sensitized allergen, producing nasal itching, nasal 
congestion, and rhinorrhea.11 The late-stage reaction occurs during the 4-hour to 8-hour 
period after allergen introduction and results in nasal blockage, hyposmia, increased mucus 
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secretion, and nasal hyperresponsiveness to the same or different allergens. Additionally, 
even in the absence of overt symptoms, IgE has an increased presence in the lymphoid tissue 
of the atopic patient, which can result in persistent mucosal inflammation.12
III.B. Allergic rhinitis classification
Seasonal vs perennial allergic rhinitis—The Allergic Rhinitis and its Impact on 
Asthma (ARIA) proposals have categorized AR by presumed cause and seasonal vs 
perennial presentation. Classically, this has included seasonal AR (SAR; hay fever) and 
perennial allergic rhinitis (PAR).7 SAR is triggered by a wide assortment of outdoor 
allergens, especially pollens.7 PAR is commonly brought about by indoor allergens that are 
present through-out the year, such as dust mites, molds, insects (cock-roaches), and animal 
dander.7
Intermittent vs persistent allergic rhinitis—The classification of “seasonal” and 
“perennial” AR can often be in conflict, as manifestations of perennial allergy may not occur 
throughout the entire year. This is particularly the case for patients allergic to house dust 
mites (HDM), who may demonstrate mild or moderate/severe intermittent allergic rhinitis 
(IAR).9,13-15 In addition, because of the priming effect on the nasal mucosa initiated by low 
levels of pollen allergens16-21 and minimal persistent nasal inflammation in patients with 
“symptom-free rhinitis,”14,22,23 symptoms may not occur entirely in conjunction with the 
allergen season, therefore resulting in nonspecific exacerbations. Air pollution may also 
contribute to alterations in allergen sensitivity, resulting in varying degrees of symptoms 
depending on location and air quality.24 Furthermore, individuals sensitized to multiple 
pollens may have symptoms across several seasons while individuals with PAR may 
encounter symptoms for short periods of time with frequent, repetitive relapses.
Because of the issues outlined above, ARIA proposed a new method of classification based 
on the length and recurrence of the symptom manifestations.25 IAR is characterized by 
symptoms for less than 4 days per week or less than 4 consecutive weeks. Persistent AR 
(PER) is characterized by symptoms occurring more than 4 days per week for at least 4 
consecutive weeks; therefore, PER patients are symptomatic most of the time.26 It has been 
recommended that the previous categories of seasonal and perennial AR (ie, SAR and PAR) 
not be used along with the new classification of IAR and PER, as they do not represent the 
same stratification of the disease state. As such, IAR and PER are not synonymous with 
seasonal and perennial.25,27-30 In describing AR, one should determine which classification 
scheme best conveys the message that he/she wishes to relay: seasonal/perennial or 
intermittent/persistent.
Severity of allergic rhinitis—AR can result in significant disturbances in quality of life 
(QOL), sleep, exercise tolerance, productivity, and social functioning. The ARIA guidelines 
have likewise proposed the stratification of severity (mild and moderate-severe) in view of 
these disabilities.13 (See section VII. Disease Burden for additional information on this 
topic.)
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Sensitization vs clinical allergy—Monosensitization is sensitization (as indicated by 
positive reactions on standardized SPTs or serum sIgE levels) to only 1 allergen, such as 
grass pollen, tree pollen, HDM, or cat dander (even though extracts of these concentrates 
contain numerous diverse polypeptides).31 Monoallergy is defined as a single sensitizing 
allergen causing clinical allergy symptoms. Polysensitization is sensitization to 2 or more 
allergens. Polyallergy is affirmed clinical symptoms to 2 or more sensitizing allergens. 
Findings of allergy testing, either skin testing or sIgE must be correlated with clinical 
symptoms to identify the allergen(s) likely responsible for the symptoms.32 Allergen 
challenges (ie, nasal provocation testing, conjunctival challenge, or allergen challenge 
chambers (ACCs)) can reproducibly confirm the clinical significance of a sensitized 
allergen, but these tests may be difficult to perform, subjective, and limited by irritant 
effects.33
Allergy skin testing and sIgE titer must be carefully interpreted at the patient level, and can 
also be valuable at the population level when evaluating sensitization for epidemiological 
studies.34 With increasing availability of component-resolved diagnosis (CRD), physicians 
will have a more objective means of identifying clinically relevant allergens and 
distinguishing true co-sensitization from polysensitization due to cross-reactivity. (See 
section VIII.F.6. Evaluation and diagnosis - In vitro testing - Component resolved diagnosis 
(CRD) for additional information on this topic.)
III.C. Allergic rhinitis differential diagnosis
The symptoms of AR may be similar to symptoms of other types of sinonasal disease, and at 
times multiple types of rhinitis may coexist. It is important to correctly determine the 
etiology of rhinitis to appropriately treat the patient and have the best chance of resolving his 
or her symptoms. In the following sections, a discussion of the differential diagnosis of AR 
is presented, along with a description of how each rhinitis entity differs from AR. Of note, 
this section on AR differential diagnosis is specific to various etiologies of rhinitis. Other 
entities that may enter into the differential diagnosis of AR, such as structural sinonasal 
conditions (ie, deviated septum), tumors, and cerebrospinal fluid leak are not discussed here 
(Table III.C).
III.C.1. Drug-induced rhinitis—Rhinitis secondary to systemic medications can be 
classified into local inflammatory, neurogenic, and idiopathic types35,36 (Table III.C.1). The 
local inflammatory type occurs when consumption of a drug causes a direct change in 
inflammatory mediators within the nasal mucosa. The neurogenic type occurs after use of a 
drug that systemically modulates neural stimulation, leading to downstream changes in the 
nasal mucosa. Idiopathic drug-induced rhinitis is used to classify drugs without a well-
defined mechanism contributing to symptoms. Topical nasal decongestants can cause drug-
induced rhinitis, known as rhinitis medicamentosa (RM). (See Section III.C.2. Definitions, 
classifications, and differential diagnosis - Allergic rhinitis differential diagnosis - Rhinitis 
medicamentosa (RM) for additional information on this topic.)
Local inflammatory type.: Systemic ingestion of non-steroidal anti-inflammatory drugs 
(NSAIDs) in patients with a disorder of eicosanoid synthesis can result in rhinitis and nasal 
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congestion, which may also be associated with chronic rhinosinusitis (CRS) and asthma.37 
In brief, NSAIDs inhibit cyclooxygenase (COX)-1 and COX-2 enzymes, shifting 
arachidonic acid metabolism toward the lipoxygenase pathway, with decreased production of 
prostaglandins and thromboxane in exchange for inflammatory leukotrienes (LT). Reduction 
in nasal mucosal prostaglandin E2, as well as increased LTC4, LTD4, and LTE4 causes 
mucus production and nasal mucosal edema, hallmarks of rhinitis.35,38
Neurogenic and neuromuscular type.: Neurogenic type non-allergic rhinitis (NAR) is 
caused by drug-induced modulation of the autonomic nervous system. Antihypertensives 
and vasodilators are among the many classes of drugs that cause drug-induced NAR. Other 
nonspecific drugs, such as psychotropics and immunosuppressants, have unknown 
mechanisms and are categorized as idiopathic, but can cause neuromodulatory effects as 
well. Modulation of the autonomic nervous system leads to downstream changes in nasal 
mucosa, blood vessels, and secretory glands.39 For example, α- and β-adrenergic 
antagonists, and presynaptic α-agonists, cause decreased sympathetic tone and unopposed 
parasympathetic stimulation producing mucosal engorgement, nasal congestion, and 
rhinorrhea.40-42
Phosphodiesterase (PDE)-5 specific inhibitors promote penile vasodilation and erection. 
PDE-3 and nonselective PDE inhibitors result in vasodilation and increased extremity blood 
flow, relieving symptoms of peripheral artery disease. Nitric oxide (NO)/cyclic nucleotide-
mediated vasodilation occurs in the nasal mucosa as well, causing nasal mucosal 
engorgement and edema.43-46 Finally, angiotensin converting enzyme inhibitors (ACE-Is) 
inhibit the conversion of angiotensin I to angiotensin II in the lungs, resulting in a decrease 
in sympathetic activity. Bradykinin is also formed. Bradykinin B1 and B2 receptors have 
been demonstrated in nasal mucosa47; bradykinin application to the nasal mucosa has been 
shown to increase sneezing,44,48 suggesting a role of ACE-Is in NAR.
Illicit drug use.: The nose provides a unique portal for illicit drug use, as nasal mucosa is 
well vascularized and easily accessible. The illicit drug user can avoid invasive intravascular 
or intramuscular administration of a desired product by applying a crushed solid, liquid, or 
aerosolized form of the product directly to the nasal cavity. For some drugs, nasal 
administration increases bioavailability and shortens time to onset when compared to oral 
ingestion.49,50 Cocaine is most commonly associated with nasal illicit drug use and exerts its 
effect by modulating dopamine transporters to inhibit reuptake at the synapse, increasing 
dopamine available for postsynaptic stimulation.51 Cocaine-induced rhinitis is a result of 
vasoconstrictive events, which can be followed by rebound nasal mucosal edema and 
mucous production, similar to those seen in RM.52-55 In the repeat user, vasoconstriction, 
direct trauma compounded by anesthetic effects, and/or injury secondary to contaminants 
may result in nasal septal perforation.56-59 Similarly, prescription narcotics,59 
antidepressants,47 anti-cholinergics, and psychostimulants can be abused by intranasal 
administration.47,60 Intranasal hydrocodone has been shown to induce nasal tissue necrosis 
and loss in a similar manner to cocaine.59 Antidepressants such as bupropion have been used 
to achieve a euphoria similar to that of cocaine and may induce seizures.47
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In summary, systemic medications and intranasal illicit drugs affect the nasal mucosa. 
Increased mucosal edema, vasodilation, and inflammatory mediators are a consequence of 
systemic medications. Vasoconstriction and direct mucosal injury often accompanies illicit 
drug use. The physiologic response in drug-induced rhinitis differs from AR as it is not 
allergen-induced nor dependent on IgE mechanisms, although symptomatology may be 
similar.
III.C.2. Rhinitis medicamentosa (RM)—RM, or rebound rhinitis, is a condition 
induced by prolonged use of topical intranasal decongestant (IND)26,61 (Table III.C.2). 
Although no consensus diagnostic criteria exist, RM is classically associated with the triad 
of prolonged IND use, constant nasal obstruction, and poor shrinkage of the nasal mucosa61 
in the setting of nasal congestion, rhinorrhea, and decreased efficacy of further INDs.55,62,63 
Physical exam findings consist of mucosal edema, erythema, and hyperemia.
The exact physiologic mechanism causing RM is unclear. Continuous IND use may decrease 
endogenous norepinephrine production and cause upregulation of the parasympathetic 
system, leading to rebound congestion once the decongestant is discontinued.54,55 This may 
be further exacerbated by recurrent nasal tissue hypoxia and negative neural feedback with 
chronic decreased α-2 receptor responsiveness.64 Mucosal changes include ciliary damage 
and loss, epithelial metaplasia and hyperplasia, dilated intercellular spaces, goblet cell 
hyperplasia, and edema.65-67 Benzalkonium chloride (BKC), an antimicrobial preservative 
used in many nasal decongestants, has been implicated in the mechanism of RM. Studies 
have suggested that BKC is toxic to nasal epithelium and may propagate RM, although the 
data are inconclusive.68-71
Neither duration, nor cumulative dose of IND needed to initiate RM is known. Rebound 
congestion has developed after 3 to 10 days of medication use,55,66 but may not occur until 
after 30 days.72,73 Other studies have demonstrated a lack of rebound after 8 weeks of 
continuous use.72-75 Furthermore, doubling the dose of intranasal imidazoline did not 
increase the extent of rebound edema.72 Although inconclusive, studies suggest that IND use 
should be discontinued after 3 days to avoid rebound congestion.62,76,77
Treatment of RM involves discontinuation of INDs. Various medications have been used to 
improve nasal decongestion including nasal cromolyn, sedatives, nasal saline spray, oral 
antihistamines, oral decongestants, and intranasal corticosteroids (INCSs; sometimes used in 
conjunction with brief courses of systemic corticosteroids).50,62,78-82 Only the use of INCSs 
has been demonstrated to mitigate rebound congestion after discontinuation of topical INDs.
67,81-83 Often there is an underlying rhinitis and/or anatomic issue that initiated the 
decongestant use. This underlying issue should be addressed to diminish the drive to 
continue to use INDs.
Importantly, RM is typically associated with repeated exposure to INDs, with increasing 
symptoms at times when the medication is withheld. In contrast, AR is classically associated 
with an allergic trigger with similar symptoms increasing upon allergen exposure, and is 
dependent upon IgE-mediated inflammation.
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III.C.3. Occupational rhinitis—Occupational rhinitis is an inflammatory condition of 
the nasal mucosa, characterized by intermittent or persistent nasal congestion, sneezing, 
rhinorrhea, itching, and/or hypersecretion due to causes and conditions attributable to a 
particular work environment, and not to stimuli encountered outside the workplace.84 
Occupational rhinitis is considered a form of “work-related rhinitis,” which also 
encompasses work-exacerbated rhinitis, which is preexisting or concurrent rhinitis that is 
worsened by workplace exposures84,85 (Fig. III.C.3).
Occupational rhinitis may be allergic, consequent to exposure to a sensitizing high-
molecular (HMW) or low-molecular weight (LMW) compound acting through an 
immunological mechanism, and characterized by the presence of a latency period between 
beginning of exposure and symptom onset. Alternatively, occupational rhinitis may be non-
allergic, mediated by and irritant or non-immunological mechanism. Symptoms occur after 
single or multiple exposures to irritant compounds, and usually present without a latency 
period. Non-allergic occupational rhinitis resulting from a single exposure to a very high 
concentration of irritants is also referred as reactive upper airways dysfunction syndrome 
(RUDS). The most severe form of irritant-induced occupational rhinitis is corrosive rhinitis, 
which is characterized by permanent inflammation of the nasal mucosa sometimes 
associated with ulcerations and perforation of the nasal septum.84,85
The results of cross-sectional studies in working groups show a wide range of prevalence of 
occupational rhinitis (3-87%),86 lower prevalence for LMW-agent exposure, and higher 
prevalence for HMW-agent exposure. Examples of occupations at increased risk are reported 
in Table III.C.3.87-98 Occupational rhinitis due to HMW-agents tend to be 3 times more 
prevalent than occupational asthma,86 with which it is often associated (up to 92% of cases).
99
Occupational rhinitis and occupational asthma share etiologic agents and pathogenic 
mechanisms,100 and can be considered in the broader context of the Unified Airway Disease 
model.85,93,101,102 The severity of occupational rhinitis may also affect the severity of 
occupational asthma.103 In a high proportion (20-78%) of workers exposed to sensitizers, 
work-related nasal symptoms tend to develop 5 to 6 months before the onset of bronchial 
symptoms.84,86 Consequently, occupational rhinitis may be considered a marker of the 
likelihood of developing occupational asthma.
The clinical presentation of occupational rhinitis is nonspecific. Nasal symptoms do not 
differ from those of non-occupational rhinitis. An occupational origin should be sought for 
all rhinitis of new onset in adults, especially in subjects employed in high-risk occupations 
(Table III.C.3). The diagnostic assessment first includes a thorough clinical and occupational 
history, aimed to investigate type of symptoms and work-relatedness, and to collect 
information on occupational exposure. Typical nasal symptoms are often accompanied by 
crust formation, sporadic epistaxis, olfaction impairment, or conjunctivitis, or are associated 
with pharyngeal, laryngeal, or bronchial symptoms (which should always be evaluated). The 
presence of a latency period between an occupational exposure and symptom onset suggests 
an allergic mechanism. Documentation of noxious compounds (sensitizers and irritants) in 
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the work-place to which the worker is more directly exposed are typically posted by the 
employer (ie, Material Safety Data Sheets).84,85
Nasal examinations by anterior rhinoscopy and nasal endoscopy, assessing nasal 
patency85,104 and inflammation in nasal secretions,105 are often performed as part of the 
clinical evaluation. Sensitization to a suspected HMW-agent can be evaluated through SPT 
and/or in vitro sIgE assessment, when standardized and validated extracts are available. A 
suggestive history associated with a positive immunological test for an occupational agent 
could be considered as probable allergic occupational rhinitis. A definitive diagnosis is 
obtained by objective demonstration of the causal relationship between rhinitis and the work 
environment through a nasal provocation test (NPT) with the suspected agent(s) in the 
laboratory, which is considered the gold standard for diagnosis.84,85 If NPT is negative, 
further evaluation of work-related changes in nasal parameters at the workplace is 
recommended, especially in the presence of a highly suggestive clinical history. In subjects 
exposed to HMW-agents with a suggestive history and negative immunological tests, the 
type of inflammatory response to NPT might demonstrate the presence of an occupational 
local allergic rhinitis (LAR).106,107 Due to the relationship between the upper and lower 
airways, spirometry, measurement of nonspecific airway responsiveness, and measurement 
of bronchial inflammation by means of exhaled NO may also be performed.84,85
Primary treatment of allergic occupational rhinitis is avoidance or reduction of culprit 
exposures.108 Pharmacologic treatment does not differ from that of non-occupational 
rhinitis.101 In allergic occupational rhinitis due to HMW-sensitizers, specific immunotherapy 
may be proposed when validated extracts are available.109 The prevention and early 
identification of occupational rhinitis during medical surveillance of exposed workers and of 
young apprentices may provide an excellent opportunity to prevent the development of 
occupational asthma.110,111
III.C.4. Chemical rhinitis—Chemical rhinitis largely falls under the category of 
occupational rhinitis; however, there are chemical exposures that are not necessarily 
occupational (and vice versa). Some chemicals may cause sensory irritation, which can 
include congestion, rhinorrhea, nasal discomfort, postnasal drainage, headache, and even 
epistaxis.112 Exposures, or exposure risk, are important elements to elicit in the history. 
There are many chemicals with which specific occupations are closely associated, though 
household chemicals and sport/leisure exposures (ie, chlorine-induced rhinitis in 
swimmers113) may play a role as well. Larger chemical particles are typically the culprit in 
this form of rhinitis as smaller particles usually pass through to the lower airways. Water 
soluble agents such as ammonia, formaldehyde, or sulfur dioxide may readily dissolve into 
the mucous membrane layer.114 These responses are non-IgE-mediated by a reflex response 
which is often termed neurogenic inflammation.115 A subset of these individuals involved in 
high-level single-exposure incidents may develop persistent symptoms. This phenomenon 
has been described as RUDS when only rhinitis symptoms are present, and Reactive 
Airways Dysfunction Syndrome when asthma-like symptoms are present.116,117
Although chemicals are not always thought of as sensitizers, some of these compounds can 
induce immunologic disease. Chemicals known to cause sensitization of the respiratory tract 
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include diisocyanates, acid anhydrides, some platinum salts, reactive dyes, glutaraldehyde, 
plicatic acid, and chroamine.118-120 There is still much debate as to the exact mechanism 
behind sensitization to these chemicals. However, smaller chemical compounds must 
associate with larger protein molecules to induce an immune response. While specific IgE 
production toward chemicals causing respiratory allergy is seen, evidence to show symptoms 
related to chemical exposure without concomitant rise in IgE has also been documented.121 
It is possible that these findings may be due to the inability to synthesize appropriate in vitro 
conjugates for diagnostic assays to detect serum IgE that binds these chemicals.122,123
Typically, the differential should include causes of both AR and NAR, as well as mixed 
rhinitis, recurrent acute rhinosinusitis (RARS), and potentially CRS. Some symptoms of 
chemical rhinitis may be similar to AR with nasal discharge, congestion, sneezing, and 
itching all being reported. Nasal discharge may be anterior or posterior with chemical 
rhinitis or AR but is typically not unilateral with either of these diagnoses. Chemical-
induced rhinitis may be associated with olfactory dysfunction, both temporary and 
longlasting. These disturbances include hyposmia or anosmia, as well as dysosmia or 
agnosmia (inability to identify smells).112 Nasal discomfort, discharge, congestion, 
headaches, and sometimes epistaxis may also be present.112
III.C.5. Smoke-induced rhinitis—Environmental tobacco smoke exposure is 
associated with chronic rhinitis and in some cases, AR.124,125 In several studies, self-
reported symptoms tend to be elicited by exposure to smoke and can correlate with serum 
cotinine levels.126-128 Symptoms common to both AR and smoke-induced rhinitis include 
rhinorrhea and congestion, but smoke-induced rhinitis does not appear to be driven by IgE-
mediated hypersensitivity (which tends to exhibit a constellation of congestion, rhinorrhea, 
and sneezing on exposure to a specific allergen). As AR symptoms are immunologically 
mediated, there must be a sensitization period prior to the exposure that elicits symptoms. In 
contrast, smoke induced-rhinitis typically does not require sensitization, although there has 
been report of potential allergenic compounds in smoke.129 Interestingly, although active 
smokers are likely to have an elevated serum IgE, they exhibit a lower skin test reactivity to 
allergens than allergic nonsmokers.130
In contrast to AR, smoke-induced rhinitis is likely multi-factorial, and other mechanisms 
such as neurogenic or irritant etiologies play a more predominant role.131,132 Neurogenic 
nasal inflammation is mediated by neuropeptides such as substance P, neurokinin A, and 
calcitonin gene-related peptide. These mediators are released by sensory nerve fibers in the 
nose and result in vasodilation, edema, and inflammation.133 Patients who are reactive to 
tobacco exposure are identified by both subjective (congestion, rhinorrhea, sneezing) and 
objective response (increased nasal resistance) to controlled challenge with tobacco smoke. 
In a prospective study, patients were defined as demonstrating reactivity if nasal resistance 
on acoustic rhinometry increased by over 35% in response to tobacco smoke. Patients with 
less than 5% increase in nasal resistance were defined as nonreactive.131 In addition, altered 
mucociliary clearance (MCC) resulting from tobacco smoke exposure has been 
demonstrated. Congestive responses have been demonstrated on challenge with both brief 
and prolonged exposure to tobacco smoke. In individuals who report a history of smoke-
induced rhinitis, brief smoke exposure (45 parts per million [ppm] for 15 minutes) led to 
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increased nasal resistance as measured by posterior rhinometry. In individuals with and 
without a history of smoke-induced rhinitis, prolonged exposure to moderate levels of smoke 
(15 ppm for 2 hours) also induced a congestive response lasting for an hour or longer.134 
Even though the objective response was short lived, patients reported symptoms lasting 
hours to days following exposure. Significant symptom overlap may exist, but a thorough 
history and allergy testing can help further differentiate smoke-induced rhinitis from AR. 
(See section VI.E. Risk factors for allergic rhinitis - Tobacco smoke for additional 
information on this topic.)
III.C.6. Infectious rhinitis—Infectious rhinitis may be classified into acute and chronic 
forms, with both bacterial and viral etiologies. Physical findings and chronicity of symptoms 
play an important role in differentiating between different forms of rhinitis, including 
infectious, allergic, and the inflammation associated with CRS. Symptoms suggestive of a 
noninfectious etiology include nasal itching and sneezing, while findings of mucosal 
inflammation and rhinorrhea may be present in either infectious or noninfectious rhinitis.26 
Taken in isolation, dark or purulent rhinorrhea is not pathognomonic for bacterial rhinitis/
rhinosinusitis. Additional findings suggestive of infectious etiologies include associated 
pharyngeal inflammation or cervical lymphadenopathy.135
Viral rhinitis typically manifests in an acute form, and accounts for up to 98% of infectious 
rhinitis in the young child. The incidence of viral rhinitis in young children is 6 episodes per 
patient-year.136 In adult viral rhinitis, the incidence is 2 to 3 episodes per year. Symptoms 
associated with viral rhinitis include clear rhinorrhea, nasal obstruction, and often, fever. The 
responsible organisms of viral rhinitis can be rhinovirus, adenovirus, influenza virus, and 
parainfluenza virus.81 Most viral rhinitis is self-limiting within 4 to 5 days, with prolonged 
symptoms lasting longer than 2 weeks suggestive of a noninfectious etiology or conversion 
to bacterial infection. There are instances when continued rhinitis beyond 10 days is felt to 
be due to worsening infection (ie, possible superimposed bacterial rhinosinusitis) and these 
patients should be treated more aggressively.137 Approximately 2% of viral rhinitis episodes 
are secondarily infected by bacterial organisms such as Streptococcus pneumoniae, 
Haemophilus influenzae, and Moraxella catarrhalis, with subsequent presentation of acute 
bacterial infection.138
III.C.7. Rhinitis of pregnancy and hormonally-induced rhinitis—The 
development of a type of rhinitis unique to the pregnant patient has been referred to as 
rhinitis of pregnancy or pregnancy rhinitis. It occurs in about 22% of pregnancies139 and, 
although symptoms may occur at any time, it typically starts after the second month of 
pregnancy and is most severe in the second trimester.26,140 Rhinitis of pregnancy has been 
defined as nasal congestion in the last 6 or more weeks of pregnancy, without other signs of 
respiratory tract infection or allergic cause, followed by complete, spontaneous resolution of 
symptoms within 2 weeks after delivery.141
The symptoms of rhinitis of pregnancy, like those of AR, include rhinorrhea and nasal 
congestion, which can be prominent and prolonged. Clinical history frequently elicits a prior 
history of chronic rhinitis, obscuring the extent to which pregnancy is a causal or 
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aggravating factor.139 In addition, preexisting AR can worsen in approximately one-third of 
pregnant women.142
There are several etiologic factors potentially associated with the nasal symptoms in rhinitis 
of pregnancy. Hormonal changes, such as increased progesterone, estrogen, prolactin, 
vasoactive intestinal peptide, and/or placental growth hormone have been implicated,143,144 
but there is little evidence to support this theory.145 Other physiologic phenomena occurring 
during pregnancy that may contribute to increased nasal congestion or obstruction include 
vasodilation, progesterone-induced smooth muscle relaxation, and a massive expansion of 
the circulating blood volume, which may contribute to increased nasal vascular pooling.146
Rhinitis of pregnancy does not usually require therapy, nor does it respond well to standard 
allergy medications. Its management is made more difficult by the lack of high-quality 
studies on the efficacy of treatment and fetal out-comes. In those who seek treatment, 
conservative non-pharmacologic measures are suggested. These can include elevation of the 
head of the bed,147 nasal dilator strips,148 and exercise.149,150 Saline lavage using hypertonic 
saline has been demonstrated to be effective without obvious deleterious effects on the fetus.
151 Several medications, including INCS, have been studied in rhinitis of pregnancy but have 
failed to demonstrate clear efficacy.152 More recently, a systematic review by Kumar et al.
153 identified only 1 RCT that failed to demonstrate any additional benefit of fluticasone 
compared to placebo for symptom control in this patient population. Although an extensive 
discussion of rhinitis of pregnancy management is beyond the scope of this document, the 
use of various other medications (ie, topical and oral decongestants) is controversial and 
should be addressed at the individual patient level, with close involvement of the 
obstetrician.
Direct stimulation of the nasal mucosa by estrogen may induce mucosal gland hyperactivity 
resulting in increased nasal secretions/rhinorrhea.154 As such, nasal symptoms can be 
associated with conditions other than pregnancy that affect hormone balance, such as 
hypothyroidism and acromegaly.155 Rhinitis may also arise as a result of changing blood 
hormone concentrations during puberty, menstruation, and the perimenopausal years.145 
Although oral contraceptives have also been implicated as causes of nasal symptoms, a study 
by Wolstenholme et al.156 found no nasal physiologic effects in patients receiving oral 
contraceptive treatment.
In summary, there are numerous metabolic conditions with symptoms like those of AR. 
Accurate diagnosis can be made on history and presentation, but additional testing may be 
required for symptoms that are persistent or severe.
III.C.8. Food- and alcohol-induced rhinitis
Food-induced rhinitis.: Certain food ingestions may result in rhinitis based on a 
nonimmunologic reaction, and therefore are not characterized as an allergy. For instance, in 
subjects with gustatory rhinitis, shortly after ingestion of hot or spicy foods, unilateral or 
bilateral watery rhinorrhea develops in the absence of nasal congestion, pruritus, or facial 
pain. This is considered a reflex response due to an adrenergic and cholinergic neural 
reaction of the nose.157
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The prevalence of “food-induced rhinitis” seems to be under 1%.157 While rhinitis may 
frequently be observed as part of systemic IgE-mediated food allergy reaction, it is rarely the 
only presenting symptom. In a double-blind, placebo-controlled food challenge study of 480 
children, 185 children (39%) experienced ocular and upper respiratory symptoms, but only 
5% had symptoms confined to the upper respiratory tract alone.158
Patients with pollen-food allergy syndrome (PFAS), also referred to as oral allergy syndrome 
(OAS), often experience oropharyngeal itching, tingling, and/or mild swelling of the lips, 
tongue, palate, and throat, and less commonly AR symptoms, after ingestion of certain raw 
fruits and vegetables. The assessed prevalence of this disorder ranges from 5% to 17%, and 
it affects up to one-half of pollen-allergic patients.159-161 It occurs in individuals who are 
sensitized to pollen aeroallergens through the respiratory tract, which then predisposes them 
to clinical symptoms of PFAS after ingestion of cross-reactive, heatlabile food proteins of 
plant origin. Because the antigens are heatlabile, patients are usually able to tolerate cooked 
forms of the causative fruits and vegetables.162 (See section X.E. Associated conditions - 
Food allergy and pollen-food allergy syndrome (PFAS) for additional information on this 
topic.)
Alcohol-induced rhinitis.: Nasal symptoms can also occur after alcohol consumption.
163,164 However, very little is known about the prevalence and presentation of alcohol-
induced nasal symptoms. Additionally, there is a paucity of information about the 
relationship between alcohol-induced nasal symptoms and other diseases, such as AR, nasal 
polyposis, asthma, and other chronic lower airway diseases.165
Airway symptoms are predominantly initiated by inhaled components that contact the 
airway mucosal membrane. However, several forms of rhinitis and asthma may not operate 
through this mechanism. One such example is known as alcohol-induced asthma. In these 
patients, alcoholic beverages, particularly red and white wines, have been shown to trigger 
bronchial symptoms.163,166,167
Alcohol-induced nasal symptoms are about twice as common in females as in males,165 but 
the basis for this predilection is not well understood.168-170 Nasal congestion is the 
predominant symptom, and red wine is the most common alcoholic beverage to elicit 
symptoms. Additionally, wine, particularly red, is also the most widely recognized trigger of 
alcohol-induced bronchial symptoms.163 Finally, direct alcohol utilization has also been 
associated with a trend toward developing SPT positivity,171 and with increased serum total 
IgE (tIgE) levels.172
III.C.9. Non-allergic rhinitis with eosinophilia syndrome (NARES)—Non-
allergic rhinitis with eosinophilia syndrome (NARES) is a clinical disorder comprising 
symptoms consistent with PAR in which an absence of atopy has been demonstrated, and 
eosinophilia is found on nasal cytology.173 The pathophysiology of NARES is not well 
understood, but a key component involves an eosinophilic, self-perpetuating inflammation, 
with nonspecific histamine release. It is the most common type of inflammatory NAR, and 
was first described in 1981 by Jacobs et al.174
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NARES patients report symptoms that are typical, although often more pronounced, than 
those of PAR. These include, nasal congestion, profuse aqueous rhinorrhea, sneezing, and 
nasal and ocular pruritis. A prominent feature not shared with AR is anosmia, a frequent 
finding in NARES patients.175 NARES is diagnosed by careful history, findings on physical 
exam (pale, boggy turbinates, like those found in PAR patients), and negative skin or in vitro 
allergy testing. Cytologic examination in NARES reveals the presence of prominent 
eosinophilia, usually 10% to 20%173 on nasal smear, with a diagnostic criterion (described 
by some) of more than 25% eosinophilia.176 In addition, nasal biopsies from these patients 
commonly show increased numbers of mast cells and prominent mast cell degranulation.
177,178
Research has supported the role of chronic inflammation in the development of NARES. 
Though there is still a lack of understanding as to the exact pathophysiology, studies have 
shown an increased transendothelial migration of eosinophils, attracted and activated by 
chemokines and cytokines.179,180 Specifically, NARES is characterized by elevated nasal 
fluid levels of tryptase (also seen in PAR patients) and eosinophilic cationic protein (ECP) 
(markedly increased solely in NARES).181 In addition, increased Th2 cytokines (interleukin 
[IL]-6 and IL-17) appear to be a factor in the remodeling process seen in NARES.182 Other 
proinflammatory chemokines that have been implicated for their role in eosinophil 
chemotaxis and infiltration include macrophage/monocyte chemoattractant protein (MCP)-1 
and regulated on activation, normal T-cell expressed and secreted (RANTES). Elevated 
RANTES concentrations have been found in the nasal fluid of patients with PAR and 
NARES.183 Recently, Peric et al.184 demonstrated a correlation between the concentration of 
RANTES with nasal symptoms and eosinophil counts in PAR patients. However, levels of 
MCP-1 and RANTES were significantly higher in the nasal fluid of NARES compared to 
PAR subjects, which again, correlated with nasal symptom scores and density of 
eosinophilia in these patients. Nasal neural dysfunction has also been described as a 
contributing factor to the symptomatology in NARES.185
NARES usually occurs in isolation but may be associated with aspirin-exacerbated 
respiratory disease (AERD), characterized by asthma, nasal polyps, and NSAID intolerance.
173 NARES has also been identified as a risk factor for the induction or augmentation of 
obstructive sleep apnea (OSA).186
The treatment of NAR centers on its underlying cause. Given the inflammatory changes 
demonstrated on nasal cytology and physical exam, NARES is primarily treated with INCS 
sprays.154 This method of treatment is known to decrease neutrophil and eosinophil 
chemotaxis, reduce mast cell and basophil mediator release, and result in decreased mucosal 
edema and local inflammation.187 The intranasal antihistamine azelastine is U.S. Food and 
Drug Administration (FDA)-approved for both AR and NAR. In clinical trials, azelastine has 
been shown to reduce symptoms of rhinitis, including postnasal drainage, sneezing, 
rhinorrhea, and congestion.188 However, these multicentered, placebo-controlled trials 
studied azelastine for the treatment of vasomotor rhinitis (non-allergic rhinopathy) rather 
than NARES specifically.
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III.C.10. Vasomotor rhinitis (nonallergic rhinopathy)—Vasomotor rhinitis is the 
most common cause of NAR, and is found in 71% of cases.189-191 The absence of an IgE-
mediated immune response differentiates vasomotor from allergic forms of rhinitis.101 
Therefore, the term “non-allergic rhinopathy” is recommended to replace vasomotor rhinitis, 
as inflammation is not regarded as a crucial part in the pathogenesis of non-allergic 
rhinopathy. In Europe, “idiopathic rhinitis” has also been used to describe this condition.
Non-allergic rhinopathy is a diagnosis of exclusion, and other etiologic factors for 
rhinopathy must be evaluated. These include CRS, NARES, AERD, infectious rhinitis, 
anatomical abnormalities, RM, drug side effects, cerebrospinal fluid (CSF) rhinorrhea, and 
rhinitis of pregnancy. Clinical characteristics of non-allergic rhinopathy have been 
summarized in a consensus paper by Kaliner et al.40 Non-allergic rhinopathy represents a 
chronic disease with primary symptoms of rhinorrhea. Associated symptoms of nasal 
congestion, postnasal drip in the absence of acid reflux, throat clearing, cough, Eustachian 
tube dysfunction, sneezing, hyposmia, and facial pressure/headache may also be present 
with non-allergic rhinopathy. These symptoms may be perennial, persistent, or seasonal, and 
are typically elicited by defined triggers, such as cold air, climate changes (ie, temperature, 
humidity, barometric pressure), strong smells, tobacco smoke, changes in sexual hormone 
levels, environmental pollutants, physical exercise, and alcohol. While often associated with 
non-allergic rhinopathy, the lack of a defined trigger does not preclude this diagnosis. In 
addition, nasal hyperreactivity to nonspecific stimuli may occur in both allergic and non-
allergic rhinitis.192
Non-allergic rhinopathy is primarily found in adults, with a female-to-male ratio of 2:1 to 
3:1. On physical exam, the nasal mucosa usually appears normal, but may show signs of 
erythema and clear rhinorrhea. While systemic allergy testing (skin or in vitro testing) is 
typically sufficient to differentiate between AR and non-allergic rhinopathy, a diagnosis of 
LAR may be considered in the setting of negative systemic testing. Individuals with LAR 
suffer from typical allergic symptoms upon allergen exposure, but display a lack of systemic 
IgE sensitization. Local provocation is necessary to definitively exclude this diagnosis.
193,194
While the exact pathophysiology of non-allergic rhinopathy remains incompletely described, 
neurosensory abnormalities are thought to play a crucial role.40 In a prior study of central 
responses to olfactory stimuli, subjects with non-allergic rhinopathy underwent functional 
magnetic resonance imaging following exposure to different odors (vanilla and hickory 
smoke). Findings included increased blood flow to the olfactory cortex, leading to the 
hypothesis of an altered neurologic response in non-allergic rhinopathy.195,196 Patients with 
non-allergic rhinopathy with a predominant symptom of rhinorrhea will often respond to 
treatment with intranasal anticholinergics such as ipratropium bromide (IPB).
III.C.11. Age-related rhinitis (ie, elderly)—Age-related changes occur in every organ 
system, including the respiratory system. Specific to the nasal cavity, the physiological 
process of aging results in neural, hormonal, mucosal, olfactory, and histologic alterations 
that cause morphological and functional changes in the aging nose.197,198 This makes the 
elderly population more vulnerable to symptoms such as rhinorrhea, nasal congestion, 
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postnasal drip, dry nose, intranasal crusting, and decreased olfaction.199,200 A recent 
publication by DelGaudio and Panella201 reviewed the literature pertaining to intranasal 
findings of the aging nose, which they have termed “presbynasalis.”
Age-related rhinorrhea.: Rhinitis of the older adult (ie, “drippy nose” or “senile 
rhinorrhea”) is a well-recognized entity. Rodriguez et al.202 used a questionnaire to 
demonstrate that clear rhinorrhea increases with age. Results showed that only 33% of the 
younger age group respondents (n = 76, mean age 19 years) regularly reported clear anterior 
drainage as compared to 74% of the older age group respondents (n = 82, mean age 86 
years).
The physiologic reason for increased rhinorrhea with age is not entirely known. However, it 
is known that α and β receptors become less sensitive and autonomic function declines with 
age, which leads to an imbalance of sympathetic and parasympathetic tone.202-204 It is 
possible that decreased sympathetic tone with unopposed parasympathetic stimulation 
results in a rise in glandular activity in the nasal cavity, leading to increased nasal drainage.
202,205 This mechanism is similar to vasomotor rhinitis/non-allergic rhinopathy, where the 
autonomic response to certain stimulants causes the nasal mucosal blood vessels to 
vasodilate and the mucus glands to become over-active, resulting in hypersecretion and 
drainage.206 Vasomotor rhinitis/non-allergic rhinopathy is the most common type of NAR,
205 and the highest prevalence of NAR is seen in the elderly.144,189,200,207 This would 
suggest an autonomic dysregulation as the reason for increased rhinorrhea in the aging 
population.
Age-related nasal obstruction and congestion.: Factors that contribute to an increase in 
nasal obstruction/congestion in the aging nose include thicker mucus secondary to a 
decrease in body water content,208-210 nasal airflow obstruction secondary to structural 
changes caused by the loss of nasal cartilage elasticity and tip support,198,200,210 and mucus 
stasis secondary to less effective MCC.200,209 Ho et al.211 demonstrated a decline in MCC 
effectiveness with age in 90 healthy subjects aged 11 to 90 years. Subjects over 40 years of 
age had a slower ciliary beat frequency, increased microtubule disarrangement, and longer 
MCC times on saccharin testing. Thickened mucus and a less effective MCC system may 
also lead to postnasal drip, which is a common nasal complaint in the elderly population.200
Another factor contributing to nasal obstruction/congestion in the elderly is age-related 
central nervous system changes that affect the physiologic nasal cycle.208,212 Mirza et al.212 
measured the relative airflow of the 6 nasal chambers at 15-minute intervals for 6 hours 
across 4 different age groups (n = 60) using liquid crystal thermography. They found that the 
proportion of subjects exhibiting the classic nasal cycle decreased with age, being lowest in 
the 70-year-old to 85-year-old group.
Age-related nasal dryness and intranasal crusting.: Nasal dryness and intranasal crusting 
are more common in the elderly population. This is likely due to age-related changes of the 
nasal mucosa,199 such as a decrease in mucosal blood flow and an increase in epithelial 
atrophy.213 Schrodter et al.214 evaluated nasal mucosa samples from the middle turbinate of 
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40 healthy subjects between the ages of 5 and 75 years, and found an age-related increase in 
atrophic epithelium and thickened basement membranes in patients over 40 years old.
Nasal dryness in the elderly population may also be caused by a decrease in intranasal 
temperature and humidity.200 Lindemann et al.199 measured these values in 80 healthy 
patients and found them to be significantly lower in older patients (age 61 to 84 years) than 
in younger patients (age 20 to 40 years). The authors attributed the difference to an increase 
in intranasal volume (INV) from age-related atrophy of the nasal mucosa, with INV 
measured by minimal cross-sectional areas and volumes of each nasal cavity. An increase in 
INV with age has also been demonstrated by Loftus et al.215 using 3D-volumetric analysis 
of computed tomography (CT) scans from subjects without sinonasal pathology. Mean INV 
was 15.73 mL in the 20 to 30 year age group (n = 22), 17.30 mL in the 40 to 50 year age 
group (n = 20), and 18.38 mL in the over 70 year age group (n = 20).
Allergic rhinitis in the elderly.: Although there is overlap between age-related rhinitis and 
AR in the elderly in terms of symptoms and recommended treatment with INCS,210,216 the 
underlying physiologic process of each is quite different. AR is a type I IgE-mediated 
hypersensitivity reaction,217,218 whereas allergy and allergens do not play a role in the 
symptoms and physiologic changes of age-related rhinitis. However, it has been shown that 
aging does not reduce the prevalence of AR and that AR in the elderly is likely 
underdiagnosed, so AR should be considered when diagnosing new-onset nasal symptoms in 
the elderly population.210
III.C.12. Empty nose syndrome and atrophic rhinitis—The descriptive term 
“empty nose syndrome” (ENS) was originally coined in 1994 by Kern and Stenkvist to 
describe empty space in the region of the inferior and middle turbinates on coronal CT 
images of patients who had partial or total inferior and middle turbinectomies.219 Today, 
ENS is defined as an upper airway disorder characterized by impaired nasal airflow 
sensation and often involves tissue loss from nasal surgery. ENS is divided into at least 3 
subtypes: ENS-inferior turbinate, ENS-middle turbinate, and ENS-both, which are classified 
based on the site of tissue loss.219 ENS-inferior turbinate is the most common type.220 A 
fourth subtype is ENS-type, wherein a patient has sufficient appearing turbinate tissue but 
suffers ENS symptoms after surgery affecting the mucosal surface of the turbinates.
ENS typically occurs following surgery in the turbinates. Most turbinate surgery has 
successful outcomes, with ENS occurring after a very small percentage of sinonasal 
procedures.221,222 ENS occurs most frequently after total turbinate excision, but also with 
lesser procedures such as submucosal cautery or resection, laser therapy, and cryosurgery.223 
Patients often complain of dryness and crusting, although the hallmark complaint of ENS 
patients is paradoxical nasal congestion that may be so severe that they feel as if they are 
suffocating.223 Recent research has validated that the primary physiological mechanism that 
produces the sensation of ample nasal airflow is activation of trigeminal cool 
thermoreceptors, specifically TRPM8, by nasal mucosal cooling.224-228 Beyond alterations 
in airflow and a reduction in surface area, aberrations in neurosensory systems likely play a 
major role in the abnormal sensations ENS patients experience. Not only does turbinate 
resection remove nasal mucosa and consequently airflow sensing thermoreceptors, such 
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surgery causes nerve damage that if improperly healed, results in failure to return to a 
normal physiologic state.221 Differences in nerve recovery after surgery may explain why 
only some patients develop ENS despite identical turbinate surgeries. Indeed, certain 
surgeons have identified patients with unilateral ENS symptoms while their normal sensing 
side looks like a mirror image in terms of absent inferior turbinate tissue. Diagnosis is made 
based on history, physical exam, and the cotton test, where a piece of slightly moist cotton is 
placed in the nasal cavity for 10 to 30 minutes with alleviation of symptoms, validating the 
diagnosis.223 Other conditions that present with nasal dryness and crusting should be ruled 
out (ie, atrophic rhinitis, sarcoidosis, etc.). The Empty Nose Syndrome 6-Item Questionnaire 
has documented validity in identifying ENS patients.229 Surgery for submucosal expansion 
of the internal nasal mucosa can often bring relief for patients.223 It has also been reported 
that depression and anxiety are prevalent among ENS patients.230
Atrophic rhinitis is a chronic, degenerative condition characterized by inflammation and 
atrophy of the nasal and paranasal mucosa.231 Primary atrophic rhinitis runs a protracted 
course. It can occur spontaneously with unknown etiology, but it is also associated with a 
bacterial infection, almost exclusively Klebsiella ozaenae. In a study examining 45 patients 
diagnosed with primary atrophic rhinitis, all nasal cultures were positive for Klebsiella 
ozaenae.231 Mucosal injury is hypothesized to result from prolonged microvascular or 
ischemic injury.231-233 Secondary atrophic rhinitis is far more common and usually develops 
following direct injury from trauma, irradiation, reductive nasal or sinus surgery, or in 
certain rare granulomatous diseases.231,234 Secondary atrophic rhinitis is also associated 
with a bacterial infection, but Staphylococcus aureus, Proteus mirabilis, and Escherichia coli 
are the more common pathogens, with Klebsiella ozaenae rarely isolated.231
Atrophic rhinitis presents as thick, adherent nasal crusting, nasal congestion, foul odor, and 
atrophy of mucosal and turbinate surfaces, with severe cases having complete absence of 
recognizable anatomic landmarks, septal perforations, or saddle nose deformity.231-233 
Hyposmia, epistaxis, and facial pain or pressure may also occur. Histological examination of 
intranasal tissue demonstrates squamous metaplasia, glandular atrophy, and diffuse 
endarteritis obliterans in both types of atrophic rhinitis.231 Diagnosis is established from 
clinical examination, nasal biopsy, and nasal cultures for associated bacteria.
Both atrophic rhinitis and ENS patients complain of nasal congestion. For atrophic rhinitis 
patients, this is often a result of significant nasal crusting, although as the disease progresses 
and mucosa and turbinate tissue is lost, the widened nasal cavity can very closely resemble 
that of an ENS patient. The pathophysiology of the paradoxical sensation of nasal 
congestion at this point is the same in both disease states, although the origin of the inciting 
event differs.
In the literature, ENS has repeatedly been described erroneously as a form or subset of 
atrophic rhinitis. ENS results from iatrogenic removal of turbinate tissue and is not 
associated with a bacterial infection whereas atrophic rhinitis results from a chronic, often 
idiopathic inflammatory process associated with bacterial infection that progresses to 
resorption of turbinate tissue. Atrophic rhinitis patients suffer from heavy crusting whereas 
ENS patients exhibit only minor crusting or no crusting.
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To differentiate AR [allergic rhinitis] from atrophic rhinitis, it should be noted that AR is an 
immunological response to a benign substance, the allergen, that manifests primarily as 
nasal inflammation. AR is IgE-dependent235 and characterized by sneezing, clear 
rhinorrhea, watery eyes, and nasal and ocular pruritus.1 This condition has a clear distinction 
from ENS and atrophic rhinitis in its clinical presentation and pathophysiology.
III.C.13. Autoimmune, granulomatous, and vasculitic rhinitis—Both the upper 
and lower airways can be affected by systemic disorders including vasculitic, 
granulomatous, and autoimmune diseases. Commonly, affected patients may present with 
nonspecific sinonasal symptoms (nasal obstruction, rhinorrhea, facial pain, and loss of 
smell) mimicking AR. Allergy testing will, however, be negative or not clinically relevant. 
Clinicians should consider broadening the differential to consider systemic etiologies if 
either crusting or recurrent epistaxis is seen.236 Oral steroids are the mainstay of treatment 
for the entities discussed in this section, although the recent introduction of monoclonal 
antibodies targeting specific biomarkers represents an important hallmark for future therapy.
Granulomatosis with polyangiitis.: Previously referred to as Wegener’s disease, 
granulomatosis with polyangiitis (GPA) is an idiopathic disease characterized by necrotizing 
and granulomatous inflammation of the upper and lower airways (85%), glomerulonephritis 
(75%) and systemic vasculitis.237-239 Limited forms of GPA involving only the head and 
neck may also be seen. GPA predominantly affects small to medium sized arteries and vein 
walls.240 GPA affects both men and women in a similar proportion, being frequently 
diagnosed in the fourth to sixth decades of life.240 In the US, estimated prevalence is 13 to 
30 cases permillion people per 5-year period. Nasal symptoms include obstruction, 
rhinorrhea, recurrent epistaxis, crusting, and pain over the nasal dorsum.237,241 Nasal 
mucosa disruption may lead to anosmia while tissue necrosis with secondary infection may 
lead to cacosmia.236 Nasal endoscopy can reveal an erythematous, friable mucosa with 
crusting and granulation that is seen in the septum and inferior turbinate.240 Patients with 
severe forms can present with nonvascular necrosis causing perforation or bony destruction 
of the nasal septum and/or other nasal structures.242 Diagnosis is based on clinical 
symptoms, physical findings, radiological examinations, laboratory tests (positive c-ANCA 
[anti-nuclear cytoplasmic antibody] in 60–90%), and biopsy of affected tissue for 
pathological examination.237,238,240 Profiling the nasal transcriptome in GPA reveals unique 
gene expression signatures related to innate immunity, inflammatory cell chemotaxis, 
extracellular matrix composition, and epithelial barrier integrity that may eventually be used 
clinically.243,244 Treatment includes prednisone, cyclophosphamide, or methotrexate.
237,238,245 Rituximab, anti-CD20 monoclonal antibody, may be an effective therapy in 
refractory or relapsing c-ANCA vasculitis,246 although additional study is needed.
Eosinophilic granulomatosis with polyangiitis.: Previously known as Churg-Strauss 
Syndrome, eosinophilic granulomatosis with polyangiitis (EGPA) is a rare small-sized vessel 
vasculitis with a prevalence of 1.3 cases per 100,000,247 typically diagnosed in patients age 
30 to 50 years.236 Rhinitis (75% of patients) is one of the initial manifestations of EGPA,248 
in addition to CRS with nasal polyps (CRSwNP), and partial/total smell loss.249 Diagnosis 
should be suspected in patients with asthma, with increased peripheral blood eosinophil 
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count (>10%) and pulmonary manifestations.238,248 EGPA is often associated with the 
presence of p-ANCA.247 CRSwNP is present in approximately 50% of patients.238 Nasal 
pain with purulent or bloody nasal discharge, nasal crusting, or nasal septal perforation can 
be present but are less common than in GPA patients.238,250 Treatment usually includes high 
doses of corticosteroids and immunosuppressants.248,251 Anti-IL-5 therapy (mepolizumab) 
is a potential biological treatment offering clinical benefit and stability and reducing 
corticosteroid needs.252
Sarcoidosis.: Sarcoidosis is a chronic multisystem disorder characterized by bilateral hilar 
adenopathy, pulmonary infiltration, ocular, and skin lesions.238,253 More commonly seen in 
young and middle-aged adults,254 females more frequently than males, and African-
Americans,255 a prevalence of 50 per 100,000 individuals has been reported.236 The 
involvement of the upper respiratory tract epithelium is infrequent236 and nasal symptoms 
are nonspecific: obstruction, epistaxis, nasal pain, epiphora, and anosmia.237 The most 
consistent findings are erythematous, edematous, friable, and hypertrophied mucosa in the 
septum and inferior turbinate. Submucosal yellow nodules representative of intramucosal 
granulomas may be identified in mucosal biopsies, while nasal polyps, rhinophyma, and 
septal perforations have also been reported.238,256 Aggressive non-caseating granulomas can 
cause hard or soft palate erosions as well as septal perforations leading to saddle-nose 
deformity.257,258 The diagnosis of sinonasal sarcoidosis is based on the clinical findings 
with either polypoid changes or characteristic yellowish submucosal nodularity.238 Tissue 
for diagnosis is usually obtained by transbronchial-lung biopsy254 or nasal biopsy, as well as 
from skin lesions, minor salivary glands, and lymph nodes.238 The primary treatment for 
sarcoidosis is systemic steroids, chloroquine, immunosuppressants, and lung-transplantation.
237,238,256,257 The emergence of biological therapies has increased the therapeutic options to 
treat refractory organ-threatening sarcoidosis, with monoclonal anti-TNF (tumor necrosis 
factor) agents (infliximab) being the most promising.259
Systemic lupus erythematosus.: Systemic lupus erythematosus (SLE) is an autoimmune 
disease that can affect any body system. SLE predominantly affects women (10:1) with an 
incidence of 5.6 per 100,000 people.260 The skin of the nose and nasal vestibule can also be 
involved in the skin rashes.237 Mucosal lesions are seen in 9% to 18% of cases, with oral, 
nasal, and pharyngeal mucosa being commonly affected.260 The diagnosis requires a 
detailed medical history, a physical examination, and laboratory tests (anti-nuclear antibody 
[ANA] or anti-double-stranded DNA), including a complete blood count, chemistry panel, 
and urinalysis.236,261 Therapy with corticosteroids, immunomodulators (prasterone, vitamin 
D, hydroxychloroquine), or immunosuppressants (azathioprine, cyclophosphamide, or 
mycophenolate) is prescribed for symptom control,238,262 while belimumab is a recent 
biological (anti-BAFF [B-cell activating factor] monoclonal antibody) to potentially treat 
SLE.263
III.C.14. Rhinosinusitis—The symptoms of AR may overlap with other forms of nasal 
inflammation, including rhinosinusitis. It is important to differentiate between AR and 
rhinosinusitis to ensure the correct diagnosis and subsequent treatment can be pursued. AR 
may be associated with comorbid rhinosinusitis, although whether AR increases the risk of 
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rhinosinusitis is debatable.1 Identifying comorbid rhinosinusitis is essential to ensure the 
appropriate management of both conditions. Of note, these conditions are not mutually 
exclusive and there may be an association between rhinosinusitis and AR. It is possible to 
have concurrent AR and rhinosinusitis, and this possibility should be considered when 
patients meet diagnostic criteria for both independently and when patient symptomatology 
or response to treatment does not fit with a single diagnosis.1 A high degree of clinical 
suspicion is required; however, careful consideration of these factors may help guide 
clinicians to the correct diagnosis or diagnoses.
Rhinosinusitis is a broad term that includes the diagnoses of acute rhinosinusitis (ARS), 
RARS, and CRS, demarcated as CRSwNP or CRS without nasal polyposis (CRSsNP). 
Symptomatically, these conditions are characterized by nasal obstruction, nasal congestion, 
facial pressure or pain, anterior or posterior nasal discharge, and anosmia/hyposmia for 
varying durations of time.1,138 AR shares several overlapping symptoms, namely rhinorrhea 
and nasal congestion, which may be confused with the subtypes of rhinosinusitis.264,265 
Conversely, rhinosinusitis may be mistaken for AR due to the similar symptomatology.1 
Understanding the diagnostic criteria for the subtypes of rhinosinusitis will aid clinicians in 
solidifying the correct diagnosis, as well as identifying comorbid conditions.
ARS is defined as the sudden onset of sinonasal symptoms with associated sinonasal 
inflammation that lasts less than 4 weeks.1,137,138,266,267 Symptoms include nasal 
congestion, nasal obstruction or nasal discharge, and facial pressure or pain, or anosmia/
hyposmia. Nasal discharge is often purulent and may be discolored, with a tendency to be 
unilateral although may be bilateral.1,138 Facial pressure and pain is described as moderate 
to severe.137 ARS may be viral or bacterial. In general, viral ARS is present for less than 10 
days. A longer duration of illness suggests bacterial ARS.137,138 Progressive worsening over 
a short period of time (ie, 5 days) is also suggestive of bacterial ARS.137,138 In the European 
Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) statement, fever and elevated 
serum markers of inflammation (C-reactive protein or erythrocyte sedimentation rate) are 
also included as diagnostic criteria.138 Fever is not included in other guidelines, due to its 
low specificity and sensitivity.137 RARS is defined as at least 4 episodes of ARS per year, 
with disease-free intervals between episodes.1,137,138,266,268
CRS is an inflammatory condition of the sinonasal cavity persisting for more than 12 weeks 
with at least 2 symptoms of nasal obstruction and congestion, mucopurulent nasal drainage 
(anterior or posterior), facial pressure or pain, and anosmia/hyposmia.1,137,138,266,267 In 
addition, patients must have objective evidence of sinonasal inflammation on either nasal 
endoscopy (polyps, edema, mucopurulent rhinorrhea) or on CT scans of the sinuses.
137,138,266,267 CRS is divided into 2 main phenotypic groups: CRSwNP and CRSsNP.
Comparatively, AR is characterized by nasal obstruction, nasal congestion, clear watery 
rhinorrhea (anterior or posterior), and allergic symptoms.264,265 The presence of these 
symptoms should raise suspicions of AR as either a primary or comorbid diagnosis. 
Conversely, AR is typically not associated with purulent or unilateral nasal discharge. 
Moderate to severe facial pain and/or fever would also be atypical for isolated AR and may 
indicate the presence of an episode of ARS or an acute exacerbation of CRS, differentiated 
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by duration and chronicity of symptoms.1,137,138 The timing of symptoms may also help 
delineate between rhinosinusitis and AR as ARS symptoms typically last days to weeks (but 
no more than 4 weeks), CRS symptoms persist daily for greater than 12 weeks. In 
comparison, while AR symptoms are variable in duration, they tend to have seasonal or 
exposure-related fluctuations.1,137,138 AR symptoms are present for at least 1 hour on most 
symptomatic days; however, patients may have symptom-free intervals.264,265 AR symptoms 
are also exacerbated by exposure to allergens in a time dependent fashion.264 The early 
reaction occurs immediately after exposure and is characterized by sneezing, nasal and 
ocular itching and rhinorrhea, which typically resolves within 30 minutes.264 The late 
reaction takes place up to 6 hours after exposure and is characterized by nasal obstruction 
and congestion.264 Superimposed late reactions may blunt the manifestation of acute phase 
symptoms and make the diagnosis of AR less obvious.
When attempting to determine whether a patient has AR, ARS, RARS, or CRS, it is 
important to elicit a history of specific symptoms from the patient that includes onset and 
duration of symptoms. A history of allergic symptoms or allergen exposure-related 
symptoms support a possible diagnosis of AR, as these are not associated with rhinosinusitis 
and AR may or may not be seasonal in nature, which can also be elicited by history.264,265 
The development of acute, moderate to severe symptoms, and nasal purulence may be 
consistent with ARS or RARS rather than AR.1,137,138 A prolonged duration of symptoms 
(greater than 12 weeks) should raise suspicions for CRS and prompt further investigation.
1,137,138 (See section X.B. Associated conditions - Rhinosinusitis for additional information 
on this topic.)
IV. Pathophysiology and mechanisms of allergic rhinitis
A background understanding of the pathophysiology and underlying mechanisms of AR is 
necessary as we examine the clinical presentations, physical manifestations, goals of allergy 
testing, and response to treatment. This section addresses the cellular inflammation, soluble 
mediators, local allergic manifestations, and systemic effects associated with AR. While this 
document is not intended to provide an extensive review of the pathophysiology of AR, the 
following short section provides a foundation for understanding the clinical expression of 
AR and its treatment.
IV.A. IgE-mediated allergic rhinitis
IV.A.1. Systemic mechanisms and manifestations—The immune response leading 
to IgE production in AR is often a systemic phenomenon, and patients with AR demonstrate 
evidence of systemic atopy.269,270 One manifestation of systemic atopy in AR is the 
cutaneous reaction elicited during traditional allergy skin testing.271 Further evidence for the 
systemic nature of the IgE response in AR includes the temporal relationship of AR to a 
number of other allergic diseases, including atopic dermatitis (AD), food allergy, and 
allergic asthma, a phenomenon known as the “atopic march.”272 This pattern of atopic 
disease progression is well-known and supported by prospective studies.273
The immunologic processes underlying IgE-mediated AR are similar to those of other atopic 
conditions and involve activation of the adaptive immune system. The adaptive immune 
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response can be broadly classified into 2 categories based upon the predominant Th 
lymphocyte subtype.274 The Th1 profile is responsible for defense against intra-cellular 
pathogens, while Th2 responses are implicated in the defense against parasitic infections as 
well as the IgE-mediated eosinophilic inflammation of allergy.272 Whether AR will develop 
as a result of inhalant allergen exposure therefore depends largely upon the balance between 
Th1 and Th2 effector cells.274
A number of steps in the sensitization process are responsible for eliciting the Th2-
predominant response. The process begins with exposure of the nasal mucosa to inhalant 
allergens.275 While mucosal epithelial cells were once thought to function simply as a 
mechanical barrier to allergen penetration, recent research suggests that epithelial cells play 
a much more sophisticated role in allergy development, through the secretion of numerous 
inflammatory mediators including cytokines, chemokines, eicosanoids, and endopeptidases, 
as well as through upregulation of cellular adhesion molecules and release of matrix 
metalloproteinases.276 They also provide an important early stimulus toward a Th2-weighted 
immune response, through the secretion of thymic stromal lymphopoietin (TSLP).272,275,276 
TSLP causes maturation of dendritic cells into Th2-promoting subtypes,277 which secrete 
chemokines that attract Th2-destined T lymphocytes, foster clonal amplification of Th2 
cells, and enhance survival of memory B-cells.272 TSLP also promotes recruitment of 
eosinophils and enhanced activity of basophils and mast cells.272
Allergens are then engulfed by dendritic cells, which migrate to lymphoid organs where the 
antigen is presented to naive helper T (Th0) cells on MHC class II molecules.274 Th2 
differentiation also requires co-stimulation via the interaction of CD28 on T cells with CD80 
and CD86 on antigen-presenting cells (APCs).278 Additionally, the presence of the cytokine 
IL-4 is required.279 IL-4 binds STAT-6 on the Th0 cell, activating the master switch 
GATA-3.272 This stimulates IL-4, IL-5, and IL-13 production,274 which is characteristic of 
the Th2 response. These cytokines, produced by the newly differentiated Th2 cell, have 
several effects that further promote IgE-mediated eosinophilic inflammation and allergy.
IgE is produced by B-cells under the influence of Th2 effector cells and the cytokines they 
secrete.275 Development of an IgE-secreting B cell requires the presence of IL-4 or IL-13, 
which induce class switching via upregulation of ε-germline gene transcription and clonal 
expansion, as well as interaction between CD40 ligand on the T-cell surface and CD40 on 
the B-cell surface, which promotes B-cell activation and the production of IgE.279 Allergen-
specific IgE (sIgE) is then released into the circulation by plasma cells.
IgE antibodies subsequently bind high-affinity receptors (FcεRI) on the surface of mast cells 
and basophils, rendering them sensitized.280 Future allergen exposure results in crosslinking 
of IgE on the surface of mast cells and basophils causing degranulation, release of 
inflammatory mediators such as histamine, and the classic symptoms of AR.
IV.A.2. IgE-IgE receptor cascade—IgE plays a central and defining role in the 
pathophysiology of acute allergic reactions as well as chronic atopic disease.281 In 
individuals with AR, exposure to specific allergens results in the production of allergen-
specific IgE, which then binds to effector cells such as mast cells and basophils via the high-
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affinity receptor FcεRI. Although IgE in plasma is short-lived, IgE that is receptor-bound 
remains attached to these cells for weeks or months. Moreover, when IgE bound to FcεRI 
cross-links with a specific allergen, it induces the release of preformed inflammatory 
mediators from mast cells and basophils, resulting in clinical manifestations of allergic 
diseases.
Cytokines including IL-4 and IL-13 released from T cells and mast cells drive the 
differentiation of B cells into IgE-secreting plasma cells. Several studies, both in vivo and in 
vitro have confirmed the production of local IgE in the nasal mucosa of patients with AR.
282-284 The locally produced IgE plays a key role in ongoing inflammation by up-regulating 
FcεRI expression in mast cells.283-285 The augmented expression of FcεRI allows them to 
bind greater numbers of IgE-antigen complexes, which in turn enhances the sensitivity of 
mast cells to allergen. This results in an increased production of immunomodulatory 
cytokines and chemical mediators, forming an important positive-feedback amplification 
loop involving the IgE-IgE receptor cascade, thus perpetuating ongoing inflammation.285,286 
Interestingly, the density of IgE receptors and IgE molecules in mast cells within the nasal 
mucosa of patients with AR have been shown to correlate with levels of serum IgE.285 The 
presence of elevated levels of IgE in nasal secretions has been demonstrated in non-allergic 
rhinopathy as well, which potentially further highlights a significance of the IgE-IgE 
receptor cascade in driving the disease process of rhinitis.287
IV.A.3. Local IgE production and local allergic rhinitis (LAR)—LAR is a regional 
inflammatory condition defined by local symptoms and sIgE-mediated inflammation 
without evidence of systemic hypersensitivity.107,194,284,288 It is important to remember that 
conventional allergy testing, such as SPT and the radioallergosorbent test (RAST), only 
indicates sensitization (atopy), but not symptomatic allergy. While it is possible for a 
positive allergy skin or in vitro test result to lack clinical relevance, the opposite is also true, 
as a negative allergy skin or in vitro test result does not exclude regional IgE-mediated 
sensitivity, as in the case of LAR.194,288-290 LAR may affect more than 47% of children and 
adults previously classified as NAR,290-295 and persists throughout the years with a low rate 
of conversion to clinical AR.296-298 However, LAR may evolve to the development of 
asthma.296,297 Diagnosis of LAR is based on demonstration of a positive response to NPT 
and/or the detection of nasal sIgE and/or a positive basophil activation test (BAT) in the 
absence of systemic atopy. The pathophysiology of LAR is complex and not completely 
understood. Immunologic studies have revealed the existence of a Th2 inflammatory 
response in the nasal mucosa of LAR patients,177,299-301 with positive response to NPT,
291,300-302 and local production of sIgE177,290,299-301,303-305 and inflammatory mediators.
304,306,307
Nasal Th2 inflammatory response.: Flow cytometry studies in nasal secretions have 
confirmed that aeroallergen exposure induces a Th2 inflammatory response in the nasal 
mucosa of LAR patients with increased eosinophils, basophils, mast cells, CD3+, and CD4+ 
T cells.300,301 NPT studies have demonstrated the existence of characteristic immediate/
early and late-phases of the allergic response in LAR patients with local production of sIgE, 
mast cell, and eosinophil activation, with mucosal secretion of tryptase and ECP.306,307 A 
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recent study showed that 83% of LAR subjects sensitized to Olea europaea pollen responded 
to NPT with nOle e 1 (the most significant allergen of Olea europea), demonstrating that 
purified allergens can also induce an allergic response with secretion of ECP.308
Local sIgE production.: The respiratory airway mucosa is a site of IgE production during 
allergic inflammation, as has been demonstrated in patients with AR309-312 and LAR,
299-301,303-307 with both somatic hypermutation and class switching occurring in the nasal 
mucosa.309,312-315 Cellular studies have confirmed the expression of ε-germline gene 
transcripts and messenger RNA (mRNA) for the ε heavy-chain of IgE in nasal mucosal B-
cells.310 The rate of local IgE production316 is sufficient to saturate IgE receptors on local 
mast cells, and potentially spill over into the circulation.316,317 In LAR, the presence of sIgE 
in nasal secretions has been confirmed after natural allergen exposure,300,301 NPT,
300,301,303-305 and periods of non-exposure.300,301 Furthermore, local sIgE in LAR has the 
capability of activating basophils via the high-affinity receptor FcεRI, leading to the release 
of inflammatory mediators characteristic of AR.308,318
IV.B. Non–IgE-mediated inflammation in allergic rhinitis
It is commonly accepted that AR is primarily an IgE-driven response.319 However, in recent 
years our understanding and appreciation of the important contributions of the nasal innate 
immune response to the pathogenesis of AR has grown substantially.320 The 
pathophysiologic mechanisms of inflammatory airway disease are related to large 
physiologic networks that influence host-environment interactions. The nasal epithelium is 
the first structure to encounter inhaled aeroallergens. Intrinsic proteolytic activity of 
allergens may disrupt the nasal epithelial barrier, facilitating allergen penetration and chronic 
inflammation.321 Recent data provide additional evidence that epithelial barrier dysfunction 
contributes to the development of inflammatory diseases such as AR, but it remains to be 
elucidated to what extent primary (genetic) vs secondary (inflammatory) mechanisms drive 
this breakdown.322 Epithelial cells not only act as a physical barrier toward inhaled 
allergens, but also actively contribute to airway inflammation by detecting and responding to 
environmental factors. The nasal epithelium expresses pattern recognition receptors in the 
form of toll-like receptors (TLRs) that, after activation by allergens or pathogens, lead to the 
production of different mediators.323,324 These mediators affect recruitment of inflammatory 
cells to local tissues and create a microenvironment that affects the function of immune 
cells, thereby propagating local inflammatory processes.325 In allergic disease, the nasal 
epithelium seems to be in a permanently activated state,326 potentially as a consequence of 
the inability to switch off the activation response.327
An interesting recent development was the discovery of innate lymphoid cells (ILCs) as 
potential key players in the pathogenesis of Th2-type diseases such as AR, CRSwNP, and 
asthma.328-330 ILCs are a family of effector cells that are important for protection against 
infiltrating pathogens and restoration of tissue integrity. ILCs do not express antigen-specific 
T-cell receptors, but can react promptly to “danger signals” and produce an array of 
cytokines that direct ensuing immune responses. Three major subsets have been defined 
based on their phenotype and functional similarities to Th1 (ILC1), Th2 (ILC2), and Th17 
(ILC3) cells. Upon exposure to environmental antigens, including viruses and allergens, 
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airway epithelial cells rapidly release the cytokines IL-25, IL-33, and TSLP which directly 
activate ILC2s that then produce the prototypical type 2 cytokines IL-5 and IL-13.331 
Allergen challenge in AR subjects induces an increased number of peripheral serum 
ILC2s332,333; however, a similar increase in the nasal mucosa is yet to be demonstrated. In 
addition to treatments aimed at modulating IgE-mediated inflammation, novel therapies 
directed toward the innate immune system are in development for treatment of AR.334,335
IV.C. Unified airway concept
The upper and lower airways are linked from anatomical, histological, and immunological 
perspectives with inflammation in one part of the airways influencing the other part, thus 
forming a united airway system.336 New systemic treatment options make understanding of 
the relationship between upper and lower airways even more important.337
The mucosa of the upper and lower airways is similar, containing pseudostratified 
epithelium with ciliated columnar cells lining. Basal epithelial cells are also present, 
attached to the basement membrane (lamina reticularis), and have an epithelial stem cell 
function. In the submucosa there are vessels, mucus glands, fibroblasts, and some 
inflammatory cells. The main difference in mucosal components is the absence of smooth 
muscles in the upper airways as compared to the lower airways, and the lack of extensive 
subepithelial capillaries, arterial systems, and venous cavernous sinusoids in the lower 
airways as compared to the upper airways.
The characterization of phenotypes of rhinitis and asthma are very similar, with emphasis on 
allergy and eosinophilia, non-allergic phenotypes in both upper and lower airways, and the 
link between CRS, especially with nasal polyps, and late onset asthma.319,338,339 Both AR 
and asthma may also be characterized by hyperreactivity that is not correlated to the atopic 
state.192,340 Also in endotyping, similarities can be pointed out with emphasis on type 2 vs 
non-type 2 immune responses. In allergic diseases, the prominent endotype is type 2 (eg, 
Th2 cells, type 2 B-cells, IL-4-producing natural killer [NK]/T cells, basophils, eosinophils, 
mast cells, ILC2, IL-4, IL-5, IL-13, IL-25, IL-31, IL-33).319,341 In general, the type 2 profile 
in AR and asthma is associated with a good response to corticosteroid treatment. New 
targeted treatments that focus on (subgroup) type 2 elements, such as anti-IgE antibodies, 
anti-IL-5 (mepolizumab), and anti-IL-4/IL-13 (dupilumab) are currently used in asthma, but 
are not currently approved for use in the upper airways.342 Similarities are not only found in 
the acquired immune response, but also in the role of innate immunity like epithelial barrier 
function334 and innate lymphoid cells.332 Epithelial barrier leakiness, particularly tight 
junctions that seal the upper and lower respiratory mucosal epithelial surface, has been 
shown in asthma, AR and CRS.343,344
Several mechanisms may explain the influence of sinonasal inflammation on the lower 
airways; ie, altered breathing pattern, pulmonary aspiration of nasal contents, the 
nasobronchial reflex, and the uptake of inflammatory mediators in the systemic circulation.
345 The nose acts as a filter and air conditioner, protecting the lower airways. Reduced filter 
and air-conditioning functions of the nose may lead to increased exposure of the lower 
airways to allergens. Mouth breathing is independently associated with asthma morbidity, 
indicating that air conditioning can be of major importance. The efficacy of the nasal filter 
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depends on the size of the inhaled particles. Small molecules, such as molds and cat dander, 
are more associated with an increased risk for asthma, whereas larger molecules, such as tree 
and grass pollen, are primarily associated with upper airway symptoms. The role of 
preferential mouth breathing in the development of asthma is unclear.346
Although there is a relationship between postnasal drip and coughing, no direct association 
has been proven between overproduction of nasal secretions and bronchial hyperreactivity. 
Moreover, after nasal application, deposits of radioactive-labeled allergen can be found in 
the digestive tract but not in the respiratory tract.347 Stimulation of pharyngolaryngeal 
receptors is more likely to be responsible for a postnasal drip-related cough.348 Interestingly, 
cough is not induced in patients with rhinitis or healthy controls in simulated models of 
postnasal drip.349
There is not much evidence supporting the nasobronchial reflex as an important contributor 
to the unified airway. Nasal allergen challenge can be blocked with a vasoconstrictor but not 
with lidocaine. Moreover, lower airway responses after allergen challenge are in general 
more delayed than would be expected following a nasal-bronchial reflex.350
Allergen provocation studies represent a good model to study nasal-bronchial crosstalk in 
allergic airway disease. In patients with AR, segmental bronchial or nasal provocation can 
induce allergic inflammation in both the nasal and bronchial mucosa.347-349 Presumably, 
absorption of inflammatory mediators (eg, IL-5 and eotaxin) from sites of inflammation into 
the systemic circulation results in the release of eosinophils, basophils, and their progenitor 
cells from the bone marrow.351 The systemic allergic response is further characterized by 
increased expression of adhesion molecules, such as vascular cell adhesion molecule 1 and 
E-selectin on nasal and bronchial endothelium, which facilitates the migration of 
inflammatory cells into the tissue.352
Increases in CD34+ cells capable of eosinophil differentiation, as well as other circulatory 
mediators (IL-5, eotaxin, and cysteinyl leukotrienes), are associated with impaired lung 
function parameters and enhanced mucosal inflammation in asthmatic patients,353 and react 
to local corticosteroids in AR.354 Treatment with anti-IL-5 and other interleukins relevant in 
the eosinophilic pathway has been shown to be effective in asthma, with some beneficial 
results in eosinophilic upper airway disease.342
In conclusion, these studies demonstrate that the same mechanisms behind AR may be 
important in airway inflammation throughout the respiratory tract, even in the absence of 
clinical asthma. Systemic factors, such as the number of circulatory eosinophils and atopic 
severity are indicative of more extensive airway disease.
IV.D. Cellular inflammatory infiltrates
A variety of cells are involved in the pathophysiology of AR. Due to the nature of the 
disease, with different mechanisms and endotypes, it is practically impossible to 
comprehensively describe each of these inflammatory cells in detail. This suggests a need 
for an extensive endotyping and characterization of the cellular infiltrate for each endotype.
355 In addition, many studies focusing on cell types in allergic diseases, including recently 
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identified cells such as type 2 ILCs, Th17 cells, and Th22 cells, have been mostly restricted 
to investigations of peripheral blood cells, not tissue biopsies. There is evidence from a 
limited number of studies that different cells are involved at different stages of 
inflammation, such as exacerbation, remission, and extensive remodeling. Furthermore, 
different tissue sites such as sinus mucosa, polyp tissue, or inferior turbinates show a variety 
of different infiltrating immune and inflammatory cells.
Nasal epithelial cells are at the interface of the human body and the environment, and often 
act as the first line of defense against external pathogens. Epithelial cells interfere with non-
self allergens and regulate infiltrating cells in AR through the production of various co-
stimulatory molecules, chemokines, cytokines, and lipid mediators. These cytokines start to 
orchestrate a type 2 immune response characteristic of AR.356 However, when allergens 
have additional protease activity and/or they are accompanied by microbial components such 
as endotoxins or inorganic particles, epithelial secretory responses can lead to mixed type 2 
and type 17 immunity, or even type 1 responses.357,358 In response to respiratory viruses, 
epithelial cells produce a wide range of mediators such as type I interferons, granulocyte 
macrophage colony-stimulating factor (GM-CSF), RANTES/C-C Motif Chemokine 5 
(CCL5), and interferon gamma-induced protein 10/C-X-C Motif Chemokine 10 (IP-10/
CXCL10).359 These mediators orchestrate further downstream innate and adaptive antiviral 
cellular immune responses.
To activate allergen-specific CD4 T-cells, adequate co-stimulation is required. Dendritic 
cells are professional APCs that are directly related to AR, with increased numbers and 
concentrations of IgE in atopic disease.360 They are in close contact with epithelial cells and 
ILCs and control T-cell and B-cell activation and differentiation.356 Also, elimination of 
dendritic cells has been shown to suppress the development of AR.360
Both innate and effector mechanisms play essential roles during the development of allergic 
disease.361 T-helper subset imbalance and production of typical Th2 cytokines,362 along 
with increased expression of GATA-3,363 is generally seen in AR nasal mucosa. 
Furthermore, CD4+ memory T-cells and gamma/delta-T-cells are increased in PAR patients’ 
mucosa.364 Effector Th2 cells produce IL-4, IL-5, IL-9, and IL-13.356,365 In addition, TSLP, 
IL-25, IL-31, and IL-33 contribute to the development and intensity of Th2 responses and 
inflammation. These cytokines have roles in production of sIgE, eosinophilia, mucus, tissue 
migration of Th2 cells and eosinophils, regulation of tight junctions, and epithelial barrier 
integrity.343,356,366,367 T-regulatory (Treg) cell subsets have distinct phenotypes and include 
constitutive and inducible subsets of CD4+CD25+ Forkhead box P3 (FOXP3)+ Treg cells, 
and type 1 Treg cells.368-370 Treg cells play a major role in allergen tolerance and allergen 
immunotherapy (AIT).371-373 The production of IL-10 and transforming growth factor 
(TGF)-β from other cells is decisive for their immune regulatory functions. The ratio 
between effector and regulatory cell types determines whether an allergic response is 
triggered by an allergen or not.
Populations of lymphoid cells that lack rearranged antigen receptors and markers for 
myeloid and lymphoid lineages, such as T-cells, B-cells, and NK-cells have been defined as 
ILCs. Type 1 ILCs (ILC1) mainly produce interferon (IFN)-γ, ILC2s produce IL-5 and 
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IL-13,374 and ILC3s produce IL-17 and IL-22.361 Type 2 ILCs are found in AR, where they 
closely interact with epithelial and other cells controlling the mucosal environment. Through 
the production of cytokines and induction of chemokines, a type 2 immune response is 
favored, supporting further development of an allergic tissue inflammation.375
Although it was believed that IgE-producing B-cells reside in lymphoid follicles of the 
Waldeyer ring376 and antibodies were then transferred to the mucosa, newer evidence has 
identified B-cells and plasma cells capable of producing IgE in nasal tissue of AR patients.
377 The local production of allergen-specific antibodies is further supported by the detection 
of secondary lymphoid tissue and IgE formation to Staphylococcus aureus in CRSwNP.378
Within the nasal epithelium of allergic individuals increased numbers of major basic protein-
positive and EG2+ (activated) eosinophils can be encountered during the pollen season. 
Similarly, mast cells are found within the epithelium and the submucosal layer; however, no 
increases are observed in cell counts of T-lymphocytes or their subsets, nor of neutrophils or 
macrophages during seasonal allergen exposure.379 Basophil numbers in the lamina propria 
of the nasal mucosa increase within 1 hour of allergen provocation.380 Degranulation of both 
mast cells381 and basophils occurs during the early and late phases of a type I reaction after 
allergen encounter and crosslinking of IgE molecules as well as upon stimulation by 
IL-33.382
In the late phase of the allergic reaction, the influx of inflammatory cells is facilitated by 
chemoattractants and upregulation of adhesion molecules.383 This leads to further 
infiltration of the tissue by eosinophils, basophils, and T-cells. Last, those inflammatory cells 
driving remodeling of the mucosa in AR, and upregulating factors such as matrix 
metalloproteinases and angiogenic factors, remain to be identified.384
IV.E. Cytokine network and soluble mediators
Cytokines are immunomodulatory proteins important in cellular signaling. Complex 
interactions of innate and adaptive immune cells, as well as structural cells and their 
cytokines, play crucial roles in regulating allergic airway inflammation. The inflammatory 
process underlying AR is coordinated by a network of cytokines.
Type 2 cytokines such as IL-4, IL-5, IL-6, and IL-13 are crucial in regulating the allergic 
inflammatory cascade characterized by an increased presence of eosinophils and mast cells 
and an upregulation of IgE production. Besides their role in the induction of IgE synthesis, 
type 2 cytokines up-regulate the production of other cytokines and chemokines from 
epithelial cells and fibroblasts,283 which then leads to the influx of inflammatory cells 
including eosinophils and mast cells.385,386 Scadding et al.387 demonstrated the 
immunological aspects of rhinitis with nasal allergen challenge. After nasal challenge with 
grass pollen in sensitive individuals, the levels of IL-4, IL-5, and IL-13 were elevated 2 to 3 
hours postchallenge and increased for up to 5 or 6 hours.387 Similarly, levels of chemokines 
such as thymus-regulated and activation-regulated chemokine (TARC, CCL17), macrophage 
derived chemokine (MDC, CCL22), eotaxin, RANTES, MCP-1, and macrophage 
inflammatory protein (MIP)-1α were elevated.388-391 Increases in these type 2 cytokines and 
associated chemokines were strongly correlated to allergic clinical responses.
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Although type 2 cytokines were originally referred to as Th 2 cytokines after their suspected 
cellular source, several other cells have been identified as significant sources including mast 
cells, epithelial cells, type 2 ILCs, and eosinophils. Airway mast cells are an important 
source of type 2 cytokines, proinflammatory cytokines, chemokines, and the IL-7–like 
cytokine TSLP.283,392-394 IL-13 from mast cells plays a crucial role in mast cell–induced 
local IgE synthesis by B cells,286,395 which in turn upregulate FcεRI expression on mast 
cells.286 Further, several mast cell products heavily influence epithelial cells. TNF-α, a 
proinflammatory cytokine produced by mast cells, in concert with IL-4 and IL-13, enhances 
the production of TARC, TSLP, and eotaxin from epithelial cells.385 And chemokines such 
as tryptase and chymase can upregulate RANTES and GM-CSF production from epithelial 
cells.385 Thus, there appears to be a crucial interplay between mast cells and epithelial cells 
in promoting and regulating the allergic inflammatory cascade.
In addition to the cytokines and chemokines listed in the previous paragraphs, nasal 
epithelial cells are an important source for IL-1, IL-6, IL-8, and TNF-α. Through these 
signals, epithelial cells play a crucial role in the migration and activation of eosinophils, 
basophils, and Th2 cells.396 In addition, epithelial cells release the cytokines IL-25, IL-33, 
and TSLP that orchestrate both the innate and adaptive Type 2 immune response. These 
same cytokines are also released by tissue damage, pathogen recognition, and allergen 
exposure. They can regulate Th2 cell function either directly or via innate lymphoid cells, 
which in turn produce IL-5, IL-9, IL-13, TSLP, IL-25, and IL-33, which are all increased in 
the nasal mucosa of AR patients, indicating a role of these cytokines in the pathophysiology 
of AR.397-400 In fact, levels of IL-33 in nasal secretions have been shown to correlate with 
total nasal symptom scores.400 Further, TSLP has been shown to activate dendritic cells, 
promote Th2 responses, and activate mast cells.401
Eosinophils are another cell type that appears to play a significant role in the 
pathophysiology of AR. They are a major source of the inflammatory cytokines macrophage 
migration inhibitory factor (MIF)402 and nerve growth factor (NGF).403 Eosinophils express 
5-lipoxygenase, LTC4S, and CysLT1 and CysLT2 receptors, which play a role in the 
arachidonic acid pathway.404 IL-5 has a key role modulating eosinophil maturation, 
differentiation, and survival.405 Eosinophilic chemoattractants include eotaxin, MCP4, 
RANTES, and cysteinyl leukotrienes, among others.406-408 As discussed in earlier 
paragraphs within this section, mast cells and epithelial cells either directly produce or 
upregulate many of these same chemoattractants.
Finally, Th17 cells are a unique subpopulation of CD4+ T cells. They produce IL-17A, 
IL-17F, IL-22, TNF-α, and IL-21.409 They have been demonstrated to be in the nasal 
mucosa of AR patients and are therefore thought to play a role in allergic inflammation.
409,410 Further, IL-17A has been shown to be upregulated in SAR patients 5 hours after nasal 
allergen challenge.411 Finally, increased numbers of IL-17A+ cells and IL-17A mRNA were 
demonstrated in the nasal mucosa of patients with dust mite allergy, indicating a possible 
role in AR.412
In summary, AR is a type 2–mediated disease, characterized by important regulatory 
cytokines such as IL-4, IL-5, and IL-13. Newer type 2 cytokines have been identified in AR, 
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including IL-17 family cytokines. Finally, Type 2 ILCs and epithelial cell-derived cytokines 
such as TSLP, IL-25, and IL-33 play a crucial role in the regulation of the allergic 
inflammatory cascade.
IV.F. Histologic and epithelial changes
Normal nasal mucosa comprises pseudostratified columnar ciliated epithelium with goblet 
cells over a basement membrane. The nasal submucosa contains stromal elements including 
fibroblasts, blood vessels, seromucinous glands, sensory nerves, and leukocytes. Leukocytes 
present in the nasal mucosa include CD4+ and CD8+ T lymphocytes, B lymphocytes, 
eosinophils, neutrophils, basophils, mast cells, and macrophages. The combined functions of 
ciliated and secretory cells allow for nasociliary clearance, removing pathogens and 
allergens as a host defense mechanism. In addition to the physical barrier, nasal epithelium 
plays an important role in the innate and acquired immunologic defense against 
pathogens359,413,414 by: (1) expressing pattern recognition receptors that recognize 
pathogen-associated molecular patterns; (2) secreting a vast arsenal of host defense 
molecules, such as antimicrobial enzymes, opsonins, permeabilizing proteins, collectins, and 
binding proteins; and (3) producing inflammatory cytokines in response to antigenic stimuli.
Allergy mediates epithelial change in the nasal mucosa. Nasal epithelium is thicker in 
patients with AR after allergen challenge,415,416 but studies on epithelial thickness in AR 
without allergen challenge are conflicting.415-417 While epithelial remodeling is a key 
feature of CRS (epithelial hyperplasia, goblet cell hyperplasia, and squamous 
metaplasia)418-420 and asthma (epithelial desquamation, subepithelial fibrosis, and smooth 
muscle hypertrophy), remodeling in AR is less marked. In general, limited studies have 
found no significant increase in basement membrane thickness, subepithelial fibrosis, goblet 
cell hyperplasia, or blood vessel volume and surface density,415,421,422 though increased 
vascular permeability was noted.423 In contrast to epithelial remodeling, epithelial 
inflammatory response to allergens is a key feature of AR. Upon allergen exposure, there is 
significantly higher infiltration of inflammatory cells, and increased levels of cytokines 
(such as IL-4, IL-5, and IL-13) in the nasal epithelium of allergic compared to non-allergic 
patients.182 This inflammatory response translates into mucosal edema, autonomic neural 
stimulation, and increased mucosal secretions, which manifest as the hallmark symptoms of 
nasal obstruction, pruritus, sneezing, rhinorrhea, and smell loss in severe cases.
The epithelial barrier is noted to have specific functions in allergy. Penetration of allergens 
through this barrier may lead to allergen sensitization and local and/or systemic 
inflammatory response. In the nasal mucosa, this barrier is comprised of mucus and 
epithelial cells, which are linked by apical junctional complexes (tight junctions and 
adherens junctions).367 Mechanical or infective insults to the epithelium or defective 
epithelium leads to barrier breach and allergen penetration.367,424-426 Loss-of-function 
mutations and polymorphisms in genes coding for epithelial barrier markers such as 
filaggrin are associated with AR and eczema.427,428 Some allergens can induce junctional 
dysfunction, leading to penetration of the epithelial barrier by allergens.322,429 Proteolytic 
allergens directly disrupt the apical junctional complex via proteolysis, leading to barrier 
dysfunction.430 Detection of allergens by APCs, and the ensuing Th2 responses and 
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cytokine release (such as IL 4, IL-13, and IFN-γ) induces further “leakiness” of the apical 
junctional complex via various mechanisms, allowing increased levels of allergen 
penetration.367 Evidence suggests that this barrier impairment may be reversed with 
corticosteroids. Fluticasone propionate has been found to increase expression of tight 
junction proteins zonula occludens 1 and occludin and a more intact nasal epithelial barrier.
322 Corticosteroids have not, however, been shown to cause thinning of nasal epithelium.
322,431
Allergy is now considered both a systemic and local epithelial condition.337 Evidence points 
to the epithelium being an active participant in the development and progress of allergy, 
rather than as a passive barrier.432 Birch pollen has been found to rapidly bind to Bet v 1–
binding proteins in sensitized nasal epithelium, and is transported through a lipid raft and 
caveolar-dependent process before binding to mast cells in the lamina propria.433-435 
Epithelial response to allergens differs from healthy individuals in that allergic patients do 
not mount as robust an epithelial defense response to allergens, leading to increased 
penetration of allergens.432
IV.G. Microbiome
The human microbiome comprises the complex community of microorganisms that resides 
in and interacts with the human body. The adult intestine is a haven to approximately 100 
trillion microbes and it is thought that the microbiome accounts for roughly 90% of all the 
cells in the human body.436,437 The microbiomes of individuals vary, likely due to the fact 
that the growth, development, and composition of the microbiome are affected by intricate 
interactions between the environment, diet, and host-related factors.437
With the advent of culture-independent high-throughput bacterial DNA sequencing 
techniques, a detailed description of the composition and variety of the microbiome can be 
described among organs and individuals.438 The Human Microbiome Project began in 2007, 
and as a result, extensive data have emerged examining the associations of the microbiota of 
the respiratory tract, oral cavity, gut, skin, and genitourinary tract to the development of 
disease processes including allergy and asthma.437
Increasing literature in animals and humans has implicated changes in the microbiome with 
the development of allergic disease.439,440 Mechanistically, a disruption in gastrointestinal 
bacteria is thought to alter mucosal immunological tolerance.441 Several authors have found 
associations of reduced gut microbial diversity with development of allergic disease in 
school-aged children.442,443 For example, the development of allergic symptoms in children 
has been associated with overall lower microbial diversity, increased prevalence of 
Bacteroides and Bifidobacterium adolescentis, and lower counts of Akkermansia 
muciniphilia, Faecalibacterium prausnitzii, and Clostridium.444 In addition, Fujimura et al.
445 recently noted that a lower abundance of Bifidobacterium, Akkermansia, and 
Faecalibacterium were associated with a higher risk of development of polysensitization by 
age 2 years and physician-diagnosed asthma by age 4 years. The authors concluded that 
neonatal intestinal microbial dysbiosis may foster CD4+ T-cell dysfunction associated with 
childhood allergic disease.445,446
Wise et al. Page 34













The most comprehensive collection of evidence evaluating a potential association between 
the microbiome and the development of allergic disease is from a recent systematic review 
by Melli et al.444 Studies included in this systematic review compared intestinal microbiota 
of allergic patients with healthy controls. A total of 21 studies were noted to report an 
association between the intestinal microbiota and allergic disease when stool collection was 
performed prior to the outcome assessments. Only 4 of the analyzed studies had specific 
outcomes related to AR or sensitization. Penders et al.447 found that the presence of 
Clostridium difficile at 1 month of age was associated with an increased risk for allergic 
sensitization (odds ratio [OR] 1.54; 95% confidence interval [CI], 1.09 to 2.31) until the age 
of 2 years. Adlerberth et al.448 noted an increased ratio of gram-negative to gram-positive 
bacteria at 1 year of age to be associated with IgE levels greater than 100 kU/L at 1.5 years 
of age. Bisgaard et al.449 found lower bacterial diversity was associated to higher risk of 
allergic sensitization (p = 0.003) and AR (p = 0.007). Johansson et al.450 reported lower 
frequency of colonization with Lactobacilli and Bifidobacterium bifidum in allergic 
children.15 Ultimately, Melli et al.444 found that most of the studies linking the microbiome 
to the development of atopic disease were varied and difficult to interpret due to differing 
methodologies, samples sizes, and culture techniques.
There are some thoughts that the composition and/or dysbiosis of the microbiota (viruses, 
fungi, and/or bacteria) of other sites such as the nasopharynx, lungs, and sinonasal cavities 
may also play a role in the development of allergic disorders. However, these studies are in 
their infancy and little can be concluded at this time.451
A thorough understanding of the role of the microbiome and how it influences allergic 
disease has not been fully elucidated. Although some data suggest associations between 
allergic disease and the microbiota, based on the current evidence it is difficult to distinguish 
between protective microorganisms and those that increase risk for allergic disease.446 
Future research should provide an enriched and diverse understanding of the human 
microbiome and the way it impacts AR.
V. Epidemiology of allergic rhinitis
V.A. Prevalence of allergic rhinitis in adults
A variety of population-based surveys have been used to estimate the prevalence of AR 
within the adult population. Prevalence estimates largely rely on self-reports of “hay fever” 
or “nasal allergies,” or of nasal symptoms “when you did not have a cold or the flu.” 
Questions on seasonality (to separate seasonal from perennial rhinitis) are sometimes asked, 
but there are few large-scale well-conducted population-based studies that have evaluated 
persistent (lasting more than 4 days/week for more than 4 consecutive weeks) vs intermittent 
symptoms. Because many surveys differ in terms of disease definitions, geography, and 
seasonality prevalence estimates drawn from surveys vary widely.
One of the earliest studies, conducted in Tecumseh, Michigan, in 1959–1960 included a 
physician assessment and suggested that the prevalence of hay fever (diagnosed as “upper 
respiratory symptoms believed to be allergic in origin and occurring predominantly in either 
spring, summer or autumn”) was about 11% in those aged over 20 years.452 About 20 years 
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later, the National Health and Nutrition Examination Survey (NHANES) 1976–1980 was 
conducted among a geographically representative sample of the U.S. population. This survey 
gave broadly similar estimates for prevalence of AR, defined as “physician diagnosis of hay 
fever or frequent nasal and/or eye symptoms that varied by both season and pollen during 
the last 12 months, not counting colds or the flu.”453 A more recent report based on 
NHANES (2005-2006), presented population prevalence figures in which two-thirds were 
over the age of 20 years, and showed the lifetime prevalence of physician-diagnosed hay 
fever was 11.3%, with 6.6% having symptoms in the last 12 months. However, reliance on 
physician diagnosis of AR is likely to considerably under-estimate the actual prevalence of 
AR, since many patients self-diagnose and self-treat. Surveys involving patient self-
reporting AR have shown that one-third of the population reported “sneezing and/or nasal 
symptoms in the absence of cold or a flu,” with about 24% reporting that this was seasonal 
in nature, and a further 10% reporting these symptoms occurred year-round (ie, perennial).
454
In the early 1990s, the European Community Respiratory Health Survey (ECRHS), a 
multicenter population-based study of adults age 20 to 44 years in 23 countries (mainly 
Western Europe, but also Australia and New Zealand), used a self-completed questionnaire 
to estimate the prevalence of “hay fever or nasal allergies.” Prevalence varied between 10% 
and 40% across participating centers,455 with even more participants (12-65%) reporting 
that they experienced a runny or stuffy nose or started to sneeze on exposure to sources of 
allergen.456 If a positive SPT was included in the disease definition, the prevalence of AR 
fell by a variable amount (absolute fall in prevalence between 4% and 16% across all 
centers). In the Swiss Study of Air Pollution and Lung Disease in Adults (SAPALDIA), 
conducted around the same time as the ECRHS, the prevalence of self-reported “nasal 
allergies including hay fever” in adults aged 18 to 60 years was 17.9%, and the prevalence of 
current symptoms (“hay fever this year or last year”) was 14.2%.457 Prevalence estimates 
were lower if a positive SPT was included (11.2% for current hay fever with at least 1 
positive SPT and 9.1% for current hay fever with positive SPT to 1 of grass, birch, or 
Parietaria). More recently, the Global Allergy and Asthma Network of Excellence 
(GA2LEN) study suggested the prevalence of “nasal allergies and hay fever” varied between 
22% and 41% in adults age 18 to 75 years living in the 12 participating European nations.458
Population-based studies have shown increases in AR prevalence in the adult population in 
recent decades. For example, in Renfrew Paisley, UK, the prevalence of hay fever was higher 
in adults and children in 1996 than in their mothers and fathers at an equivalent age in 
1972.459 Hay fever prevalence doubled between 1981 and 1990 in Busselton, Australia,460 
increased in Italy from 1991 to 2010,461 and increased in 8 of 11 cities in China surveyed in 
2005 and again in 2011.462 In Uppsala, Umea, and Goteborg, in Sweden, “hay fever and 
nasal allergies” increased from 21% to 31% between 1990 and 2008,463 although recent 
reports from Stockholm suggest there may be a leveling off in the increase in nasal allergies 
over more recent years.464
From these data, the lifetime prevalence of AR in the United States can be estimated 
between 11% (physician-diagnosed) and approximately 33% (self-reported). In Europe, 
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prevalence of AR in adults likely ranges between 10% and 41%, depending on the specific 
country.
V.B. Incidence and prevalence of allergic rhinitis in children
There are relatively few studies on the incidence of AR in children. There is evidence that 
AR may start as early as during the first year of life. In the Cincinnati Childhood Allergen 
and Air Pollution Study (CCAAPS), 9% of the 12-month-old children with a parental 
history of respiratory allergy fulfilled the criteria of AR.465 In the Pollution and Asthma 
Risk: an Infant Study (PARIS) birth cohort, 9.1% of the 18-month-old children had AR-like 
symptoms with a strong association with atopy and sensitization to inhalant allergens. Of 
these, 23.7% had rhinoconjunctivitis.466 In a study of 29,662 children from the United States 
that used health care records to follow participants, the incidence of physician-diagnosed AR 
during the first year of life was 1%. From 1 to 5 years of age, the annual incidence was 
between 3.6% and 4.5%, with the highest incidence between 2 and 3 years of age.467 This is 
broadly in line with estimates of a SAR incidence of 3% to 4% per year from 3 to 7 years of 
age reported in a birth cohort of 1314 German children.468
In longitudinal studies, AR often occurs for the first time in childhood and increases in 
prevalence with increasing age.467-471 Most children with symptoms of AR early in life have 
persistent symptoms for several years.469-471 The International Study of Asthma and 
Allergies in Childhood (ISAAC) estimated the prevalence of allergic diseases in 2 different 
age groups, 6 to 7 years and 13 to 14 years, through a multicenter global survey. Two cross-
sectional surveys were performed approximately 7 years apart (range, 5 to 10 years). 
Overall, an increase in rhinoconjunctivitis prevalence was observed between the 2 surveys.10 
However, there were geographical differences in both baseline prevalence and in the 
increases observed; therefore, it is difficult to determine whether the observed differences 
represented a true increase in prevalence over time. The proportion of children with 
symptoms of rhinoconjunctivitis was higher in the older age group. Data from the second 
survey (ISAAC Phase Three 1999–2004) state that the worldwide prevalence of current 
rhinoconjunctivitis in the 6-year to 7-year-old age group was 8.3% (range between countries, 
1.8% to 24.2%) and in the 13-year to 14-year age group was 15.1% (range, 4.5% to 45.1%).
472 In a more recent meta-analysis of all studies performed according to the ISAAC-protocol 
(1,430,329 children aged 0 to 18 years), the overall prevalence of AR was 12.66%.473
Rhinoconjunctivitis has been reported to be slightly more common among boys than girls in 
the 6-year to 7-year-old age group, with the opposite tendency seen in the 13-year to 14-
year-old age group.474 However, gender differences were not seen in all countries in the 
survey. Other studies show a greater prevalence of AR among boys of all ages. For example, 
in the Isle of Wight (UK) birth cohort of 1456 children, the prevalence of rhinitis among 
boys as compared to girls was higher across all age groups (4 years 4.7% vs 2.1%, 10 years 
14.9% vs 11.7%, 18 years 31.0% vs 24.0%).469
V.C. Geographic variation of allergic rhinitis
The prevalence of AR shows marked geographic variation. Many factors likely contribute to 
this disparity and not all are completely understood. The central difficulty in meaningfully 
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comparing AR prevalence rates between locations is the difference in methods used to 
recruit participants to studies and differences in assessing the presence of disease. For 
example, Bauchau and Durham9 diagnosed Belgian patients via serological IgE testing after 
a positive telephone screen and reported that Belgium had an AR prevalence of 28.5% (the 
highest of the European countries evaluated). In contrast, Bousquet et al.456 skin-tested a 
random sample of Belgian subjects and reported a positive rate in Belgium of 16.4% (one of 
the lowest of 15 countries examined).
There have been major international efforts to compare variations in the national prevalence 
of AR using standardized methods (ie, ECRHS and ISAAC). These studies show marked 
geographic variation of “hay fever or nasal allergies” (adults) or “a problem with sneezing, 
or a runny, or a blocked nose when you DID NOT have a cold or the flu that was 
accompanied by itchy-watery eyes?” (children). A higher prevalence of these responses is 
seen in people living in “English-speaking” countries (eg, UK, Australia, New Zealand), a 
lower prevalence in Eastern Europe than in Western Europe, and a diagnosis of AR is more 
frequently seen in countries with higher asthma rates and sensitization to seasonal allergens.
455,475 Because these studies have evaluated national rates based on only one or a few 
centers within each country, substantial intracountry variation may have been overlooked.
In understanding the effects of geographic location, differentiating between seasonal and 
perennial AR is an important consideration not examined in the ECRHS or ISAAC studies. 
Smaller studies over more limited geographic regions that examined PAR suggest increased 
sensitivity rates in urban settings and colder climates.476-479 Several hypotheses have been 
put forward for these observed differences. Li et al.477 theorized that urban dwellers 
participate in more indoor activities compared to their rural counterparts, amplifying their 
exposure to HDM, and possibly leading to increased sensitization to these perennial 
allergens. Additionally, some reports suggest that exposure to urban pollutants may be 
associated with increased risk for developing AR in children.476 Latitude may also play a 
role with regard to PAR. For example, the prevalence of persistent AR was found to be 
higher in both Northern Europe and Northern China compared to their southern 
counterparts.9,477
Latitude may also be an important determinant of SAR. Allergenic plant species may have a 
propensity for growing in certain geographic locations, and pollen concentrations of various 
species depend on the climate conditions of the area. Colder climates present at northern 
latitudes tend toward shorter growing seasons, and many allergenic species do not thrive in 
extreme northern climates. For instance, grass pollen, which is found across Europe, causes 
wide variations in atopic sensitizations across regions with different climates.480 
Additionally, this increased environmental exposure has been shown to affect development 
of AR and patient symptoms of atopic nasal diseases.481,482
Overall, improved knowledge of the prevalence and seasonal variations in AR based on 
geographic location is important in that it allows patients to anticipate and better manage 
their symptoms through avoidance techniques and preemptive use of pharmacologic 
therapies.480,482 Currently, prevalence data do not fully address the different phenotypes of 
AR and further study is needed to expand epidemiologic understanding of this disease.
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VI. Risk factors for allergic rhinitis
VI.A. Genetics
AR is well-known to run in families, and 1 of the strongest risk factors is the presence of 
disease in first-degree family members.483 Studies of twins support the genetic 
underpinnings of AR with a higher concordance rates for AR in monozygotic twins 
compared to dizygotic twins.484,485 The estimated heritability of AR has been suggested to 
be as high as 70% to 80%. Like many complex diseases, no single gene or polymorphism 
accounts for the hereditary effect on AR. Instead, many genes and several variants, each with 
small effects, are believed to contribute to disease initiation, persistence, and severity. In this 
section, the current literature on the genetics of AR is reviewed, including candidate gene 
studies and recent large-scale genome-wide association studies (GWASs). In addition, gene-
environment interaction effects and epigenetics studies are briefly covered.
Single-nucleotide polymorphisms associated with AR
GWASs.: GWASs with an unbiased approach that include hundreds of thousands of 
common gene variants, or single-nucleotide polymorphisms (SNPs), have successfully 
identified important variants for complex diseases over the past decade. Five GWASs on AR 
(or hay fever) have been published as of September 2016, as summarized in Table VI.A. 
SNPs in leucine-rich repeat-containing protein 32 (LRRC32) have been strongly associated 
with AR in 3 of the GWASs,486-488 and with asthma,487,489 eczema,488,490 and other 
allergy-related comorbidities.486,489,491 At the protein level, LRRC32 is known to regulate 
T-cell proliferation, cytokine secretion, and TGF-β activation.492 These associations suggest 
shared genetic mechanisms for AR and other allergy-related diseases, evidence further 
supported by the large-scale GWAS on self-reported cat, HDM, and pollen allergies (as well 
as AR), which revealed 16 shared susceptibility loci with strong association (p < 5 × 10−8; 
TLR-locus top hit).487 In an accompanying GWAS on allergic sensitization, there was strong 
overlap between top hits for sensitization and self-reported allergies.487,493 In the GWAS by 
Ferreira et al.,489 11 variants were associated with the combined asthma phenotype and hay 
fever below the genome-wide significance level (HLA-DQB1 top hit). TLRs play a crucial 
role in immune regulation and SNPs in different TLRs have been associated with AR in both 
GWASs (TLR1, TLR6, TLR10)486,487 and candidate gene studies (TLR8), as discussed in 
the next paragraph.494 In addition to shared genetic effects between different allergy-related 
diseases, a significant overlap between susceptibility loci for allergy and autoimmune 
diseases has been observed.495
Candidate gene studies.—The candidate gene approach for selecting disease-relevant 
genes is based on previous associations reported from GWAS or biological features which 
could be relevant for disease risk. Studies on AR using this approach have found several 
well-replicated genes as summarized previously.496-498 Notably, SNPs in genes involved in 
antigen presentation (for example HLA-DQA1), pathogen recognition (TLR2, TLR7, 
TLR8), IL signaling and proinflammation (IL13, IL18, and TSLP) are considered important 
susceptibility variants for AR.496-502 Recently, functional evidence in blood immune cells 
for genetic variants in brain-derived neurotrophic factor (BDNF), a secretory 
proinflammatory protein implicated in AR pathogenesis, was reported.503 However, many of 
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the candidate genes reported in the literature have not been well-replicated across studies 
and populations.427,504 This could be due to inadequate statistical power related to small 
sample sizes, inconsistent phenotype definition, or lack of true disease association. 
Additionally, rare variant studies focusing on candidate genes have not been particularly 
successful.494 The candidate gene approach is particularly necessary for hypothesis-driven 
analyses and functional genetic analyses, for example in populations with specific 
environmental exposures or with mixed ethnic backgrounds.
Gene-environment interactions and epigenetic effects—Epigenetic mechanisms, 
defined as changes in phenotype or gene expression caused by mechanisms (eg, 
methylation) other than changes in the underlying DNA sequence, have been proposed to 
constitute a link between genetic and environmental factors. Recent studies show that DNA 
methylation in children is very strongly influenced by well-known risk factors for allergic 
diseases such as maternal smoking during pregnancy505 and air pollution exposure.506 
Currently, however, it is not known if these methylation changes are causally related to the 
development of AR and asthma, or if these “biomarkers” are solely markers of exposure. 
Several studies have convincingly linked methylation profiles to AR507-509 and IgE-related 
outcomes,510,511 but large-scale studies have yet to be completed.
In summary, a family history of AR remains a risk factor for disease development, and 
strong associations have been identified with genes involved in T-cell activation (eg, 
LRRC32) and innate immunity (eg, TLRs). Shared genetic mechanisms for AR and other 
allergy-related diseases have been very clearly identified in recent large-scale studies. There 
is, however, a need to functionally characterize variants in these candidate genes to 
understand mechanisms underlying the pathogenesis of AR. With increasing evidence for 
the role of epigenetics in AR, future research should also focus on investigating epigenetic 
mechanisms, thereby providing a functional explanation for the link between environmental 
exposures, genetic variants, and disease development.
• Aggregate Grade of Evidence: C (Level 2a: 5 GWASs. Candidate gene studies 
not assessed regarding grade of evidence).
VI.B. Inhalant allergens (in utero and early childhood exposure)
AR is characterized by a loss of immunological and clinical tolerance toward a specific 
allergen. This involves production of sIgE which initiates allergic inflammation following 
allergen exposure. Therefore, sIgE is a hallmark of allergy and its production defines 
sensitization. Sensitization is a complex phenomenon, regulated by genetic and 
environmental factors, requiring a primitive exposure to a specific allergen. If a subject is 
never exposed to an allergen, sensitization to that allergen cannot occur. On the other hand, it 
is fundamental to distinguish between sensitization and allergy. Allergy, which involves the 
development of symptoms after the sensitizing exposure, is different from mere 
sensitization. Without sensitization allergy cannot exist, but not vice versa. In this section, 
the in utero and early childhood exposure to inhalant allergens, including mites, pollens, 
animal dander, and fungal allergens, will be evaluated as risk factor the development of AR.
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Mites—There are 6 studies on the topic of early mite exposure and the development of AR 
(Table VI.B-1). Most of the studies failed to demonstrate an association between early 
exposure to mites and the development of AR.468,516-519 Marinho et al.520 reported that 
early exposure to HDM is not a protective factor for current AR, and Kim et al.521 proposed 
exposure to spider mites as a risk factor for AR. Interestingly, pets may be a relevant source 
of mites, as their fur is often settled by mites; this association may confound AR evaluation 
and treatment. Ultimately, the studies on early mite exposure and the development of AR are 
conflicting and additional research is needed.
• Aggregate Grade of Evidence: C (Level 2b: 5 studies; Level 3b: 1 study; Table 
VI.B-1).
Pollens—There are only 2 studies that addressed the impact of early pollen exposure on 
AR (Table VI.B-2). Kihlström et al.519 reported no association to allergic rhinoconjunctivitis 
whereas Erbas et al.481 showed that pollen exposure during infancy is a risk factor for hay 
fever.
• Aggregate Grade of Evidence: C (Level 2b: 1 study; Level 3b: 1 study; Table 
VI.B-2).
Animal dander—Numerous studies have evaluated the association between early exposure 
to animal dander and subsequent development of AR, with conflicting results (Table 
VI.B-3). Studies are divided according to the findings: positive studies (reporting a 
protective effect on AR development522-535), negative studies, (showing that early exposure 
to pets represents a risk factor for AR523,536-542), and neutral studies (reporting that early 
exposure to animal dander is not associated with 
AR468,517,518,520,524,528,530,532,536,538,539,543-554). Additional factors should be considered: 
pet age, gender, and species; number of household pets; home characteristics; atopic 
predisposition of the pet owners; and others. Considering these complex variables, debate 
regarding the influence of early pet exposure on developing allergic disease remains 
unresolved. Thus, evidence-based guidelines regarding having pets at home cannot be 
established. (See section VI.G.2. Risk factors for allergic rhinitis – Protective factors against 
allergic rhinitis – Childhood exposure to pets for additional information on this topic.)
• Aggregate Grade of Evidence: C (Level 2b: 15 studies; Level 3b: 24 studies; 
Table VI.B-3).
Fungal allergens—Several studies have explored the role of early exposure to fungal 
allergens as a predisposing factor for AR (Table VI.B-4). Most studies demonstrated 
evidence that early exposure to fungal allergens represents a risk factor for AR development.
527,538,551,553,555-560 However, 3 studies demonstrated that early exposure to fungal 
allergens is not associated with AR.465,542,557 Home moisture level, which is closely and 
positively associated with the presence of fungal allergens in the home, may be a 
confounding factor in interpreting the evidence on fungal exposure and AR. Ambient 
humidity may an intrinsic risk factor, but high moisture is also associated with increased 
level of mites, as mites grow in presence of elevated moisture. Moisture can be easily 
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assessed both by direct measurement with a hygrometer and indirectly by observing the 
presence of mold spots on the walls.
• Aggregate Grade of Evidence: C (Level 2b: 3 studies; Level 3b: 10 studies; Table 
VI.B-4).
In summary, the clinical relevance of early inhalant allergen exposure to AR development is 
still debated. Despite several indepth reviews and a growing body of literature,561-563 no 
definitive and consensus may be drawn regarding risk-benefit of early inhalant allergen 
exposure, and further research is welcomed to address the unmet needs on this issue.
VI.C. Food allergens (in utero and early childhood exposure)
In some studies, early sensitization to food allergens has been linked to the development of 
AR in childhood.468,564,565 A meta-analyses by Alduraywish et al.564 demonstrated that 
food sensitization in the first 2 years of life was associated with an increased risk of AR 
during childhood (OR = 3.0; 95% CI, 2.1 to 4.2) (Table VI.C). The relationship between 
sensitization to food allergens and the subsequent development of AR during childhood has 
been investigated in both population-based and high-risk cohorts.468,565-568 While there is a 
statistically significant correlation in the high-risk cohort,567 there are mixed results in the 
population-based studies.566,568,569 These findings prompted prospective investigation of the 
effects of allergen avoidance in utero and during early childhood.
In an RCT evaluating the effects of in utero exposure to food antigens and the development 
of AR, 162 high-risk pregnant women (history of respiratory allergy to animal danders 
and/or pollens) were randomized 1 of 2 diets during the last 3 months of pregnancy: either 
very low ingestion of hen’s egg and cow’s milk, or a daily ingestion of 1 hen’s egg and 1 
[liter] of cow’s milk. A total of 163 infants were followed prospectively up to 18 months of 
age, at which time the incidence of atopic disease, including AR, was evaluated in a blinded 
fashion. There was no significant difference in the incidence of AR between the 2 groups.570 
In another RCT, restricted diet during pregnancy (cow’s milk-free and egg-free diet from 
week 28 to delivery) was associated with a small but statistically significant lower mean 
gestational weight gain and did not protect the offspring from atopy.571 The pooled results of 
2 trials suggest that maternal food antigen avoidance may be associated with a higher risk of 
preterm birth and a possible adverse effect on mean birth weight without beneficial effects 
on AR development in the children.570,571
Studies have also evaluated the early introduction of foods compared to food avoidance with 
respect to the effects on development of allergic disease. In a prospective birth cohort study 
of 2073 children, delayed introduction of solids (past 4 or 6 months of age) was not 
associated with decreased odds for AR, asthma, or sensitization against food or inhalant 
allergens at 6 years of age. In fact, food sensitization occurred more frequently in children 
who were introduced to solids later.572 In a prospective RCT of food allergen avoidance in 
infancy, the incidence of subsequent allergic disease, including AR, was assessed. The 
intervention arm of the trial required mothers to avoid cow’s milk, egg, and peanut during 
the last trimester of pregnancy and subsequent lactation, and required infants to avoid cow’s 
milk until age 1 year (casein hydrolysate supplementation before age 1), egg until age 2 
years, and peanut and fish until age 3 years. Compared to maternal-infant control pairs who 
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followed standard feeding practices, infants in the food-avoidance arm showed a significant 
reduction in rates food allergy and milk sensitization before age 2 years. However, by the 
age of 7 years, the prevalence of food allergy was no longer different between the 2 groups. 
Furthermore, there was no difference in rates of AR, AD, asthma, and other atopic disease at 
age 7 years.573
Based on the presented meta-analysis, prospective randomized studies, and a large 
prospective birth cohort study, there is no data to support maternal diet as a contributing 
factor for the development of food allergy and AR; however, there is some evidence that the 
presence of food allergy during childhood (greater than 2 years old) is a risk factor for AR.
• Aggregate Grade of Evidence: A (Level 1b: 3 studies; Level 2a: 1 study; Level 
2b: 1 study; Table VI.C).
VI.D. Pollution
The relationship between pollution and AR has received increasing attention over the past 
decade. Environmental air pollutants contain several compounds; however, most studies 
have primarily focused on particulate matter <10 μm (PM10), particulate matter <2.5 μm 
(PM2.5), nitrogen dioxide (NO2), sulfur dioxide (SO2), carbon monoxide (CO), and ozone 
(O3). These particles may potentiate atopy through multiple mechanisms, including injuring 
the nasal epithelium, altering the immune response, and increasing the allergenicity of 
certain antigens.574,575 For example, pollution may damage the nasal mucosa and impair 
MCC, thereby facilitating the access of inhaled allergens to cells of the immune system.576 
Additionally, airborne particles, including diesel fuel exhaust, are also able to carry 
allergens, thus potentially increasing the spread of allergens or the duration of their 
exposure.574 In nasal provocation studies of HDM-sensitive individuals, a combined nasal 
challenge with HDM allergens and diesel exhaust particles led to enhanced mast cell 
degranulation and increased severity of rhinitis symptoms compared to a challenge with 
HDM alone.577
Numerous studies have examined the effects of air pollutants on the development of AR in 
both pediatric and adult patients (Table VI.D). However, 3 prospective cohort studies (the 
highest level of evidence identified for this topic) found no significant correlation.578-580 
Codispoti et al.578 specifically looked at the relationship between exposure to diesel exhaust 
particles (DEP) at 1 year of age and the subsequent development of AR at 2, 3, and 4 years 
of age. While they found that DEP had a marginally positive association with aeroallergen 
sensitization at 2 and 3 years, and increased aeroallergen sensitization increased the risk of 
AR, they failed to identify a significant direct correlation between DEP and AR 
development. Additionally, Kim et al.579 evaluated exposure to NO2, SO2, CO, and PM10 in 
children and found no significant association with a new diagnosis of AR after 2 years. 
However, they did note a positive association between increased levels of O3 and an AR 
diagnosis in industrial areas only; O3 was also significantly associated with the development 
of new sensitizations to outdoor allergens, which may explain the mechanism for the related 
increase in AR prevalence. Finally, Gehring et al.580 pooled 4 prospective pediatric birth 
cohort studies with 14 to 16 year follow-up and found no indication that NO2, PM2.5, or 
PM10 levels influenced the development of rhinoconjunctivitis.
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Several international case-control and cross-sectional studies have also evaluated the 
relationship between pollution and AR with varied results. Anderson et al.581 performed the 
largest cross-sectional study evaluating the effect of PM10 levels on the development of 
rhinoconjunctivitis in 322,529 children from 51 countries. There was no between-country 
association of rhinitis with modeled pollution levels, and within countries (24 countries had 
more than 1 study center) there were weakly positive associations between PM10 levels and 
rhinoconjunctivitis symptoms in 6-year-olds to 7-year-olds and diagnosed hay fever in 13-
year-olds to 14-year-olds. Interestingly, they did show a positive association between high 
PM10 levels and the development of atopy.581 Some pediatric studies have identified a 
positive correlation between increased exposure to various pollutants and an increased 
diagnosis of AR during childhood.476,557,582-589 Liu et al.586 and Deng et al.557 even found 
that prenatal/gestational exposure to high concentrations of NO2 were associated with a 
higher prevalence of AR diagnosis during childhood. However, almost all of these studies 
utilize nearby traffic density or home address geocodes to estimate local pollution exposure. 
In many countries, people living in more polluted areas with high levels of traffic may also 
be more likely to have other confounding features that influence their development of AR 
(ie, socioeconomic status [SES], exposure to different aeroallergens) and not all studies fully 
adjust for these potential confounders. Additionally, several of these studies were restricted 
to specific cities in Asia, in turn, limiting generalizability.
Overall, the relationship between pollution exposure and the development AR is currently 
unclear. More prospective pediatric and adult studies in diverse geographic locations are 
needed to better understand this complex relationship.
• Aggregate Grade of Evidence: C (Level 2b: 3 studies; Level 3b: 2 studies; Level 
4: 9 studies; Table VI.D).
VI.E. Tobacco smoke
AR has frequently been associated with both active and passive (secondhand) exposure to 
tobacco smoke. However, the pathophysiology behind this relationship is complex and, at 
times, contradictory. Studies have shown that tobacco smoke exposure can propagate the 
development of atopic diseases via several mechanisms including direct surface damage to 
nasal mucosa, altered epigenetic mechanisms through histone acetylation, expression of 
microRNA, and DNA methylation.590,591 Alternatively, it has also been shown that nicotine 
may exert an immunosuppressive effect on allergic disease by suppressing eosinophil 
trafficking and Th2 cytokine/chemokine responses.592
Recently, 2 large meta-analyses were published which sought to better define the 
relationship between tobacco and AR (Table VI.E). Saulyte et al.593 identified a significant 
correlation between passive smoke exposure and the development of AR, but no significant 
relationship between active smoking or maternal prenatal passive smoke exposure and AR. 
However, they did find a significant correlation between active smoking and non-allergic/
chronic rhinitis. Hur et al.594 also systematically evaluated the relationship between 
secondhand smoke and AR and that meta-analysis of studies in adults showed an association 
between passive smoke and AR, while a similar analysis of pediatric studies did not. This 
raises the possibility that the atopic effects of secondhand smoke in the nasal mucosa may 
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take several years to manifest. In fact, Lin et al.595 found that allergic adults were more 
likely to have been exposed to secondhand smoke 20 years prior when compared to non-
allergic adults.
Five prospective cohort studies examined the effect of tobacco on the development of AR, 
all of which failed to find a correlation between active or passive tobacco smoke and the 
development of AR.596-600 Keil et al.596 found that while passive smoke was not 
significantly related to AR, it was strongly associated with allergic sensitization and asthma 
symptoms in children with a genetic predisposition (at least 1 or more atopic parents). 
Additionally, Wright et al.597 found that while there was no significant association between 
secondhand smoke exposure and AR, 63% of asthmatics born to heavy smokers developed 
rhinitis in the first 6 months, vs 43% of asthmatics whose mothers did not smoke. Finally, 
Bendtsen et al.598 found that actively smoking more than 15 cigarettes per day actually 
decreased a patient’s risk of developing AR.
This inverse correlation has been identified in several other studies.124,601-603 Eriksson et al.
124 found that while smoking was associated with a high prevalence of chronic rhinitis in 
both men and women, it was correlated with a low prevalence of AR in men. Additionally, 
they found a significantly lower prevalence of sensitization to common airborne allergens in 
current and exsmokers compared to nonsmokers. In contrast, the significant positive 
association between tobacco and the development of non-allergic/chronic rhinitis has been 
repeatedly identified.124,128,604 Therefore, when discussing the effects of tobacco on rhinitis, 
differentiating between allergic and non-allergic/chronic is paramount.
Finally, tobacco does not appear to influence the efficacy of AR treatment. Katotomichelakis 
et al.605 evaluated 163 patients (both smokers and nonsmokers) receiving sublingual 
immunotherapy (SLIT) for AR and found that, regardless of tobacco status, total symptom 
scores and QOL questionnaires equally improved. Overall, while most studies evaluating 
AR and tobacco are case-control or cross-sectional in nature, multiple prospective cohort 
studies and 2 systematic reviews predominantly found no correlation between active or 
passive tobacco smoke and AR. Additionally, some studies suggest that tobacco may have a 
protective effect against the development of AR. Further investigation is needed to identify if 
specific patient populations (eg, asthmatics or those with atopic parents) or temporal 
variations (eg, exposure for 20+ years) may alter our understanding of this relationship.
• Aggregate Grade of Evidence: C (Level 2a: 1 study; Level 2b: 5 studies; Level 
3a: 1 study; Table VI.E).
VI.F. Socioeconomic factors
In 1829, John Bostock described 29 cases in the UK, including himself, of individuals who 
suffered from catarrhus aestivus or “summer cold,” which he noted occurred in patients of 
middle to high SES.606 During the 1870s, Blackley found no hay fever among farmers and 
people living in deprived areas of cities.606 The positive association between hay fever and 
high social class was later reported in the British 1958 and 1970 cohorts,607,608 as well as a 
Swedish survey of conscripts born from 1952 to 1977.609 However, during the study period, 
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this association seemed to weaken with an OR estimate for AR among subjects with low 
SES changing from 0.79 to 0.92.
In 2000, an article was published from the German Multicentre Allergy Study (MAS) birth 
cohort including 1314 children born in 1990.610 In this study, it was found that the lifetime 
prevalence of hay fever was elevated in parents of high SES compared to low. However, in 
their children, the occurrence of hay fever was not elevated in families with high SES. 
Alternatively, in the Swedish birth cohort BAMSE (Swedish abbreviation for Children 
Allergy, Milieu, Stockholm, Epidemiology) with 4089 children born between 1994 and 
1996, it was noted that high SES actually resulted in a decreased risk of AR, along with 
decreases in asthma and food sensitization rates.611 In a recent study from Denmark of 9720 
children born between 1994 and 2006, AR was associated with low educational level of the 
parents.612 Interestingly, in the follow-up of the German MAS birth cohort study, SES was 
not associated with AR at all by the age of 20 years.613 Thus, among children born in the 
Western world before 1970 high SES was a risk factor, but among children born in the same 
regions after 1990 low SES, particularly early in life, seemed to be a risk factor614 (Table 
VI.F).
More recently, 2 studies from Korea have reconfirmed the previously noted association 
between high SES and the development of AR. Ahn et al.478 found a positive association 
between higher family income and symptom-based AR diagnosis (but not allergy test-based 
AR diagnosis). Lee et al.615 also found family affluence, or high SES, to be a significant risk 
factor for AR in Korean adolescents. However, additional recent studies from South America 
and Europe have shown varying results. In 2016, Penaranda et al.616 found high SES to be 
associated with AR in children/adolescents but not in adults, while Wronka et al.617 
identified a significantly higher incidence of AR in adult female university students (19 to 25 
years old) from families with high SES.
Overall, SES is likely a proxy for various exposures like number of siblings, viral infections, 
exposure to tobacco smoke, housing conditions and location, allergen exposures, dietary 
factors, and nutrition including breastfeeding and general diet. Some of those exposures are 
associated with the hygiene hypothesis, introduced by Strachan618 in the late 1980s. 
However, it is worth noting that exposures relevant to the hygiene hypothesis were important 
predictors for the development of AR at an early age.614
Currently, there is conflicting evidence regarding the association between SES and AR. 
While most studies show an association between high SES and the diagnosis of AR, this is 
not a consistent outcome. This disparity may be explained by the additional factors evaluated 
in several of these studies which may confound the exact relationship between SES and AR. 
Additionally, there may be a temporal relationship between SES and AR considering 
different outcomes in children compared to adults. Additional investigation is needed to 
determine the true relationship between AR and SES.
• Aggregate Grade of Evidence: C (Level 2b: 4 studies; Level 4: 6 studies; Table 
VI.F).
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VI.G. Protective factors against allergic rhinitis VI.G.1. Breastfeeding
Breastfeeding is associated with several beneficial effects on mother and child health and 
therefore has been recommended for all infants.619 One potential benefit is the prevention of 
allergic disease.620 Breast milk is an immunologically complex solution, containing multiple 
compounds that support infant growth and facilitate development of the infant immune 
response.621,622 The association between breastfeeding and the prevention of allergic disease 
has been frequently studied and often debated.
Mimouni Bloch et al.623 performed a meta-analysis of prospective studies evaluating the 
effects of exclusive breastfeeding for the first 3 months of life on the development of AR 
(Table VI.G.1). Six prospective studies met the inclusion criteria. In their pooled analysis, 
they found a protective effect of exclusive breastfeeding for the first 3 months of life that 
approached statistical significance in the general population (OR 0.74; 95% CI, 0.54 to 
1.01). Interestingly, the protective effect was not seen in children with a family history of 
atopic disease (OR 0.87; 95% CI, 0.48 to 1.58).
More recently, Lodge et al.624 performed a systematic review and meta-analysis in 2015. 
Their analysis evaluated the association between breastfeeding and AR and included 5 
cohort studies550,599,607,625,626 and 11 cross-sectional studies.627-637 The number of 
participants varied between 361 and 13,889 for the cohorts, and 1402 to 206,453 for the 
cross-sectional studies. Pooling of estimates from the various studies found a nonsignificant 
protective effect of breastfeeding on the development of AR (OR 0.92; 95% CI, 0.84 to 
1.01). The results were then stratified by incidence of AR in different age groups. After 
stratification by age, a reduced risk of AR in patients under 5 years of age was associated 
with breastfeeding (OR 0.79; 95% CI, 0.63 to 0.98). However, there was no association after 
5 years of age (OR 1.05; 95% CI, 0.99 to 1.12). While the authors of this meta-analysis 
argued for the benefit of breastfeeding in the prevention of AR, they do acknowledge that 
the protective effect of breastfeeding seen in patients less than 5 years of age may have been 
confounded by known protective effects of breast milk against viral respiratory infections. 
The authors hypothesized that, given the difficulty of differentiating between AR and viral 
rhinitis in young children, a reduction in viral respiratory infections have been possibly 
interpreted as a reduction in rhinitis symptoms.624
• Aggregate Grade of Evidence: C (Level 3a: 2 studies; Table VI.G.1).
• Benefit: Possible benefit from breastfeeding with reduction in AR, especially 
seen in young children.
• Harm: None. No studies have shown harm with breast-feeding for 6 months.
• Cost: Low.
• Benefits-Harm Assessment: Possible benefit with no harm.
• Value Judgments: There is evidence that breastfeeding may reduce the risk of AR 
with no perceived harm. Given the general benefits to the mother and child, 
breast-feeding for 4 months and possibly 6 months has been advocated.
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• Policy Level: Option for breastfeeding for the specific purpose of AR prevention, 
based upon current evidence. In general, breastfeeding has been strongly 
recommended due to its multiple benefits.
• Intervention: Breastfeeding is generally encouraged for at least 4 months due to 
its multiple benefits. When specifically related to the prevention of AR, 
breastfeeding is an option.
VI.G.2. Childhood exposure to pets—Among subjects sensitized to pet allergens, 
exposure tends to exacerbate symptoms. However, the association of pet-keeping in 
childhood with the subsequent development of AR is more controversial, and difficult to 
establish. (See section VI.B. Risk factors for allergic rhinitis – Inhalant allergens (in utero 
and early childhood exposure) – Animal dander for additional information on this topic.)
Prevalence of household pet ownership is used to estimate pet allergen exposure. However, 
pet owners are frequently contaminated with pet allergens, leading to generalized exposures 
via social contact. Therefore, a non-exposed reference population does not exist, limiting our 
ability to clearly understand the relationship between exposure to pet allergens and 
development of AR.
The timing of pet allergen exposure early in life may be an important factor for the maturing 
immune system. Therefore, self-reported perinatal and newborn exposures are frequently 
analyzed. Few studies have measured the concentration of the major cat (Felis catus) 
allergen (Fel d 1) or the major dog (Canis familiaris) allergen (Can f 1) in home dust. Rather, 
most studies merely report exposure to cats and/or dogs, or furred pets, and some to rodents 
and birds. In a systemic review of epidemiologic studies of allergy and asthma, only 10 of 
96 included studies reported avoidance of pets.638 Additionally, studies may often fail to 
account for confounding variables such as a family history of pet allergy which, in turn, may 
predispose likely atopic children to pet avoidance.
There is significant inconsistency with regard to pet ownership in childhood and the 
subsequent development of allergy. Demographic features related to pet-keeping, including 
race, urban vs rural environment, family size, and SES may help account for some of the 
conflicting results. A meta-analysis of 32 studies reported a lower prevalence of AR among 
subjects with furred pets in cross-sectional studies, and less asthma among cat-exposed 
subjects.639 An extensive systematic review of 62 studies found different associations 
depending on study design.640 In most of the birth cohort studies, dog exposure in early 
childhood was protective for sensitization against aeroallergens.640,641 On the contrary, 
cross-sectional studies reported inconsistent associations between cat or dog exposure and 
sensitization as well as the subsequent development of atopic diseases later in life562,640 
(Table VI.G.2).
The impact of pet avoidance on AR development is best evaluated via longitudinal birth 
cohort studies. A systematic review of 9 studies conducted solely in urban environments 
evaluated perinatal pet exposure.642 Six studies found that exposure to dogs, or cats/dogs 
protected against allergic disease. Two studies found increased risk of allergy only in highly 
atopic families. Furthermore, in a cohort of 620 children with family history of allergic 
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diseases, exposure to cats or dogs was protective only in children with non-allergic fathers.
534
In a pooled analysis of 11 European birth cohorts, any furred pet ownership during the first 2 
years was associated with lower risk of sensitization to aeroallergens, but not with a 
decreased prevalence of AR later in childhood.552 In a recent study which investigated urban 
vs rural differences, the risk of AR in adulthood was 20% lower in subjects exposed to pets 
at birth or during childhood. However, pet keeping did not explain the protective effect of 
living on farm with livestock compared to urban dwelling.643
Overall, pet allergens are ubiquitous. There is no evidence that pet avoidance in childhood 
prevents the development of AR or sensitization to aeroallergens later in life. Alternatively, 
early pet exposure may induce immune tolerance and thus reduce the chance of development 
of allergic disease. This protective effect seems to be strongest in non-allergic families with 
dog exposure in early childhood.
• Aggregate Grade of Evidence: C (Level 2a: 6 studies; Level 2b: 2 studies; Table 
VI.G.2).
VI.G.3. Hygiene (aka biodiversity or microflora) hypothesis—The inverse 
association of the number of siblings and the prevalence of hay fever was reported nearly 3 
decades ago in British cohorts.618 Strachan618 proposed the term “hygiene hypothesis” and 
speculated that exposure to frequent infections in large families could be the protective 
factor. The hygiene hypothesis has evolved toward a more contemporary “biodiversity 
hypothesis” that looks beyond the effect of infections and single protective microbes to the 
potential protective effect of the colonization of mucous membranes and the skin with 
diverse environmental microflora.644 Recently, the term “microbiota hypothesis” has been 
proposed. In addition, the term “microflora” should be substituted for the term “microbiota.” 
Various related potential cofactors and their relationship to the development of AR are 
discussed in this section.
Number of siblings.: The association between number of siblings and presence of allergic 
diseases has been studied extensively. In a meta-analysis of 53 studies, 48 studies 
demonstrated that higher number of siblings was associated with decreased atopy, an effect 
that was more evident for AR than for sensitization and asthma645 (Table VI.G.3). A large 
study based on questionnaire data for children aged 6 to 7 years from 31 countries and 13 to 
14 years from 52 countries confirmed that the inverse association between the number of 
older siblings and prevalence of hay fever was strongest in more affluent countries.646
Farming.: Since the first publications in 1999–2000, there is a growing interest in the “farm 
effect” on allergy. In a meta-analysis of 8 studies, the risk of sensitization, measured by sIgE 
or SPT in childhood or adulthood, was 40% lower (OR 0.60; 95% CI, 0.52 to 0.70) among 
subjects who had lived on a farm during the first year of life.647 In a recent U.S. case-control 
study, farm exposure in utero and in early childhood protected against allergen sensitization 
but not asthma in adulthood.648 The protective farm effect seems to be stronger when 
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exposed to farm animals and stables.522,649-655 The protective effect is greatest with highest 
exposure occurring early in life.650
Bacterial endotoxin.: Exposure to bacterial endotoxin has been studied as a possible 
protective factor. Inverse association between exposure to endotoxin in infancy and 
childhood and the development of allergic sensitization has been shown in rural and urban 
environments, but the results have not been uniform between the studies.656,657
Probiotics.: A meta-analysis of 29 randomized controlled studies showed no significant 
association of probiotics supplementation of pregnant or breastfeeding mothers or infants 
with sensitization or allergic rhinitis at age 12 to 36 months.658 (See section IX.B.9. 
Management – Pharmacotherapy – Probiotics for additional information on this topic.)
Microbial diversity.: Changes in lifestyle, urbanization, diet, and the use of antibiotics have 
changed the microbiota of the environment, human skin and mucosal membranes. 
Differences in the microbiota may explain the difference in atopic diseases between rural 
and urban areas, as well as Finland and the Russian Karelia (a part of Russia geographically 
adjacent to Finland).659-661 Households with dogs have rich, diverse house dust microbiota 
with abundance of Firmicutes and Bacteroides species.662
In the GABRIEL study the mattress dust of farm children and their controls was analyzed by 
quantitative DNA analysis. Especially high mattress levels of Mycobacterium sp., 
Bifidobacteriaceae sp., and Clostridium sp. were found among farm children, and that high 
level was inversely associated with atopy.661
Low diversity of gut microbiota in early infancy has been related to greater risk of asthma 
and sensitization in some longitudinal studies with different designs in childhood.
442,445,449,663 The dysbiosis of the microbiome driven by higher Bacteroides and reduced 
Clostridia taxa in adulthood was associated with greater prevalence of seasonal and nut 
allergies in adulthood in the American Gut Project.664
Skin microbiota may also be associated with protection from atopy. Compared with healthy 
individuals, atopic individuals have shown to have lower environmental bio-diversity at 
home and significantly lower generic diversity of gammaproteobacteria on their skin.665 
Skin Acinetobacter (gammaproteobacteria) species were associated with anti-inflammatory 
immune responses only in healthy subjects.666
In summary, hygiene is important to prevent infections worldwide. Urbanization first in 
affluent and later in developing countries has led to reduced microbial diversity in the 
environment. Large microbial diversity of the skin, airways, and gut in childhood is 
important for the prevention of sensitization and of allergic disease in populations. More 
longitudinal studies are needed to show the association.
• Aggregate Grade of Evidence: B (Level 2a: 2 studies; Level 2b: 10 studies; Level 
3a: 2 studies; Level 3b: 1 study; Table VI.G.3).
• Studies included in the Aggregate Grade of Evidence are systematic reviews and 
meta-analyses for the various aspects of the hygiene hypothesis discussed above. 
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Also included are recent studies, published after the noted systematic reviews 
and meta-analyses. If systematic reviews and meta-analyses are not available, 
individual studies are listed.
VII. Disease burden
VII A. Individual burden
VII.A.1. Effect on quality of life—Two systematic reviews have evaluated the effect of 
AR on QOL, with both concluding that AR patients suffer from significantly decreased 
general and disease-specific QOL due to the impact of physical and mental health. 
Furthermore, both studies demonstrated that treatment of AR leads to improvement in 
QOL667,668 (Table VII.A.1). While the impact of AR on QOL has been suggested in the 
literature for decades, only recently has the effect of AR on QOL been rigorously studied. 
This is in part due to the development of validated general and disease-specific QOL 
instruments, and their use in clinical investigations and trials. The most commonly used 
general QOL instruments in the AR literature appear to be the Short Form 12 and 36 
(SF-12/36),669,670 which measure generic physical and mental health-related QOL. The 
most commonly used AR disease-specific QOL tool is the Rhinoconjunctivitis Quality of 
Life Questionnaire (RQLQ), or 1 of its variations (ie, mini-RQLQ, nocturnal RQLQ).671 
However, despite the availability of these instruments, many studies in the published 
literature rely upon nonvalidated methods to assess QOL, leading to difficulty comparing 
outcomes between some studies.
Several high-quality studies have evaluated the impact of AR on overall and disease-specific 
QOL (Table VII.A.1). Most level 1b evidence includes RCTs evaluating the effect of topical 
nasal corticosteroids,671-673 antihistamines,672,674-677 or AIT.678,679 The general consensus 
of these studies is that AR has a significant negative impact on general and disease-specific 
QOL, and that the successful treatment of AR by any of the aforementioned therapies leads 
to the improvement of symptoms and QOL. One RCT that examined monotherapy vs poly-
therapy showed that the combination of mometasone with either levocetirizine or 
montelukast led to greater symptom and QOL improvement than mometasone alone, but 
there was no difference between the levocetirizine and montelukast groups.672 Additionally, 
a RCT of acupuncture vs medical therapy showed that the improvement in QOL occurred in 
both groups, but the degree of improvement was larger in the acupuncture group.680
While the remaining evidence is of lower quality, it includes important and interesting 
findings in addition to the conclusions reached by the RCTs and systematic reviews. For 
example, extranasal symptoms, particularly ocular symptoms, have a significant impact on 
QOL and should not be ignored in the evaluation and management of AR.681-684 
Furthermore, the productivity, practical/activity, emotional, social, and memory function of 
patients appear to be significantly impacted by AR.685-689
No high-quality studies have explicitly attempted to establish variations of QOL in AR 
patients over time, and most have short follow-up periods or only a single follow-up. 
However, some observations regarding the natural variation in QOL in AR can be extracted 
from the placebo arms of level 1 studies. Two RCTs have studied the effect of levocetirizine 
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over 6 months.675,677 These RCTs show that over a 6-month period, both the placebo and 
treatment group experience clinically and statistically significantly improvements in generic 
and disease-specific QOL; however, the improvement is greater in the treatment arm. The 
AIT RCTs have longer follow-up periods (12 to 18 months) and show similar results, with 
placebo patients either staying at their baseline QOL impairment, or improving to a lesser 
degree than the treatment arms.678,679 As expected in patients with SAR, QOL is better 
outside of peak season and worsens during allergen exposure.690,691
• Aggregate Grade of Evidence: B (Level 1b: 11 studies; Level 2a: 2 studies; Level 
2b: 16 studies; Level 2c: 1 study; Level 3b: 3 studies; Table VII.A.1).
• Benefit: Successful management of AR leads to improved overall and disease-
specific QOL.
• Harm: Management strategies for AR are associated with variable levels of harm 
and are further specified in Section IX. Management.
• Cost: Management strategies for AR are associated with variable levels of cost 
and are further specified in Section IX. Management.
• Benefits-Harm Assessment: The benefits of treating patients with AR to improve 
QOL may outweigh risks of treatment.
• Value Judgments: Successful control of AR symptoms leads to important 
improvements in generic and disease specific QOL.
• Policy Level: Recommend treatment of AR to improve QOL.
• Intervention: AR patients may be offered various management strategies to 
improve general and disease-specific QOL.
VII.A.2. Effect on sleep—Like generic and disease-specific QOL, validated tools exist 
for the assessment of sleep-related QOL in AR, but they are not always utilized in studies 
reported in the AR literature. Some studies evaluating generic and disease-specific QOL 
suggest that AR negatively impacts patients’ sleep673,685,687 (Table VII.A.1). Several studies 
have specifically investigated the relationship between AR and sleep in adults and children 
(Table VII.A.2-1 and Table VII.A.2-2). The general conclusion from the aggregate data is 
that, like overall and rhinitis-specific QOL, AR negatively impacts sleep QOL and the 
successful treatment of AR reduces sleep disturbance. The overall quality of the data is 
higher for adults than for children. For the adult population, there is level 1b evidence 
supporting the conclusion that AR negatively impacts sleep.705-709 These data deal with 
subjective reporting of daytime sleepiness, sleep quality, and symptoms usually through 
validated tools, in the setting of testing the effect of nasal corticosteroids and/or montelukast. 
Results demonstrate that AR patients have improvements in sleep quality and daytime 
sleepiness, in addition to sinonasal symptoms and QOL after treatment with nasal 
corticosteroids705,706,709,710 or a combination of corticosteroids and montelukast.709 
Additionally AR has been associated with worse sleep fragmentation711,712 and snoring.
713,714 Treatment of AR has been also suggested to also improve continuous positive airway 
pressure (CPAP) compliance in patients with OSA.715 The data on the effects of AR on 
polysomnogram (PSG) parameters in adults is mixed. Most studies that included PSG 
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analysis found that AR is associated with worsened PSG parameters712,714,716-719; however, 
2 level 3b studies found either no difference or a modest change.720,721
Two studies looked at variations in sleep symptoms with changes in nasal inflammation over 
time. It seems that changes in nasal cytokine levels are associated with changes in PSG719 
and that AR patients have worse PSG parameters and sleep disturbance when their 
symptoms are present or during their peak allergen season.718 In children, level 2 and 3 
studies suggest that AR is associated with sleep disturbance in the form of increased risk of 
snoring, sleep disordered breathing, and OSA. Furthermore, AR has been suggested to be a 
risk factor for deterioration of OSA QOL after adenotonsillectomy.722 (See section X.K. 
Associated conditions – Sleep disturbance and obstructive sleep apnea for additional 
information on this topic.)
• Aggregate Grade of Evidence: B (Level 1b: 5 studies; Level 2b: 10 studies; Level 
2c: 3 studies; Level 3a: 1 study; Level 3b: 21 studies; Level 4: 6 studies; Tables 
VII.A.2-1 and VII.A.2-2).
• Benefit: Successful management of AR leads to decreased sleep disturbance.
• Harm: Management strategies for AR are associated with variable levels of harm 
and are further specified in Section IX. Management.
• Cost: Management strategies for AR are associated with variable levels of cost 
and are further specified in Section IX. Management.
• Benefits-Harm Assessment: The benefits of treating patients with AR for 
symptoms of sleep disturbance may outweigh risks of treatment.
• Value Judgments: Successful control of AR symptoms leads to improvements in 
sleep.
• Policy Level: Recommend treatment of AR to decrease sleep disturbance.
• Intervention: AR patients may be offered various management strategies to 
improve sleep.
VII.B. Societal burden
As described in Section VII.A.1, AR may have significant negative effects on QOL with 
considerable consequences if left untreated. For many years, AR has been trivialized despite 
its prevalence, chronicity, and the burden it imposes on individuals and society.101,681,753 
The total burden for AR lies not only in the impairment of physical and social functioning, 
but also in the financial burden, which is greater when its role in comorbid conditions such 
as asthma and rhinosinusitis are taken into account.754-756 In Europe, the total societal cost 
of AR and its comorbidities in 2002 was estimated at 355.06 Euros per patient per month.755 
The burden of AR is now being recognized by the European Academy of Allergy & Clinical 
Immunology (EAACI) and also at the European Union (EU) parliament level in order to 
feature the dramatic impact this condition has on the QOL of patients with AR.757,758
In terms of the overall economic burden of illness, AR ranks fifth among chronic conditions 
in the United States.759 Estimates of the annual direct cost of AR range from $2 billion to $5 
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billion, with more than one-half of the AR direct costs coming from prescription 
medications.760-762 The direct costs attributed to AR include physician office visits, 
laboratory tests, medications, and AIT.763 Compared with matched controls, patients with 
AR have an almost 2-fold increase in medication costs and a 1.8-fold increase in visits to a 
healthcare provider.756,764,765 Hidden direct costs include treatment of comorbid conditions 
that occur at an increased incidence in patients with AR.
Recently, the TOTALL (TOTal costs of ALLergic rhinitis in Sweden) study estimated the 
total cost of AR using a sample representing the entire Swedish working-age population. 
Data from this study suggested that patients with mild AR have less impact on the health 
economy, with costs averaging about 25% of the costs for those with moderate to severe 
disease.667,766 Patients with moderate to severe AR reported visiting their primary care 
provider for their AR more frequently than those with mild AR (1.61 vs 1.19 times per 
year).753
The indirect costs of AR, such as absenteeism and presenteeism, are also significant and 
actually make up the majority of the cost burden of AR.767,768 Impaired productivity and/or 
missed work occurred as a result of AR in 52% of patients.753 In a survey of over 8000 U.S. 
employees at 47 employer locations, 55% reported AR symptoms for an average of 52.5 
days per year. They reported missing 3.6 days of work per year because of AR and reported 
being unproductive 2.3 hours per workday when symptomatic. The mean total productivity 
losses (absenteeism and presenteeism) for AR were calculated at $593 per employee per 
year.769 In another UK study, patients with moderate to severe AR reported 37.7 days a year 
when their productivity was affected by their AR symptoms; this is almost double that 
reported by patients in the same study with mild AR symptoms (21.0 days).753
Health impairments associated with AR are often not severe enough to cause absenteeism, 
but they do interfere with cognitive functioning, resulting in fatigue and an impaired ability 
to learn, concentrate, and make decisions.770 In a study by Blanc et al.,771 more than one-
third of AR patients reported reduced workplace performance.
In the United States, AR results in 3.5 million lost workdays and 2 million lost school days 
annually.772 On any given school day in the United States, approximately 10,000 children 
are absent from school because of AR.773 This absence from school may also affect parents’ 
productivity or cause them to be absent from work themselves.
In a study by Hellgren et al.,774 the average productivity loss for all Swedish workers 
because of absenteeism, presenteeism, and caregiver absenteeism during a year was 5.1 
days, of which 2.3 days were accounted for by absenteeism and 2.0 days by presenteeism. If 
only those with children aged 0 to 7 years in their household were included in the analyses, 
the average number of days for caregiver absenteeism was 3.6 days. The cost of caregiver 
absenteeism comprised 19% of the mean total costs per year in this study. The cost related to 
caregiver absenteeism was highest for women aged 30 to 44 years.
AR is the most common chronic disorder in the pediatric population. AR can affect sleep, 
result in daytime sleepiness, and impair cognition and memory, which may significantly 
affect the learning process and impact school performance. Even when present during school 
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hours, children with AR exhibit decreased productivity. Comorbidities associated with AR, 
such as like rhinosinusitis, Eustachian tube dysfunction, and associated conductive hearing 
loss may further contribute to learning dysfunction.775,776
AR poses a substantial burden to individuals and society. It can reduce productivity and 
QOL in affected patients, and contribute to comorbid conditions. This results in a significant 
impact to the overall health system.773
VIII. Evaluation and diagnosis
In an individual patient, the clinical suspicion for a diagnosis of AR is highlighted by the 
clinical history and often supported by the physical examination. The diagnosis is confirmed 
by objective testing, which may be performed by various means. This section reviews the 
existing evidence behind various aspects of evaluation and diagnosis of the AR patient.
VIII.A. Clinical examination History
Clinical history is an essential part of the evaluation of patients with a suspected diagnosis of 
AR.7,26,218,761,777 History taking includes the type of symptoms experienced, timing and 
duration of symptoms, frequency of symptoms, any environmental exposures eliciting 
symptoms at home/work/school, and medications or other measures that relieve or 
exacerbate symptoms.7,26,218,761,777,778 In addition, past medical history including comorbid 
conditions such as asthma or obstructive sleep apnea, family history of atopic disorders, 
social history (ie, pets, work exposures, home environment), and current medications should 
be obtained.7,26,218,761,777,778 Information regarding patient response to self-treatment with 
over-the-counter medications for AR is also helpful.
Nasal congestion or obstruction, nasal pruritis, clear rhinorrhea, and sneezing are classic 
symptoms of AR.7,26,218,761,777,778 Patients may complain of associated symptoms of ocular 
pruritis, erythema, and/or tearing, oral cavity or pharyngeal pruritis, and wheezing or cough 
(reactive airway disease and/or asthma).7,26,778 Additional associated symptoms may 
include hyposmia or anosmia, snoring or sleep-disordered breathing, aural congestion or 
pruritis, and sore throat.778,779 Commonly, patients with suspected AR will present with 
multiple complaints, with 96% presenting with 2 or more symptoms.778 Patients with PAR 
tend to report more congestive symptoms (sinus pressure, nasal block-age/congestion, and 
snoring) than patients with SAR. Patients with persistent AR are more likely to report the 
presence of sore throat, cough, sneezing, rhinorrhea, and postnasal drip.778 Rhinorrhea, 
sneezing, sniffing, hyposmia/anosmia, nasal obstruction, and itchy nose rank highest for 
diagnostic utility among symptoms of AR.779
Several guidelines suggest the diagnosis of AR be made when patients present with a history 
consistent with an allergic cause and 1 or more of the symptoms listed in the previous 
paragraph, despite the lack of high-level evidence to support such a 
recommendation7,26,218,761,777,780 (Table VIII.A). However, the lack of higher level 
evidence is not surprising as a clinical history and physical examination is essential to any 
medical diagnosis and randomized studies would require participants to receive an 
intervention without a clinical history. Using a physical examination alone to diagnose AR 
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has been shown to have poor predictive value.781 The reliability and predictive value of the 
patient history alone for AR exceeds that of the physical exam alone.781 In clinical practice, 
the diagnosis of AR is often made by history alone.780
Physical examination—Physical examination is part of the evaluation of patients with 
suspected AR.7,26,218,761,777 This includes an assessment of the multiple organ systems of 
the head and neck, such as the integumentary system; external auditory canal, tympanic 
membrane, and middle ear; nasal cavities; orbits and periorbital tissues; oral cavity and 
pharynx; larynx via indirect laryngoscopy; and cervical tissues.26,218,761,777 It may include 
auscultation of the lungs, given comorbid conditions of asthma, or complaints of wheezing 
or coughing with exposure.7
It is not uncommon for physical examination of patients with AR complaints to be 
completely normal, particularly in patients with intermittent exposure.779 However, physical 
signs suggestive of AR may include mouth-breathing, nasal itching, or a transverse supratip 
nasal crease, throat clearing, periorbital edema, or “allergic shiners” (dark discoloration of 
the lower lids and periorbital area).26,777 Examination of the ear may reveal retraction of the 
tympanic membrane or transudative fluid.26,218,777 Examination of the nose may reveal 
inferior turbinate hypertrophy, congested/edematous nasal mucosa, purplish or bluish nasal 
mucosa, and clear rhinorrhea.26,218,761,777 Examination of the eyes may reveal conjunctival 
erythema and/or chemosis.26,777
Physical examination alone is poorly predictive and more variable when compared to history 
taking in the diagnosis of AR, with the average sensitivity, specificity, positive predictive 
value, and negative predictive values of the patient history higher than those of the physical 
examination.781 Most guidelines recommend a physical examination as part of the diagnosis 
of AR, despite a lack of high-level evidence. Without a physical examination, other potential 
causes of symptoms such as CRS, could not be fully evaluated or eliminated. A patient 
history combined with a physical examination improves diagnostic accuracy.781
• Aggregate Grade of Evidence: D (Level 3b: 1 study; Level 4: 3 studies; Level 5: 
4 guidelines; Table VIII.A).
• Benefit: Improve accuracy of diagnosis, avoid unnecessary referrals, testing, or 
treatment. Possible improved diagnosis of AR with physical examination 
findings, evaluation/exclusion of alternative diagnoses.
• Harm: Possible patient discomfort from routine examination, not inclusive of 
endoscopy. Potential misdiagnosis, inappropriate treatment.
• Cost: Minimal.
• Benefits-Harm Assessment: Preponderance of benefit over harm, potential 
misdiagnosis and inappropriate treatment if physical exam used in isolation.
• Value Judgments: Making a presumptive diagnosis of AR on history (ideally 
combined with physical examination) is reasonable and would not delay 
treatment initiation. Confirmation with diagnostic testing is required for 
progression to AIT, or desirable with inadequate response to initial treatment.
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• Policy Level: Recommendation.
• Intervention: History taking is essential in the diagnosis of AR. Physical 
examination is recommended in the diagnosis of AR, and when combined with 
patient history, it increases diagnostic accuracy and excludes alternative causes.
VIII.B. Nasal endoscopy
Diagnostic nasal endoscopy is an option for the evaluation of patients with suspected AR. 
Several uncontrolled observational studies evaluated the association of endoscopic findings 
with symptomatic rhinitis, with inconsistent results (Table VIII.B). Ameli et al.782 evaluated 
children with suspected AR, reporting that endoscopic findings of inferior or middle 
turbinate septal contact was predictive for AR, while pale turbinates were not. Conversely, 
Eren et al.783 evaluated a population of adult patients with rhinitis, concluding that findings 
of nasal endoscopy do not provide a reliable diagnosis of AR. Among adults and children 
with AR that is confirmed by allergy testing, no significant correlation was found between 
nasal endoscopy and specific nasal symptoms.784
Central compartment atopic disease (CCAD) represents the recently described association 
between atopic states and centrally-located inflammation involving the middle/superior 
turbinates or superior nasal septum.785-787 In a recently published parallel case series (LOE 
= 4), Brunner et al.788 evaluated patients with CRSwNP vs isolated polypoid change of the 
middle turbinate. Significant findings include a higher prevalence of AR in patients with 
middle turbinate polypoid change (83% vs 34%, p < 0.001), further supporting CCAD as a 
unique atopic condition.
Although the association of endoscopic findings with AR has been shown to be inconsistent, 
nasal endoscopy may aid in the identification or exclusion of other possible causes of 
symptoms, such as nasal polyposis or CRS.
• Aggregate Grade of Evidence: D (Level 3b: 2 studies; Level 4: 3 studies; Table 
VIII.B).*
• Benefit: Possible improved diagnosis with visualization of turbinate contact or 
isolated central compartment edema.
• Harm: Possible patient discomfort.
• Cost: Moderate equipment and processing costs, as well as procedural charges.
• Benefits-Harm Assessment: Equal.
• Value Judgments: None.
• Policy Level: Option.
• Intervention: Nasal endoscopy may increase diagnostic sensitivity among 
children and adults with AR and may aid in ruling out other causes for nasal 
symptoms.
*Due to recent publication and in accordance with ICAR methodology, DelGaudio et al.787 
and Brunner et al.788 are excluded from the Aggregate Grade of Evidence.
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Routine radiographic imaging is not recommended for the diagnosis of AR, although may be 
considered to rule in/out other conditions (ie, rhinosinusitis). Some recent studies have 
established the association between central compartment mucosal disease and aeroallergen 
sensitivity.787,788 However, concerns regarding unnecessary exposure to ionizing radiation, 
with the risk for future cancer development, preclude recommendations for routine use.
789,790
• Aggregate Grade of Evidence: Not applicable.*
• Benefit: None appreciated.
• Harm: Unnecessary radiation exposure with concern for tumor development.
• Cost: High equipment and processing costs.
• Benefits-Harm Assessment: Preponderance of harm over benefit.
• Value Judgments: Long-term risks of unnecessary ionizing radiation exposure 
outweigh potential benefit.
• Policy Level: Recommend against.
• Intervention: Routine imaging is not recommended in the evaluation of suspected 
AR, but may be considered to rule in/out other sinonasal conditions.
*Due to recent publication and in accordance with ICAR methodology, DelGaudio et al.787 
and Brunner et al.788 are excluded from the Aggregate Grade of Evidence.
VIII.D. Use of validated survey instruments
Validated clinical outcome surveys and questionnaires may be used as precise clinical 
assessment instruments to evaluate patients with suspected AR. Clinicians often use SPT, 
sIgE serology, and other laboratory tests to confirm or refute the diagnosis, but these tests 
are only useful in the context of an effective clinical history.791 Validated clinical assessment 
tools offer a more structured way to expose important historical elements. Furthermore, in 
regions where resources are scarce, SPT and laboratory testing may not be as readily 
available. Advancing technologies such as multiplex allergen screening, component 
serology, and automated SPT imaging devices may be expensive and unattainable by some 
clinicians.792-795 In these settings, validated surveys offer a rapid and simple point-of-care 
tool to formally evaluate allergic disease.
Patient reported outcome measures (PROMs) can assess a number of different aspects of 
how AR affects patients.796 These include symptom severity surveys, such as the Total Nasal 
Symptom Score (TNSS) and health-related QOL questionnaires, such as the RQLQ. 
Additional surveys measure aspects such as medication usage (Daily Medication Score), 
disease prediction (Respiratory Allergy Prediction) and disease control (Rhinitis Control 
Test). Each of these surveys examines slightly different, although related aspects of clinical 
outcomes. Several of these instruments have been used extensively in many large clinical 
trials to determine the effectiveness of drugs and biologics for treating AR.797-802 SPT and 
nasal challenge may be used to cross-validate these clinical survey tools but ultimately, how 
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a patient reports their own symptoms could very well be the best predictor of disease 
control.
Validated clinical surveys for AR often include questions about congestion, rhinorrhea 
and/or sneezing and may either be instantaneous or reflective over a period of days or weeks. 
The TNSS is typically administered as an instantaneous daily survey comprised of only 4 
questions about runny nose, nasal itching, sneezing, and congestion. Some studies have used 
the TNSS as a reflective score calculated as the average of both the 12-hour nighttime and 
12-hour daytime average (rTNSS). The TNSS score can be combined with questions about 
rescue medication use to yield the Daily Combined Score (DCS) and the Total Combined 
Rhinitis Score (TCRS). Both have been used in many therapeutic intervention studies.803 
The RQLQ is a more comprehensive survey that asks the patient to reflect upon the past 
week and includes global QOL questions. While this test can suffer somewhat from potential 
recall bias, it can be administered on site and avoids the possibility that self-administered 
daily scores could be missed periodically when the patient is home. The Control of Allergic 
Rhinitis and Asthma Test (CARAT10) evaluates rhinoconjunctivitis and asthma symptoms 
over the past 4 weeks giving a broader evaluation of seasonal symptom control.804 The 
Respiratory Allergy Prediction (RAP) test is a 9-question survey incorporating upper and 
lower respiratory queries as well as a question about medication use. If conjunctivitis is to be 
assessed simultaneously with rhinitis symptoms, then the Rhinitis Total Symptom Score 
(RTSS) can be combined with Rescue Medication Score (RMS) to yield the combined score 
(CS).805 Table VIII.D-1 lists several validated clinical survey tools.696,804,806-813
The choice of which validated survey to use depends on which aspect of clinical outcomes is 
being studied. For example, if the goal is for a primary care physician to determine the need 
for referral and further testing, then the RAP test may be used because it has been 
scrutinized in this setting.814 The mini-RQLQ and DCS have been used extensively in 
clinical trials to evaluate the effectiveness of drugs and immunotherapies,797-801 and 
therefore may be helpful in selecting the right medication for a given population. It is 
important to note that some tools use a higher score to indicate severe disease whereas other 
tools use a higher score to indicate better control of symptoms. For example, a high score on 
the RCAT, ARCT, and CARAT10 indicate good control of allergic symptoms.
Unfortunately, not all studies use consistent terminology and interpretation of the scoring 
systems.801 Inconsistent use of questionnaires can weaken the conclusions drawn in certain 
therapeutic intervention studies. However, a well-executed and validated survey can be 
essential in research settings and help clinicians screen patients for AR and further render 
specific diagnostic decisions.
Overall, validated clinical survey instruments may be used as a tool to assist with the 
diagnosis of AR and determine the success of various therapies. This conclusion is based on 
review of more than 30 studies of which 9 of these reports range from level 1a to 2b (overall 
Grade A evidence) (Table VIII.D-2). An example approach using specific validated survey 
instruments is as follows. The TNSS may be used for daily symptom monitoring to 
determine the effectiveness of therapies and control of AR. The TNSS should be combined 
with a daily medication score to account for the effects of pharmaceuticals on 
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symptomatology. Assessment of both conjunctivitis and rhinitis symptoms as well as 
medication use can be performed with the Combined Score (RTSS + RMS) or the 
Rhinoconjunctivitis Allergy Control Score (RC-ACS). The RQLQ or mini-RQLQ can be 
used as an additional measure to incorporate disease impact on QOL and can be 
administered in person by the clinician. For quick assessments or to follow a patient’s 
therapeutic success, a simple visual analogue scale (VAS) or global assessment is 
acceptable. The RAP test can be used as quick and easy tool for primary care physicians to 
determine the need to refer to an allergist for further testing. Many validated options are 
available for AR and should be tailored to the patient and clinical setting.
• Aggregate Grade of Evidence: A (Level 1a: 2 studies; Level 1b: 4 studies; Level 
2b: 4 studies; Table VIII.D-2). Note: multiple additional studies were reviewed, 
but Grade A evidence was reached with these 10 studies, so an extensive listing 
of all studies employing validated survey instruments is not provided here.
• Benefit: Validated surveys offer a simple point-of-care option for screening and 
tracking symptoms, QOL, and control of allergic disease.
• Harm: Minimal to none.
• Costs: No financial burden to patients. Some fees associated with validated tests 
used for clinical research.
• Benefits-Harm Assessment: Preponderance of benefit over harm. Low risk of 
misdiagnoses leading to unnecessary additional testing. Likewise, there is a low 
risk that false negative responses may lead to delay in testing and further 
management.
• Value Judgments: Level 1 evidence to use validated surveys as a screening tool 
and primary or secondary outcome measure.
• Policy Level: Strong recommendation.
• Intervention: Validated surveys may be used to screen for AR, follow treatment 
outcomes and as a primary outcome measure for clinical trials. Specific tests are 
optimized for various clinicopathological scenarios and should be tailored to the 
patient and clinical setting.
VIII.E.1. Skin-prick testing (SPT)—SPT can be used, along with the history and 
physical examination, to confirm the diagnosis of AR and differentiate from non-allergic 
types of rhinitis. The confirmation of an IgE-mediated process guides avoidance measures 
and appropriate pharmacologic therapy. Skin testing is crucial to directing AIT, and 
therefore, should be utilized in eligible patients when AIT is being considered. According to 
the ARIA guidelines, patients should be considered for AIT when they have failed a 2-week 
to 4-week trial of moderatedose INCS combined with antihistamines.101
When an antigen is applied to the skin of a sensitized patient, the antigen cross-links IgE 
antibodies on the surface of cutaneous mast cells resulting in degranulation and release of 
mediators (including histamine), which leads to the formation of a wheal and flare reaction 
within 15 to 20 minutes.816,817 Given the limited depth of penetration, SPT is safe with very 
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rare reports of anaphylaxis and no reported fatalities.818 SPT can be performed in any age 
group and is of particular value in pediatric populations given the speed at which multiple 
antigens can be applied and the limited discomfort experienced during testing.
Skin testing is not appropriate in all patients. Absolute or relative contraindications to SPT 
include uncontrolled or severe asthma, severe or unstable cardiovascular disease, concurrent 
beta-blocker therapy, and pregnancy. Certain medications and skin conditions may interfere 
with skin testing. These are covered in detail in section VIII.E.4. Issues that affect the 
performance or interpretation of skin tests: VIII.E.4.a. Medications; and VIII.E.4.b. Skin 
conditions, respectively.
Aside from an excellent safety profile, SPT has a reported sensitivity and specificity around 
80%.818-820 It is reported to be more sensitive than serum testing with the added benefit of 
lower cost.818,821,822 Despite studies aimed at comparing SPT, intradermal testing, and 
serum testing, conclusive evidence that one type of testing is superior to the others is 
lacking.761
The number and choice of antigens used in testing varies considerably between clinical 
practices. A panel of antigens representing an appropriate geographical profile of allergens 
that a patient would routinely be exposed to is recommended. Positive (histamine) and 
negative (glycerin or saline) controls should always be included. Variability in quality and 
potency between commercially available allergen extracts has been demonstrated.823,824 
Therefore, whenever possible, standardized allergens should be used.820
SPT is performed with lancets, which come in a variety of forms. Generally, lancets are 
designed to limit skin penetration depth to 1 mm. However, varying amounts of pressure 
applied to the delivery device can alter the depth of skin penetration, which ultimately 
influences the skin reaction to an antigen.825 Prick testing devices can come as single-lancet 
devices or multiple-lancet devices. Multiple-lancet devices have the advantage of being able 
to rapidly apply multiple antigens to the skin at 1 time with a more consistent amount of 
pressure.826,827 Wheal size, sensitivity, and reproducibility all differ from 1 device to 
another826-828; therefore, any healthcare provider performing SPT must thoroughly 
familiarize themselves with his/her testing device. Typically, the lancet is dipped into a well 
containing an antigen and then applied to the skin.
The volar surfaces of the forearms and the back are the most common testing sites for SPT. 
Choice of site is directed by the age/size of the patient. Tests should be applied 2 cm or 
greater apart as placing them closer to one another can cause cross-contamination.829 After 
15 to 20 minutes, the results are read by measuring the size of the wheal by its greatest 
diameter. A wheal 3 mm or larger than the negative control is considered positive.
There is a large body of evidence detailing the use of SPT in clinical practice (Table 
VIII.E.1). Based upon several prospective studies and systematic reviews, SPT has been 
demonstrated to be a safe method of allergy testing. It is not inferior to serum or intradermal 
testing and is less expensive than serum testing. It does carry a risk of systemic reaction, so 
caution should always be exercised. It is also associated with some discomfort during 
testing; however, the discomfort is generally less than that experienced during intradermal 
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testing. Reviewing the available literature, a preponderance of benefit over harm for SPT 
exists. Therefore, the use of SPT is recommended in situations where the diagnosis of AR 
needs to be supported or a patient with presumed AR has failed appropriate empiric medical 
therapy.
• Aggregate Grade of Evidence: B (Level 1a: 1 study; Level 3b: 7 studies; Table 
VIII.E.1).
• Benefit: Supports diagnosis and directs pharmacological therapy while possibly 
avoiding unnecessary/ineffective treatment; guides avoidance; directs AIT.
• Harm: Adverse events from testing including discomfort, pruritus, erythema, 
worsening of asthma symptoms, and anaphylaxis, inaccurate test results, and 
misinterpreted test results.
• Cost: Low.
• Benefits-Harm Assessment: Preponderance of benefit over harm.
• Value Judgments: Patients can benefit from identification of their specific 
sensitivities. SPT is a quick and relatively comfortable way to test several 
antigens with accuracy similar to other available methods of testing.
• Policy Level: Recommendation.
• Intervention: SPT is recommended for evaluation of allergen sensitivities in 
appropriately selected patients. Regular use of the same SPT device will allow 
clinicians to familiarize themselves with it and interpretation of results may 
therefore be more consistent. The use of standardized allergen extracts can 
further improve consistency of interpretation.
VIII.E.2. Skin intradermal testing—The placement of allergenic proteins in the 
intradermal space is often used for diagnosing AR. Intradermal testing has also been 
described in the evaluation of sensitivities to other substances, including local anesthetic 
agents, neuromuscular blocking agents, antibiotics, and contrast media.837-840 While 
previous protocols have described the use of intradermal testing for suspected food or 
chemical allergies, this type of diagnostic testing is currently not recommended in routine 
practice.841,842 Intradermal testing may be used as a primary testing modality, or as a 
secondary test following SPT. Intradermal testing has also been used, primarily by 
otolaryngic allergists, as a method to help determine the starting point for specific AIT and 
as a vial safety test prior to an injection from a new treatment vial, though the level of 
evidence supporting these uses is low.843,844
Intradermal testing may be performed as a single injection. A short bevel needle is used to 
inject a diluted allergenic extract solution into the superficial dermis. Approximately 0.02 
mL is used, or enough to produce a well-defined wheal, which is 4 mm in diameter.845 The 
wheal will expand to 5 mm by hydrostatic forces, and the reaction is observed for 10 
minutes. The positive control for intradermal testing is histamine and the negative controls 
are typically phenolated saline and a glycerin solution that equals the concentration of 
glycerin in the test solution. If the diameter of the resulting wheal is at least 7 mm, and at 
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least 2 mm wider than the glycerin control, this is considered a positive test.846 While this is 
a very reproducible test, it is more technically demanding than SPT, is difficult to perform in 
young children, and carries a higher risk of adverse reactions.847 Severe adverse events 
related to intradermal testing are rare. Over a 42-year period, from 1945 to 1987, only 5 
fatalities were attributed to intradermal testing without prior prick/puncture testing.848
Intradermal testing may also be performed using multiple dilutions of the same allergen to 
more precisely quantify the level of sensitivity to that allergen and suggest a starting point 
for immunotherapy.849 A series of dilutions of concentrated allergenic extract (typically 
supplied as a 1:20 wt/vol solution) can be prepared in either a 1:5 or 1:10 ratio. Intradermal 
dilutional testing (IDT, previously referred to as skin endpoint titration, or SET) begins with 
the intradermal placement of a dilute allergen, along with appropriate controls, followed by 
the placement of progressively more concentrated dilutions of that allergen. The dilution 
producing the first positive test (defined earlier in this section as a wheal is at least 7 mm and 
at least 2 mm wider than the glycerin control) followed by progressively larger wheals is 
called the “endpoint.” To establish progression, a confirmatory wheal, produced by the next 
higher concentration, must be at least 2 mm wider than the suspected endpoint. IDT 
endpoint correlates with SPT wheal.844,850,851 While IDT endpoints have been shown to 
correlate with biologically relevant measures, such as basophil histamine release, a clear 
correlation with other measures, such as in vitro sIgE levels, has not yet been established.
852,853 Currently, no studies have demonstrated a clear benefit of quantitative intradermal 
testing over single intradermal testing with regard to the diagnosis of clinical allergy or the 
outcome of specific immunotherapy (Table VIII.E.2).
As a stand-alone diagnostic test for AR, estimates for sensitivity for intradermal testing 
range between 60% (95% CI, 31% to 83%) and 79% (95% CI, 63% to 90%), while 
estimates for specificity range between 68% (95% CI, 49% to 82%) and 69% (95% CI, 52% 
to 86%).793,833 This is lower than the pooled estimates of sensitivity (85-88%) and 
specificity (77%) for SPT, calculated from recent meta-analyses.830,854 Factors affecting the 
predictive value of intradermal testing include the comparator used and the concentration of 
allergen used with the intradermal test.855
It has been suggested that intradermal testing could potentially increase the sensitivity of 
SPT by injecting allergenic proteins into deeper tissue layers beneath the keratinized 
epidermis.847 However, the literature has not supported a clear benefit of intradermal testing 
for this purpose. Using intradermal testing in addition to SPT to predict a positive response 
from nasal challenge with Timothy grass only increased the sensitivity from 87% to 93%.832 
In a similar study, Krouse et al.831 determined that adding intradermal testing to SPT as a 
method to predict positive nasal challenge to Alternaria increased the sensitivity from 42% 
to 58%. These studies suggest marginal increase in sensitivity that may vary based upon the 
allergen being tested.
Nelson et al.856 studied 28 individuals with a history of SAR. One group had negative SPT 
to Timothy and Bermuda grass, but positive intradermal testing for Timothy grass, while the 
other group had negative SPT and negative intradermal testing for Timothy and Bermuda 
grass. In both groups, 11% of individuals had a positive nasal challenge with Timothy grass. 
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Likewise, when 39 individuals with clinical cat allergy and negative SPT underwent a cat 
challenge, there was no difference in the development of upper respiratory symptoms 
between those who had positive or negative intradermal testing (24% vs 31%, p = 0.35).793 
Reddy et al.857 evaluated allergy test results in 34 patients with perennial rhinitis. Patients 
with only intradermal positive skin tests (SPT negative) did not have a positive RAST nor a 
positive leukocyte histamine release. In contrast, SPT positivity was associated with positive 
RAST test and leukocyte histamine release assay.857 Schwindt et al.858 studied 97 subjects 
with allergic rhinoconjunctivitis symptoms. Prick testing was followed by intradermal 
testing if prick was negative. If patients were prick-negative and intradermal-positive, a nasal 
challenge was performed against 5 different allergens. If SPT with the multi-test II device 
was negative, only 17% of subjects had a positive intradermal test that corresponded with 
clinical history. None of these positive ID tests corresponded with a positive nasal challenge.
858 Taken together, these studies suggest that intradermal testing does not improve the 
diagnosis of allergy in subjects with negative SPT.
Nevis et al.830 conducted a systematic review of 4 studies to determine the sensitivity and 
specificity of intradermal testing when used as a confirmatory test following negative SPT. 
Sensitivity ranged from 27% (95% CI, 10% to 57%) to 50% (sample sizes were too small to 
calculate CI), while specificity ranged from 69% (95% CI, 51% to 83%) to 100% (95% CI, 
83% to 100%). From a retrospective study by Larrabee and Reisacher,859 when the clinician 
was guided by high clinical suspicion, the incidence of positive intradermal testing following 
negative SPT was 36.9% for indoor allergens (D. pteronyssinus, D. farinae, cat, dog, and 
cockroach), 12.7% for outdoor allergens (ragweed, red birch, Timothy grass, white oak, and 
red maple) and 9.2% for molds (Aspergillus, Candida, Penicillium, Alternaria, and 
Cladosporium). However, no correlation between positive intradermal testing and nasal 
challenge testing was performed in this study. Escudero et al.860 found that in rhinitis 
patients, SPT, intradermal and conjunctival challenge were more sensitive than serum sIgE. 
All testing methods had the same specificity.
In summary, current evidence supports the use of intradermal testing for the diagnosis of AR 
due to airborne allergens as a stand-alone test, although this form of testing demonstrates no 
clear superiority over SPT when comparing sensitivity and specificity. There were no studies 
identified that directly compared single-dilution intradermal testing with IDT in terms of 
sensitivity, specificity, or patient outcomes. There appears to be a small gain in sensitivity 
when intradermal testing is used as a confirmatory test following negative SPT; however, 
positive intradermal test results in this setting could represent false-positive test results. It is 
also more likely that an intradermal test following a negative SPT will be positive when 
indoor allergens are being tested and least likely to be positive when testing for mold 
sensitivity. It is unknown whether the type of allergen has an impact on the sensitivity and 
specificity, as most studies examined used only 1 allergen, but intradermal testing seemed to 
be least sensitive and specific when mold was being tested. Other limitations of the studies 
identified for this review include low sample population sizes (the largest included 120 
participants), variable study design, and the lack of randomized, controlled trials.
• Aggregate Grade of Evidence: B (Level 1a: 1 study; Level 2b: 11 studies; Level 
3b: 4 studies; Level 4: 1 study; Table VIII.E.2).
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• Benefit: Generally well tolerated, easy to perform, and a favorable level of 
sensitivity and specificity when used as a stand-alone diagnostic test.
• Harm: Very low risk of severe adverse reactions.
• Cost: Low.
• Benefits-Harm Assessment: Benefit over harm when used as a stand-alone 
diagnostic test. Balance of benefit and harm when used to confirm the results of 
SPT, as a quantitative diagnostic test or as a vial safety test.
• Value Judgments: It is important to determine the presence of IgE-mediated 
sensitivity for individuals with suspected AR. If SPT is negative, there is limited 
clinical benefit to performing intradermal testing for confirmation.
• Policy Level: Option for using intradermal testing as a stand-alone diagnostic test 
for individuals with suspected AR. Option for using intradermal testing as a 
confirmatory test following negative SPT for nonstandardized allergens. The 
evidence for quantitative IDT is sparse and prevents a recommendation for this 
specific testing technique.
• Intervention: Intradermal testing may be used to determine specific airborne 
allergen sensitization for individuals suspected of having AR.
VIII.E.3. Blended skin testing techniques—Blended allergy skin testing involves the 
combined use of SPT and intradermal testing to establish an “endpoint” for a specific 
antigen.844,847,850 The protocol, initially described by Krouse and Krouse,861 and referred to 
as “modified quantitative testing” (MQT), serves as an example of a blended technique. 
MQT involves an algorithm where a SPT is used initially to apply an antigen. Depending 
upon the SPT result, an intradermal test may or may not be applied.844,847,850,861 With these 
results, the algorithm is used to determine an endpoint for each antigen tested.844,847,850,861 
The endpoint signifies the skin reactivity to the applied antigen on a graded scale and is 
considered to be a safe starting dose for the application of AIT.861 There is a small amount 
of literature on blended techniques, but AIT based upon the MQT results has been shown to 
be successful, with immune system alterations in line with other skin testing techniques861 
(Table VIII.E.3).
The advantages of blended techniques, such as MQT, are that they provide the practitioner 
with both qualitative data (the patient demonstrates sensitivity) and quantitative data 
(endpoint; safe starting dose for AIT) for specific antigen sensitivities in less time than IDT.
844,847,850 Disadvantages include the additional risk and time involved in placing 
intradermal tests. In comparison to IDT and in vitro testing methods, MQT has been shown 
to be more cost-effective when the prevalence of AR in a population is 20% or higher.862 
While blended skin testing techniques may be considered in the evaluation of AR, especially 
to determine the starting point for AIT, the evidence to support this technique is not strong.
• Aggregate Grade of Evidence: D (Level 3b: 1 study; Level 4: 4 studies; Table 
VIII.E.3).
• Benefit: Ability to establish an endpoint in less time than IDT.
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• Harm: The additional risks, including systemic or anaphylactic reactions, of 
intradermal tests; additional time and discomfort.
• Cost: Similar to intradermal testing.
• Benefits-Harm Assessment: Benefit outweighs harm.
• Value Judgments: AIT can be initiated from SPT results alone; however, 
endpoint-based AIT may decrease time to reaching therapeutic dose.
• Policy Level: Option.
• Intervention: MQT is a skin testing technique that may be used to determine a 
starting point for AIT.
VIII.E.4. Issues that affect the performance or interpretation of skin tests
VIII.E.4.a. Medications.: The wheal and flare reaction seen in allergy skin testing 
depends upon the physiologic actions of histamine released from mast cells upon 
degranulation. Thus, any medications that inhibit mast cell degranulation or that function as 
histamine H1 receptor antagonists have the potential to suppress appropriate skin test 
responses. The suppressive effects of H1 antihistamines on allergen and histamine induced 
wheal and flare responses vary greatly,863,864 and the duration of this suppression depends 
upon the skin tissue concentration and half-life of these agents.865,866 In fact, skin test 
suppression can be used as a biological assay for the onset and duration of action of 
antihistamines.865 Agents such as astemizole (now removed from the market due to QT 
prolongation) have the potential to suppress skin test reactions for a period of weeks after 
cessation.867 However, most antihistamines only suppress skin test responses for a period of 
2 to 7 days after cessation.867,868 Topically administered antihistamines have the potential to 
suppress skin wheal and flare responses. One randomized placebo-controlled study showed 
that 14 days of azelastine nasal spray treatment reduced the histamine induced wheal and 
flare response, and this suppression disappeared by 48 hours after cessation869 (Table 
VIII.E.4.a-1).
Randomized, placebo-controlled trials have demonstrated that H2 receptor antagonists such 
as ranitidine can reduce skin whealing responses,870,871 and 1 study showed an additive 
effect of H1 and H2 antihistamines on skin wheal suppression.872 Some antidepressants have 
the potential to suppress skin wheal and flare responses, in particular the tricyclic 
antidepressants that have antihistaminic properties (such as doxepin).873 However, newer 
classes of antidepressants such as selective serotonin reuptake inhibitors (SSRI) do not 
appear to affect allergy skin test responses.874
Recombinant humanized anti-IgE monoclonal antibody (mAb), omalizumab, interferes with 
IgE-mediated mast cell degranulation reactions in the allergy skin test response. A 
randomized placebo-controlled trial demonstrated a significant reduction in allergen-induced 
skin whealing after 4 months of treatment.874 Omalizumab appears to suppress skin test 
reactivity in tandem with dramatic reductions in serum free IgE, and allergy skin test 
responses return to normal within 8 weeks of discontinuation.875
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Leukotriene receptor antagonists (LTRAs) do not appear to interfere with allergy skin test 
results. Hill and Krouse876 as well as Simons et al.866 found no effect of montelukast on 
intradermal skin test results in allergic subjects. Cuhadaroglu et al.877 found no change in 
SPT results in allergic subjects before and treatment with zafirlukast.
In general, the highest level evidence shows that systemic steroid treatment has no effect on 
SPT and intradermal test results,878,879 though some less rigorous retrospective studies 
suggest that systemic steroid treatment could affect skin whealing responses.880,881 Topical 
steroid treatment has been demonstrated to suppress the wheal and flare reaction in treated 
skin areas, creating the possibility of false-negative test results.882-885 No studies were 
identified that examined the effect of intranasal or inhaled steroids on skin test results.
The effects of many classes of medications on allergy skin test responses remain 
inadequately studied. Benzodiazepines have been implicated as possibly suppressing skin 
test responses.886,887 The calcineurin inhibitor tacrolimus was shown to inhibit SPT 
whealing,885 whereas a study of a similar drug, pimecrolimus, did not show any effect on 
skin whealing responses.888 The pharmacologic effects of herbal preparations are generally 
unstudied, and it is unclear which of these agents could interfere with allergy skin test 
responses. More et al.889 performed a double-blind, placebo-controlled, single-dose 
crossover study in 15 healthy volunteers, examining the histamine-induced skin test 
response. None of the 23 herbal supplements tested caused suppression of the histamine-
induced wheal response.
There are many classes of medications for which the actual impact on allergy skin testing 
are unknown. To mitigate against the risk of false-negative skin test results induced by 
medications, all allergy testing should be performed after application of appropriate positive 
controls (usually histamine) to ensure that the histamine-induced skin test reaction is intact 
at the time of testing. See Table VIII.E.4.a-1 for a comprehensive review, with Aggregate 
Grades of Evidence in Table VIII.E.4.a-2.
VIII.E.4.b. Skin conditions.: The usefulness of allergy skin testing depends upon the 
ability to detect a Type I hypersensitivity reaction after allergen introduction into the skin. 
Abnormal skin (eg, dermatitis) may not respond appropriately to histamine, glycerin, or 
allergen. Additionally, the physical trauma of prick/puncture or intradermal testing may 
induce a local inflammatory response. The wheal and flare reaction also may be difficult to 
detect due to preexisting skin changes. Further, skin color may inhibit the ability to visualize 
the flare reaction, especially in darker skinned individuals.
Common sense dictates that allergy skin testing should not be performed at sites of active 
dermatitis, but clinical studies to investigate this phenomenon are lacking. Individuals with 
dermatographism may have exaggerated responses to allergy skin testing, requiring close 
attention to the results of negative control tests. In some cases, it may be preferable to 
perform in vitro specific IgE testing in patient with skin disease or dermatographism, but 
this is not based on data or outcomes from controlled studies.
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Due to the lack of published studies on this topic, an Aggregate Grade of Evidence and 
evidence based recommendation cannot be provided.
VIII.F. In vitro testing
VIII.F.1. Serum total IgE (tIgE)—The literature addressing the role of serum tIgE in the 
evaluation and diagnosis of allergic disease offers conflicting outcomes and divergent 
opinions. Positive studies, demonstrating a relevant role of measuring tIgE in the evaluation 
and diagnosis of AR, are listed in Table VIII.F.1-1. Negative studies that report a limited role 
of measuring tIgE are listed in Table VIII.F.1-2. When taken together, however, this body of 
literature provides some information that can inform decisions related to the utility of tIgE in 
directing patient care decisions.
Perhaps the strongest statement that can be made on behalf of tIgE is its ability to generally 
identify patients or populations with atopic or allergic disease. For example, Ando and 
Shima892 reported that tIgE is higher in children with AR than in peers with NAR. Marinho 
et al.893 found a borderline association between tIgE and current rhinitis. In a retrospective 
study, Kalpaklioglu and Kavut894 reported that tIgE is higher in AR than in NAR. Jung et al.
895 conducted a prospective study that showed a tIgE cutoff of 98.7 IU/mL as a strong 
predictor of AR. Salo et al.454 performed a cross-sectional study reporting significant 
associations between tIgE levels and current hay fever in different age classes. Demirjian et 
al.896 demonstrated that a tIgE level over 140 IU/mL is suggestive of an atopic cause for 
patients with clinical symptoms of AR. Hatcher et al.897 showed that an elevated tIgE in the 
presence of a negative inhalant-specific IgE screen may suggest the presence of unidentified 
inhalant allergen sensitization or chronic respiratory inflammatory disease other than AR. 
Karli et al.898 reported that tIgE is helpful in confirming the diagnosis but it cannot be 
recommended for routine use due to its high cost and the time to perform the test. Chung et 
al.899 reported that tIgE (cutoff value 150 IU/mL) is a reliable biomarker for AR diagnosis. 
Jacobs et al.900 reported a favorable role of measuring tIgE in diagnosing AR, mainly if 
levels are higher than 100 IU/mL. Li et al.901 observed that tIgE is higher in AR than in 
NAR in a retrospective study. Finally, in a 2-year follow-up study, Park et al.902 showed that 
in subjects without allergic sensitization at the initial examination, tIgE greater than 17.7 
IU/mL was associated with the risk for allergic sensitization, whereas in patients with 
allergic symptoms but negative SPT results at the initial examination, tIgE greater than 17.4 
IU/mL was associated with newly developed allergic sensitization.
In contrast, there are 4 studies with negative results in the setting of tIgE and AR/allergy. 
Satwani et al.903 reported no association between tIgE level and AR diagnosis. Tu et al.904 
demonstrated an insufficient diagnostic accuracy of tIgE levels to detect allergic diseases 
regardless of which cutoff value is being used; tIgE was linked more to atopy than directly to 
symptoms. In the same follow-up study noted above, Park et al.902 reported that in subjects 
without allergic sensitization at the initial examination, tIgE less than 17.7 IU/mL was not 
associated with newly developed allergic nasal symptoms. Finally, Tay et al.905 conducted a 
retrospective analysis in patients with high tIgE levels (> 1000 IU/mL) and concluded that 
the elevated IgE level in AR is of limited clinical/diagnostic value.
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Another opportunity offered by tIgE assessment is the ratio between allergen-specific and 
tIgE. It has been reported that this ratio might be useful in the prediction of AIT 
effectiveness,906-908 as recently outlined by the EAACI Position Paper.909
In summary, tIgE is frequently increased in AR, but the clinical utility is modest in common 
practice. In fact, the literature is a divergent set of studies that fails to find a consistent role 
or value for tIgE in the management of AR patients.
• Aggregate Grade of Evidence: C (Level 2b: 5 studies; Level 3b: 10 studies; 
Tables VIII.F.1-1 and VIII.F.1-2).
• Benefit: Possibility to suspect allergy in a wide screening.
• Harm: Low level does not exclude allergy.
• Cost: Modest cost of test.
• Benefits-Harm Assessment: Slight preponderance of benefit over harm. In 
addition, the ratio tIgE/sIgE may be useful.
• Value Judgments: The evidence does not support a routine use.
• Policy Level: Option.
• Intervention: Total IgE assessment is an option to assess atopic status.
VIII.F.2. Serum antigen-specific IgE (sIgE)—sIgE testing became commercially 
available in 1967 with an assay reliant on radioactive anti-IgE for labeling IgE in serum.
910,911 This radioactive technique, known as RAST, has largely been replaced with other 
technologies using enzymatically-driven reactions to produce a chemiluminescent, 
colorimetric, or fluorimetric reaction quantified or “read” by an autoanalyzer.910,912 The 
process is as follows: allergens are bound to a substrate (typically in the form of a solid or 
liquid phase) to which a patient’s serum is added. sIgE in the patient’s serum then binds to 
the allergen on the substrate. Excess serum is washed off and with it, any unbound IgE. Non-
human anti-IgE antibodies tagged by a marker are subsequently added and bind any 
corresponding sIgE that is immobilized. Excess anti-IgE antibodies are then washed off and 
the autoanalyzer reads the intensity of the radioactive, chemiluminescent, colorimetric, or 
fluorimetric reaction. The intensity of the reaction is proportional to the amount of sIgE in 
the serum and a report is generated. All tests approved by the FDA are calibrated against a 
World Health Organization (WHO) tIgE standard serum.913 Different units are reported 
depending on the assay system used, but many vendors offer conversion factors.
Serum sIgE testing offers several benefits. The safety profile of serum sIgE testing is the 
best of all available allergy tests as the risk for anaphylaxis is nonexistent. Furthermore, the 
use of skin testing is limited by the presence of certain medical conditions. In patients where 
skin testing is contraindicated or potentially impacted by medications or skin conditions, 
sIgE testing offers a safe and effective option for determining the presence of sensitization as 
a biomarker of IgE-mediated hypersensitivities and confirming specific allergen triggers.
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There are some important similarities and differences between skin testing and sIgE testing 
that warrant discussion. First, studies have indicated that while patients are accepting of both 
in vitro and in vivo allergy testing, skin testing may be preferred because it allows for 
immediate feedback and visible results.914 Second, neither skin or sIgE testing can 
definitively predict the severity of a patient’s sensitivity to an aeroallergen. Third, cross-
reacting allergens and poly-sensitizations can confound both skin and in vitro testing, 
leading to false-positive results.915 In contrast to skin testing, sIgE tests use more 
extensively quality-controlled allergens and defined human serum controls. Whereas skin 
testing depends upon the clinician administering and interpreting the test, sIgE tests have 
coefficients of variation less than 15% in the College of American Pathologists diagnostic 
allergy proficiency survey, which is performed 3 times per year by all Clinical Immunology 
Laboratories licensed by the Clinical Laboratory Improvement Act of 1988. However, 
several reports have demonstrated poor agreement in results from testing the same sera by 
different commercially available assay systems.916,917 As with skin testing, sIgE results 
should be interpreted within the context of the patient’s clinical history.
One application of sIgE technology is multiallergen screens consisting of 10 to 15 allergens. 
In scenarios where a clinician wishes to either rule in or out allergy as a driving factor 
behind symptoms without subjecting patients to the time and cost of a full testing battery, 
sIgE screens are an option. Generally, either a negative or positive result is given. Screens 
testing for 10 to 12 allergens (ie, molds, regional pollens, cat, and mite) are positive in up to 
95% of patients who would have tested positive on a larger battery.912,918 Therefore, they 
are effective in identifying allergic patients. Conversely, if the test is negative, there is 
evidence that this reliably supports an absence of allergy.910 A second application lies in the 
fact that levels of sIgE may correlate with severity of AR symptoms.919-923 Given that 
patients with more severe symptoms have been shown to respond better to AIT than those 
with milder symptoms, sIgE may help in the selection of candidates for AIT and possibly 
predict the response.919,924 Third, in polysensitized patients, it can be difficult to determine 
the most relevant allergen on SPT. In these situations, sIgE levels can help discriminate the 
most relevant allergen and guide AIT.920
Studies have shown that sIgE testing has a sensitivity between 67% and 96% and specificity 
of between 80% and 100%.793,822,835,925,926 Further, it has been demonstrated that sIgE 
shows excellent correlations with both NPT and SPT in the diagnosis of AR.
793,822,835,857,911 There is good evidence to show that sIgE is, in many ways, equivalent to 
SPT.218,818,925 The decision to perform sIgE must be based upon a thorough history and 
physical examination to confirm the presence of allergy and guide therapy when necessary. 
It is important to note that while sIgE levels are a biomarker of allergic sensitization, this test 
alone cannot provide a definitive diagnosis of allergy due to the high rate of clinically 
irrelevant (false-positive) tests without an indicative clinical history. Based on the reviewed 
literature, sIgE testing is an acceptable alternative to skin testing and is safe to use in 
patients who are not candidates for skin testing (Table VIII.F.2).
• Aggregate Grade of Evidence: B (Level 3b: 7 studies; Table VIII.F.2).
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• Benefit: Confirms sensitization in support of an AR diagnosis and directs 
appropriate therapy while possibly avoiding unnecessary/ineffective treatment; 
guides avoidance measures; and directs AIT.
• Harm: Adverse events from testing including discomfort from blood draw, 
inaccurate test results, false-positive test results, misinterpreted test results.
• Cost: Moderate cost of testing.
• Benefits-Harm Assessment: Preponderance of benefit over harm.
• Value Judgments: Patients can benefit from identification of their specific 
sensitivities. Further, in some patients who cannot undergo skin testing, sIgE 
testing is a safe and effective alternative.
• Policy Level: Recommendation.
• Intervention: Serum sIgE testing may be used in the evaluation of AR. Using 
standardized allergens and rigorous proficiency testing on the part of laboratories 
may improve accuracy.
VIII.F.3. Correlation between skin and in vitro testing—Allergen skin testing has 
been used to diagnose allergic disease since first introduced by Blackley 140 years ago.
791,928 The discovery of IgE in 1969 allowed for the development of in vitro serological tests 
which have become increasingly utilized.929 However, skin testing and sIgE serology 
portend unique biological functions. Therefore, the 2 tests are not fully interchangeable.
Modern SPT of aeroallergens can be up to 25% more sensitive than sIgE serology depending 
on the patient population and the methodologies employed.793,930-934 In the United States, 
SPT also generally costs about one-half as much as sIgE serology ($6.82 vs $12.50 per 
allergen tested).935 Other factors to consider include access to laboratory technology, 
comorbid disease, and the age of the patient. In vitro testing avoids the need to withhold 
medications that affect skin testing and allows for testing in subjects with dermatographism 
or other widespread skin disorders. SPT measurements are directly observable within 20 
minutes, which is typically much faster than laboratory reports are obtained. Both sIgE 
serology and SPT are considered very safe techniques; however, SPT does carry a very small 
risk of anaphylaxis.
The sensitivity and specificity of SPT depends on the allergen tested, quality of reagents, the 
specific methodologies employed, technician expertise, and patient demographics.928,937-942 
For example, SPT wheal size and sensitivity depend on the specific device selection and the 
choice of control reagents used for testing.928,938 Nonetheless, a recent meta-analysis 
indicates that SPT remains an accurate test, which when combined with a detailed clinical 
history, helps confirm the diagnosis of AR830 (Table VIII.F.3-1).
The performance and reliability of serum sIgE testing likewise depends on several factors 
including the choice of reagents, modernization of equipment, and patient demographics.932 
The cutoff value for a positive test affects both the sensitivity and specificity.943 In a Korean 
population, SPT was found to be superior to ImmunoCAP for measuring dust mite 
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sensitivity if the patient was less than 30 years of age.792 For the group older than age 50 
years, ImmunoCAP was more sensitive.792 Intradermal or epicutaneous testing demonstrates 
higher sensitivity but lower specificity than SPT for several allergens.793,856,931,932,944 
Based on this, intradermal tests should be selected judiciously. There is evidence to suggest 
that a positive intradermal reaction to grass pollen in the setting of negative prick testing 
may not be clinically relevant.793,856
In recent years, microarray allergy testing systems such as ImmunoCAP ISAC (Thermo 
Fisher Scientific/Phadia AB, Uppsala, Sweden) have been introduced in an effort to offer a 
comprehensive in vitro allergen test panel.794 The precision and utility of microarray testing 
needs more rigorous scrutiny so that consensus guidelines can be more firmly established.
794,945 The cost of a single Immuno-CAP ISAC test, which includes 112 components from 
51 allergens, is approximately $500 to $600 in the United States.794,945
Various studies have compared sIgE serology to allergen SPT.793,943,946,947 Both techniques 
are sensitive and are generally well correlated; however, interpretation of the results depends 
upon the gold standard reference used to define allergic status. Environmental chambers, 
nasal challenge, and validated questionnaires are typically used to determine the diagnostic 
accuracy of allergen testing. Table VIII.F.3-2 summarizes several comparative studies 
between skin testing for aeroallergens, specific IgE serology, and other in vitro tests.
It is important to understand that selection and interpretation of allergen testing is not based 
on sensitivity and specificity alone. The intended physiological mechanism to be 
interrogated also needs to be considered. SPT and intradermal testing both measure end-
organ pathological mechanisms associated with sIgE bound to the surface of mast cells. In 
contrast, serum sIgE testing and microarray approaches measure circulating IgE that may or 
may not represent downstream allergic inflammatory responses. Both intradermal testing 
and SPT rely heavily on technician skill for interpretation of the wheal and flare reaction.
856,928,937 In the case of subjects with dermatographism (or other inflammatory skin 
conditions in the testing area), hairy arms, or darkly pigmented skin color, the interpretation 
of the SPT can prove to be difficult.942 Specialized imaging systems have been developed to 
measure the wheal reaction in an automated fashion in both light and dark skinned 
individuals, but additional validation is required. Until these automated systems become 
more widespread, in vitro testing affords the benefits of temporal and multicenter 
reproducibility.
The average pooled sensitivity of SPT is 85% which is often slightly higher than that of 
serum sIgE testing830; however, this is not universally true depending on the allergen tested 
and the characteristics of the patient. Based on accuracy, convenience, cost, and promptness 
of results, SPT is often chosen as the first line diagnostic instrument to detect sensitivity to 
aeroallergens. Intradermal testing can be used as a second line test to exclude reactivity if 
the clinical suspicion is very high. In cases where dermatographism is present and/or 
patients are unable to wean off medications that affect skin testing, sIgE testing may be a 
better choice. More studies are required to determine the role of small volume blood testing 
through emerging microarray technology such as the ImmunoCAP ISAC.
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• Aggregate Grade of Evidence: B (Level 1a: 1 study; Level 1b: 7 studies; Level 
1c: 1 study; Level 2a: 1 study; Level 2b: 6 studies; Level 3a: 2 studies; Level 5: 1 
study; Table VIII.F.3-1).
VIII.F.4. Nasal specific IgE—AR is classically diagnosed by clinical history and with 
objective testing for confirmation, usually SPT or in vitro testing with serum sIgE.301 In 
addition to positive systemic sIgE, AR patients have been shown to have sIgE in the nasal 
mucosa with evidence that class switching and antibody production occurs locally.
309-312,377,950,951 However, some patients have negative SPT or serum sIgE despite a clinical 
history suggestive of AR and meeting ARIA clinical criteria.101,300 These patients are 
usually given the diagnoses of idiopathic rhinitis, vasomotor rhinitis, or NAR.300 However, it 
has been demonstrated that many of these patients may have local allergic phenomena or 
LAR, a type of rhinitis characterized by the presence of a localized allergic response in the 
nasal tissues, with local production of sIgE and positive response to NPT without evidence 
of positive SPT or serum sIgE elevation.107 LAR may affect more than 45% of patients 
otherwise categorized as NAR,296,302,952 and up to 25% of patients referred to allergy 
clinics with suspected AR.291 Like traditional AR patients, LAR can be classified as 
perennial or seasonal, and similar findings in the nasal mucosa have been reported in both of 
these populations.300,301,953 It has even been suggested that some patients with occupational 
rhinitis may suffer from LAR.107 Recent studies suggested a low rate of conversion of LAR 
to systemic AR.296,302 The first 5 years of a long-term followup study performed in a cohort 
of 194 patients with LAR and 130 healthy controls found that patients with LAR of recent 
onset (less than 18 months from the diagnosis) had a similar conversion to systemic AR 
when compared to controls.296 A small retrospective study performed in 19 patients with a 
long clinical history of LAR (greater than 7 years from the diagnosis) and negative SPT to a 
wide panel of allergens had a similar rate of development of systemic AR302 compared with 
epidemiologic data of prevalence of atopy in a healthy population from that geographic area.
954 Upcoming data from the 10-year follow-up study should help to clarify the rate of a 
long-term conversion to systemic AR in patients with LAR. In fact, LAR can present later in 
life, and in elderly patients with rhinitis the incidence of LAR has been reportedly been as 
high as 21%.304
The diagnosis of LAR is confirmed by positive response to NPT, and evidence of sIgE in the 
nasal secretions. A variety of allergens have been tested in this fashion including dust mites, 
grasses, pollens, and molds.300,301,306,307,955 The production of nasal mast cells, 
eosinophils, and sIgE rapidly increases after allergen-specific stimulation in the nasal 
mucosa.288,294,307 Different methods have been reported regarding how to best identify 
nasal sIgE including nasal lavage, cellulose disks, mucosal biopsy, and brushing (Table 
VIII.F.4). While there is no gold standard, most of these techniques appear to yield similar 
results in identifying nasal sIgE in LAR patients. Additionally, normative data for nasal sIgE 
levels and their clinical correlations have yet to be established and agreed upon, but work 
has begun in this area.956
When evaluating a rhinitis patient, in the setting of negative systemic testing, the 
differentiation of LAR from NAR can provide important information for management. 
While both typically respond to pharmacologic treatment, identification of offending 
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allergens in LAR may permit allergen avoidance and immunotherapy.107 AIT is the 
treatment of choice for patients with AR who have failed allergen avoidance and medical 
therapy. Patients who are classified as NAR, would not typically be candidates for AIT. 
However, as previously noted, roughly 50% of patients with negative systemic testing have 
been shown to have LAR. In this LAR population, early studies suggest that AIT can 
decrease symptoms and medication usage, and improve QOL.288,957
• Aggregate Grade of Evidence: C (Level 2b: 13 studies; Level 3b: 3 studies; Level 
4: 8 studies; Table VIII.F.4).
• Benefit: Identifying patients with LAR allows for the opportunity to treat a 
subset of patients who may respond to avoidance or AIT. Identification of nasal 
sIgE allows for diagnosis and AIT.
• Harm: Measurement of nasal sIgE is minimally invasive, and no adverse effects 
have been reported.
• Cost: Associated costs consist of the direct costs of testing, and indirect cost of 
increased time and effort for performing nasal sIgE diagnostic test.
• Benefits-Harm Assessment: The benefits of identifying patients with an allergic 
component to their rhinitis may outweigh any associated risks.
• Value Judgments: In patients with rhinitic symptoms and negative systemic 
testing, identifying nasal sIgE may assist with appropriate treatment. Standards 
for abnormal levels of nasal sIgE have not been established nor correlated with 
clinical outcomes.
• Policy Level: Option.
• Intervention: Nasal sIgE levels is an option in patients with suspected or known 
LAR to aid in diagnosis or guide allergen-specific therapy.
VIII.F.5. Basophil activation test (BAT)—The basophil activation test (BAT) is an ex 
vivo peripheral blood test that has been shown to be useful in the diagnosis of allergy to food 
and drugs, along with other hypersensitivity syndromes, when first-line tests (SPT and 
serum sIgE) are discordant with clinical history or do not exist, and for monitoring of AIT.
966 Within the field of AR, there are small-scale trials evaluating the utility and reliability of 
BAT in testing for the diagnosis of specific allergens related to AR symptoms and 
monitoring therapy (Table VIII.F.5).
BAT methodology was found to be heterogeneous between trials. Most data pertaining to its 
accuracy used the tetraspanin CD63 (lysosome-associated membrane glycoprotein 3 [LAMP 
3]) as an activation marker.967-971 CD203c (ecto-nucleotide pyrophosphatase/
phosphodiesterase 3) is less frequently used.968,972 In 1 trial, it held potential as a sensitive 
and specific method of testing for AR as compared to CD63.968
The diagnosis of AR is a clinical decision guided by skin or serological tests; ex vivo 
basophil testing is rarely required. However, BAT has been shown to be comparable with 
traditional allergen testing methods.967,970,973,974 BAT has been shown to be useful in 
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defining the allergen responsible for LAR in patients who have had false-negative results 
with first-line tests and a high suspicion for clinically-relevant allergy.308,318
Basophil reactivity (% CD63+ cells determined at 1 allergen concentration) does not reflect 
the effect of allergen immunotherapy. There is good evidence to suggest that basophil 
sensitivity (EC50, or eliciting concentration at which 50% of basophils respond; also named 
CD-sens if it is inverted and multiplied by 100) is a marker for treatment effect of 
AIT969-971,975-977 and anti-IgE treatment.975
In summary, BAT may be a useful ex vivo test when diagnosis of AR is in doubt or the 
allergen responsible for clinical symptoms is unknown. Basophil sensitivity is also useful for 
measuring response to AIT. When the methodology of BAT is more clearly standardized, it 
may become a more useful second line test in AR diagnosis, as using an ex vivo test is 
beneficial in terms of time taken to undergo testing and symptoms evoked during testing. 
Most studies included small samples sizes with less than 100 patients. There is an 
opportunity for a meta-analysis of these studies or a larger scale trial to confirm the findings 
of the works included in this review.
• Aggregate Grade of Evidence: B (Level 1b: 2 studies; Level 2b: 2 studies; Level 
3b: 8 studies; Level 4: 3 studies; Table VIII.F.5).
• Benefit: Ex vivo test, patient discomfort minimal, less time consuming than nasal 
provocation and SPT for patient, reliable correlation between clinical symptoms 
and basophil sensitivity when measuring response to therapy, no risk of 
anaphylaxis compared to provocation testing.
• Harm: None known.
• Cost: Requires proximity of laboratory trained in basophil testing. Cost of 
testing.
• Benefits-Harm Assessment: Balance of benefit over harm.
• Value Judgments: Basophil sensitivity may be a useful marker for following 
response to immunotherapy. Differences in BAT methodology for diagnosis of 
AR and rare need for laboratory tests to diagnose AR make it likely to be 
implemented for diagnosis in tertiary care centers only.
• Policy Level: Option.
• Intervention: BAT is an option for AR diagnosis when first-line tests are 
inconclusive or for measuring response to AIT. Many small-scale studies have 
been completed. There is scope for meta-analysis and for larger trials to be 
completed.
VIII.F.6. Component resolved diagnosis (CRD)—Molecular diagnosis (MD) or 
component resolved diagnosis (CRD) is used in allergy to define the allergen sensitization of 
a patient at the individual protein level by measuring sIgE to purified natural or recombinant 
allergens, allowing identification of the potential disease-eliciting molecules. Overall, MD 
can potentially improve diagnostic accuracy (specificity), distinguish cross-reactivity 
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phenomena from true co-sensitization, resolve low-risk markers from high-risk markers of 
disease activity, and may improve the indication and selection of suitable allergens for AIT 
when compared to diagnosis based on SPT and/or sIgE determination with raw commercial 
extracts.980-984 Indeed, changes in immunotherapy prescription aided by MD have been 
demonstrated to be cost-effective in some scenarios.985 Certain patterns of sensitization to 
grass or olive pollen allergens may also identify patients with higher risk of adverse reaction 
during immunotherapy.986,987 Nevertheless, all in vitro test results should be evaluated 
alongside the clinical history, since allergen sensitization does not necessarily imply clinical 
responsiveness.
IgE to purified or recombinant allergens is usually measured by using a fluorescence 
enzyme immunoassay in singleplex platforms. However, a multiplex platform with 112 
allergens is also available (ISAC, Thermo Fisher Scientific, Uppsala, Sweden). Results of 
singleplex and multiplex platforms are not interchangeable. When comparing the singleplex 
and multiplex assays, concordance of results vary between allergens tested, and the 
sensitivity of multiplex platform is lower than that of singleplex, particularly when sIgE 
levels are low.983 Otherwise singleplex platforms are quantitative assays and multiplex are 
semiquantitative.
Specific antigens.: In the case of mite sensitivity, markers of specific sensitization include 
Der p 1 and Der p 2 for Dermatophagoides pteronyssinus and Dermatophagoides farinae,988 
Lep d 2 for Lepidoglyphus destructor (storage mite, with limited cross-reactivity with other 
HDMs),989 and Blo t 5 for Blomia tropicalis (non-Pyroglyphidae mite).990 Der p 10, a 
tropomyosin from D. pteronyssinus, has been shown to be a good maker of clinical 
sensitivity to crustaceans but not a marker of sensitization to mites.991,992
Can f 1, Can f 2, and Can f 5 are specific allergen components indicating specific 
sensitization to dog.993 Interestingly, Can f 5, a prostatic kallikrein produced only by male 
dogs is responsible for monosensitivity in up to 25% to 38% of dog-allergic patients.994,995 
In these cases, patients can tolerate exposure to female dogs. Fel d 1 is the major allergen 
component in cat allergy, indicating specific sensitization.996 Other cat allergens have some 
cross-reactivity with allergens from other sources; eg, Fel d 2 is likely to cross-react with 
other mammal albumins, such as dog Can f 3, horse Ecu c 3, pig Sus s PSA, and cow Bos d 
6,997 and Fel d 4 is shown to cross-react with major allergens from horse Equ c 1, dog, or 
cow.998 Therefore, CRD for cat allergy provides more information about cross-reactivity and 
specificity of the diagnosis. Equ c 1, is the major allergen of horse dander and has some 
cross-reactivity with mouse Mus m 1 and cat Fel d 4.999 Equ c 3 is a serum albumin showing 
cross-reactivity with other mammals’ serum albumins mentioned above (i.e. Fel d 2). In 
summary, CRD in patients with allergy to dog, cat, and horse are not only predictive markers 
of allergy, but may also help clinicians to predict clinical symptoms and their severity, since 
some patterns of sensitization are related to more severe rhinitis and asthma.994,995
Allergens related to sensitization to cockroaches are Bla g 1, Bla g 2, Bla g 4, and Bla g 5, 
although in certain populations tropomyosins (Bla g 7 and/or Per a 7) can be important.1000 
Alt a 1 is a major allergen that is recognized in approximately 80% to 100% of Alternaria-
allergic patients.1001 Markers of sensitization to several pollen are summarized in Table 
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VIII.F.6. Sensitization to profilin has been associated with more severe respiratory 
symptoms in grass-allergic patients, as well as sensitization to the minor olive allergens Ole 
e 7 and Ole e 9.987,1002 IgE antibodies to Phl p 1 and/or Phl p 5 can be used as specific 
markers of sensitization to grass pollen and Phl p 4 as a marker of sensitization to non-
Pooideae grasses. However, Phl p 6 is contained only in Pooideae grasses. Allergens from 
groups 1, 2, 5 and 6 are only expressed in grasses but not in other plants, so they detect a 
genuine sensitization to grasses.981
In summary, CRD in patients with AR can help to better define the sensitization to inhalant 
allergens, especially in those who are polysensitized, have unclear symptoms and/or 
sensitization patterns, or who do not respond to treatment. On the contrary, monosensitized 
patients with a clear case history and symptom profile may not benefit from CRD compared 
to traditional diagnostic tests. Nevertheless, CRD remains a third-level approach, not to be 
used as a screening method in current practice. One of the most useful aspects of CRD is 
that it can help clinicians to better select patients and allergens for prescribing AIT,1003 and 
in some cases, predict the risk of adverse reactions. The pattern of sensitization to allergens 
may predict the severity of the disease and could potentially predict the efficacy of AIT, 
provided these immunotherapy products contain a sufficient amount of allergen. As there are 
multiple individual allergens available for CRD and several different uses for CRD, 
extensive evidence grading is not undertaken in this document.
VIII.G. Sensitization vs clinical allergy
Sensitization vs allergy—Although IgE-mediated sensitization has been consistently 
shown to be an important risk factor for rhinitis,520,1004 the strength of this association is not 
consistent.1005,1006 In epidemiology and clinical practice, patients are typically diagnosed as 
being “sensitized” based on a positive SPT (usually ≥3 mm wheal diameter), or a positive 
specific serum IgE (usually ≥0.35 kU/L [specific IgEs are reported in arbitrary units, thus 
the unit kU]).1007,1008 However, both of these tests can be positive in the absence of any 
symptoms, and neither positive SPT nor IgE can confirm the expression of rhinitis 
symptoms upon allergen exposure.1009,1010 Thus, a clear distinction has to be made between 
“sensitization” (which usually refers to positive allergy tests, irrespective of any symptoms), 
and clinical allergic disease such as AR, which denotes the presence of sensitization and 
related clinical symptoms.
“Positive” allergy test vs sIgE titer or SPT wheal size—Quantification of atopic 
sensitization by using the level of sIgE antibodies or the size of SPT wheals increases the 
specificity of allergy tests in relation to the presence and severity of rhinitis.893,1004 This has 
changed the way we interpret the results of allergy tests, with a move from dichotomization 
(labeling patients as being sensitized based on a “positive” test using arbitrary criteria), to 
quantification of blood or skin tests using sIgE titer and SPT wheal size.893,1010-1012
Whole-allergen extract vs individual allergenic molecules—Homologous proteins 
present in the whole-allergen extracts from different allergen sources may be cross-reactive 
(eg, profilins and PR-10 proteins in various plants, or tropomyosin present in mites, various 
insects, and shrimp). Thus, a positive test to the whole-allergen extract may reflect 
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sensitization to a cross-reactive component.1013 Measuring sensitization to individual 
allergen molecules in a CRD may more be informative than standard tests using whole-
allergen extracts.470,1014-1016 Current multiplex CRD platforms allow the testing for 
component-specific IgE to more than 100 allergenic molecules in a single assay, and in a 
small volume of serum.1013,1015 The patterns of component-specific IgE responses to 
multiple allergenic proteins have a reasonable discrimination ability for rhinoconjuinctivitis,
1017 and distinct patterns of IgE responses to different protein families are associated with 
different clinical symptoms. For example, sensitization to proteins of plant origin strongly 
predicts AR, and sensitization to animal lipocalins is predictive of asthma.1018,1019 The risk 
of allergic disease increases with the increasing number of sensitizations to individual 
allergenic proteins, and IgE polysensitization to several HDM molecules strongly predicts 
rhinitis.1019,1020 It is important to emphasize that the age of onset of sensitization is 
crucially important, and that development of AR may be predicted by the unique molecular 
nature of IgE responses to individual allergen components.1019
Disaggregating atopic sensitization—It is becoming increasingly clear that “atopic 
sensitization” is not a single phenotype, but an umbrella term for several different atopic 
vulnerabilities which differ in their association with rhinitis and asthma.1021,1022 Different 
subtypes of atopy are characterized by a unique pattern of the responses to different 
allergens and the timing of onset of allergen-specific sensitization.1023 Translation of these 
findings into clinical practice requires the development of biomarkers which can 
differentiate between different subtypes of sensitization, and can be measured at the time of 
clinical evaluation.
Beyond IgE—Recent data suggest that among individuals sensitized to grass pollen, the 
decreasing ratio of grass allergen-specific IgG/IgE antibodies is associated with increasing 
risk of symptomatic SAR,1024 suggesting that the IgG/IgE ratio may help distinguish 
between “benign” sensitization (sensitization with no symptoms) and “pathologic” 
sensitization.1024 However, the measurement of allergen-specific IgG cannot as yet be 
recommended in a routine clinical practice.1009,1010
VIII.H. Allergen challenge testing
VIII.H.1. Allergen challenge chambers (ACCs)—Environmental exposure chambers 
(EECs) have been used for decades for controlled exposure of subjects to a well-defined 
atmosphere of a variety of substances such as allergens, particulate and gaseous air 
pollutants, chemicals, or climate conditions. The generation of valid exposure conditions 
with high temporal and spatial stability is technically demanding, and there are a limited 
number of EECs world-wide. Besides the opportunity to use EECs for well-designed 
mechanistic studies on the effect of environmental pollutants on human health, allergen 
challenge in the chamber setting with induction of symptoms in patients with allergic 
disease is an intriguing way for efficacy testing of new drugs. Therefore, several chamber 
facilities were installed in recent years with the focus on allergen exposure resulting in 
currently 15 allergen challenge chamber (ACC) facilities around the globe.1025
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ACC studies have contributed to our understanding of the pathophysiology of allergic 
diseases. For example, it has been demonstrated that controlled allergen exposure 
exacerbates atopic dermatitis.1026 Also, the impact of exposure with pollen allergen 
fragments on AR symptoms has been shown.1027 Furthermore, the importance of the 
integrity of the epithelial barrier for induction of local and systemic inflammatory responses 
has been investigated in patients with allergic rhinoconjunctivitis using the ACC setting.1028
The use of ACCs in clinical trials for efficacy testing of investigational new drugs, and their 
acceptance by regulatory authorities is peremptorily dependent on the technical and clinical 
validation of ACCs. Many ACCs have been intensively validated regarding specificity and 
dose-dependency of symptom induction as well as technical aspects such as temporal 
stability and spatial homogeneity of the allergen exposure.1029-1037 Also, repeatability of 
outcome measures in the ACC has been systematically investigated and found to have 
excellent repeatability as measured by TNSS.1038 With the given level of technical and 
clinical validation, ACCs have been intensively used in clinical drug development to study 
pharmacological properties of new drugs during phase II trials, such as dose-finding,
1039-1041 onset of action,1042-1046 and duration of action.1047-1049 In this respect, numerous 
randomized, placebo-controlled clinical trials have been conducted using parallel-group or 
crossover designs in order to test the efficacy of drugs with immediate therapeutic activity, 
such as antihistamines,1050-1053 or with prophylactic therapeutic potential, such as topical 
steroids,1054-1056 novel anti-inflammatory compounds,1057-1060 or probiotics.1061 Major 
advantages in the ACC setting compared to field studies are better signal-to-noise ratios, a 
safeguarded minimum level of symptomatology in the ACC, and repeatability of symptoms 
allowing intraindividual comparisons.
With availability of a variety of validated allergen atmospheres in challenge chambers,
1029,1030,1034,1035 efficacy testing for dose-finding of AIT has also been performed in RCTs.
1062-1066 While regulatory authorities accept the use of ACC in phase II of drug 
development,1067,1068 they have been reluctant to approve them in pivotal phase III studies 
because the clinical validation is still imperfect. Differences between natural exposure in 
field studies and ACC studies exist, for example with regard to exposure time (continuous vs 
intermittent), exposure atmosphere complexity (natural mix vs artificial purity), or selection 
of study population (all-comers vs allergen-challenge responders). Therefore, evaluation of 
efficacy during natural exposure in phase III field studies is still mandatory. However, recent 
joint activities of the EAACI with experts from academia, chamber owners, and regulators 
have defined the most relevant unmet needs and prerequisites for clinical validation to 
further develop the use and regulatory acceptance of ACC in pivotal phase III studies.
In summary, numerous well-designed RCTs using technically validated ACCs for efficacy 
testing of investigational new drugs with detailed analysis of dose-response, onset of action, 
and duration of action provide evidence for the use of ACCs in phase II of clinical drug 
development.
VIII.H.2. Local allergen challenge tests—Challenging the target organs of 
respiratory allergy (ie, nose, bronchi, eye) with a suspected allergen is aimed at 
demonstrating the actual clinical reactivity when the results of the initial allergy tests (skin 
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tests, in vitro measurement of sIgE) are inconclusive. The NPT is designed for AR, while 
conjunctival provocation test (CPT) may be used in patients with rhinoconjunctivitis or AR 
alone.1069,1070
Nasal challenge.: The aim of nasal challenge is to reproduce the response of the upper 
airway upon nasal exposure to allergens.1071,1072 However, currently the only technique 
fulfilling this aim is the EEC (as described in the previous section), while the allergen 
amounts administered during an NPT usually exceed natural exposure levels, sometimes to a 
large extent. The allergen for NPT can be administered by various devices, including 
syringes, nose droppers, micropipettes, nasal sprays, or impregnated disks, none of them 
being free from limitations or pitfalls.1071 The result of a NPT can be assessed by several 
measures, including symptom scores (especially the TNSS), rhinomanometry, acoustic 
rhinometry, optical rhinometry, peak nasal inspiratory flow, inflammatory markers in nasal 
lavage fluid, and nasal NO concentration.1072 Contraindications to NPT are acute bacterial 
or viral rhinosinusitis, exacerbation of AR, history of anaphylaxis to allergens, severe 
general diseases, and pregnancy.1073 Recent studies evaluating the sensitivity and specificity 
of the different techniques using specific allergens are available (Table VIII.H.2). It is 
apparent from the contrasting findings that a standardized technique for NPT is not yet 
available. In fact, in the coming years, the use of NPT in the diagnosis of AR is likely to 
decrease, due to the diagnostic ability of emerging tools such as CRD1074 and the BAT,1075 
which are able to identify the causative allergen in patients with dubious results from initial 
analysis.
Despite its limitations, a pivotal role for NPT is currently acknowledged in diagnosis of 
occupational rhinitis and LAR. According to the position paper of the EAACI, occupational 
rhinitis “can only be established by objective demonstration of the causal relationship 
between rhinitis and the work environment through NPT with the suspected agent(s) in the 
laboratory, which is considered the gold standard for diagnosis.”84 The best time to perform 
a NPT is in the morning to limit the effects of common daily-life stimuli. Baseline 
evaluation of symptoms and nasal function should be done after adaptation to room 
temperature. A control test must be performed to ensure that the nasal response is specific to 
the tested agent.1076 A positive control test suggests rhinitis induced by irritants or 
nonspecific hyperresponsiveness.
In regard to LAR, the absence of sIgE in serum and in the skin requires that IgE are found 
locally or that they are revealed by a positive NPT.1077 Despite the introduction of 
techniques to detect IgE in the nose in the 1970s,1078 the ability to measure locally-present 
IgE in the clinic setting is not currently available. This makes NPT of critical importance, 
though contrasting observations have been reported. NPT with mites, pollens and Alternaria 
was positive in 100% of 22 adults with previously diagnosed LAR,1079 but in a case-
controlled, prospective study on 28 children with a diagnosis of NAR, tested with mites and 
grass pollen, NPT was positive in only 25% of subjects.293
Conjunctival challenge.: While several different techniques exist for NPT, CPT is generally 
performed by instilling 20 to 30 μL of an allergen solution into the inferior external quadrant 
of the ocular conjunctiva, using diluent in the contralateral eye as a control.1069 Also, the 
Wise et al. Page 80













positive response to CPT is simple to evaluate, because it consists of an immediate reaction 
(from 5 to 20 minutes from the instillation) with ocular itching, tearing, redness, and 
possibly conjunctival edema. In 1984, a study of 20 children with seasonal 
rhinoconjunctivitis tested 3 times with CPT reported good reproducibility.1080 In 2001, a 
diagnostic sensitivity and specificity of 90% and 100%, respectively, was reported in mite-
allergic patients.1081 A very recent systematic review was performed and the results were 
published in the EAACI guidelines for daily practice of CPT, with grade B evidence for the 
capacity to individuate the allergen trigger.1082 The conclusion highlighted that allergists 
should be more familiar with CPT due to its simplicity. However, the scales to assess the 
symptoms need to be validated, the standardization of allergen extracts must be improved 
and the indication to perform CPT in patients with forms of conjunctivitis other than allergic 
remains uncertain.
• Aggregate Grade of Evidence for Nasal Provocation Testing: C (Level 2b: 4 
studies). Of note, this evidence grade is based on the studies listed in Table 
VIII.H.2. However, due to the variation in NPT technique and outcome 
measures, a reliable evidence grade for NPT is difficult to determine.
VIII.I. Nasal cytology and histology
Nasal cytology (NC) is a simple diagnostic procedure that evaluates the health of the nasal 
mucosa by recognizing and counting cell types and their morphology.1087 NC requires 3 
steps. The first is sampling the surface cells in the nasal mucosa with an appropriate device 
via anterior rhinoscopy. The most commonly used collection device is the Rhino-probe 
(Arlington Scientific, Springville, UT, USA).1088 The second step is staining by the May-
Grunwald-Giemsa method, which allows for identification of all inflammatory cells present 
in the nasal mucosa (ie, neutrophils, eosinophils, lymphocytes, and mast cells) as well as 
normal mucosal cells (ciliated and mucinous), and even bacteria or fungi. The third step is 
examination through an optical microscope able to magnify up to 1000×. For the analysis, at 
least 50 microscopic fields must be read to be sure to detect all the cells in the sample.1087 
NC may detect viruses, fungi, and bacteria (including biofilms) in the nose, allowing for the 
diagnosis of infectious rhinitis.1089 Specific cytological patterns on NC can help in 
discriminating among various forms of rhinitis, including AR, NAR, idiopathic rhinitis, and 
overlapping forms. AR is commonly diagnosed by the combination of clinical history and 
results of in vivo and/or in vitro tests for sIgE antibodies.1090 When assessed by NC, the 
predominant cell type is the eosinophil, followed by mast cells and basophils.1091-1094 In a 
logistic regression model, elevated nasal eosinophil counts on NC has an OR of 1.14 (95% 
CI, 1.10 to 1.18) to identify AR.1092 It has been described that NC in polyallergic patients 
shows a more intense inflammatory infiltrate than in monoallergic patients.1093 NC has also 
demonstrated seasonal changes of inflammatory cells in the nose, probably mirroring the 
variations in allergen exposure, in patients with mite-induced rhinitis.1095
Negative allergy testing in patients with persistent rhinitis usually suggest a diagnosis of 
NAR.1096 The first variant of NAR, known as NARES, was described after the identification 
of a subset of patients with perennial rhinitis, negative skin tests, and marked eosinophilia in 
nasal secretions.174 In more recent years, other variants have been defined, including NAR 
with mast cells (NARMA), with neutrophils (NARNE), and with eosinophils and mast cells 
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(NARESMA).1097 Idiopathic rhinitis is also characterized by high levels of eosinophils and 
mast cells in some patients.1098 Overlapping forms may occur.1099
NC is 1 method of diagnosing NAR and has been used to differentiate between variants in 
experiments.1100 However, few studies investigating the diagnostic performance of NC in 
diagnosing AR or NAR are available (Table VIII.I-1).
• Aggregate Grade of Evidence: C (Level 3b: 3 studies; Level 4: 1 study; Table 
VIII.I-1).
Nasal histology as assessed by biopsies of the nasal cavity was the only technique to study 
tissues and cells in patients with AR for many decades. In the 1990s, biopsy-based 
investigations allowed researchers to define the role of the different inflammatory cells in 
AR.379 The original technique begins by spraying a local anesthetic and topical 
vasoconstrictor into the nasal passages. After anesthesia has taken effect, a piece of tissue is 
removed from the middle turbinate using small punch biopsy forceps. After immediately 
placing the tissue in buffered formalin, each specimen can then be stained with various 
reagents to detect different tissue components and cells.1101 Reagents used include Giemsa, 
hematoxylin/eosin, periodic acid-Schiff, Masson trichrome, azure A, and chloroacetate 
esterase.299,415,1101 After staining, the slides are examined by an optical double-headed light 
microscope, using a grid reticule divided into 100 squares to quantitate cells and tissue per 
square millimeter.
The introduction of NC made it possible to obtain the similar information as histology, but 
without the associated discomfort and potential risk for bleeding. Further, NC allows for 
sequential sampling where histology does not. In addition, when Lim et al.415 compared 
nasal histology with cytology in patients with perennial and seasonal rhinitis compared to 
controls, the results suggested that nasal secretions and the nasal mucosa represent 2 distinct 
cellular compartments. Specifically, following allergen challenge an influx of inflammatory 
cells was detected by cytology, while the epithelial layer assessed by histology was 
unchanged from baseline.415 In 2005, Howarth et al.1102 stated that, compared to simple 
techniques such as NC or nasal lavage, nasal biopsy requires expertise both in tissue 
sampling and in biopsy processing, thus being applicable only in specialist centers. This 
issue, as well as the previously reported drawbacks, makes nasal histology a technique of 
interest in the research on pathophysiology of AR but hardly feasible for routine clinical 
practice. Table VIII.I-2 shows the available studies on AR pathophysiology as evaluated by 
nasal histology.




Allergen avoidance and environmental controls (ECs) are frequently discussed as part of the 
treatment strategy for AR, along with pharmacologic management and AIT. AR patients are 
keen to learn about avoidance measures and ECs, especially those who wish to avoid 
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medications or cannot commit to an AIT regimen. Considering this, it is important to 
examine the evidence supporting allergen avoidance and EC measures for the allergic 
patient.
IX.A.1. House dust mite—Techniques to reduce environmental HDM exposure have 
been investigated for the treatment of AR. HDMs represent 1 of the most common triggers 
of AR,1114 and EC measures have been advocated as a management strategy, with evaluation 
of both physical barriers and chemical treatments.1114-1118 Various physical techniques (eg, 
heating, ventilation, freezing, barrier methods, air filtration, vacuuming, and ionizers) have 
been evaluated for the treatment of AR, with variable findings. While several studies have 
demonstrated decreased concentrations of environmental HDM antigens,1119-1124 an 
associated reduction in clinical symptoms has not been reliably demonstrated (Table 
IX.A.1). Despite reductions in HDM antigen concentration, Ghazala et al.1120 and 
Terreehorst et al.1124 both found no clinical benefits of HDM-impermeable bedding as an 
isolated intervention. Similar findings were reported by Antonicelli et al.1125 following a 
trial of high efficiency particulate air (HEPA) filtration.
Chemical techniques include the use of acaricides in household cleaners to reduce HDM 
concentration. Geller-Bernstein et al.1119 evaluated an acaricide spray in the bedrooms of 
patients with HDM sensitization, demonstrating improved mean symptom scores vs control 
patients without acaricide. Similar findings were reported by Kniest et al.1121 No serious 
adverse effects were reported from any of the evaluated interventions, and no study 
evaluated cost-effectiveness as an outcome measure. A 2010 Cochrane review examined the 
effectiveness of environmental measures for HDM including impermeable covers, HEPA 
filters, acaricides, or combination treatments.1126 This systematic review found acaricides to 
be the most effective as a single measure or in combination with other measures to decrease 
HDM levels and improve AR symptoms.
• Aggregate Grade of Evidence: B (Level 1a; 1 study; Level 1b: 3 studies; Level 
2a: 1 study; Level 2b 7 studies; Table IX.A.1).
• Benefit: Reduced concentration of environmental HDM antigens with potential 
improvement in symptom scores and QOL.
• Harm: None.
• Cost: Low to moderate; however, cost-effectiveness was not evaluated.
• Benefits-Harm Assessment: Benefit outweighs harm.
• Value Judgments: The use of acaricides and/or bedroom-based control programs 
in reducing HDM concentration is promising, but further, high-quality studies 
are needed to evaluate clinical outcomes.
• Policy Level: Option.
• Intervention: Concomitant use of acaricides and EC measures, such as 
personalized air filtration techniques, are options for the treatment of AR.
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IX.A.2. Cockroach—Cockroach infestation and allergen concentrations are often high in 
multi-occupant dwellings in densely populated inner city areas; although elevated levels of 
cockroach allergen are also found in homes in warmer, rural regions.1129-1131 Interventions 
are targeted at eliminating infestations and abating cockroach allergen in homes. A 
systematic review by Le Cann et al.,1132 identified 3 key strategies for home environmental 
interventions: (1) education-based methods that included instruction on house cleaning 
measures and sealing cracks and crevices in areas where infestation occurs (ie, kitchens); (2) 
physical methods using insecticides or bait traps; and (3) combination therapy containing 
both educational-based interventions and physical methods (Table IX.A.2).
Most studies included 1 or more interventions aimed at reducing cockroach counts and 
allergen (Bla g 1 and Bla g 2) levels1133-1140; however, a few focused on eliminating 
multiple allergens (eg, HDM, cockroach, rodent, cat, dog).1141,1142 The most effective 
treatment for eliminating infestation and reducing allergen load was professional pest 
control.1135 Sever et al.1133 found placement of insecticide bait traps to be more effective in 
reducing cockroach populations with a concomitant reduction in cockroach allergen 
compared to homes that received applications of insecticide formulations to baseboards, 
cracks, and crevices monitored over a 12-month period.
When cost was considered, the price of bait traps along with labor and monitoring costs 
were found to be less expensive than multiple commercial applications of insecticide sprays 
to baseboards and cracks.1133 As the expense of integrated home management consisting of 
professional cleaning, education, and pest control is not economically sustainable, 
investigations are focused on assessing the efficacy of single interventions, such as 
extermination alone, to assess possible cost benefits.1135,1143 In addition, family adherence 
to home-based interventions was generally poor, resulting in elevated cockroach 
concentrations over time.1138
Although there are a substantial number of RCTs that evaluated the efficacy of specific 
environmental control measures to eliminate the number of cockroaches and reduce 
cockroach allergen level, respiratory health outcomes were rarely measured. Even though 
cockroach count and Bla g1 and Bla g2 allergen levels were reduced in many studies with 
home interventions, the level of cockroach allergen following treatment remained higher 
than acceptable median levels associated with clinical benefits in sensitized individuals.
1134,1137-1140 Although cockroach count could be significantly reduced in single-family 
homes using bait traps, re-infestation and high allergen levels remained an ongoing problem 
in multifamily buildings.1140 Thus it is difficult to dramatically reduce cockroach allergen 
levels in the home unless a significant reduction in cockroach counts is maintained over 
time.1133 Most studies did not include clinical endpoints; however, those that did evaluate 
clinical outcomes focused on asthma symptoms, hospitalizations or emergency room visits, 
and medication usage.1141,1142 No studies included any assessment of symptoms associated 
with AR or its treatment.
• Aggregate Grade of Evidence: B (Level 1a: 1 study; Level 1b: 8 studies; Level 
2b: 1 study; Level 3b: 1 study; Table IX.A.2).
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• Benefit: Reduction in cockroach count, but allergen levels (Bla g 1 and Bla g 2) 
often above acceptable levels for clinical benefits. No studies included clinical 
endpoints related to AR.
• Harm: None reported.
• Cost: Moderate. Multiple treatments applications required as well as a multi-
interventional approach.
• Benefits-Harm Assessment: Balance of benefit and harm, given lack of clear 
clinical benefit.
• Value Judgments: Control of cockroach populations especially in densely 
populated, multifamily dwellings is important to controlling allergen levels.
• Policy Level: Option.
• Intervention: Combination of physical measures (such as insecticide bait traps, 
house cleaning) and educational-based methods are options in the management 
of AR related to cockroach exposure.
IX.A.3. Pets—Pet avoidance and EC represent options for the treatment of AR. Pet 
removal is a commonly cited strategy without high-quality outcomes evaluation.
1118,1144,1145 Sánchez et al.1146 evaluated compliance rates among sensitized patients (n = 
288), finding 4% of patients with direct exposure to home animals complied with removal 
recommendations (Table IX.A.3). EC has therefore been evaluated to decrease antigen 
exposure, with mixed results. Björnsdottir et al.1147 evaluated outcomes of multimodality 
EC among 40 patients with diagnosed cat (Fel d 1) sensitization, finding significant 
improvements in nasal airflow and clinical symptoms. However, despite reductions in 
environmental antigens, single-modality EC has not been associated with improved 
symptoms. Wood et al.1148 evaluated HEPA filtration in a high-quality randomized 
controlled study of 35 patients with Fel d 1 sensitization, finding unchanged nasal symptom 
scores, sleep disturbance, rescue medication usage, and spirometry following a 3-month 
trial. Several lower-quality studies have evaluated the duration of antigen reduction 
following pet washing, finding that cat and dog washing must be completed at least twice 
weekly to maintain significant reductions in environmental antigens.1149,1150 Furthermore, 
pet removal may only result in decreased allergen levels after several months1151 and Can f 
1 levels in homes with “hypoallergenic” animals are generally similar to homes with non-
hypoallergenic species.1152
An additional study has identified benefits of pet avoidance in the secondary prevention of 
asthma among previously sensitized individuals.1153 Similarly, current asthma treatment 
guidelines recommend pet removal from a sensitized individual’s home.1154
• Aggregate Grade of Evidence: B (Level 1b: 1 study; Level 2b: 2 studies; Table 
IX.A.3.)
• Benefit: Decreased environmental antigen exposure with possible reduction in 
nasal symptoms and secondary prevention of asthma.
Wise et al. Page 85













• Harm: Emotional distress caused by removal of household pets. Financial and 
time costs of potentially ineffective intervention.
• Cost: Low to moderate.
• Benefits-Harm Assessment: Equivocal.
• Value Judgments: While several studies have demonstrated an association 
between EC and reductions in environmental antigens, only a single, 
multimodality RCT has demonstrated clinical improvement in nasal symptoms 
among patients with Fel d 1 sensitivity. The secondary prevention and treatment 
of asthma in sensitized individuals must also be considered.
• Policy Level: Option.
• Intervention: Pet avoidance and EC strategies, particularly multimodality EC 
among patients with diagnosed Fel d 1 sensitivity, are an option for the treatment 
of AR related to pets.
IX.A.4. Other (pollen, occupational)—For patients with pollen allergy, avoidance 
measures aim to minimize allergen exposure during the respective pollen season.101 
However, pollination is a global natural phenomenon which periodically occurs, making it 
nearly impossible for patients to thoroughly avoid exposure. There are some practical 
methods to minimize patients’ exposure via EC measures. However, there is a paucity of 
clinical trials evaluating the clinical efficacy of therapeutic strategies. Most of the 
recommended strategies are based on expert consensus and clinical experience.1155
One potential EC strategy is limiting residential exposure during periods of high pollination 
(ie, vacationing in geographical regions with a reduced intensity of local pollen 
concentration).1156 Patients can get further information about the current pollen count in 
their respective region through internet sources (ie, the European Aeroallergen Network 
[EAN] database [https://ean.polleninfo.eu/Ean/]; Foundation German Pollen Information 
Service [http://www.pollenstiftung.de/]; American Academy of Allergy Asthma and 
Immunology [AAAAI] [http://www.aaaai.org/global/nab-pollen-counts]). This information 
may be used, for example, in avoidance of extensive outdoor exercise during peak pollen 
levels or timing of preventive medication.1157,1158 Although expert opinion endorses these 
strategies, there is no evidence to support their clinical efficacy.
In addition, patients may open their home windows when the pollen counts are low or keep 
windows closed and use air conditioning during times of high pollination. Special dust and 
pollen filters may be used in cars to reduce the pollen concentration within the car. 
Furthermore, pollen-allergic patients may be educated on removal of clothing and washing 
their hair before entering their bedrooms during pollen season as pollen grains stick to both 
hair and clothing. Again, expert opinion endorses these strategies, but there is no evidence to 
support their clinical efficacy.1159,1160
Another EC strategy utilizes physical barriers to minimize mucosal exposure to airborne 
allergens. In a prospective trial, 70 patients with SAR caused by grass pollen were 
randomized to receive wrap-around eyeglasses in addition to standard medical care (first 
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study group) or just standard medical care (second study group) during 3 consecutive grass 
pollen seasons.1161 Interestingly, the authors found a significant improvement in ocular and 
nasal symptoms as well as RQLQ in the group provided with wraparound eyeglasses 
compared to the controls. Another approach is an active nasal filter by means of a membrane 
removing particles from the inhaled air.1162 In a prospective, single-center, randomized, 
double-blind, placebo-controlled, crossover study performed in an ACC, 24 adult patients 
with grass-pollen induced SAR were randomly assigned to either a group that received this 
nasal filtering membrane or to a group that did not.1162 Under repeated exposure in the 
ACC, patients with the membrane filter significantly improved in some of their nasal 
symptoms. However, the primary endpoint measuring maximum TNSS in this trial was not 
significant; thus, meaningful conclusions are difficult to draw from this study.1162 The small 
sample size was a notable limitation. A real-world, single-center, double-blind, crossover 
trial of 65 patients by the same researchers, however, did find significant reductions in daily 
TNSS and maximum TNSS with nasal filters used in-season compared to placebo1163 (Table 
IX.A.4).
Avoidance of exposure to occupational inhalant allergens is feasible, in principle, in 
occupational allergic patients.112 Several modalities of reducing workers’ exposure to 
occupational allergens such as “engineering controls” and “administrative controls” have 
been described in the literature.1164 The former includes substitution of a hazardous 
chemical with a nonhazardous or less-hazardous alternative, isolation of the hazardous 
chemical, or efficient ventilation to reduce workers’ exposure. The latter includes workers’ 
education and personal protective equipment. A prospective controlled trial of 20 patients 
with confirmed diagnosis of occupational allergy demonstrated that cessation of the 
exposure of the causal allergen in the workplace led to a significant improvement of 
patients’ nasal symptom scores as well as disease-specific QOL.1165
• Aggregate Grade of Evidence: B (Level 1b: 3 studies; Level 2b: 1 study; Table 
IX.A.4).
• Benefit: Decreased allergen exposure with possible reduction in symptoms and 
need for allergy medication, along with improved QOL.
• Harm: Financial and time costs of potentially ineffective intervention.
• Cost: Low, but dependent on the EC strategy (ie, for occupational allergy 
ventilation measures and other “engineering controls” may be high).
• Benefits-Harm Assessment: Equivocal.
• Value Judgments: A limited number of studies show clinical effects of 
investigated EC measures. General EC recommendations are mainly based on 
expert opinions rather than evidence.
• Policy Level: Option.
• Intervention: Pollen and occupational allergen avoidance by EC strategies are an 
option for the treatment of AR; however, clinical efficacy has not been 
definitively demonstrated. More RCTs with larger samples are warranted to 
prospectively evaluate clinical efficacy.
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Whether selected by patients themselves or prescribed by medical personnel, medications 
are the primary modality for control of allergic symptoms. There are numerous options for 
oral or systemic use, topical intranasal application, and alternative therapies that can be 
considered. It is, therefore, imperative to understand the data supporting the efficacy and 
appropriate use of these pharmacotherapy options.
IX.B.1. Antihistamines
IX.B.1.a. Oral H1 antihistamines.: Histamine is a major mediator associated with the 
symptomatology of AR. Oral H1 antihistamines block the action of histamine by binding the 
histamine H1 receptor, thereby inhibiting the proinflammatory effects of histamine. 
Antihistamines are typically categorized by generation, such as first or second-generation 
agents. The older first-generation agents (ie, diphenhydramine, chlorpheniramine, 
brompheniramine) were lipophilic and readily crossed the blood-brain barrier. This caused 
unwanted side effects such as sedation, drowsiness, fatigue, and impaired concentration, and 
memory as well as anti-muscarinic effects. First-generation antihistamines are also inhibitors 
of the CYP2D6 hepatic enzymes. They may, therefore, alter the metabolism of other 
medicines dependent upon CYP2D6 metabolism, such as tricyclic antidepressants, some 
antipsychotics, β-blockers, anti-arrhythmics, and tramadol. Because of these significant side 
effects, in previously published guidelines and other papers, first-generation antihistamines 
have not been recommended for the treatment of AR.218,1166,1167 The newer-generation 
agents (ie, loratadine, desloratadine, fexofenadine, cetirizine, levocetirizine) were developed 
to minimize the adverse effects of earlier drugs. They are highly selective for the H1 
receptor, lipophobic, and have limited penetration across the blood-brain barrier.
Newer-generation antihistamines, except for cetirizine, levocetirizine, bilastine, and 
fexofenadine, are metabolized by the hepatic cytochrome P450 CYP3A4 system. 
Practitioners should be cognizant that the concurrent use of other medicines (eg, macrolides, 
antifungals, or calcium-channel blockers) that inhibit CYP3A4 can result in accumulation of 
drug concentrations and increase the risk for side effects and toxicity. Furthermore, adverse 
cardiac effects (torsades de pointes, arrhythmia, and prolongation of the QT interval) were 
reported with astemizole and terfenadine, leading to their ultimate withdrawal from the 
market.1168,1169 RCTs have established the long-term safety and efficacy of the newer-
generation H1 antihistamines cetirizine, desloratadine, fexofenadine, levocetirizine, and 
loratadine (Table IX.B.1.a-1).
Because oral antihistamines have been in use since the early 1940s, there have been many 
RCTs establishing oral antihistamines as an appropriate pharmacotherapy for AR.218 As 
such, this section does not list every published study but summarizes the highest-grade 
evidence that has been published. Guidelines on AR have been published, including those by 
the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS)761 and the 
ARIA group.1167 The AAO-HNS concluded, based upon RCTs and a preponderance of 
benefit over harm, a “strong recommendation” for the use of newer-generation oral H1 
antihistamines for patients with AR.218 Similar consensus came from ARIA where a “strong 
recommendation” was given for oral H1 antihistamines for AR.1167 Furthermore, ARIA and 
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EAACI have published a set of recommendations that outline the pharmacological criteria 
that should be met by medications commonly used in the treatment of AR.1170 The main 
thrust of the ARIA/EAACI criteria was to assess the efficacy, safety, and pharmacology of 
newer-generation oral H1 antihistamines using level 1a studies. Using these criteria, a 
favorable risk-benefit ratio was determined for using newer-generation oral H1 
antihistamines over first-generation oral antihistamines.1170 The evidence was further 
strengthened with several meta-analyses of the current data, where accurate and robust effect 
estimations can be derived from a large population1171 (Table IX.B.1.a-1).
The choice of a specific oral H1 antihistamine is often based upon the dosing, onset, drug 
interactions, and potential cost (Table IX.B.1.a-2). Systematic reviews evaluating multiple 
oral H1 antihistamines note benefits of certain drugs that may be important in deciding 
which drug to recommend or prescribe. Direct costs of newer-generation antihistamines are 
similar given the availability of many of these drugs as over-the-counter medications. In 
contrast, the cost of prescription-only formulations (levocetirizine and desloratadine) is 
much higher. Indirect costs would be expected to be similar among the newer-generation 
oral antihistamines given similar side-effect profiles.
• Aggregate Grade of Evidence: A (Level 1a: 21 studies; Table IX.B.1.a-1). There 
is a preponderance of high-grade investigations that have examined oral H1 
antihistamines. Only level 1a studies are summarized in the table.
• Benefit: Reduced nasal itching, sneezing, rhinorrhea, and nasal obstruction.
• Harm: Mild drowsiness, fatigue, headache, nausea, and dry mouth.
• Cost: Direct costs low (average $2 per daily dose). Indirect costs for newer 
generation agents lower than first-generation agents.1172,1173
• Benefits-Harm Assessment: Benefits outweigh harm for use of newer-generation 
oral H1 antihistamines.
• Value Judgments: Due to the central nervous system side effects of the first-
generation oral H1 antihistamines, their use is not recommended for typical AR.
• Policy Level: Strong recommendation for use of newer-generation oral 
antihistamines to treat AR.
• Intervention: Prescribing newer-generation oral H1 antihistamines for patients 
with AR should be considered early in treatment.
IX.B.1.b. Oral H2 antihistamines.: The role of the H2 receptor in mediating histamine-
related nasal symptoms in AR is controversial. Few small studies have investigated the 
impact of H2 receptor antagonism, with varied results (Table IX.B.1.b). Further, no data 
exists comparing H2 receptor antagonism efficacy to common modern first-line therapy such 
as nasal topical corticosteroids. Finally, the clinical significance of the changes associated 
with H2 antihistamines has not been clearly defined. Despite these caveats, some studies 
support the addition of an H2 antihistamine for patients with recalcitrant nasal airway 
obstruction while on oral H1 antihistamines. There are drug-drug interactions that can occur 
with H2 antihistamines through decreased gastric acidity and inhibition of P450.1192 
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However, due to the low cost of these medications, clinical situations may arise that would 
justify their use.
All but 1 of the RCTs investigating the efficacy of H2 antihistamines are within the context 
of pretreatment of a subject prior to a nasal allergen challenge. Wood-Baker et al.1193 
compared oral cetirizine to oral ranitidine. Objective measures of nasal airway resistance 
showed greater improvement with ranitidine, yet cetirizine decreased objective measures of 
nasal secretion more than ranitidine. Taylor-Clark et al.1194 found similar improvement in 
nasal airway resistance between cetirizine and ranitidine, but a significant improvement with 
the use of combination therapy. Combination therapy was also shown to improve nasal 
airflow when cimetidine was added to cetirizine.1195 Two studies did not find improvement 
in nasal airflow with the addition of an H2 antihistamine.1196,1197 The clinical significance 
of these objective findings is unclear, and the studies that employed PROMs did not 
demonstrate subjective improvement in nasal obstruction.
Four studies investigated the impact of H2 antagonism on symptoms; however, these studies 
did not utilize standardized outcome measures as they pre-dated the development of such 
tools. Subjects were asked to report some combination of congestion, blockage, itching, 
drainage, sneezing, eye symptoms, and asthma with a categorical severity measure. Three of 
the 4 studies examined symptoms after nasal allergen challenge, and none demonstrated 
efficacy of H2 antihistamines, either alone or in conjunction with an H1 antihistamine in 
diminishing allergic symptoms.1195-1198 One study of 23 subjects1198 did investigate the 
impact of cimetidine in conjunction with chlorpheniramine in a real-world setting. Subjects 
with known late-summer AR were randomized during this season to receive alternating 2-
week courses of either chlorpheniramine plus placebo, or chlorpheniramine plus cimetidine, 
and symptom scores were recorded twice daily along with adjuvant medical therapies 
(specifically, oral corticosteroids). Patients receiving both H1 and H2 antihistamines reported 
decreased medication usage (28 corticosteroid days vs 44 corticosteroid days, p < 0.02) and 
decreased symptoms scores during 1 of the 8 weeks when weed pollen counts were high. A 
caveat of this study is its utilization of a first-generation antihistamine that is no longer 
recommended as a first-line treatment of AR.
The data existing on the use of H2 antihistamines in AR are limited in scope and quality. The 
objective findings of improved nasal airway resistance suggest that the H2 histamine 
receptor does modulate nasal tissue response to histamine.1193-1195 However, the clinical 
significance of this mechanism is not clear, particularly in the context of modern treatment 
algorithms.1195-1198 The relatively manageable side effect profile and costs of H2 
antihistamines, does offer patients with otherwise recalcitrant AR symptoms an additional 
treatment option.
• Aggregate Grade of Evidence: B (Level 1b: 6 studies; Table IX.B.1.b).
• Benefit: Decreased objective nasal resistance, and improved symptom control in 
1 study when used in combination with H1 antagonists.
• Harm: Drug-drug interaction (P450 inhibition, inhibited gastric secretion and 
absorption),
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• Cost: Increased cost associated with H2 antagonist.
• Benefits-Harm Assessment: Unclear benefit and possible harm.
• Value judgments: No studies evaluating efficacy of H2 antihistamines in context 
of topical nasal corticosteroids.
• Policy Level: No recommendation. The data available does not adequately 
address the question as to the benefit of H2 antihistamines in clinical AR as part 
of modern treatment protocols.
• Intervention: Addition of an oral H2 antagonist to an oral H1 antagonist may 
improve symptom control in AR; however, the evidence to support this is not 
strong.
IX.B.1.c. Intranasal antihistamines.: The use of intranasal antihistamine spray for AR 
has been well studied. Two agents are currently available in North America for intranasal 
use as a topical spray, azelastine hydrochloride and olopatadine hydrochloride. A systematic 
review of the English-language literature was performed for clinical trials of azelastine or 
olopatadine for the treatment of AR. A total of 44 papers were identified that reported results 
of RCTs of intranasal antihistamine monotherapy against either placebo or active 
control1046,1199-1241 (Table IX.B.1.c). Of these, 11 studies included comparison of different 
doses of intranasal antihistamine1204,1205,1207,1211,1212,1216,1218,1219,1231,1235,1237 and 29 
studies utilized inactive placebo.
1201,1202,1204,1205,1207-1209,1211-1214,1216,1218-1222,1224,1225,1227-1231,1233,1235,1237-1239 
Overall, there were 38 studies of azelastine1046,1199-1201,1203,1205,1207-1213,1215,1217,1220-1241 
and 10 studies of olopatadine1202,1204,1206,1208,1210,1211,1214,1216,1218,1219 as monotherapy.
Outcome measures were predominantly patient-reported symptom scores or QOL 
assessments. The most common outcome measure was the TNSS (23 studies), which records 
the severity of runny nose, sneezing, itching, and congestion. Other outcome measures 
included the RQLQ (7 studies), the Total Ocular Symptom Score (TOSS, 5 studies), the 
Caregiver Treatment Satisfaction Questionnaire (2 studies), the Pediatric Rhinoconjunctivitis 
Quality of Life Questionnaire (1 study), the Short Form-36 (1 study), the Epworth 
Sleepiness Scale (ESS, 1 study), the Rhinitis Severity Score (1 study), and a Subjective 
Global Assessment (1 study). Multiple studies, particularly those published prior to 2002, 
used a variety of nonvalidated symptom scoring systems ranging from 5 to 13 items each (19 
studies). Objective measures included nasal lavage (3 studies), response to methacholine 
challenge (2 studies), nasal flow rate (2 studies), and rhinomanometry (1 study).
Study duration ranged from 2 days to 8 weeks, with the most frequent duration being 14 
days of treatment. The number of subjects in each study ranged from 20 to 1188. Intranasal 
antihistamine was compared to placebo in 29 studies,
1201,1202,1204,1205,1207-1209,1211-1214,1216,1218-1222,1224,1225,1227-1231,1233,1235,1237-1239 with 
primary outcomes showing superiority to placebo in all studies. Intranasal antihistamine was 
trialed against an active treatment comparator of a different medication class in 24 studies.
1046,1199,1203,1206,1213-1215,1217,1220,1221,1224,1226,1227,1229,1231-1236,1238-1241 Although not 
reported in all studies, the intranasal antihistamine spray consistently had a more rapid onset 
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of action, occurring as early as 15 minutes after administration. Azelastine and olopatadine 
were directly compared in 3 studies, with no significant difference in symptom relief 
between agents.1208,1210,1211 In 2 additional studies, azelastine was compared with an 
experimental formulation of intranasal levocabastine, with either comparable or superior 
results for azelastine.1200,1223
Intranasal antihistamine was compared to INCS in 12 studies, with the primary outcome 
favoring antihistamine in 2 studies,1213,1214 corticosteroid in 3 studies,1224,1227,1229 and 
showing equivalency in 7 studies.1199,1203,1206,1233,1238,1239,1241 In 2 of the studies showing 
equivalency, antihistamine was superior for ocular symptoms.1203,1239 The 3 studies 
showing superiority of corticosteroids were all conducted prior to 2000 and used 
heterogeneous nonvalidated symptom scores as primary outcomes. Intranasal antihistamine 
was compared to oral antihistamine monotherapy in 8 studies, with the primary outcome 
favoring intranasal antihistamine in 3 studies1215,1217,1232 and showing equivalency in 5 
studies.1221,1234-1236,1240 One study included a treatment arm with oral chlorpheniramine as 
a positive control without intent to compare efficacy with azelastine.1231 One study 
comparing azelastine spray with oral loratadine plus intranasal beclomethasone found that 
azelastine monotherapy was at least as effective as combination therapy.1226 Two studies 
comparing intranasal azelastine plus oral antihistamine to intranasal azelastine monotherapy 
showed no additional benefit for combination therapy.1220,1221
The minimum age of subjects in the included studies was generally 12 years or older. 
Children aged 6 to 12 years old were included in 3 studies, which in aggregate showed 
superiority of intranasal antihistamine to placebo in improving symptoms and QOL.
1202,1204,1228
Serious adverse effects were not reported in any study. Intranasal antihistamine was 
generally well tolerated, with the most commonly reported adverse effect of an unpleasant 
taste. One study that compared the commercially available form of azelastine with a 
reformulated vehicle found no difference in taste aversion.1205 One study directly comparing 
olopatadine with azelastine reported better sensory attributes for olopatadine.1210 Other 
reported adverse effects included somnolence, headache, epistaxis and nasal discomfort, all 
occurring in less than 10% of cases in any study.
• Aggregate Grade of Evidence: A (Level 1b: 43 studies; Level 2b: 1 study; Table 
IX.B.1.c). Due to the large number of studies with high level of evidence, studies 
of lower evidence levels are not considered here.
• Benefit: Intranasal antihistamines have a rapid onset, are more effective for nasal 
congestion than oral antihistamines, are more effective for ocular symptoms than 
INCS, and show consistent reduction in symptoms and improvement in QOL in 
RCTs compared to placebo.
• Harm: Concerns for patient tolerance, especially due to taste. Intranasal 
antihistamines are less effective for congestion than INCS.
• Costs: Low-to-moderate financial burden; available as prescription only.
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• Benefits-Harm Assessment: Preponderance of benefit over harm. Intranasal 
antihistamine as monotherapy is consistently more effective than placebo. Most 
studies show intranasal antihistamines superior to INCS for sneezing, itching, 
rhinorrhea, and ocular symptoms. Adverse effects are minor and infrequent.
• Value Judgments: Extensive level 1 evidence comparing intranasal antihistamine 
monotherapy to active and placebo controls demonstrates overall effectiveness 
and safety.
• Policy Level: Recommendation.
• Intervention: Intranasal antihistamines may be used as first-line or second-line 
therapy in the treatment of AR.
IX.B.2. Corticosteroids
IX.B.2.a. Oral corticosteroids.: The anti-inflammatory effect of oral corticosteroids in 
AR is well known and has been demonstrated experimentally using the nasal challenge 
model and clinically in the context of seasonal disease. Compared to placebo, premedication 
with oral prednisone for 2 days prior to an allergen challenge showed a reduction in sneezes, 
and levels of histamine and mediators of vascular permeability in nasal lavages during the 
late phase response884 (Table IX.B.2.a). Further, active treatment resulted in a reduction in 
the priming response to consecutive allergen challenge.884 Prednisone has also been shown 
to reduce the influx of eosinophils and levels of the eosinophil mediators (major basic 
protein and eosinophil derived neurotoxin) into nasal secretions during the late-phase 
response compared to placebo.1242,1243 Non–placebo-controlled studies have demonstrated 
efficacy of oral corticosteroids for SAR. Schwartz et al.1244 demonstrated that 15 days of 
cortisone 25 mg 4 times daily during the ragweed season resulted in significant relief of 
symptoms in 21 of 25 patients. Similarly, 100 mg of cortisone daily for 4-day courses during 
the pollen season showed rhinitis symptom relief in 42 of 51 patients, with 20 patients 
relapsing within 7 days after cessation of therapy.1245 Oral hydrocortisone 40 to 80 mg daily 
has also been shown to reduce symptoms of ragweed allergies.1246 Brooks et al.1247 
performed a placebo-controlled study comparing the efficacy of methylprednisolone 6, 12, 
or 24 mg PO daily for 5 days to placebo in controlling nasal symptoms during the ragweed 
season. Whereas the 6-mg and 12-mg doses led to a significant reduction in some of the 
symptoms compared to placebo (congestion, postnasal drainage, and eye symptoms), the 24-
mg dose resulted in a significant reduction of all symptoms (congestion, runny nose, 
sneezing, itching, postnasal drainage, and eye symptoms).
Because of the recognized systemic adverse events associated with oral corticosteroids,101 
their use has been largely replaced by the intranasal preparations. In a double-blind, placebo-
controlled trial, the effect of intranasal flunisolide and its oral dose bioequivalent (an oral 
dose that would lead to similar systemic levels) were compared in ragweed-induced SAR.
1248 The intranasal preparation was shown to be efficacious in reducing rhinitis symptoms 
while the oral dosing was not. This suggested that INCSs achieve their benefit primarily by 
their local activity as opposed to systemic bioavailability. In a head-to-head comparison of 
the efficacy of intranasal vs systemic steroids, Karaki et al.1249 performed an open-label, 
parallel, randomized trial during the cedar pollen season in Japan. Patients received 
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loratadine 10 mg daily alone, loratadine with intranasal mometasone furoate (200 μg once 
daily), or loratadine with oral betamethasone 0.25 mg twice daily for 1 week. The groups 
receiving some form of steroid in addition to loratadine had significantly lower symptoms of 
sneezing, rhinorrhea, and nasal obstruction compared to loratadine alone, with no significant 
difference between the intranasal and oral preparations. The oral steroid was more effective 
than the INCS in controlling allergic eye symptoms.
The above data suggest that oral corticosteroids are effective for the treatment of AR. 
However, given the significant systemic adverse effects related to using oral corticosteroids 
for prolonged periods of time these agents are not recommended for the routine treatment of 
AR.
• Aggregate Grade of Evidence: B (Level 1b: 5 studies; Level 2b: 1 study; Level 4: 
3 studies; Table IX.B.2.a).
• Benefit: Oral corticosteroids can attenuate symptoms of AR.
• Harm: Oral corticosteroids have known undesirable adverse effects. These 
include effects on the hypothalamic-pituitary axis, growth and musculoskeletal 
system, gastrointestinal system, hypertension, glycemic control, mental/
emotional state, and others.
• Cost: Low.
• Benefits-Harm Assessment: The risks of using oral corticosteroids outweigh the 
benefits when compared to similar symptom improvement with the use of INCS.
• Value Judgments: In the presence of effective symptom control using INCS, the 
risk of adverse effects from using oral corticosteroids for AR appears to 
outweigh the potential benefits.
• Policy Level: Recommendation against the routine use of oral corticosteroids for 
AR.
• Intervention: Although not recommended for routine use in AR, certain clinical 
scenarios warrant the use of short courses of systemic corticosteroids after a 
discussion of the risks and benefits with the patient. This may include patients 
with significant nasal obstruction that would preclude penetration of intranasal 
agents (INCS or antihistamines). In these cases, a short course of systemic oral 
corticosteroids could improve congestion and facilitate access and efficacy of the 
topical agents.
IX.B.2.b. Injectable corticosteroids.: Corticosteroids have been injected intramuscularly 
or into the turbinates for management of AR. The evidence evaluating deep intramuscular 
injections will be reviewed first. Overall, several early studies1250-1254 demonstrated clinical 
effectiveness in improving allergic symptoms; however, the safety outcomes demonstrated 
the risk of undesired systemic corticosteroid adverse effects. More recent evidence1255 
confirms the increased risk of endogenous cortisol suppression along with other 
corticosteroid-related adverse effects such as osteoporosis and hyperglycemia (Table 
IX.B.2.b).
Wise et al. Page 94













Kronholm1250 demonstrated that a single injection of either betamethasone dipropionate/
betamethasone phosphate or methylprednisolone acetate given at the onset of the hay fever 
season led to a significant reduction of both nasal and ocular symptoms during the 5 weeks 
of the study, with the betamethasone combination being more effective. Ohlander et al.1251 
compared 3 long-acting corticosteroid injections given at the beginning of the season, and 
showed that all treatments led to significant reductions in nasal and ocular symptoms during 
the season with no difference between groups. However, all preparations also suppressed 
endogenous cortisol, in some cases for more than 14 days after injection, and 2 out of the 3 
injections resulted in increases in blood sugar levels.
When compared to other agents, injected corticosteroids demonstrated similar effectiveness 
outcomes. Specifically, there were similar clinical outcomes when comparing preseasonal 
steroid injections to both daily oral prednisolone1252 and daily intranasal beclomethasone 
dipropionate spray.1253 An adrenal corticotropic hormone (ACTH) test performed at 3 
weeks showed significant suppression of adrenal function in the oral steroid treatment group 
and no evidence of suppression in the corticosteroid injection or topical intranasal 
corticosteroid groups.1252 This was probably related to the short duration of adrenal 
suppression expected after a single injection of corticosteroids compared to continuous 
administration.
When evaluating the timing of injectable corticosteroid therapy, Borum et al.1254 compared 
the effects of a single depot injection of methylprednisolone given either at the beginning of 
the allergy season or later when pollen counts peaked. Compared to placebo, intramuscular 
methylprednisolone was efficacious against nasal congestion with less pronounced effects 
against rhinorrhea and sneezing. The authors argue that depot injectable steroids may be 
considered after other safer medical therapy fails and may provide an effective alternative 
treatment even if provided late in the allergy season.
Injectable corticosteroid preparations may have significant side effects that include adrenal 
suppression and growth retardation.1256 In a large retrospective study of Danish National 
Registries, the relative risk and incidence of both osteoporosis and diabetes were higher in 
allergic individuals receiving at least 1 depot corticosteroid injection during the allergy 
season compared to those receiving immunotherapy.1255
Several early reports detailed significant improvement in symptoms of AR in a large 
proportion of patients who received intraturbinate injections of cortisone,1257 hydrocortisone 
acetate,1258 or prednisolone.1259 Similar, noncontrolled, studies showed improvement in AR 
symptoms after intraturbinate injections.1260,1261 A more recent randomized, placebo-
controlled, single-blind trial by Yang et al.1262 compared the efficacy of intraturbinate 
injections of either onabotulinum toxin A, triamcinolone, or isotonic saline in patients with 
PAR. Both onabotulinum toxin A and triamcinolone therapy showed better control of nasal 
symptoms than placebo with onabotulinum toxin A efficacy lasting longest.
Orbital complications have been reported with intraturbinate but not intramuscular 
injections. Based on a large clinical experience, Mabry cites an estimated incidence of visual 
loss after intraturbinate injections to be 0.006%.1263 Other complications have included 
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transient visual loss and diplopia,1264 blurred vision and temporary blindness,1265 temporary 
distorted vision, and decreased visual acuity and paresis of the medial rectus.1265 Martin et 
al.1266 reported the rapid onset of ocular pain, blurred vision, and decreased visual acuity 
after an intraturbinate injection of triamcinolone acetonide. Choroidal and retinal arterial 
embolization were confirmed as the cause and they resolved completely within 24 hours. 
The mechanism of embolization is likely related to retrograde flow from the anterior tip of 
the inferior turbinate to the ophthalmic artery, followed by anterograde flow with the 
particles lodging in the end arteries of the choroid and retinal vessels. Steroids with larger 
particle size (eg, methylprednisolone) are thought to present higher risk than lower-sized 
particles (eg, triamcinolone).
• Aggregate Grade of Evidence: B (Level 1b: 3 studies; Level 2b: 3 studies; Level 
4: 7 studies; Table IX.B.2.b).
• Benefit: Injectable corticosteroids improve symptoms of AR in clinical studies.
• Harm: Injectable corticosteroids have known adverse effects on the 
hypothalamic-pituitary axis, growth suppression, osteoporosis, hyperglycemia, 
and other systemic adverse effects. Intraturbinate corticosteroids have a small, 
but potentially serious, risk of ocular side effects including decline or loss of 
vision.
• Cost: Low.
• Benefits-Harm Assessment: In routine management of AR, the risk of serious 
adverse effects outweighs the demonstrated clinical benefit.
• Value Judgments: Injectable corticosteroids are effective for the treatment of AR. 
However, given the risk of significant systemic adverse effects, the risk of serious 
ocular side effects, and the availability of effective alternatives (ie, topical INCS 
therapy), injectable corticosteroids are not recommended for the routine 
treatment of AR.
• Policy Level: Recommendation against.
• Intervention: None.
IX.B.2.c. Intranasal corticosteroids (INCSs).: INCSs are effective for the treatment of 
AR. Their potent anti-inflammatory properties directly affect the pathophysiologic 
mechanisms of nasal inflammation in AR. In both nasal allergen challenge models and 
seasonal disease, treatment with INCS results in significant reduction in mediator and 
cytokine release along with a significant inhibition in the recruitment of basophils, 
eosinophils, neutrophils, and mononuclear cells to the nasal mucosa and secretions.
187,389,1267,1268 INCSs also reduce the antigen-induced hyperresponsiveness of the nasal 
mucosa to subsequent challenge by antigen187 and histamine.1269,1270
Multiple placebo-controlled clinical trials in adults and children have demonstrated the 
effectiveness of INCS in the reduction of nasal symptoms in AR, including sneezing, 
itching, rhinorrhea, and congestion.1271,1272 With the reduction of nasal symptoms, INCS 
significantly improve the QOL1272-1274 and sleep673,706,707,1275,1276 of these patients. No 
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significant differences in efficacy between available agents have been demonstrated in 
studied populations1273; therefore, sensory attributes may be an important factor in patient 
preference and adherence to therapy.1277 These sensory attributes include aftertaste, nose 
runout, throat rundown, and smell. Addressing some of these concerns are 2 intranasal non-
aqueous preparations with hydrofluoroalkane (HFA) aerosols recently approved for the 
treatment of AR in the United States. These include beclomethasone dipropionate and 
ciclesonide, both approved and effective for SAR and PAR in adults and children 12 years 
and older.688,1278-1281 Onset of action for INCS starts at time points ranging from 3 to 5 
hours to 60 hours after first dosing.1282-1285 Although the recommended continuous daily 
use of INCS is superior to other dosing strategies,1286,1287 studies have demonstrated the 
efficacy of as-needed use of intranasal fluticasone propionate compared to placebo1288,1289 
(Table IX.B.2.c-1).
Along with improved nasal symptoms, INCSs have beneficial effects on allergic eye 
symptoms including itching, tearing, redness, and puffiness.1290-1292 This is secondary to a 
reduction in the naso-ocular reflex, which contributes to these eye symptoms.1293 Most 
INCSs lead to improved ocular symptoms, but the evidence suggests that the effects are not 
equal among INCS preparations.1294 Some studies have suggested that INCSs improve 
asthma control measures in patients suffering from both AR and asthma1295,1296 (Table 
IX.B.2.c-2).
In comparative studies, INCSs have shown superior efficacy to H1 antihistamines in 
controlling nasal symptoms, including nasal congestion, with no significant difference in the 
relief of ocular symptoms.1297-1299 INCSs are more effective than LTRAs1299,1300 (Table 
IX.B.2.c-3).
The most common side effects of INCSs are a result of local irritation and include dryness, 
burning, stinging, blood-tinged secretions, and epistaxis. The incidence of epistaxis with 
different preparations ranges from 4% to 8% over short treatment periods (2 to 12 weeks) 
with no differences between placebo and active therapy.1301,1302 In studies carried over 1 
year, epistaxis is as high as 20%.1303,1304 Septal perforations are rare complications of 
INCS.51 A systematic review of published articles looking at biopsy studies in patients with 
AR or CRS using INCS identified 34 studies. Of those, 21 studies included patients with 
AR, mixed rhinitis, and NAR, and 13 involved patients with CRS with/without polyposis.
1305 None of the studies that included atrophy of the nasal mucosa as an outcome measure 
reported any atrophy with INCS. A meta-analysis of a subgroup of the studies showed no 
significant chance of developing atrophy while taking INCS, and no difference between 
active and control groups in basement membrane characteristics. The review also found a 
significant reduction in the OR for the development of squamous metaplasia in patients 
using INCS, suggesting a favorable effect. Studies in adults and children evaluating effects 
of INCS on the hypothalamic pituitary axis have assessed morning cortisol concentrations, 
cosyntropin stimulation, 24-hour serum cortisol and 24-hour urinary free cortisol excretion. 
They show no adverse effects.1304,1306-1317 Although there has been a report of an 
association between the use of INCS and the development of posterior subcapsular cataracts,
1318 a systematic review of controlled trials did not demonstrate a clinically relevant impact 
of INCS on either ocular pressure, glaucoma, lens opacity, or cataract formation.1319 The 
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effect of INCS on growth in children has been investigated in controlled studies using both 
knemometry in short-term studies (2 to 4 weeks) and stadiometry in long-term (12 months) 
studies. A meta-analysis of 8 randomized controlled trials with appropriate controls showed 
that, compared to children using placebo, mean growth was significantly lower among 
children using INCS in trials using knemometry (n = 4) and that there was no significant 
growth difference in studies using stadiometry (n = 4).1320 The data suggests that INCS 
might have deleterious effects on short-term growth in children, but the heterogeneity in the 
stadiometry studies makes the effects on long-term growth suppression unclear (Table 
IX.B.2.c-4).
INCSs are first-line therapy for the treatment of AR due to their superior efficacy in 
controlling nasal congestion and other symptoms of this inflammatory condition. Subjects 
with known SAR should start prophylactic treatment with INCS several days before the 
pollen season with an evaluation of the patient’s response in 2 weeks. In addition to making 
changes to the treatment regimen according to the patient’s response, a nasal exam evaluates 
for signs of local irritation due to the drug or mechanical trauma from the applicator itself. 
Aiming the spray away from the nasal septum may also reduce irritation in this area. 
Children receiving INCS should be on the lowest effective dose to avoid negative growth 
effects.
• Aggregate Grade of Evidence: A (Level 1a: 15 studies; Level 1b: 33 studies; 
Level 2a: 3 studies; Level 2b: 1 study; Level 5: 1 study; Tables IX.B.2.c-1, 
IX.B.2.c-2, IX.B.2.c-3, and IX.B.2.c-4).
• Benefit: INCSs are effective in reducing nasal and ocular symptoms of AR. They 
have superior efficacy compared to oral antihistamines and LTRAs.
• Harm: INCS have known undesirable local adverse effects such as epistaxis with 
some increased frequency compared to placebo in prolonged administration 
studies. There are no apparent negative effects on the hypothalamic-pituitary 
axis. There might be some negative effects on short-term growth in children, but 
it is unclear whether these effects translate into long-term growth suppression.
• Cost: Low.
• Benefits-Harm Assessment: The benefits of using INCS outweigh the risks when 
used to treat SAR and PAR.
• Value Judgments: None.
• Policy Level: Strong recommendation for the use of INCS to treat AR.
• Intervention: The well-proven efficacy of INCSs, as well as their superiority over 
other agents, make them first-line therapy in the treatment of AR.
IX.B.3. Decongestants
IX.B.3.a. Oral decongestants.: Oral decongestants, such as pseudoephedrine, act on 
adrenergic receptors and lead to vasoconstriction, which can relieve nasal congestion in 
patients with AR. With extended-release oral decongestants nasal decongestion can last up 
to 24 hours. Oral decongestants are available for use alone or in combination with oral 
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antihistamines. (See section IX.B.10.a. Management – Pharmacotherapy – Combination 
therapy – Oral antihistamine and oral decongestant for additional information on this topic.)
Availability of pseudoephedrine in the United States has been limited to behind-the-counter 
at pharmacies since 2006 due to stricter control over the distribution and sale of substances 
that can be used to manufacture methamphetamine. In a study by Mucha et al.,1321 
pseudoephedrine resulted in significant improvement in all symptoms in adults with 
ragweed-induced AR (Table IX.B.3.a). Phenylephrine has been marketed as an over-the-
counter (OTC) medication as a substitute for pseudoephedrine for nasal decongestion. 
However, an RCT by Horak et al.1322 found that while pseudoephedrine was significantly 
more effective at reducing nasal congestion than both placebo and phenylephrine, there was 
no significant difference between phenylephrine and placebo. In addition, Meltzer et al.1323 
performed a randomized, open-label, dose-range trial in 539 patients with SAR and found 
phenylephrine to be no more effective than placebo in reducing symptomatic nasal 
congestion.
Known side effects of this class of medications include insomnia, nervousness, anxiety, 
tremors, palpitations, and increased blood pressure (BP). Two systematic reviews by Salerno 
et al.1324,1325 looked at the effect of oral decongestants on blood pressure. The first study 
showed that phenylpropanolamine significantly increased systolic blood pressure (SBP) by 
5.5 mmHg (95% CI, 3.1 to 8.0) and diastolic blood pressure (DBP) by 4.1 mmHg (95% CI, 
2.2 to 6.0) with no effect on heart rate as compared to placebo.1324 The second study found 
that pseudoephedrine also caused a small but significant increase in SBP by 0.99 mmHg 
(95% CI, 0.08 to 1.9) and heart rate (HR) by 2.83 beats/minute (95% CI, 2.0 to 3.6) with no 
effect on DBP.1325 Additionally, higher doses and immediate-release preparations of 
pseudoephedrine were associated with greater BP elevations.1325 Further, in a study by 
Kernan et al.,1326 phenylpropanolamine use in women was an independent risk factor for 
hemorrhagic stroke. Phenylpropanolamine is no longer available on the market. Given these 
cardiovascular side effects, oral decongestants should be used with caution in patients who 
are already at risk for hypertension and its sequelae (eg, coronary artery disease, cerebral 
vascular disease, hyperthyroidism, arrhythmias). Blood pressure should be closely 
monitored for any changes when using oral decongestants in this population.
Oral decongestants are known to be effective in children older than 6 years of age. However, 
care should be taken in the younger population (less than 2 years of age) as this population is 
more prone to toxicity, and safe dosing recommendations have not yet been established for 
this age group.1327 In infants and young children, oral decongestants may have central 
nervous system (CNS) stimulatory effects with known cases of psychosis, ataxia, and 
hallucinations with ingestion.1328,1329 Evaluation of risk and benefits should be considered 
in patients less than 6 years old.
• Aggregate Grade of Evidence: B (Level 1a: 2 studies; Level 1b: 3 studies; Level 
3b: 2 studies; Level 4: 2 studies; Table IX.B.3.a).
• Benefit: Reduction of nasal congestion with pseudoephedrine. No benefit with 
phenylephrine.
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• Harm: Side effects include insomnia, loss of appetite, irritability, palpitations, 
and increased blood pressure. Risk of toxicity in young children.
• Cost: Low.
• Benefits-Harm Assessment: Balance of benefit and harm for pseudoephedrine. 
Harm likely outweighs benefit for phenylephrine.
• Value Judgments: Patient’s other comorbidities and age should be considered 
before use.
• Policy Level: Option for pseudoephedrine. Recommendation against for 
phenylephrine.
• Intervention: Pseudoephedrine as an oral decongestant can be effective in 
reducing symptom of nasal congestion in patients with AR; used for short-term 
symptom relief. Side effects, comorbidities, and age of patient should be 
considered before use.
IX.B.3.b. Intranasal decongestants.: Topical decongestants, such as xylometazoline and 
oxymetazoline, are alpha-adrenergic stimulators delivered directly to nasal mucosal tissue 
that result in vasoconstriction and reduction of mucosal thickness. In an 18-day study, 
Barnes et al.1330 found that nasal xylometazoline was a stronger decongestant than nasal 
corticosteroids (Table IX.B.3.b). Topical decongestants relieve the symptom of nasal 
congestion, however they have no effect on other symptoms of AR, such as sneezing, 
rhinorrhea, or nasal itching.
Rhinitis medicamentosa (RM), a condition thought to result from prolonged usage of topical 
decongestants, involves an increase in symptomatic nasal congestion, thereby precluding a 
recommendation for chronic use of this medication. Studies to identify the duration of 
topical decongestant use that leads to rhinitis medicamentosa have shown variable results. 
Some studies show prolonged use up to 8 weeks does not produce any symptoms of rebound 
nasal congestion,83,1331 while others note development of RM within 3 days of use.72
Known adverse effects of topical decongestants include nasal burning, stinging, dryness, 
epistaxis, and mucosal ulceration. While topical decongestants are effective at reducing 
nasal congestion, short-term use of the medication, 3 days or less, is recommended to avoid 
the potential for rebound nasal congestion and effects on mucociliary activity. (See section 
III.C.2. Definitions, classifications, and differential diagnosis – Allergic rhinitis differential 
diagnosis – Rhinitis medicamentosa (RM) for additional information on this topic.)
• Aggregate Grade of Evidence: B (Level 1b: 3 studies; Level 2b: 1 study; Table 
IX.B.3.b).
• Benefit: Reduction of nasal congestion with topical decongestants.
• Harm: Side effects include nasal burning, stinging, dryness, and mucosal 
ulceration. Potential for rebound congestion when used long term.
• Cost: Low.
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• Benefits-Harm Assessment: Harm likely outweighs benefit if used more than 3 
days.
• Value Judgments: Topical decongestants can be helpful for short-term relief of 
nasal congestion.
• Policy Level: Option.
• Intervention: Topical decongestants can provide effective short-term nasal 
decongestion in patients with AR, but recommend against chronic use due to risk 
for RM.
IX.B.4. Leukotriene receptor antagonists (LTRAs)—LTRAs have been studied and 
used in the treatment of AR. Montelukast is approved by the FDA for the treatment of SAR 
in adults and children over 2 years of age, and for PAR in adults and children over 6 months 
of age. Several systematic reviews and meta-analyses of RCTs have demonstrated symptom 
reduction and improved QOL in patients treated with LTRA monotherapy compared to 
placebo.1300,1332-1335 Nevertheless, in a clinical practice guideline on AR from the AAO-
HNS there was a recommendation against LTRA monotherapy, citing decreased 
effectiveness compared to other first-line agents.761
Systematic review identified 28 studies, of which 19 were considered level 1 evidence, 
examining the use of LTRA monotherapy in AR (Table IX.B.4). Multiple systematic 
reviews1300,1332-1335 and RCTs1336-1344 demonstrated that LTRA monotherapy was superior 
to placebo at improving patient symptoms and QOL. This effect was consistent in studies of 
SAR,1340-1344 PAR,1339 and artificial allergen exposure.1336-1338 Furthermore, in a double-
blind RCT by Philip et al.1341 montelukast improved both AR and asthma disease-specific 
QOL in patients with concurrent SAR and asthma.
Despite multiple studies demonstrating superior effect of LTRA monotherapy over placebo 
in the treatment of AR, there is consistent evidence that LTRA is inferior to INCS.
1300,1333-1335,1345,1346 Multiple systematic reviews and meta-analyses have shown that INCS 
result in greater symptom reduction and QOL improvement compared to LTRA.
1300,1333-1335 A double-blinded RCT by Pullerits et al.1346 showed decreased numbers of 
activated tissue eosinophils in nasal mucosa biopsies in patients treated with intranasal 
beclomethasone compared to zafirlukast and placebo. There is conflicting evidence on the 
relative effect of LTRA compared to oral antihistamines, with 2 systematic reviews 
demonstrating that oral antihistamines have superior symptom reduction and QOL 
improvement1300,1333 and a third study indicating equivalent effect.1334 Moreover, a double-
blind RCT by Mucha et al.1321 indicated that montelukast and pseudoephedrine yielded 
equivalent symptom reduction and QOL improvement. In that study, objective measurement 
of nasal peak inspiratory flow was not different between the montelukast and 
pseudoephedrine treatment groups.
In addition to less relative effectiveness compared to other agents, the AAO-HNS clinical 
practice guideline on AR cited increased costs of LTRA in the recommendation against this 
drug class as monotherapy in patients with AR without asthma.761 Goodman et al.1347 
examined the relative cost effectiveness of montelukast compared to several second-
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generation oral antihistamines. Montelukast was determined to have increased cost for 
relative effectiveness compared to levocetirizine, desloratadine, and branded and generic 
fexofenadine. The annual drug and incurred medical costs for montelukast were estimated to 
be $631.
LTRA monotherapy may be a useful alternative in rare patients with contraindications for 
both INCS and oral antihistamines, but this limits recommendations or options for these 
agents in general. In patients with concurrent AR and asthma, LTRA can contribute to 
symptom management of both respiratory diseases. LTRA monotherapy is not recommended 
as first-line treatment for patients with concurrent AR and asthma, although this may be a 
consideration in patients with contraindications to INCS.
• Aggregate Grade of Evidence: A (Level 1a: 6 studies; Level 1b: 17 studies; Level 
2a: 2 studies; Level 2b: 3 studies; Level 4: 3 studies; Table IX.B.4).
• Benefit: Consistent reduction in symptoms and improvement in QOL compared 
to placebo, as demonstrated in RCTs and systematic review of RCTs.
• Harm: Consistently inferior compared to INCS at symptom reduction and 
improvement in QOL in RCTs and systematic reviews of RCTs. Equivalent-to-
inferior effect compared to oral antihistamines in symptom reduction and 
improvement of QOL.
• Cost: Annual incurred drug and medical costs estimated to be $631 for generic 
montelukast.
• Benefits-Harm Assessment: Preponderance of benefit over harm. LTRAs are 
effective as monotherapy compared to placebo. However, there is a consistently 
inferior or equivalent effect to other, less expensive agents used as monotherapy.
• Value Judgments: LTRAs are equivalent to oral antihistamine alone and more 
effective than placebo at controlling both asthma and AR symptoms in patients 
with both conditions. Control of AR symptoms with LTRAs, however, is less 
effective than INCS, and inferior or equivalent to oral antihistamines. Therefore, 
evidence is lacking to recommend LTRAs as first-line or second-line 
monotherapy in the management of AR alone or in combination with asthma.
• Policy Level: Recommendation against as first-line therapy for AR.
• Intervention: LTRAs should not be used as monotherapy in the treatment of AR 
but can be considered as second-line therapy, such as when INCSs are 
contraindicated.
IX.B.5. Cromolyn—Disodium cromoglycate (DSCG) [synonyms: cromolyn sodium, 
sodium cromoglycate, disodium 4,4′-dioxo-5,5′-(2-hydroxytrimethylenedioxy)-di(4H-
chromene-2-carboxylate)] was first used by ancient Egyptians for its spasmolytic properties. 
It is derived from the plant Ammi visnaga. DSCG is a mast cell stabilizer that prevents 
histamine release. It impedes the function of chloride channels important in regulating cell 
volume and prevents extracellular calcium influx into the cytoplasm of the mast cell, thus 
preventing the degranulation of sensitized cells.1349,1350 DSCG is best used prophylactically 
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to prevent the onset of symptoms by interrupting the physiological response to nasal 
allergens.
DSCG was discovered over 50 years ago, and since that time other cromoglycate type agents 
(chromones) have been developed. The chromones have demonstrated the ability to inhibit 
the early-phase and late-phase reactions of asthma.1351 Initial studies focused on histamine 
and cytokine release from mast cells. More recent studies have shown anti-allergy activity 
unrelated to mast cell activation, but rather through the inhibition of macrophages, 
eosinophils, monocytes, and platelets.1352-1354
DSCG can be used in an inhaled form as a prophylactic agent in the treatment of mild to 
moderate asthma, as a nasal spray to treat SAR, or as an ophthalmic solution to treat allergic 
or vernal conjunctivitis. DSCG may also be taken orally to control allergic reactions to 
certain foods. It can be used for patients 2 years and older but has a short half-life requiring 
dosing of 3 to 6 times daily.1355 DSCG has an excellent safety profile, although the need for 
frequent dosing may affect compliance. Minor adverse effects include nasal irritation or 
burning, sneezing, epistaxis, and bad taste.1355
Most studies comparing DSCG directly to placebo have shown that it is effective in patients 
with SAR (Table IX.B.5). Studies on the efficacy of DSCG in PAR have been controversial.
1356-1360 In a recent RCT, Lejeune et al.1356 examined the role of DSCG in monosensitized 
PAR patients and found that DSCG resulted in significant reduction in symptom scores for 
nasal obstruction, discharge, and sneezing compared to placebo. When compared to INCS, 
DSCG has been shown to be less effective.1357,1361-1369 To date, there have been no direct 
comparisons between DSCG and intranasal antihistamines. Ultimately, the role of DSCG as 
a primary treatment for AR is limited given its lower efficacy when compared to INCS and 
potential compliance challenges secondary to frequent dosing regimen.
• Aggregate Grade of Evidence: A (Level 1b: 13 studies; Level 2b: 9 studies; Table 
IX.B.5).
• Benefit: DSCG is effective in reducing sneezing, rhinorrhea, and nasal 
congestion.
• Harm: Rare local side effects include nasopharyngeal irritation, sneezing, 
rhinorrhea, and headache.
• Cost: Low.
• Benefits-Harm Assessment: Preponderance of benefit over harm. Benefit is 
considered mild to moderate. Less effective than INCS.
• Value Judgments: Useful for preventative short-term use in patients with known 
exposure risks.
• Policy Level: Option.
• Intervention: DSCG may be considered for the treatment of AR, particularly in 
patients known triggers who cannot tolerate INCS.
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IX.B.6. Intranasal anticholinergics—Ipratropium bromide (IPB) nasal spray acts by 
controlling watery nasal secretory output from seromucous glands. IPB is used primarily to 
reduce rhinorrhea and is effective in adults and children with perennial rhinitis and common 
cold.1378,1379 It has a quick onset of action and short half-life administered up to 6 times per 
day, with less than 10% absorption over a range of 84 μg/day to 336 μg/day.1380 Local side 
effects include nasal dryness, irritation, epistaxis, and burning. Systemic side effects have 
not been observed with therapeutic dosing, as plasma concentrations of greater than 1.8 
ng/mL are needed to produce systemic anticholinergic effects.1380 However, care should be 
taken to avoid over-dosage that could lead to high serum concentrations of ipratropium.
All studies have shown that the use of IPB significantly controls rhinorrhea in children and 
adults with PAR (Table IX.B.6). The combined use with INCS have also been shown to be 
more effective than either agent alone, suggesting a role of IPB for patients with persistent 
rhinorrhea.1381
• Aggregate Grade of Evidence: B (Level 1b: 9 studies; Level 2b: 5 studies; Table 
IX.B.6).
• Benefit: Reduction of rhinorrhea with topical anticholinergics.
• Harm: Local side effects include nasopharyngeal irritation, burning, headache, 
pharyngitis, epistaxis, nasal dryness, nasal congestion, and dry mouth. Care 
should be taken to avoid over-dosage leading to systemic side effects.
• Cost: Low to moderate.
• Benefits-Harm Assessment: Preponderance of benefit over harm in PAR patients 
with rhinorrhea.
• Value Judgments: No significant benefits in controlling symptoms other than 
rhinorrhea. Evidence for combined use with INCS is limited but encouraging for 
patients with persistent rhinorrhea.
• Policy Level: Option.
• Intervention: IPB nasal spray may be considered as an adjunct medication to 
INCS in PAR patients with uncontrolled rhinorrhea.
IX.B.7. Biologics (omalizumab)—Biologics have been studied in the treatment of AR, 
specifically omalizumab, either alone or in combination with specific AIT. Omalizumab is a 
humanized antibody that binds to human IgE. No biologic is currently approved by the FDA 
for the treatment of AR. One systematic review and meta-analysis of RCTs has 
demonstrated reduced symptoms, reduced rescue medication use, and improved QOL in 
patients treated with omalizumab.1391 However, the cost of omalizumab is very high, 
estimated to be over $18,000 year in the United States.
Systematic review identified 5 level 1 evidence studies examining the use of omalizumab in 
AR (Table IX.B.7). Four RCTs1392-1395 demonstrated that omalizumab monotherapy was 
superior to placebo at improving patient symptoms and QOL. The first RCT evaluating 
different delivery routes and dose-ranges did not show efficacy against ragweed-induced 
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AR, but reported no significant adverse events associated with omalizumab.1396 A second 
study randomized birch pollen-induced SAR patients to receive either 300 mg of 
omalizumab (originally named rhumAb-E25) or placebo given 2 or 3 times over the season, 
depending on baseline IgE levels. RhemAB-E25 treatment significantly reduced nasal 
symptom severity scores, the average number of tablets of rescue antihistamines per day, the 
proportion of days with any SAR medication use, and all domains of QOL.1392 A third study 
applied omalizumab, 50 mg, 150 mg, or 300 mg, vs placebo subcutaneously prior to 
ragweed season and repeated every 3 to 4 weeks during the pollen season dependent on the 
patient’s base-line serum IgE.1393 At the highest dose studied, 300 mg of omalizumab 
significantly reduced nasal symptom severity scores and rhinitis-specific QOL scores. A 
significant association was observed between IgE reduction and nasal symptoms and rescue 
antihistamine use. The frequency of adverse events was not significantly different between 
omalizumab and placebo groups.
Omalizumab was also studied in the treatment of PAR, significantly reducing the mean daily 
nasal severity score and the rescue medication, and improving QOL when given 
subcutaneously every 4 weeks for 16 weeks.1394 Omalizumab therapy was well tolerated. 
Similarly, effectiveness and safety of subcutaneously injected omalizumab was shown in the 
treatment of Japanese cedar pollen-induced SAR.1395 Omalizumab treatment markedly 
reduced serum free IgE and the clinical response to nasal allergen challenge in an open 
study, but did not affect IgE-secreting B cells and epsilon mRNA in nasal lavage fluid, 
suggesting that treatment for 6 months does not significantly modulate synthesis of nasal 
IgE.1397 The biologic also suppressed tryptase and ECP levels in nasal secretions in seasonal 
allergy.1398 Omalizumab showed significantly greater improvements than suplatast tosilate, 
a selective T-helper type 2 cytokine inhibitor, in the treatment of SAR induced by Japanese 
cedar pollens.1399
In 4 trials, a combination of omalizumab with AIT was studied to determine whether 
combined therapy could provide better efficacy and lower adverse events than AIT alone. In 
children and adolescents with SAR to birch or grass pollen, combination therapy 
significantly reduced symptom load over AIT alone independent of the allergen.1400 Anti-
IgE monotherapy alone significantly diminished rescue medication use and reduced the 
number of symptomatic days. The combined treatment with AIT and anti-IgE showed 
superior efficacy on symptom severity compared with anti-IgE alone.1401 Combination 
therapy may, therefore, be useful for the treatment of AR, particularly for polysensitized 
patients. Patients receiving omalizumab and rush ragweed AIT showed a significant 
improvement in severity scores during season compared with AIT alone.1402 Although 
omalizumab carries some risk of anaphylaxis itself, addition of omalizumab resulted in a 
significant decrease in risk of anaphylaxis caused by AIT. Combination therapy also 
significantly reduced the symptom load in HDM-allergic subjects better than AIT 
monotherapy, and improved asthma control and QOL with respect to asthma and AR.1403 
These effects were limited to the combined treatment period.1404
There are no other published studies evaluating other biologics (anti-IL5, anti-IL4, or IL-4R) 
as monotherapy for AR. A combination therapy of anti-IL4 with suboptimal AIT provided 
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no additional benefit over subcutaneous immunotherapy (SCIT) alone in suppressing the 
allergen-induced skin late-phase response.1405
Although there is consistent evidence that omalizumab monotherapy is superior to placebo 
in symptom reduction and QOL improvement in AR, the benefits are relatively small over 
pharmacotherapy. Omalizumab is superior in combination with AIT vs AIT alone and 
reduces the risk of anaphylaxis associated with AIT, but the costs of the treatment preclude a 
widespread use. The combination therapy might be indicated in selected patients who are 
polysensitized and highly sensitive.
• Aggregate Grade of Evidence: A (Level 1a: 1 study; Level 1b: 5 studies; Table 
IX.B.7).
• Benefit: Consistent reduction in symptoms and rescue medication as well as 
improvement in QOL in RCTs and systematic review of RCTs compared to 
placebo.
• Harm: Injection site reactions, possibility of anaphylactic reaction.
• Costs: High. Annual incurred drug costs estimated to be above $18,000 per year 
in the United States.
• Benefits-Harm Assessment: No therapy option as omalizumab is not registered 
for treatment of AR alone. This review was limited to evaluation of AR only; 
comorbid asthma was not evaluated.
• Value Judgments: Omalizumab monotherapy is superior to placebo, but effects 
are small over pharmacotherapy. May be evaluated in exceptional cases of highly 
sensitive polysensitized individuals in combination with AIT.
• Policy Level: No indication for the treatment of AR alone.
• Intervention: Omalizumab should not be used as monotherapy in the treatment of 
AR but may be considered in combination with AIT for highly sensitive 
polyallergic rhinitis patients with increased risk of anaphylaxis. As omalizumab 
is not currently approved by the FDA for AR treatment, in the US this treatment 
approach would likely not be performed in routine clinical practice presently.
IX.B.8. Nasal saline—Nasal saline is frequently utilized in the treatment of AR. 
However, the term “nasal saline” encompasses a wide variety of therapeutic regimens. These 
can include hypertonic saline, isotonic/normal saline, seawater, buffered or nonbuffered 
solutions, and volumes varying from 300 μL to 500 mL per administration. Irrigation 
regimens are also used with varying frequency.
This review included only level 1 evidence published in the English language. The search 
identified 5 RCTs in adults151,1406-1409 (Table IX.B.8-1), 6 RCTs in children1410-1415 (Table 
IX.B.8-2), and 1 systematic review1416 encompassing all ages (included in both tables), 
which evaluated the efficacy of nasal saline in the treatment of AR.
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In adults, all 5 studies found improvements in clinical outcomes with the use of various 
types of nasal saline. These studies varied in their evaluation of SAR vs PAR, as well as the 
type and volume of saline. Studies by Garavello et al.151 and Rogkakou et al.,1407 found that 
the addition of hypertonic saline significantly improved nasal symptoms and QOL compared 
to not using saline. Ural et al.1408 further compared the efficacy of hypertonic to isotonic 
saline irrigations, finding improved mucociliary clearance time with the isotonic solution. 
They postulated that in PAR, the rheologic properties of the mucus are enhanced most by 
isotonic saline, thus improving mucociliary clearance. Chusakul et al.1409 also identified that 
buffered isotonic saline with mild alkalinity had the greatest impact on reducing nasal 
symptom scores and was preferred by the most patients. Finally, Cordray et al.1406 found 
that Dead Sea saline spray had a significant improvement in the RQLQ compared to isotonic 
saline. Cordray et al.1406 suggested that the magnesium in the Dead Sea saline may have 
anti-inflammatory properties, resulting in improved AR outcomes.
In the pediatric population, all studies evaluating either PAR or SAR found an improvement 
in nasal symptoms or QOL with the incorporation of nasal saline. Both studies by Garavello 
et al.1410,1411 showed a significant improvement after the addition of hypertonic saline 
irrigations TID when compared to no irrigations. Marchisio et al.1413 and Satdhabudha and 
Poachanukoon1414 further identified that hypertonic saline irrigations resulted in a greater 
improvement in nasal symptom scores in children vs isotonic saline. Finally, Li et al.1412 and 
Chen et al.1415 found an additive effect in the utilization of nasal saline spray as an adjunct 
to a nasal steroid spray when compared to either therapy independently.
The systematic review by Hermelingmeier et al.1416 included 10 studies of which 7 were 
RCTs evaluating both adult and pediatric patients. Several of these studies are also included 
above.151,1406-1408,1410-1412 This review found that almost all studies showed an 
improvement in nasal symptoms from 3.1% to 70.5% with the addition of nasal saline. 
Additionally, they identified a 24.2% to 100% reduction in medication usage, as well as an 
improvement in QOL of 29.8% to 37.5%. This review also suggested that isotonic saline 
was more effective than hypertonic saline. Perhaps surprisingly, they found that nasal saline 
sprays resulted in greater symptom improvement than saline irrigations. Overall, they 
concluded that nasal saline was as effective as other frequently utilized AR pharmacologic 
treatments (ie, nasal antihistamines, oral antihistamines, etc.) in treatment of both SAR and 
PAR.
Overall, there is substantial evidence to support the use of nasal saline as an adjunct 
treatment for SAR and PAR. It appears that in adults, a buffered isotonic spray may provide 
maximum benefit. However, in children, a hypertonic solution may be more effective. Some 
studies have suggested less intranasal irritation when using isotonic solutions rather than 
hypertonic. Hypotonic saline has not been studied as a treatment for AR. Adding mild 
alkalinity (pH 7.2 to 7.4) to the solution may further improve tolerability.1409 Although nasal 
saline has been shown to improve symptoms and QOL outcomes when used alone, it is often 
implemented as an adjunct to other therapies including nasal steroid, antihistamine sprays, 
or oral antihistamines. In both adults and children, nasal saline appears to have an additive 
effect when used in combination with other standard AR treatments. Further, nasal saline is 
of relatively low cost and has an excellent safety profile. While adverse effects are rare, they 
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can include local irritation, ear pain, nosebleeds, headache, nasal burning, nasal drainage, 
and bottle contamination.1417
• Aggregate Grade of Evidence: A (Level 1a: 1 study; Level 1b: 11 studies; Table 
IX.B.8-1 and IX.B.8-2). Lower-level studies were not considered in this review.
• Benefit: Reduced nasal symptom scores, improved QOL, improved mucociliary 
clearance; well tolerated with excellent safety profile.
• Harm: Intranasal irritation, headaches, ear pain.
• Cost: Minimal.
• Benefits-Harm Assessment: Preponderance of benefit over harm.
• Value Judgments: Nasal saline should be used as an adjunct to other 
pharmacologic treatments for AR. Isotonic solutions may be more beneficial in 
adults, while hypertonic may be more effective in children.
• Policy Level: Strong recommendation.
• Intervention: Nasal saline is strongly recommended as part of the treatment 
strategy for AR.
IX.B.9. Probiotics—The relationship between microbiome and development of atopy is 
complex and incompletely understood. (See section IV.G. Pathophysiology and mechanisms 
of allergic rhinitis - Microbiome for additional information on this topic.) Preliminary data 
from observational studies suggest that microbial exposure, especially in infancy, shapes the 
gut and airway microbiome and affects subsequent Th2 or Th1 immunologic bias. Given the 
link between gut flora and atopy, manipulation of the microbiome via probiotic 
administration could theoretically lead to clinical improvement of allergic disease. Probiotics 
have been posited to elicit immunomodulatory effects on atopic disease via gut-associated 
lymphoid tissue. Stimulation of dendritic cells induces Th1 responses via IL-12 and IFN-γ, 
upregulation of Treg cells via IL-10 and TGF-β, and suppression of Th2 pathways through 
downregulation of IL-4, sIgE, IgG1, and IgA.1418
The optimal timing of probiotic administration for the treatment of atopy is unknown. A 
meta-analysis of 17 double-blind RCTs demonstrated that probiotics in pregnancy and early 
infancy were associated with decreased incidence of eczema but not asthma or rhinosinusitis 
in early childhood.1419 Many double-blind RCTs and randomized crossover studies have 
investigated the effects of probiotics on AR in older children and adults (Table IX.B.9). 
Meta-analyses of these studies have been published in 2015 by Zajac et al.1420 and 2016 by 
Guvenc et al.1421 with positive results. Adverse events due to probiotics were rare and 
minor, including diarrhea, abdominal pain, and flatulence.
Guvenc et al.1421 performed a systematic review and meta-analysis of 22 double-blind RCTs 
comprising 2242 patients aged 2 to 65 years with SAR or PAR. Patients received daily 
probiotic or placebo for 4 weeks to 12 months as an adjuvant to standard allergy therapies; 
primary outcomes included Total Nasal/Ocular Symptom Scores and QOL. Secondary 
outcomes included specific nasal symptom scores and immunologic parameters. Seventeen 
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trials demonstrated clinical benefit of probiotics, with improvement in TNSS (standardized 
mean difference [SMD] −1.23, p < 0.001), TOSS (SMD −1.84, p < 0.001), total QOL (SMD 
−1.84, p < 0.001), nasal QOL (SMD −2.30, p = 0.006), and ocular QOL (SMD −3.11, p = 
0.005). Subgroup analysis demonstrated improvement in clinical parameters for SAR and 
PAR. Th1:Th2 ratio was improved (SMD −0.78, p = 0.045) in the probiotic group, with no 
difference in tIgE, sIgE, or eosinophil count.
Zajac et al.1420 published a systematic review and meta-analysis of 21 double-blind RCTs 
and 2 randomized crossover studies comprising 1919 adult and pediatric patients with SAR 
or PAR treated with 3 weeks to 12 months of probiotic vs placebo. A total of 26 level 1b 
studies analyzed by Guvenc et al.1421 and Zajac et al.1420 are included in Table IX.B.9. 
Zajac et al.1420 limited outcomes measures to validated QOL or symptom scores and 
immunologic variables; 17 studies demonstrated clinical benefit of probiotics in AR. Meta-
analysis demonstrated improvement in RQLQ global score (SMD −2.23, p = 0.02) and 
RQLQ nasal symptom score (SMD −1.21, p < 0.00001). No effect was found for RTSS, 
tIgE, or sIgE.
The preponderance of data from meta-analyses and double-blind RCTs suggests a beneficial 
effect for probiotics in the treatment of SAR and PAR in both adults and children, but 
interpretation is limited by the heterogeneity of age and diagnosis, interventions, and 
outcomes included in the studies. Probiotics varied in dose, were delivered via milk, yogurt, 
powder, or capsules, and included a number of diverse strains: 19 studies employed 
Lactobacillus species1422-1440; 6 studies Bifidobacterium1061,1433,1437,1441-1443; and 1 study 
each Tetragenococcus halophilus,1444 Escherichia coli,1445 and Bacillus clausii.1446
• Aggregate Grade of Evidence: A (Level 1a: 2 studies; Level 1b: 26 studies; Table 
IX.B.9).
• Benefit: Improved nasal/ocular symptoms or QOL in most studies. Possible 
improvement in immunologic parameters (Th1:Th2 ratio).
• Harm: Low.
• Benefits-Harm Assessment: Balance of benefit and harm.
• Value Judgments: Minimal harm associated with probiotics, but heterogeneity 
across studies makes magnitude of benefit difficult to quantify. Variation in 
organism and dosing across trials prevents specific recommendation for 
treatment.
• Policy Level: Option.
• Intervention: Consider adjuvant use of probiotics for patients with symptomatic 
SAR and PAR.
IX.B.10. Combination therapy
IX.B.10.a Oral antihistamine and oral decongestant.: Oral antihistamines function as 
reversible competitive antagonists of the histaminic H1 receptor and prevent the binding of 
histamine to its receptors. Oral decongestants, such as pseudoephedrine and phenylephrine, 
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are alpha-adrenergic stimulatory drugs which bind to precapillary and post-capillary blood 
vessels resulting in vasoconstriction of nasal mucosa.1447 The unrelated biologic targets of 
these medications’ mechanisms of action has been shown in RCTs to result in synergistic 
improvement in AR symptoms.1448,1449
The combination of an oral antihistamine along with an oral decongestant has been shown to 
be more effective than placebo in controlling sneezing, nasal itching, and reducing nasal 
congestion in patients with AR1044,1050,1052,1167,1450-1456 (Table IX.B.10.a). Investigations 
by Kaiser et al.1450 found that both once-daily or twice-daily loratadine-pseudoephedrine 
were consistently superior to placebo in reducing total nasal and non-nasal symptom scores 
with significantly higher risk of insomnia and dry mouth in both antihistamine-decongestant 
arms compared to placebo. Additionally, Nathan et al.1451 reported in 2006 that cetirizine-
pseudoephedrine reduced AR total symptom severity scores, asthma symptom severity 
scores, and improved asthma QOL scores significantly vs placebo. However, they found no 
significant changes in pulmonary function testing in patients receiving cetirizine-
pseudoephedrine or placebo and they identified similar rates of discontinuation and adverse 
events in both treatment arms.
Oral antihistamine and oral decongestant combinations have also been shown to be more 
effective in controlling AR symptoms when compared to INCS or compared to treatment 
with either oral antihistamines or oral decongestants alone.1050,1455,1457-1460 In 2005, 
Zieglmayer et al.1449 found that the combination of cetirizine with prolonged release 
pseudoephedrine was significantly superior to budesonide nasal spray for improving nasal 
congestion after exposure to HDM, as measured by anterior rhinomanometry and nasal 
imaging. The combination of second-generation oral antihistamines and pseudoephedrine 
has been shown to significantly reduce symptom scores in patients with SAR more than 
either drug alone.1050,1455,1457-1462 Additionally, the type of second-generation 
antihistamine and medication dosing schedule does not seem to have a significant effect on 
efficacy.1463,1464
Oral decongestants have the benefit of relieving the symptoms of nasal congestion through 
their ability to vasoconstrict capillaries within the nasal mucosa; however, their mechanism 
of action can also result in unfavorable systemic adverse effects such as hypertension and 
urinary retention. Oral decongestants have also been linked to an increased incidence of 
specific birth defects including pyloric stenosis and endocardial cushion defects when 
utilized by pregnant women.1465 Furthermore, decongestants are not recommended for 
children under 4 years of age secondary to the high risk of adverse drug events associated 
with utilization in this age group.1466 Finally, oral decongestants have OTC sales restrictions 
secondary to their potential utilization in the production of methamphetamines. Therefore, 
caution must be applied in the utilization of these medications, particularly in children under 
4 years and patients who are pregnant or have a preexisting cardiovascular condition, 
hypertension, or benign prostatic hypertrophy. Oral antihistamines are well tolerated, with a 
favorable risk-benefit ratio. However, caution should still be exercised as antihistamines 
have cardiac side effects, alter the metabolism of other medicines, and have been linked to a 
higher incidence of adverse events and drug-drug interactions in the elderly.216
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It is likely because of this significant risk of adverse events and propensity for interactions 
with other medications that the ARIA 2010 guidelines recommended against the routine 
treatment of AR with a combination oral decongestant and oral antihistamine.1167 The 2010 
ARIA document suggested that oral decongestants only be added in patients who are not 
controlled by antihistamines alone and are less averse to side effects or adverse reactions. 
Additionally, they suggested that oral decongestants be limited to utilization primarily as a 
rescue medication during periods of significant symptom exacerbations.
Overall, despite the available evidence verifying the efficacy of combination oral 
antihistamines and oral decongestants in improving AR symptoms, caution should still be 
exercised when prescribing this treatment, particularly in patients with cardiovascular or 
urologic comorbidities.
• Aggregate Grade of Evidence: A (Level 1b: 21 studies; Table IX.B.10.a).
• Benefit: Improved control of nasal congestion with combination of oral 
antihistamines and oral decongestants.
• Harm: Oral decongestants can cause significant adverse effects, particularly in 
patients with hypertension, cardiovascular disease, or benign prostatic 
hypertrophy. Additionally, these medications should not be used in children 
under 4 years of age or pregnant patients. This should be weighed against the 
potential benefits prior to prescribing.
• Cost: Low.
• Benefits-Harm Assessment: Harm likely outweighs benefit when used on a 
routine basis.
• Value Judgments: Combination therapy of oral antihistamines and oral 
decongestants can be helpful for relief of an acute exacerbation of AR, especially 
nasal symptoms, when exposed to triggers. Caution should be exercised 
regarding long-term use given the possibility of significant adverse effects.
• Policy Level: Option, particularly for acute exacerbations of nasal congestion.
• Intervention: Combination therapy with oral antihistamine and oral decongestant 
can provide effective reduction of nasal congestion symptoms in patients with 
AR; however, recommend against chronic use given the significant side effect 
profile of oral decongestants.
IX.B.10.b Oral antihistamine and intranasal corticosteroid.: A combination of an oral 
antihistamine and INCS is often used in clinical practice for the treatment of AR. As 
previously mentioned, oral antihistamines function as a reversible competitive antagonist of 
the histamine H1 receptor and thereby prevent the binding of histamine that is present in the 
circulation. The newer, second-generation agents, such as fexofenadine and cetirizine, are 
less sedating, have fewer adverse effects, and provide good control of sneezing, rhinorrhea, 
and nasal itching, but with less effect on nasal congestion.1448 Additionally, INCSs, such as 
fluticasone or beclomethasone, have repeatedly been validated as an effective treatment 
option for AR while offering a good safety profile and low systemic absorption.1448
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Several RCTs have examined the efficacy of combination therapy utilizing both an oral 
antihistamine and INCS and demonstrated no added benefit of combination therapy (Table 
IX.B.10.b). In 2000, Wilson et al.1469 demonstrated that oral cetirizine and intranasal 
mometasone were effective at improving nasal peak inspiratory flow rates as well as nasal 
symptoms and total daily symptoms after 4 weeks of use. However, the combination was not 
significantly better than cetirizine and placebo or cetirizine and montelukast. In a double-
blinded crossover study, Barnes et al.1470 compared the combination of fluticasone and 
levocetirizine vs fluticasone and placebo and found, in most patients, that the benefits of an 
additional oral antihistamine to an effective nasal steroid regimen were not significant. 
Additionally, Ratner et al.1471 found that fluticasone monotherapy compared to fluticasone 
plus loratadine had comparable efficacy in nearly all clinician and patient rated symptoms. 
Finally, Di Lorenzo et al.1472 demonstrated similar results in patients with SAR, noting that 
combination therapy did not appear to offer substantial improvement in daily nasal symptom 
scores or in reduction of nasal lavage inflammatory markers.
In contrast, a 2008 study by Pinar et al.1473 compared mometasone spray monotherapy to 
mometasone plus desloratadine and found that the combination therapy group had 
significantly better nasal symptom scores at the end of study week 2 and better QOL scores 
throughout the study. A recent systematic review and meta-analysis by Feng et al.1474 
summarized the efficacy of the combination therapy of an oral antihistamine and INCS as 
compared to either therapy independently. They concluded that the combination 
demonstrated significant improvement in symptom scores in AR when compared to an oral 
antihistamine alone, but do not provide significant additional benefit when compared to 
monotherapy with an effective INCS.1474 Limitations to this data include the fact that the 
studies did not control for variations in the specific oral antihistamines or INCS utilized and 
that the studies predominantly evaluated patients with SAR, excluding patients with PAR. 
Additionally, the conclusions of this meta-analysis are supported by the updated 2010 ARIA 
guidelines, which also do not recommend the addition of an oral antihistamine to an 
effective INCS, in contrast to prior recommendations.1167 It should also be noted that 
adverse effects of oral antihistamine and INCS combination therapies include drowsiness 
and dry mouth (from oral antihistamines) as well as epistaxis and nasal irritation (from 
INCS).
• Aggregate Grade of Evidence: B (Level 1b: 5 studies; Table IX.B.10.b).
• Benefit: Reduction of nasal congestion with combination of oral antihistamines 
and INCS compared to oral antihistamines alone.
• Harm: Side effects include sedative properties of antihistamines, although 
significantly decreased with the newer second-generation agents. Side effects of 
topical INCS include nasal dryness and epistaxis, burning in the nose, and with 
prolonged usage, possible growth suppression in the pediatric population.
• Cost: Low.
• Benefits-Harm Assessment: Harm likely outweighs benefit of adding the oral 
antihistamine unless treating symptoms other than nasal symptoms.
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• Value Judgments: Combination therapy of oral antihistamine and INCS can be 
helpful when managing the symptoms of nasal congestion.
• Policy Level: Option.
• Intervention: Combination therapy of INCS and oral antihistamine does not 
improve symptoms of nasal congestion over INCS use alone, and does risk the 
adverse effects of systemic antihistamine use.
IX.B.10.c. Oral antihistamine and LTRA.: Combination therapy with LTRA and oral 
antihistamines in the treatment of AR has been studied in a single systematic review1300 and 
multiple RCTs1467,1472,1475-1483 (Table IX.B.10.c). Combination therapy generally 
improved symptoms and QOL compared to placebo in multiple RCTs.1472,1475,1479,1482,1483 
The efficacy of combination therapy compared to monotherapy with either LTRA or oral 
antihistamine is less clear. In the systematic review by Wilson et al.,1300 combination 
therapy improved patient symptoms compared to either agent as monotherapy, but there 
were no differences in standardized QOL measures. An RCT by Cingi et al.1477 indicated 
that montelukast and fexofenadine combination therapy was superior at reducing symptoms 
and nasal resistance measured by rhinomanometry, compared to either fexofenadine alone or 
fexofenadine administered concomitantly with placebo. Several other RCTs, however, did 
not demonstrate a difference in symptom reduction between combination therapy and oral 
antihistamine monotherapy.1475,1479,1482
Several studies also examined the relative effectiveness of combination LTRA and oral 
antihistamine therapy compared to INCS. Combination therapy was generally less effective 
than INCS monotherapy,1472,1479,1481 although some studies did not detect a statistically 
significant difference.1300,1484 The systematic review by Wilson et al.1300 did not discern a 
difference in symptom reduction between LTRA and oral antihistamine combination therapy 
and INCS. In contrast, 3 RCTs showed that INCS resulted in improved nasal symptoms 
compared to treatment with the combination,1472,1479,1481 in addition to decreased nasal 
mucosa eosinophil counts.1472,1481
There is conflicting evidence on whether combination therapy is more effective than oral 
antihistamine alone, and there appears to be relatively consistent evidence that INCS 
monotherapy is more effective at nasal symptom reduction than LTRA and oral 
antihistamine combination therapy. Therefore, combination therapy may be an option in 
patients whose symptoms are incompletely controlled with oral antihistamine monotherapy, 
and in whom INCS are not tolerated or contraindicated. This may be particularly useful in a 
subset of these patients with concurrent asthma. Montelukast may be effective at 
simultaneously reducing AR symptoms and improving asthma control.1341
Drug interaction and safety are an important consideration when using combination 
therapies. Reported adverse events for montelukast and loratadine in combination were 
similar to montelukast and loratadine monotherapy and placebo.1485 The most common 
reported adverse events were headache (4.5%), fatigue (1.2%), and pharyngolaryngeal pain 
(1.2%). There were no changes of vital signs, electrocardiogram, or physical exam findings 
during the monitoring period.1485 Combination LTRA and oral antihistamine therapy can be 
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administered with minimal adverse events, and with similar frequency to either agent as 
monotherapy.
• Aggregate Grade of Evidence: A (Level 1a: 1 study; Level 1b: 11 studies; Level 
2b: 1 study; Table IX.B.10.c).
• Benefit: Inconsistent evidence that combination LTRA and oral antihistamine 
were superior in symptom reduction and QOL improvement than either agent as 
monotherapy. Combination therapy is inferior in symptom reduction compared to 
INCS alone.
• Harm: No significant safety-related adverse events from combination therapy.
• Costs: Generic montelukast was more expensive than either generic loratadine or 
cetirizine on a per dose basis, according to weekly National Average Drug 
Acquisition Cost (NADAC) data provided by the Centers for Medicare & 
Medicaid Services (CMS).
• Benefits-Harm Assessment: Balance of benefit and harm.
• Value Judgments: Combination therapy of LTRA and oral antihistamines does 
not result in consistently improved AR symptoms compared to either agent 
alone. There are few reported safety-related adverse events from combination 
therapy. The addition of an LTRA may have a role in management of comorbid 
asthma.
• Policy Level: Option.
• Intervention: Combination therapy of LTRA and oral antihistamines is an option 
for management of AR, particularly in patients with comorbid asthma or those 
who do not tolerate INCS and symptoms are not well-controlled on oral 
antihistamine monotherapy.
IX.B.10.d. Intranasal corticosteroid and intranasal antihistamine.: The use of 
combination intranasal antihistamine and corticosteroid spray for AR has been well studied. 
One topical formulation is currently available in North America for intranasal use as a 
combination of azelastine hydrochloride and fluticasone propionate (AzeFlu; Mylan, 
Canonsburg, PA). This agent is also designated in the literature as MP-AzeFlu or MP29-02, 
and is marketed in the United States under the trade name Dymista. A systematic review of 
the English-language literature was performed for clinical trials of combination INCS and 
intranasal antihistamine for the treatment of AR. A total of 10 RCTs (9 double-blind, 1 non-
blinded) evaluated combination therapy against either placebo or active control.1486-1495 An 
additional 2 observational studies in the allowable search date range for this document 
reported outcomes of AzeFlu as a single treatment arm1496,1497 (Table IX.B.10.d).
Outcome measures were predominantly patient-reported symptom scores or QOL 
assessments. The most common outcome measure was the TNSS (9 studies), which records 
the severity of runny nose, sneezing, itching, and congestion. Other outcome measures 
included the TOSS (4 studies), a VAS (3 studies), the RQLQ (2 studies), the Pediatric RQLQ 
(1 study), and a threshold/discrimination/identification (TDI) score (1 study).
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The minimum age of subjects in most included studies was 12 years or older. Study duration 
was 14 days of active treatment in most studies, except 1 study with a 3-month duration1495 
and 1 study with a 52-week duration.1488 The number of subjects in each study ranged from 
47 to 3398. Combination therapy with AzeFlu was compared to placebo in 6 studies, with 
primary outcomes showing superiority to placebo in all studies.1486,1487,1489-1492 AzeFlu 
was compared to active treatment with fluticasone propionate monotherapy in 6 studies, all 
of which showed superiority of the combination therapy.1488-1490,1492,1494,1495 Similarly, 
intranasal AzeFlu was compared to active treatment with azelastine hydrochloride 
monotherapy in 4 studies, all of which showed superiority of the combination therapy.
1489,1490,1492,1494 AzeFlu was directly compared to combination therapy with intranasal 
olopatadine and fluticasone in 1 study, with no significant difference in symptom relief 
between treatment groups.1493 One study found superiority of an experimental combination 
of solubilized azelastine and budesonide compared to either a suspension-type formulation 
of azelastine and budesonide or placebo.1491
Two studies evaluated children aged between 6 and 12 years old. Like findings in adults, 
AzeFlu showed superiority to placebo in improving symptoms and QOL in children.1486,1495 
Several studies reporting time to onset found that AzeFlu had a more rapid effect compared 
to INCS alone.
Serious adverse effects were not reported in any study. Intranasal antihistamine and 
corticosteroid combination therapy was generally well tolerated, with the most commonly 
reported adverse effect being an unpleasant taste. Other reported adverse effects included 
somnolence, headache, epistaxis, and nasal discomfort, all occurring in less than 5% of cases 
in each study. One study that compared combination therapy of fluticasone propionate with 
either azelastine or olopatadine reported more treatment-related events for the azelastine 
group (16/68) than the olopatadine group (7/67).1493
• Aggregate Grade of Evidence: A (Level 1b: 9 studies; Level 2b: 1 study; Level 
2c: 2 studies; TableIX.B.10.d).
• Benefit: Rapid onset, more effective for relief of multiple symptoms than either 
INCS or intranasal antihistamine alone.
• Harm: Patient intolerance, especially due to taste.
• Costs: Moderate financial burden. Average wholesale price of $202 USD per 23-
g bottle (1-month supply when used as labeled).
• Benefits-Harm Assessment: Preponderance of benefit over harm. Combination 
therapy with intranasal antihistamine and INCS is consistently more effective 
than placebo. Low risk of non-serious adverse effects.
• Value Judgments: Despite level 1 evidence demonstrating that combination spray 
therapy (INCS plus intranasal antihistamine) is more effective than monotherapy 
and placebo, the increased financial cost and need for prescription limit the value 
of combination therapy as a routine first-line treatment for AR.
• Policy Level: Strong recommendation for the treatment of AR when 
monotherapy fails to control symptoms.
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• Intervention: Combination therapy with INCS and intranasal antihistamine may 
be used as second-line therapy in the treatment of AR when initial monotherapy 
with either INCS or antihistamine does not provide adequate control.
IX.B.11. Nontraditional and alternative therapies
IX.B.11.a. Acupuncture.: In complimentary medicine, acupuncture has the distinction of 
being 1 of the oldest forms of healing arts practiced, with its origins dating back to the 6th to 
5th centuries BC.1498 Traditional Chinese medicine holds to the concept that the body’s vital 
energy (Qi) flows through a network of meridians beneath the skin.1499 In a healthy state, 
the flow of the Qi is uninterrupted whereas disease states mark a disruption of the Qi. The 
aim of acupuncture is to stimulate acupuncture points (acupoints) with needles to recover 
equilibrium. Acupoints are specific anatomic points located along meridians that are 
believed to correspond to the flow of energy through the body.
There have been several blinded RCTs evaluating acupuncture as a treatment for AR. 
Acupuncture has an excellent safety profile with only minor side effects reported.1500,1501 
Some studies have shown acupuncture to influence allergic and inflammatory mediators 
including IgE and IL-10 levels in AR patients significantly more than controls,1501,1502 
suggesting a possible immunomodulatory effect. The clinical significance of these changes, 
however, remains to be seen.
Two meta-analyses addressing acupuncture have been performed (Table IX.B.11.a). The 
first, published in 2008 reviewed 7 RCTs and found a high degree of heterogeneity between 
studies with most studies being of low quality.1500 No overall effects of acupuncture on AR 
symptom scores or use of relief medications were identified.1500 A more recent meta-
analysis of 13 studies had more favorable findings, demonstrating a significant reduction in 
nasal symptoms, improvement in RQLQ scores, and decreased use of rescue medications in 
the group receiving acupuncture.1501 This meta-analysis included 6 of the 7 studies in the 
2008 review and 7 new studies. Again, a high level of heterogeneity between studies and 
varied quality of the studies was noted. Most important to note is that neither meta-analysis 
discussed the specific consideration of concomitant AR medication use during the trials, 
which is common in most acupuncture trials. The uncontrolled use of AR medications could 
have significantly impacted the outcomes in any of these studies and raises concerns when 
interpreting the results.
• Aggregate Grade of Evidence: B (Level 1a: 2 studies; Level 2b: 13 studies; Table 
IX.B.11.a). Only level 1a studies are presented in the table.
• Benefit: Unclear, as 1 meta-analysis showed no overall effects of acupuncture on 
AR symptoms or need for rescue medications and a second meta-analysis 
showed an effect of acupuncture on symptoms, QOL, and need for rescue 
medications.
• Harm: Needle sticks associated with minor adverse events including skin 
irritation, pruritis, erythema, subcutaneous hemorrhage, infection, and headache. 
Need for multiple treatments and possible ongoing treatment to maintain any 
benefit gained.
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• Cost: Cost of acupuncture treatment with multiple treatments required.
• Benefits-Harm Assessment: Balance of benefit and harm.
• Value Judgments: The authors determined that the evidence was inconclusive but 
that acupuncture could be appropriate for some patients to consider as an adjunct 
therapy.
• Policy Level: Option.
• Intervention: In patients who wish to avoid medications, acupuncture may be 
suggested as possible therapeutic adjunct.
IX.B.11.b. Honey.: A long-held belief has been that honey is effective in treating 
symptoms of AR; however, evidence in support of this is scarce. It is postulated that 
environmental antigens contained within locally produced honey could, when ingested 
regularly, lead to the development of tolerance in a manner similar to SLIT. It is important to 
note that heavy, insect-borne pollens do not meet Thomen’s postulates, as they are not 
airborne and hence should not be able to induce allergic sensitivity.818 Studies in animals 
have demonstrated the ability of honey to suppress IgE antibody responses elicited against 
different allergens and to inhibit IgE-mediated mast cell activation.1503-1505 As yet, these 
same effects have not been tested for in humans; however, studies in humans have 
demonstrated various anti-inflammatory properties of honey which point to a potential 
benefit for its use in the treatment of AR.1506,1507
There have been 2 randomized, double-blind, placebo-controlled trials and 1 RCT evaluating 
honey in the treatment of AR (Table IX.B.11.b). The studies differed in geographic location, 
length of honey treatment, dose of honey, and timing regarding specific allergy seasons. One 
double-blind trial and 1 RCT showed a significant decrease in total symptom scores in the 
treatment group compared to control.1508,1509 The RCT additionally reported fewer number 
of severe symptom days and decreased need for antihistamines in the honey group.1509 
Contradicting these findings, a randomized, double-blind, placebo-controlled trial by Rajan 
et al.1510 found no benefit of honey ingestion compared to controls for the relief of AR 
symptoms. Of note, it has been reported that higher doses (50 to 80 g daily intake) of honey 
are required to achieve health benefits from honey1511 and only the study by Asha’ari et al.
1508 dosed patients at that level.
• Aggregate Grade of Evidence: B (Level 1b: 2 studies; Level 2b: 1 study; Table 
IX.B.11.b).
• Benefit: Unclear, as studies have shown differing results. Honey may be able to 
modulate symptoms and decrease need for antihistamines.
• Harm: Some patients stopped treatment because they could not tolerate the level 
of sweetness. Some patients could have an allergic reaction to honey intake, and 
in rare instances, anaphylaxis. Use of this therapy in prediabetics and diabetics 
would likely need to be avoided out of concern for elevated blood glucose levels.
• Cost: Cost of honey; low.
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• Benefits-Harm Assessment: Balance of benefit and harm.
• Value Judgments: Studies are inconclusive and heterogeneous.
• Policy Level: No recommendation due to inconclusive evidence.
• Intervention: None.
IX.B.11.c. Herbal therapies.: Like acupuncture and honey, herbal remedies have been 
used for the treatment of various physical ailments, including AR, world-wide for thousands 
of years. This area of complementary/alternative medicine is an attractive alternative to 
mainstream medicine for patients who wish to avoid traditional pharmacotherapy or who 
have not tolerated various anti-allergic medications in the past. There are a vast number of 
studies looking at the effectiveness of numerous herbs and herbal supplements in the 
treatment of AR; however, most are small and of poor quality. Those herbal remedies that 
have been subjected to more rigorous study are summarized in Table IX.B.11.C
Given the lack of robust and repeated large double-blind randomized placebo-controlled 
trials on any 1 herbal remedy, no evidence based recommendations can be made supporting 
the routine use of any 1 herb or compound; this should be considered an area requiring 
further research before any such recommendations can be made.
• Aggregate Grade of Evidence: Uncertain.
• Benefit: Unclear, but some herbs may be able to provide symptomatic relief.
• Harm: Some herbs are associated with mild side effects. Also, the safety and 
quality of standardization of herbal medications is unclear.
• Cost: Cost of herbal supplements; variable.
• Benefits-Harm Assessment: Unknown.
• Value Judgments: The authors determined that there is a lack of sufficient 
evidence to recommend the use of herbal supplements in AR.
• Policy Level: No recommendation.
• Intervention: None.
IX.C. Surgical treatment
AR is a medical disease, but at times may become refractory to medical management. 
Surgery for AR is primarily aimed at reducing nasal obstruction and/or rhinorrhea, with the 
contributing structures being the nasal septum and turbinates.1551 Vidian neurectomy is 
historically a surgical technique that seeks to overcome chronic and intractable rhinitis.
No Cochrane review of septoplasty or vidian neurectomy for allergic patients currently 
exists. A Cochrane review of turbinate reduction in allergic patients refractory to medical 
management was explored, but was unable to identify any qualifying studies (selection 
criteria stringently required randomized controlled trials of inferior turbinate surgery vs 
continued medical treatment for proven AR, or comparisons between 1 technique of inferior 
turbinate surgery vs another technique, after maximal medical treatment).1552 Physicians 
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must, therefore, rely upon less scientifically rigorous data when deciding upon surgery for 
AR patients.
The role of septoplasty for the treatment of nasal obstruction in AR is poorly understood. 
The nasal septum is not a major contributor to allergic disease because it does not experience 
the extent of dynamic change the turbinate tissue does, and therefore, there is a paucity of 
literature investigating septoplasty alone to improve nasal patency in AR. The nasal septal 
swell body may serve to alter nasal airflow and humidification, but no literature exists to 
implicate a role in AR.1553 Karatzanis et al.1554 found that subjective improvement in 
patients undergoing septoplasty was higher in those without AR than those with it. For this 
reason, a cautious approach to the management of nasal septal deviation in AR is warranted. 
On the other hand, Kim et al.1555 found that AR patients undergoing septoplasty with 
turbinoplasty felt more relief of nasal obstruction then those undergoing turbinoplasty alone 
(Table IX.C).
In contrast to the septum, the inferior turbinates are a prime target of allergic effects, 
characterized by vasodilation of capacitance vessels leading to engorgement, in turn causing 
nasal obstruction and congestion. Although surgery will not eliminate the inflammatory 
origins of AR, additional patency of the nasal cavity reduces the effects of edematous 
mucosa. From a surgical standpoint, inferior turbinate reduction is the most beneficial 
treatment for nasal obstruction in AR refractory to medical therapy.1552 The inferior 
turbinate consists of 3 primary components: a mucosal covering, a submucosal layer 
(containing the capacitance vessels), and a bony center. Surgery is typically aimed at the 
submucosa or bone, or total/partial turbinectomy which involves removal of all 3 
components.
The submucosal tissue can be reduced through direct removal (eg, submucous bony 
resection or microdebrider submucosal resection) or energy applied to damage tissue with 
subsequent remodeling (eg, cautery, radiofrequency, laser, Coblation™). These various 
techniques have substantial support in the literature. Mori et al.1556 reported on long-term 
outcomes on patients undergoing submucous bony resection over a 5-year follow-up period 
and noted a significant improvement in symptoms and nasal allergen responses. 
Additionally, QOL was enhanced in postoperative patients and maintained long term. 
Microdebrider submucous reduction targets the cavernous tissue surrounding the bony 
turbinate. Advantages include real-time suction with precise tissue removal. Compared to 
submucosal bony resection, data suggests improved mucociliary time due to less tissue 
trauma.1557
Laser turbinate reduction seeks to induce scarring in the submucosa, though the overlying 
superficial mucosal layer is transgressed in the process. Caffier et al.1558 reported on the 
effects of diode laser turbinoplasty in 40 patients with AR. Statistically significant 
improvements occurred in rhinomanometry and nasal obstruction, rhinorrhea, sneezing, and 
nasal pruritus. The improvement in nasal obstruction was sustained at 2 years.1558
In radiofrequency ablation (RFA) for nasal obstruction, a probe is inserted directly into the 
inferior turbinate to deliver a low-frequency energy, causing ionic agitation of tissues.1559 
Wise et al. Page 119













The thermal effect is limited to the submucosal layer, which preserves surface epithelium 
and ciliary function.1560 Following RFA, coagulative necrosis occurs first, with scar 
contracture and tissue retraction occurring later in the healing process. Over time, portions 
of the fibrotic scar undergo resorption and the submucosal scar will adhere to the bony 
periosteum, which reduces turbinate bulk and renders it less susceptible to edema and 
engorgement.1560,1561 In the first long term study of its kind, Lin et al.1562 published a 
report on 101 patients who were followed up to 5 years postoperatively after undergoing 
RFA turbinoplasty for the treatment of AR. The 6-month and 5-year response rates were 
77.3% and 60.5%, respectively, and statistically significant improvement was achieved in 
nasal obstruction, rhinorrhea, sneezing, itchy nose, and itchy eyes.1562 Coblation™ 
technology relies on electrodissection by molecular activation. This technology can similarly 
target the submucosal layers. Siméon et al.1563 investigated the efficacy of Coblation™ on 9 
AR patients with a mean age of 12.7 years. Favorable decreases in nasal resistance, pruritus, 
sneezing, hyposmia, and rhinorrhea were observed and sustained at 6-month follow-up.1563 
RFA and Coblation™ procedures are well-tolerated with minimal adverse effects and can be 
safely performed in the operating room or the outpatient office setting.
Bony outfracture seeks to shift the bony skeleton of the inferior turbinate laterally into the 
inferior meatus, thereby creating more breathing space. Aksoy et al.1564 found statistically 
significant reductions in the distance between the inferior turbinate and the lateral nasal wall 
after outfracture in 40 patients. This effect was sustained at 6 months postoperatively, which 
suggests that lateralization persists.1564 Radical turbinate excision might overcome 
obstruction, but, at the cost of dryness and possibly empty nose syndrome.1565
Vidian neurectomy is an older technique that seeks to damage the parasympathetic nerve 
impulses to the nasal cavity. Tan et al.1566 found significant improvement in QOL measures 
in a prospective group undergoing vidian neurectomy over septoplasty/partial turbinectomy 
or medical management groups. This technique is considered more effective for non-allergic 
patients and seeks to primarily address severe rhinitis.1567 Posterior nasal nerve section may 
also be considered for recalcitrant rhinorrhea; this technique aims to avoid the dry eye 
complications of vidian neurectomy.1568
Recent publications have identified isolated middle turbinate polypoid edema or frank 
polyps to have a significant correlation with inhalant allergy, especially in more severe cases.
785,786 In cases where the polypoid changes in the middle turbinate are significant enough to 
cause nasal obstruction, conservative recontouring of the middle turbinate(s) can reduce 
nasal obstructive symptoms.
To summarize, surgical treatment of the septum, inferior and/or middle turbinates, and 
possibly vidian/posterior nasal neurectomy may be considered in both allergic and non-
allergic patients. Outcomes of these various techniques are variable in patients with AR.
• Aggregate Grade of Evidence: C (Level 1a: 1 study; Level 1b: 1 study; Level 2b: 
1 study; Level 3b: 4 studies; Level 4: 5 studies; Table IX.C).
• Benefit: Improved postoperative symptoms and nasal airway.
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• Harm: Possible septal perforation, empty nose syndrome, nasal dryness, mucosal 
damage, epistaxis.
• Cost: Office-associated vs operating room-associated procedural costs.
• Benefits-Harm Assessment: Preponderance of benefit over harm.
• Value Judgments: Properly selected patients can experience an improved nasal 
airway with judicious surgical intervention.
• Policy Level: Option.
• Intervention: Turbinate reduction with or without septoplasty may be considered 
in AR patients that have failed medical management, and have anatomic features 
which explain symptoms of nasal obstruction.
IX.D. Allergen immunotherapy (AIT)
In addition to allergen avoidance and numerous pharmacotherapy options, AIT is frequently 
considered in the management of AR. AIT involves scheduled administration of allergen 
extracts at effective doses with the goal of instituting a sustained immunologic change. AIT 
effectiveness is often measured through control of allergy symptoms and reduction in allergy 
medication use. The following section reviews the specifics of allergen extract units and 
standardization, allergen extract adjuvants and modifications, and subcutaneous and 
sublingual immunotherapy (SCIT, SLIT), as well as less traditional types of immunotherapy.
IX.D.1. Allergen extract units, potency, and standardization—Historically, 
allergy testing began with pollen grains placed directly on the conjunctiva,1569,1570 but as 
skin testing and SCIT became the diagnostic and immunotherapy treatment methods of 
choice, injectable allergen extracts were required. Inhaled allergenic particles are composed 
of a complex heterogeneous mixture of allergenic and non-allergenic proteins and 
macromolecules. Allergen extracts are created by collecting raw material from a particular 
species of plant, mold, or animal and then using a solution to extract proteins from the 
source.1571
There are multiple sources of variance in allergen extracts. There is biologic variability in 
the raw material, and proteins can vary in antigenicity and composition; furthermore, the 
relative amounts of allergenic proteins may vary.1572,1573 Impurities in the source materials, 
such as mold growing on pollen granules or bacteria on cat pelts, may also be immunogenic 
even if nonviable. Variation occurs in the collection and processing of the raw material.1573 
There is variability in the extraction process with different manufacturers using different 
techniques including filtration, extraction, sterilization, and preservation.1571,1572,1574,1575 
Only a very small fraction of the proteins extracted are allergenic.1571 Given that the protein 
composition of allergen extracts is not known, producing and labeling allergen extracts that 
are safe and effective is challenging.
Units and potency.: Allergen extracts are labeled with an assortment of units that provide 
an indirect indication of the allergen content of the extract. Most allergen extracts are labeled 
in units that do not convey information about biological composition or potency. There are 
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multiple types of units that can be grouped into nonstandardized, standardized, or 
proprietary. The difference between standardized and nonstandardized extracts is discussed 
later this section.
Potency of an allergen can have different meanings. Potency sometimes refers to the 
allergenicity of a source material’s proteins or the biologic activity. For example, grass 
pollens are generally more potent than tree pollens. The typical grass-allergic person would 
have a larger clinical reaction to grass pollen than a tree-allergic person to the same amount 
of tree pollen. However, a measure of potency of an allergen extract may also just refer to 
the strength or concentration measured in units.
Nonstandardized allergen extracts.: Most allergen extracts available in the United States 
are nonstandardized. Allergen extracts are regulated by the Center for Biologics Evaluation 
and Research (CBER) under the FDA in the United States.1576 Allergen extracts are required 
to list the biologic source, a potency unit, and an expiration date.
• Weight/volume (wt/vol). Weight/volume refers to the ratio of grams of dry raw 
material to milliliters of extract solvent. Commonly this is 1/20 wt/vol, which 
means that for every 1 g of raw material (pollen for example) there is 20 mL of 
extract solvent. This does not provide direct information about the amount of 
allergenic proteins in the allergen extract nor its biologic activity. However, it 
implies a reproducible methodology was employed.1571
• Protein nitrogen units (PNUs). This is the second most common nonstandardized 
unit currently used in the United States. PNU refers to an assay of the 
precipitable protein nitrogen by phosphotungstic acid which correlates with the 
total protein. While most of the protein is non-allergenic, the total protein is 
another method to quantitate an allergen extract’s content.1571
In Europe, many manufacturers use proprietary units and internal quality controls which 
must utilize a validated assay.1572 This European manufacturer-based quality control is 
known as “In House Reference Preparation.”1573 However, the European Medical Agency 
has been developing a standardized framework based on protein homology rather than 
source species.1577 The EU is also developing additional allergen standards with the WHO 
starting with Bet v 1 and Phl p 5a.1577
Standardized allergen extracts.: In the United States, standardized allergen extracts are 
tested by the manufacturer to be within a reference range (70-140%) when compares to a 
standard provided by the CBER. The government’s standard is referenced to the reactivity in 
highly allergic individuals, creating a standard of biologic activity.
The CBER creates the standard extract through testing in known “highly allergic” 
individuals. They use serial intradermal 3-fold titrations and measure potency by how many 
dilutions are needed to produce a flare reaction of a certain size. The size is determined by 
measuring the largest diameter and adding the length of a line 90 degrees to the largest 
diameter line. The orthogonal sums are plotted for each dilution and a best fit line drawn. 
The concentration that corresponds to where the orthogonal sum of the flare is 50 mm 
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(ID50EAL) determines the units listed in either Allergy Units (AU) or Biologic Allergy 
Units (BAU). AU is used for dust mites. A mean ID50EAL of 14 threefold dilutions is 
defined as 100,000 BAU/mL and 12 threefold dilutions 10,000 BAU/mL.1577
The FDA allergen standards are compared to the produced allergen extracts by the 
manufacturers. The process is different for extracts where the major allergen reactivity 
correlates with overall allergen reactivity (cat and ragweed) than for extracts that do not have 
a major allergen that correlates as strongly. A major allergen is defined as a specific protein 
epitope that more than 50% of individuals allergic to that species react. If there is a major 
allergen that correlates strongly with the population’s clinical reactivity, the manufacturer 
can compare their extract to the standard extract by gel electrophoresis with the gel having 
monoclonal IgG antibodies to the major allergen protein. If there is not a single allergen that 
correlates well with the reactivity of the population, the manufactured extract and the 
standard are compared through competition enzyme-linked immunosorbent assay (ELISA) 
using pooled serum IgE from known allergic subjects. The manufacturer’s extract must fall 
within a 70% to 140% range of the FDA’s reference.1576 The amount of major allergen is 
sometimes listed in μg/mL, Fel d 1 units (cat), or Antigen E units (ragweed). Standardized 
inhalant allergens within the United States include cat, Dermatophagoides pteronyssinus, 
Dermatophagoides farinae, short ragweed, and multiple grass species.1577
Some allergen extracts in Europe use the Nordic method where 10,000 biologically 
standardized units/mL is comparable to a skin reaction elicited by 10 mg/mL of histamine.
1577
In conclusion, an international consensus has not been established for allergen units or 
standardization of allergen extracts. While standardization and transparent potency assays 
increase manufacturing costs, it is widely agreed that greater standardization and consistency 
across manufacturers would be beneficial. Variations in allergen extracts between 
manufacturers may discourage medical providers from changing between vendors reducing 
the effect of price on competition. The multitude of allergen extract units and variability also 
complicates the interpretation and application of published studies between the United 
States, the EU, and other countries. The WHO has identified allergen standardization as a 
problem and the EU funded a project known as CREATE, “Development of Certified 
Reference Materials for Allergenic Products and Validation of Methods for the 
Quantification.”1578 But as of 2017, multiple allergen units are still in use worldwide.
IX.D.2. Modified allergen extracts—The goal of AIT is to suppress the underlying 
inflammatory diathesis and induce a state of clinical tolerance to the relevant allergen. This 
thereby attenuates, if not completely arrests, the inflammation that manifests as AR. 
Traditional AIT with native, unmodified extracts is successful but has several limitations. 
Immunotherapy can lead to adverse reactions which rarely can be life-threatening. Besides 
the risks, allergen extracts have significant production costs with limitations of availability 
and consistency between batches. Variations exist in pharmaceutical-produced native 
extracts in the allergen amounts, potencies, and immunogenicity of individual allergen 
molecules that cannot be controlled in the manufacturing process.1579
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New advances in AIT have focused on redirecting the untoward allergic diathesis through 
upregulation of T-regulatory and B-regulatory cells, restoring the balance between Th2 and 
Th1 cell subtypes, and establishing T-cell immune tolerance. The use of recombinant-
derived allergens, synthetic peptides, allergoids, and adjuvants has been sought to provide 
safer, more consistent, readily available, and effective allergens compared to commercially 
available native extracts1580-1582 (Table IX.D.2-1).
The laboratory production of allergens allows for modification of extracts and epitope 
structures that aim to enhance immunogenicity while decreasing the risk of adverse 
reactions. Clinical studies have reported outcomes for AIT using recombinant-produced 
molecules, synthetically-produced peptides, and modifications of allergens via allergoids 
with adjuvant molecules or through denaturing of proteins.
Recombinant allergens.: Recombinant-derived allergens are produced by cloning of native 
allergen proteins with use of recombinant DNA technology. The allergy protein is reverse 
transcribed to yield a complimentary DNA molecule which can then be transferred into 
bacteria which produce copies of the incorporated DNA. This technique allows for 
controlled production of a high-yield product with consistent structure. Immunotherapy 
trials with recombinant allergens has been reported for birch pollen and Timothy grass 
pollen (Table IX.D.2-2). Recombinant birch AIT demonstrated equivalent clinical outcomes 
to native birch extract and improved symptoms over placebo.1583-1585 Recombinant Timothy 
grass AIT showed improved outcomes compared to placebo with a good safety profile.
805,1586 Recently, a recombinant peptide carrier fusion grass vaccine has reported positive 
outcomes with a B-cell epitope-based vaccine for immunotherapy of grass pollen allergy.798
• Aggregate Grade of Evidence for birch: B (Level 1b: 3 studies; Level 2b: 1 
study).
• Aggregate Grade of Evidence for Timothy grass: B (Level 1b: 3 studies).
• These studies of recombinant allergens for birch and Timothy grass demonstrate 
safety and efficacy.
Peptide constructs. Synthetic peptides for immunotherapy are linear fragments of amino 
acids that correspond to T-cell epitopes. These fragments lack the secondary and tertiary 
structure that activate IgE receptors, but can induce immunologic tolerance by targeting 
allergen-specific T-cells to induce tolerance. The premise with synthetic peptides is that the 
lack of IgE activation will eliminate the risk of IgE-mediated adverse reaction while 
preserving the immunogenicity that leads to desensitization. AIT trials with synthetic 
peptides have been reported for cat, birch, and ragweed allergens (Table IX.D.2-2). Overall, 
studies have shown mixed outcomes from synthetic peptides with some peptide molecules 
resulting in an increase in late adverse reactions. The recently completed large-scale 
multicenter field trial (https://clinicaltrials.gov/ct2/show/NCT01620762; Phase III Cat-PAD 
Study) with cat peptide failed; however, as of this writing, the HDM peptide study is 
ongoing.1587,1588 Newer peptide constructs under investigation include overlapping peptides 
that reproduce the entire sequence of the naturally-occurring allergen in an attempt to cover 
all T-cell epitopes and natural peptide fragments that cover a broad panel of epitopes.1589
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• Aggregate Grade of Evidence for cat: B (Level 1b: 5 studies).
• Aggregate Grade of Evidence for birch: Indeterminate, based on only 1 Level 1b 
study.
• Aggregate Grade of Evidence for ragweed: B (Level 1b: 1 study; Level 2b: 1 
study).
Allergoids and polymerized allergens. Allergoids are chemically modified allergens which 
were developed for improved immunotherapy protocols via accelerated dosing and 
decreased side effects. Initial attempts at development of an allergoid by partial denaturing 
of the allergenic moiety with formalin resulted in reduced allergenicity; however, concurrent 
reduction in the immunogenicity of the allergoids, as defined by IgG antibody production, 
was seen.1590 Studies using a glutaraldehyde-linked polymerization of allergens for grass 
and ragweed allergens demonstrated efficacy and tolerability.1591,1592 However, 
standardization criteria and production factors negatively impacted regulatory approval in 
the United States. Clinical trials for allergoids employing ragweed, grass, and HDM 
allergens have been reported. Promising early results are seen for these allergoids. In 
addition, more recent work has focused on depigmented allergoid constructs, which are 
currently in use in Europe1593,1594 (Table IX.D.2-2).
• Aggregate Grade of Evidence for ragweed: B (Level 1b: 1 study; Level 2b: 1 
study).
• Aggregate Grade of Evidence for grass: B (Level 1b: 7 studies).
• Aggregate Grade of Evidence for HDM: Indeterminate, based on only 1 Level 2b 
study.
• Allergoid or polymerized allergen products have been approved in Europe but 
none has received FDA approval.
Adjuvant constructs.: The addition of molecules (adjuvants) to the native allergen has been 
attempted to improve desensitization protocols. Alum was the first adjuvant to gain 
acceptance in AIT. Early studies with alum-precipitated extracts demonstrated an augmented 
immunologic response. However, alum induced an initial IgE immune response which 
hindered its therapeutic application.1595 Clinical trials with adjuvants have been reports for 
ragweed, grass, and HDM allergens (Table IX.D.2-2).
Creticos reported the proof-of-concept study for using bacterial DNA (CpG oligonucleotide 
synthetically derived from Mycobacterium bovis) to upregulate an immunostimulatory 
response to allergen through the corresponding ligand (TLR ligand) on a specific class of 
regulatory dendritic cells.1596 The TLR-9 agonist was administered in a 2-year double-blind 
placebo-controlled study of ragweed-allergic subjects immunized with a 6-injection regimen 
administered prior to the initial ragweed season. A similar magnitude of effect vs placebo 
was observed over both ragweed seasons indicating that the vaccine conferred meaningful 
long-term efficacy (clinical and immune tolerance) over 2 ragweed seasons.1596 Subsequent 
large-scale multicenter trials were not able to satisfy regulatory approval requirements and 
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this specific product is not going forward in development.1597 However, the field of adjuvant 
approaches to immunization is moving forward.
A TLR-4 adjuvant is also currently in clinical development. This construct is comprised of 
monophosphoryl lipid A, derived from detoxified lipopolysaccharide of gram-negative 
bacterium (Salmonella minnesota, a TLR-4 inducing adjuvant), and formulated with pollen 
allergoids absorbed onto microcrystalline tyrosine. This compound reduces IgE-mediated 
allergenicity but preserves immunogenicity. A large grass study showed significant 
improvement in symptom and medication scores vs placebo with subgroup analysis showing 
greater benefit in patients with more severe symptoms.1598 An abbreviated ragweed trial 
showed clinical effect in the primary endpoint vs placebo.1066
These studies of adjuvant-modified extracts demonstrate potential for improved 
immunotherapy protocols; however, several challenges remain. Each of the modified extracts 
requires robust clinical outcomes data to demonstrate short and long-term improvement in 
both efficacy and safety over conventional allergenic extracts.
• Aggregate Grade of Evidence for ragweed: B (Level 1b: 3 studies).
• Aggregate Grade of Evidence for grass: B (Level 1b: 2 studies).
• Aggregate Grade of Evidence for HDM: Indeterminate, based on only 1 Level 2b 
study.
In summary, a wide variety of immunotherapeutic agents are currently undergoing clinical 
development with the goal of improving safety and achieving immune tolerance with long-
lasting therapeutic efficacy. This new generation of vaccines includes recombinant allergens, 
peptide constructs, allergoids/polymerized allergens, and adjuvant constructs—each of 
which must undergo rigorous clinical evaluation to demonstrate acceptable safety and 
meaningful clinical outcomes that meet regulatory guidelines for approval. For some of the 
studied preparations, there appears to be improvement over placebo and comparable 
outcomes to native allergens. The TLR-9 agonist trial showed 2 years of efficacy post-
discontinuation of drug. However, some peptide molecules demonstrated increased late 
reactions as well as mixed clinical outcomes depending on the preparation. Allergoids, 
adjuvants, and peptides have also shown efficacy in multiyear clinical trials. There is 
insufficient evidence to make recommendations based on the low number of studies for each 
preparation and lack of long-term outcomes, as no study has examined outcomes for longer 
than a 2-year period.
IX.D.3. Subcutaneous immunotherapy (SCIT)—AIT is a treatment for IgE-
mediated sensitivity to environmental allergens.101,1613,1614 SCIT involves the injection of 
increasing doses of an extract of the allergen in question, followed by repeated injections of 
the top or maintenance dose for periods of 3 to 5 years, to reduce symptoms on exposure to 
that allergen. SCIT has been practiced for over a century using aqueous extracts of the 
naturally occurring allergens.1615 SCIT has been shown to be effective for AR, allergic 
asthma, and sensitivity to hymenoptera venom, along with demonstrated benefit in selected 
patients with AD. Although meta-analyses conclude that AIT is effective, this positive 
judgment of efficacy (and safety) should be limited to products tested in the clinical trials. It 
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is incorrect to make a general assumption that “AIT is effective,” since this may lead to the 
clinical use of products that have not been properly studied.1614,1616 However, as currently 
practiced, SCIT has the drawbacks not only of the prolonged period of treatment and 
multiple visits to health care facilities but also the ever-present risk of systemic reactions. 
There are now attempts to overcome these limitations by modifying the native allergens or 
using recombinant technology to produce extracts that are less reactive with sIgE, allowing 
higher dosing with greater safety and shorter courses of treatment.1615 (See section IX.D.2. 
Management – Allergen immunotherapy (AIT) – Modified allergen extracts for additional 
information on this topic.)
Two U.S. healthcare agencies have recently commissioned systematic reviews of the medical 
literature on the use of AIT in AR1617,1618 (Table IX.D.3-1). The National Institute for 
Health Research commissioned an update of the 2007 Cochrane Review of AIT for SAR1617 
and the Agency for Healthcare Research and Quality commissioned a systematic review of 
the use of SCIT and SLIT for the treatment of AR and bronchial asthma.1618 The first of 
these systematic reviews found highly significant differences in favor of SCIT over placebo 
for improvement of symptoms and medication use for treatment of AR, as well as for 
improvement in the rhinitis QOL, all with a p value of < 0.00001.1617 The second systematic 
review found high-quality evidence for SCIT, compared to placebo, improving rhinitis and 
rhinoconjunctivitis symptoms and QOL, with moderate quality of evidence for reduction in 
medication use for treating AR.1618 A third systematic review using the EBRR methodology 
found that SCIT for SAR and PAR has Aggregate Grade of Evidence A and recommended 
SCIT for SAR or PAR patients not responsive to medical therapy, whose symptoms 
significantly affect QOL.1619
A search of the EMBASE, MEDLINE, and Cochrane Library databases for systematic 
reviews and randomized controlled clinical trials yielded a recent otolaryngology clinical 
practice guideline for AR761 and an International Consensus on Allergy 
Immunotherapy1577,1620 as well as 5 double-blind, placebo-controlled trials of SCIT in AR 
that were published since the previously discussed systematic reviews (Table IX.D.3-1). All 
5 of these trials were conducted with aldehyde-modified natural pollen extracts (allergoids).
1593,1594,1605,1621,1622 These trials all support the efficacy of SCIT in treating AR.
Patient selection.: There are 3 therapeutic options for patients with AR: avoidance, 
pharmacotherapy, and immunotherapy. The evidence supporting avoidance is reviewed in 
section IX.A. Management – Allergen avoidance. Pharmacotherapy is discussed in section 
IX.B. Management – Pharmacotherapy. There are 2 primary reasons to consider AIT.101,1623 
One is that addition of AIT to pharmacotherapy alone will likely result in a more 
pronounced decrease of symptoms (even after a short course of AIT). The second relates to 
the failure of pharmacotherapy to alter the underlying immunologic process. Patients may 
choose AIT largely to obtain a lasting benefit, prevent the progression of AR to bronchial 
asthma, or prevent new sensitizations.1624-1626
Contraindications for AIT.: The 2015 EAACI Position Paper noted contraindications for 
instituting SCIT for AR.1627 Absolute contraindications were poorly controlled or 
uncontrolled asthma, active autoimmune disorders, and malignant neoplasm. Relative 
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contraindications were partially controlled asthma, autoimmune diseases in remission, 
cardiovascular disease, and use of beta-adrenergic blocking agents. The Allergy 
Immunotherapy: Practice Parameters 3rd Update, on the other hand, found no substantive 
evidence that immunotherapy is harmful in patients with autoimmune diseases.1623 The 
Practice Parameters also list pregnancy as a contraindication to initiating SCIT.1623 It may, 
however, be continued if the patient is on maintenance dosing.
Extracts.: In the United States, most pollen, dander, insect, and fungal extracts are available 
either in a buffered saline with phenol or in 50% glycerin. The exception is those extracts 
that have been standardized by the FDA which only come in 50% glycerin. There is 1 line of 
alum-precipitated extracts, consisting solely of pollen extracts. In Europe, on the other hand, 
alum-precipitated extracts are commonly employed and there is increasing use of allergoid 
extracts consisting of natural allergens partially denatured by mixture with an aldehyde.
1593,1594,1605,1621,1622,1628 (See sections IX.D.1. Management – Immunotherapy – Allergen 
extract units, potency, and standardization and IX.D.2. Management – Immunotherapy – 
Modified allergen extracts for additional information on this topic.)
Dosing.: The beneficial results of SCIT have been repeatedly shown to be dependent on 
administering a sufficient maintenance dose of each extract with each maintenance injection.
1609,1629-1631 Reduction of the effective maintenance dose by 90% to 95% causes partial or 
complete loss of efficacy.1632 The results of many double-blind, placebo-controlled studies 
have been utilized to formulate the recommendations for dosing in Table IX.D.3-2, adapted 
from the Immunotherapy Practice Parameters 3rd Update.1623
Monosensitization vs polysensitization.: In most large studies of AR, 80% to 85% of the 
subjects are sensitized to more than 1 unrelated allergen. Analysis of some of these studies 
has shown that the polysensitized subjects respond as well to (sublingual) AIT as those with 
sensitivity only to the administered allergen.1633 There is no immunological rationale why 
this should be different in subcutaneous AIT, but this specific question is an important unmet 
need which should be addressed in future trials.28,1634
Single-allergen vs multiple-allergen AIT.: It is the common practice among US allergists 
to include in their treatment multiple allergen extracts to which the patient is sensitized. A 
recent survey of 670 patients in 6 practices found a mean of 18 allergen extracts in their 
treatment.29,1635 On the other hand, European guidelines recommend treating with the single 
most troublesome allergen identified clinically,1636 or if more than 1 extract is to be given 
they should be given at separate sites with at least 30 minutes in between administration.32 
Scientific support for the U.S. allergists’ approach of using multiple allergen mixtures for 
SCIT can be found in 4 double-blind, placebo controlled studies, 2 in patients with AR,
1629,1637 1 in children with asthma,1630 and 1 in patients with both rhinitis and asthma,1638 
all of which demonstrated significant improvement in patients receiving mixtures of 
multiple, unrelated allergen extracts. However, a recent review concluded that multiallergen 
immunotherapy in polysensitized patients, whether delivered sublingually or 
subcutaneously, requires more supporting evidence from well-designed, well-powered, 
double-blind, placebo-controlled clinical trials to validate its efficacy in practice.1634
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Mixing.: If multiple-allergen mixtures are to be used for SCIT, there are several 
considerations, in addition to ensuring that each extract in the mixture is at a concentration 
that will provide an effective dose when delivered with the maintenance injection. These 
considerations are (1) avoiding mixing extracts with strong proteolytic activity with extracts 
whose allergens are susceptible to this activity; (2) paying attention to allergenic cross-
reactivity; and (3) using preservatives that are appropriate for the allergens.1632
All fungal and some insect body extracts (but not U.S. HDM extracts) have strong 
proteolytic activity to which many pollen, mite, and animal dander allergens are susceptible.
1639 Fungal and cockroach extracts should not be mixed, but fungal extracts can be 
combined.1640
Plant pollens contain some allergens that are like the allergens of unrelated plants (pan-
allergens) but generally the major allergens are unique. When the appropriate allergens are 
available in the testing panel, the use of molecular diagnosis or CRD can be of great use in 
differentiating cross-reactivity due to pan-allergens from that due to multiple related major 
allergens. (See section VIII.F.6. Evaluation and diagnosis - In vitro testing - Component 
resolved diagnosis (CRD) for additional information on this topic.) When the patient is 
sensitized to the major allergens of botanically related plants there are 2 approaches that can 
be employed.1641 One approach is to only include the locally most important member of a 
related group (such as ragweed or northern pasture grasses); the other approach is to use a 
mixtures of related allergen extracts, but treating it as if it were 1 allergen.1641
Diluents.: Diluents containing 50% glycerin are excellent at maintaining extract potency 
and are used in the United States routinely for extracts with high protease activity.1639,1642 
The drawback to using extracts with high glycerin content is that they cause pain when 
injected.1633 A phenol-saline extract containing 0.3% human serum albumin is well tolerated 
and, in the absence of high proteolytic activity, is an excellent diluent that may be used 
routinely for making dilutions for initiation of SCIT in the United States.1643
Regimens.: For reasons of safety, SCIT is initiated at a dilution of the final dose and built up 
usually with weekly injections of increasing amounts and concentrations over a period of 
weeks or even months. Once maintenance doses are achieved, the interval between 
injections can be increased but usually not beyond 4 weeks with aqueous extracts used in the 
United States,1623 but up to 4 to 6 weeks for depot extracts as used in Europe.1614
Venue for administering SCIT.: SCIT in allergy practices in the United States is associated 
with a rate of severe systemic reactions of 0.1%.1644 For this reason the Immunotherapy 
Practice Parameters 3rd Update state that injections should be given only in a medical 
facility where prompt recognition and treatment of anaphylaxis is assured and patients 
should remain under observation for at least 30 minutes following the injection.1623 This is 
in line with the European perspective.32 There is a company in the United States that 
promotes the practice of home administration of SCIT.1645 Their protocol calls for 
administration of relatively low doses of SCIT several times per week resulting in a 
cumulative dose that approaches that recommended in the Practice Parameters. However, 
there is evidence to suggest that it is the size of the individual dose rather than the 
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cumulative amount administered that determines efficacy,1646 and no blinded studies have 
been offered to support the efficacy of this low-dose approach.
Accelerated SCIT administration.: To shorten the length of the buildup, cluster dosing is 
sometimes employed. Two or 3 injections are given on each visit on nonconsecutive days, 
with a 30-minute waiting between injections. If visits are twice weekly, maintenance dosing 
can be achieved in 4 weeks1647 or even after a shorter period depending on the product 
administered and schedule followed.1648 A retrospective analysis of rates of systemic 
reactions in a large, multiple-physician practice1649 and a double-blind randomized trial1650 
showed no increase in the rate of systemic reactions in patients, comparing cluster to 
conventional regimens. Another (open) trial supports these findings.1651
Rush regimens administer many injections per day on consecutive days, typically achieving 
maintenance dosing in 1 to 3 days. Even with the use of premedication, there is an increased 
rate of systemic reactions compared to conventional dosing.1652
Mechanism of action.: In general, the immunologic response to SCIT involves 2 sequential 
steps. The first is a generation of regulatory T-cells secreting IL-10 and TGF-β, leading to a 
switch from IgE to IgG4 antibody formation.1653,1654 With continued AIT the Treg response 
declines and an immune deviation from Th2 to Th1 responses dominates.1577,1653 (See 
section IV. Pathophysiology and mechanisms of allergic rhinitis for additional information 
on this topic.)
Modification of disease.: An advantage of SCIT over pharmacotherapy is that it alters the 
underlying immunologic response towards that which is seen in non-allergic individuals.1654 
The results of this alteration in the underlying immune response by SCIT can be seen 
clinically in the reduction in new sensitizations, in the progression from AR to asthma, and 
in the persisting benefit following an adequate course of therapy.
In children, adolescents, and young adults, who are sensitized only to the allergen being 
administered, the development of new sensitizations is reduced not only during AIT but for 
several years following completion of the course of AIT.1625,1626 A similar protective effect 
has not been demonstrated in patients polysensitized at the initiation of AIT.
SCIT has also been shown to prevent the progression from AR to asthma. A total of 205 
children, sensitized to grass, birch or both, and showing no evidence of asthma during an 
observational year, were treated with Timothy and/or birch SCIT for 3 years, or standard 
pharmacotherapy alone, and observed for an additional 7 years after completion of SCIT in 
an open trial.1624 The risk for developing asthma was significantly reduced at the end of 
SCIT and persisted for the 7 years of follow-up. The database of the German National 
Health Insurance was used to follow patients with AR without asthma who were or were not 
placed on AIT in 2006.1655 During a 5-year follow-up, those patients who received AIT 
(90% on SCIT) were significantly less likely to have developed asthma.
Duration of treatment and persistence of treatment effect.: Regarding persistence of 
benefit, a double-blind, randomized study was conducted in patients with AR who had 
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received 3 or 4 years of SCIT with Timothy grass extract.1656 Subjects were randomized to 
continue maintenance SCIT or receive placebo for 3 years. There was no difference in 
symptom/medication scores over the 3 grass pollen seasons between those receiving and not 
receiving Timothy extract injections. In another trial, grass SCIT was discontinued in 108 
grass-sensitive patients who had responded well to the treatment after 3 or 4 years of SCIT.
1657 The patients were followed through up to 4 grass pollen seasons looking for relapse. 
Approximately 30% relapsed by the third grass pollen season, with few more subsequently 
relapsing.
In the 2 studies discussed in the preceding paragraph,1656,1657 3 or 4 years of SCIT with 
grass extract induced remissions that persisted in most of the subjects for at least 3 years. 
There are only a few studies that look at longer or shorter periods of treatment. A study that 
compared 3 or 5 years of SCIT with HDM extract found significant improvement after 3 
years but added clinical improvement in rhinitis after 5 years of SCIT.1658
Safety.: Information regarding the occurrence of fatal reactions to SCIT was obtained 
retrospectively by the Immunotherapy Committee of the AAAAI by periodic surveys of its 
members from 1985 to 20011659,1660 and by an online website since 2008.1644 The earlier 
retrospective surveys suggested that a fatal reaction occurs with every 2 to 2.5 million 
injection visits.1659,1660 The online survey elicited information on 2 fatal reactions in 28.9 
million injection visits, which was thought to represent an improvement due to more careful 
monitoring of patients with asthma.1644 The rate of systemic reactions has remained steady, 
with 1.9% of patients experiencing a systemic reaction, most mild, but with 0.08% 
experiencing a grade 3 and 0.02% a grade 4 reaction.1644 The occurrence and size of local 
reactions do not predict the occurrence of a systemic reaction with the next injection.
1661,1662
Cost effectiveness.: SCIT can be administered for 3 to 5 years with continuing relief of 
symptoms for years after discontinuation. Pharmacotherapy, on the other hand, must be 
continued indefinitely, since it has no disease-modifying activity. Because of this difference, 
the initial higher cost of SCIT may be offset by the continuing benefit after it is stopped. 
This factored into a decision-making analysis that suggested if a patient with SAR requiring 
nasal steroids 6 months per year is seen before age 41 years, the cost will be less in the long 
term if they are placed on SCIT.1662,1663 If the patient has perennial need for nasal steroids, 
and they are less than 60 years of age, the most cost effective approach is SCIT. Another 
cost-effectiveness analysis found that SCIT for SAR may be more effective and less 
expensive than pharmacotherapy from the societal perspective when costs of productivity 
loss are considered.1664 A retrospective study compared U.S. Medicaid-treated adults and 
children who were newly diagnosed with AR and were or were not placed on AIT. Eighteen-
month follow-up revealed 30% and 42% healthcare cost savings, respectively, in the AIT 
treated patients.1665
• Aggregate Grade of Evidence for SCIT in the treatment of AR: A (Level 1a: 3 
recent studies listed; Level 1b: 5 recent studies listed; Table IX.D.3-1). Of note, 
due to the large body of literature supporting SCIT as a treatment for AR, only 
recent systematic reviews and select double-blind, placebo-controlled RCTs are 
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included in Table IX.D.3-1, as these achieve an Aggregate Grade of Evidence of 
A.
• Benefit: Improvement in symptoms and decreased need for rescue medication. 
Decreased likelihood of progression from AR to bronchial asthma. Persistent 
benefit for years after completion of 3 to 5 years of SCIT.
• Harm: Inconvenience of multiple visits to a medical facility to receive injections. 
Potential for systemic reactions, including anaphylaxis.
• Cost: Cost for preparation of allergen extract for treatment. Cost of visits to 
medical facilities to receive injections.
• Benefits-Harm Assessment: Benefit greater than harm for patients who cannot 
obtain adequate relief with symptomatic treatment and whose symptoms extend 
more than a few weeks each year.
• Value Judgments: Patients who can obtain adequate relief of symptoms with 
medication must decide if the short-term increased cost and inconvenience of 
SCIT is compensated for by the long-term persisting clinical benefit and relief 
from need to take medication. Pharmacoeconomic studies suggest that in the 
long term, SCIT is cost effective over symptomatic therapy.
• Policy Level: Strong recommendation for SCIT in patients unable to obtain 
adequate relief with symptomatic therapy.
• Intervention: SCIT should be recommended to the AR patient who cannot obtain 
adequate relief from symptomatic medication for significant periods of time each 
year and to those who would benefit from its secondary disease-modifying 
effects (prevention of bronchial asthma and new sensitization), particularly 
children and adolescents.
IX.D.4. Sublingual immunotherapy (SLIT)—SLIT is an alternative application 
variant of SCIT, which was first practiced over a century ago by Noon and others.1570,1666 
The first double-blind placebo-controlled trial with SLIT was not conducted until 1986 by 
Scadding and Brostoff1667 in London, UK. After that, only several small trials were 
conducted until the beginning of the new millennium, when several “big trials” finally 
demonstrated the clinical efficacy and safety of SLIT. Since then, many high-quality SLIT 
trials have been reported. As a result, the actual evidence for SLIT appears to be at least as 
solid as that for SCIT. The literature on SLIT for AR/rhinoconjunctivitis is vast and several 
good meta-analyses and systematic reviews have been published over the past decade; the 
decision was made to primarily analyze results from these reviews and to complement them 
with findings from large randomized trials published during 2016 (Table IX.D.4-1).
Efficacy in adults.: Most systematic reviews and meta-analyses show a low to moderate 
efficacy of SLIT over placebo (SMD = 0.30 to 0.50), and this approaches high efficacy with 
longer treatment1668 (greater than 12 months’ treatment SMD = 0.70). It must be considered 
that all patients, both those in the SLIT and the placebo arms, have open access to rescue 
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medication, and that SLIT results in an efficacy on top of the symptom improvement 
obtained with rescue medication.
Efficacy in children.: Over 5 years ago, Dutch colleagues analyzed systematic reviews of 
SLIT in children and concluded that the methodological quality should be improved. They 
especially questioned the heterogeneity of the included trials and the risk of bias.1669 Roder 
et al.1670 also determined in 2008 that there was not enough evidence to support the 
usefulness of SLIT in children. These flaws have been improved in recent studies. There is 
strong1671 evidence that grass pollen SLIT tablets in children reduce symptoms of AR. The 
evidence for aqueous SLIT is moderate.1672 The evidence for HDM SLIT is of moderate-to-
low quality.
Efficacy of SLIT over pharmacotherapy.: For PAR, SLIT with HDM tablets is more 
effective than any single pharmacotherapy, including antihistamines, antileukotrienes and 
INCS.1673 For SAR, grass and ragweed tablet SLIT is almost as effective as INCS and more 
effective than the other pharmacotherapies.1673 These data had already been confirmed for 
the SLIT grass pollen tablets by a previous meta-analysis; in this publication the separate 
analysis of the 5-grass tablet showed its superiority over all pharmacotherapy treatments.1332
Efficacy of SLIT compared to SCIT.: Several investigators have tried to compare the 
efficacy of SLIT against that of SCIT. Most meta-analyses are based on indirect 
comparisons, as there are only a very few direct head-to-head randomized trials comparing 
both treatments; therefore, the evidence that SCIT is more effective than SLIT is weak. Also 
in children, SCIT seems more effective than SLIT, but again the quality of evidence is low.
1672
Safety.: Rare systemic and serious adverse events have been reported with SLIT, but in 
general, meta-analyses found SLIT to be safer than SCIT. In the complete data-set of 
systemic reviews there were 7 reports of the use of epinephrine in the SLIT group and 1 case 
of eosinophilic esophagitis with a grass pollen SLIT tablet. There was no administration of 
epinephrine in trials outside of the United States. A 2012 review by Calderon et al.1674 
estimated the anaphylaxis rate of SLIT to be 1 per 100 million doses, or 1 per 526,000 
treatment years. Grass pollen SLIT tablets are just as safe in AR patients with and without 
mild asthma.1675 Starting SLIT in-season appeared to be safe. Although there were 2 serious 
treatment-related adverse events with co-seasonal SLIT initiation, none required epinephrine 
administration.1676 In the United States, the FDA requires patients be prescribed an 
epinephrine autoinjector and the first dose be given in the physician’s office for those on 
SLIT tablets. Continuing AIT during pregnancy did not augment the incidence of adverse 
outcomes during delivery nor alter the risk of developing atopic disease in the offspring. No 
conclusion can be drawn regarding the safety of starting SLIT in a pregnant woman, due to 
lack of cases.1677
Preventative effects.: There are no systematic reviews specifically addressing the 
preventative effects of SLIT that fall within the allowable search date range of this ICAR:AR 
document. The preventative effect SLIT on asthma development was investigated in an open 
RCT by Marogna et al.1678 involving 216 children treated with SLIT for 3 years. Mild 
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persistent asthma was less common in patient treated with SLIT than patients receiving only 
pharmacotherapy. In a double-blind RCT involving 812 children with grass pollen-induced 
rhinoconjunctivitis, after 3 years of therapy with SQ-standardized grass pollen tablet, 
children in the treatment group presented a reduced risk of developing asthma compared to 
placebo group at 2-year follow-up (OR 0.71; p < 0.05).1679 Although these findings are 
interesting, the overall strength of evidence for the prevention of asthma in SLIT studies is 
low at present, though the evidence for asthma symptom and medication reduction is high.
Developing new allergen sensitizations frequently occurs in the natural history of respiratory 
allergy. Preventative effects of AIT on the onset of new sensitizations is often discussed. 
However, currently available SLIT data for prevention of new allergen sensitivities is also 
limited. The above referenced Marogna et al.1678 study did note that the rate of new 
sensitizations was low, corresponding to 3.1% of SLIT-treated patients and to 34.8% of 
controls, with an OR of 16.85 to develop new sensitizations in controls. Another study by 
Marogna et al.1680 prospectively evaluated the long-term effect of SLIT given for 3, 4, or 5 
years in 78 SLIT patients vs 12 controls. Over a 15-year follow-up, all the control subjects 
developed new allergen sensitivities, while this occurred in less than 25% of the patients 
receiving SLIT (21% in treated for 3 years, 12%, in treated for 4 years, and 11% in treated 
for 5 years, respectively).
Cost-effectiveness.: The meta-analysis comparing the efficacy and cost-savings of the 5-
grass SLIT tablet vs the Timothy grass SLIT tablet has several flaws, as some trials were 
reported in several publications and thus these publications should be analyzed as one. More 
importantly, the outcome variables and the precise definition of the pollen season vary 
between the Timothy grass SLIT tablet and the 5-grass SLIT tablet trials, so direct 
comparison of outcomes should not be done, as was reviewed in detail previously.1681,1682 
The 5-grass SLIT tablet ($1003 Canadian dollar) was associated with cost savings against 
year-round SCIT (+$2471), seasonal SCIT (+$948), and the Timothy grass SLIT tablet (+
$1168) during the first year of therapy and still during the second and third year of 
treatment. The higher costs for SCIT were due to the elevated indirect costs from missing 
working hours and transportation costs due to in-office SCIT administration. The higher 
costs for the Timothy grass SLIT tablet were due to the year-round dosing vs the 
preseasonal/co-seasonal 6-month total dosing of 5-grass SLIT tablet.
A UK meta-analysis of costs showed that SCIT and SLIT may be cost-effective compared 
with standard pharmacotherapy for 6 years (when considering a threshold of pound 
20,000-30,000 per quality-adjusted life-year [QALY]). The investigators were not able to 
establish a clear difference between SCIT and SLIT in cost-effectiveness.1617
Additional data from double-blind placebo-controlled trials.: Some of the most 
important recent trials with data that add to the already presented systematic reviews are 
listed here:
• High-dose tree pollen aqueous SLIT was effective in reducing symptom-
medication scores in children in a high-quality double-blind placebo-controlled 
trial.1683
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• Double-blind, placebo-controlled trials with ragweed SLIT reduced the 
combined symptom-medication score when administered as drops1684,1685 and 
as tablets, particularly at the high dose.1686,1687
• In a small, double-blind, placebo-controlled trial of moderate-high quality, 
Alternaria SLIT for AR (and asthma) was shown to be effective in significantly 
reducing the AR combined symptom-medication score.1688
• As for the SLIT HDM tablets, a dose-effect for a reduction in AR symptoms-
medication scores has been shown in 3 double-blind, placebo-controlled trials.
1064,1689 One trial demonstrated a significant difference and a symptom score 
reduction of 29% only in those patients with more moderate-severe disease.799
• Moderate evidence for efficacy of dual grass pollen-HDM SLIT after 12 months 
of treatment and 1 year after discontinuation.1690
• Multi-allergen SLIT has been tested in a single-center, double-blind, placebo-
controlled trial with Timothy grass monotherapy, Timothy grass plus 9 other 
pollen allergens, or placebo. Only the Timothy grass monotherapy group showed 
statistically significant improvement in the nasal challenge test, titrated SPT, 
sIgE (reduction), and IgG4 (increase). Due to a very low pollen season, there 
were no differences in symptom-medication scores between any of the groups.
1691 Additional study on multi-allergen SLIT is needed.
Aggregate grade of evidence and recommendations.: In Table IX.D.4-2 the grade of 
evidence is shown and how this leads to recommendations in the decision-making 
concerning SLIT.
• Aggregate Grade of Evidence: A (Level 1a: 10 studies; Level 1b: 3 studies; Level 
2a: 11 studies; Level 3a: 1 study; Table IX.D.4-1).
• Benefit: SLIT improved patient symptom scores, even as add-on treatment on top 
of rescue medication. SLIT reduced medication use. The effect of SLIT lasts for 
at least 2 years after a 3-year course of high-dose therapy. Benefit is generally 
higher than with single-drug pharmacotherapy; however, it is possibly somewhat 
less than with SCIT. Although a very recent high-quality head-to-head trial did 
not show a statistically significant difference in efficacy between SCIT and SLIT, 
this evidence is not presented here, as the publication date is outside the review 
period for this manuscript.797
• Harm: Minimal harm with very frequent, but mild, local adverse events. Very 
rare systemic adverse events. SLIT seems to be safer than SCIT.
• Cost: Intermediate, SLIT becomes cost-effective compared to pharmacotherapy 
after several years of administration. Data on cost of SLIT compared to SCIT is 
variable.
• Benefits-Harm Assessment: Benefit of treatment over placebo is small, but 
tangible. SLIT benefit is demonstrated beyond the improvement seen with rescue 
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medications. Lasting effect at least 2 years off treatment. Minimal harm with 
SLIT, greater risk for SCIT.
• Value Judgments: SLIT improved patient symptoms with low risk for adverse 
events.
• Policy Level:
• ∘ Use of SLIT: grass pollen tablet, ragweed tablet, HDM tablet, tree pollen 
aqueous solution - Strong recommendation.
• ∘ Alternaria SLIT - Recommendation.
• ∘ Epithelia SLIT - Option.
• ∘ Dual SLIT in biallergic patients - Recommendation.
• Intervention: We recommend high-dose tablet or aqueous SLIT be administered 
in patients (adults and children) with SAR and/or PAR who wish to reduce their 
symptoms and their medication use. SLIT can be continued safely in the 
pregnant patient.
IX.D.5. Transcutaneous/epicutaneous immunotherapy—Transcutaneous or 
epicutaneous immunotherapy is a noninvasive form of AIT that consists of the application of 
allergens to the skin. The epidermis is rich in APCs while being less vascularized potentially 
reducing the risk for systemic reaction.1707,1708 To improve delivery of antigens through the 
stratum corneum to the immune cells of the epidermis and dermis, different techniques have 
been used: scarification or scratching of the skin, tape stripping, microneedle arrays, and 
sweat accumulation through the application of a patch.1709 Epicutaneous immunotherapy 
has recently been investigated in a mouse model using nanoparticles containing an allergen 
encoding DNA.1710 Records of allergen administration via the skin date back to 1926, where 
29 patients with hay fever received intradermal pollen extract administrations; all benefited 
after only 3 doses without significant side effects.1711 The first RCT was in 2009. To date, 4 
clinical trials using this procedure have been published (Table IX.D.5)
In a single-center, placebo-controlled, double-blind trial, 37 adults with positive SPT and 
nasal challenge to grass pollen were randomized to treatment with allergen (n = 21) or 
placebo patches (n = 16).1712 Treatment was started 1 month before the 2006 pollen season. 
The skin was tape-stripped 6 times; patches were applied weekly for 12 weeks, and removed 
48 hours later. Patients were assessed before, at the beginning of, and after the 2006 pollen 
season, and followed up before (n = 26) and after (n = 30) the pollen season of 2007. The 
primary outcome was nasal provocation test with grass extract; secondary outcomes 
included a rhinitis questionnaire, medication use, and adverse events. In grass 
immunotherapy-treated patients, nasal challenge test scores significantly decreased in the 
first (p < 0.001) and second year (p = 0.003). In placebo-treated patients, scores decreased 
after year 1 (p = 0.03), but the effect diminished in year 2 (p = 0.53). However, the 
improvement of nasal provocation test scores was not significantly better in the treatment vs 
placebo groups. Patients in the treatment arm had improvement in subjective symptom 
scores, both after the pollen seasons of 2006 (p = 0.02) and 2007 (p = 0.005). Eczema at the 
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application site was significantly higher in the treatment arm, and there were no serious 
adverse events.
A second single-center, double-blind RCT treated 15 children with grass transcutaneous 
immunotherapy and 15 children with placebo.1713 The adhesive patch was placed weekly 
from February to April 2008, and removed after 24 hours. There were no significant 
differences in prick tests between groups before and after treatment. Both groups had an 
increase in symptoms, but the treatment group had lower rhinorrhea, nasal obstruction, 
dyspnea, and ocular tearing. The treatment group had a significant reduction in antihistamine 
use (p = 0.019). There were no systemic or local reactions.
A third single-center, double-blind, placebo-controlled trial, published by the same authors 
enrolled 132 adults with grass pollen allergic rhinoconjunctivitis.1714 Patients received 
placebo, low-dose, medium-dose, and high-dose grass extract treatment (n = 33 in each 
arm). Weekly for 6 weeks, starting 1 month prior to the initiation of the 2008 pollen season, 
patches were applied with subsequent removal after 8 hours. SPT and conjunctival 
provocation tests were done at baseline, and after the pollen seasons of 2008 and 2009. 
Ninety-three of 132 patients were included in the efficacy analysis. The primary endpoint 
was subjective rhinoconjunctivitis symptoms using a VAS. Five months after application of 
the first patch, all treatment and placebo groups improved. One year later, only the high-dose 
treatment group had improved compared to control (p = 0.017); symptoms were reduced by 
more than 30% (2008 pollen season) and 24% (2009 pollen season) compared with placebo. 
There were no differences in rescue medication use, SPTs, or CPTs. Local reactions were 
more frequent with higher doses and improved with subsequent applications. Systemic 
reactions leading to discontinuation of treatment occurred in 11 patients (8.3%) within 45 
minutes of patch application; reactions were milder (grade 1 to 2) and did not require 
treatment with epinephrine.
A fourth single-center, double-blind, placebo-controlled trial, published by the same authors 
enrolled 98 adults with grass allergic rhinoconjunctivitis; 48 received grass patches and 50 
received placebo.1715 Treatment consisted of 6 weekly patches kept on for 8 hours. After 
treatment in the year 2009, median rhinitis symptoms improved by 48% in the treatment 
group vs 10% in the placebo group (p = 0.003); a year later, this was 40% compared to 18% 
for placebo (p = 0.43). There was no change in combined symptom and medication scores. 
CPT scores improved after the first year in the treatment group but not the placebo group. In 
the first year, allergen-specific IgG4 increased in the treatment group, while allergen-specific 
IgE decreased in the placebo group; there was no difference in both measures compared to 
baseline in the second year. Eight systemic reactions led to study exclusion. The authors 
concluded that this treatment strategy may have a potential role in treating IgE-mediated 
allergies, but further research was needed to find an optimal regimen that balances efficacy 
and safety.
• Aggregate Grade of Evidence: B (Level 1b: 4 studies; Table IX.D.5).
• Benefit: Transcutaneous immunotherapy resulted in limited and variable 
improvement in symptoms, medication use, and allergen provocation tests in 
patients with AR or conjunctivitis.
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• Harm: Transcutaneous immunotherapy resulted in systemic and local reactions. 
Systemic reactions occurred in up to 14.6% of patients receiving grass 
transcutaneous immunotherapy.
• Cost: Unknown.
• Benefits-Harm Assessment: There is limited and inconsistent data on benefit of 
the treatment, while there is a concerning rate of adverse effects. Three out of 4 
studies on this topic were published by the same investigators from 2009 to 
2015.
• Value Judgments: Transcutaneous immunotherapy could offer a potential 
alternative to SCIT and SLIT, but further research is needed.
• Policy Level: Recommend against.
• Intervention: While transcutaneous immunotherapy may potentially have a future 
clinical application in the treatment of AR, at this juncture there are limited 
studies that show variable and limited effectiveness, and a significant rate of 
adverse reactions. Given the above and the availability of alternative treatments, 
transcutaneous immunotherapy is not recommended presently.
IX.D.6. Intralymphatic immunotherapy (ILIT)—Intralymphatic immunotherapy 
(ILIT) is a novel method for AIT, where allergen is injected directly into lymph nodes.1716 
The major advantages of this route of allergen application are the markedly reduced duration 
of immunotherapy treatment (both time spent and number of visits) and the much lower 
amount of allergen required to achieve results. This lower dose of allergen also confers a 
lower risk of adverse allergic side effects.
Clinical trials have illustrated that a reduction in AR symptoms can be achieved with just 3 
doses of injected allergen, with a dosage interval of 1 month1716-1720 (Table IX.D.6). This 
contrasts with subcutaneous application, where up to 70 doses may be needed over a 5-year 
period. ILIT involves the injection of allergen directly into inguinal lymph nodes under 
ultrasound guidance.
Five of the clinical trials published to date have compared ILIT with placebo. In 2008, Senti 
et al.1716 compared ILIT to SCIT and not to placebo. All trials have used aluminum 
hydroxide-adsorbed antigen as the vaccine. Most trials1716,1718-1721 used commercially 
available grass pollen or birch pollen allergen extract as the antigen. One trial1717 used 
recombinant major cat dander allergen fused to a translocation sequence and to part of the 
human invariant chain generating a modular antigen transporter, or “MAT,” vaccine.
The general protocol for administration was 3 injections with 1000 standardized quality 
units (SQ-U) of aluminum hydroxide-adsorbed allergen at 4-week intervals. Variations to 
this included a shorter dose interval in 1 trial1721 and no translation of allergen quantities 
into SQ-U in the trial using recombinant major cat dander allergen.1717
Of the 6 trials published thus far, 5 have demonstrated clinical efficacy and safety.1716-1720 
In total, 127 patients have received active treatment and 45 patients have received placebo. 
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Witten et al.1721 demonstrated immunological changes with ILIT, but no improvement in 
symptoms. Of note, the dose interval in this trial was shorter than in the trials that 
demonstrated clinical efficacy, with allergen administered at 2-week intervals instead of 4-
week intervals.
The greatest variation between the trials to date is in the selection of clinical endpoints and 
the measurement of clinical outcomes, as illustrated in Table IX.D.6. All trials have used 
subjective measures to define clinical endpoints, most commonly in the form of symptom 
questionnaires.
Given the reduction in treatment duration, allergen dose, financial burden relative to SCIT, 
and the low risk of adverse effects, ILIT is a promising new therapy for AR. Before ILIT is 
integrated into clinical practice, a well-designed pharmacoeconomic evaluation of ILIT vs 
SCIT and larger RCTs are needed, as well as further studies investigating the impact of 
treatment protocol on outcomes.
• Aggregate Grade of Evidence: B (Level 1b: 5 studies; Level 2b: 1 study; Level 4: 
1 study; Table IX.D.6).
• Benefit: Reduced treatment period, reduced number of injections, reduced dose 
of allergen injected, decreased risk of adverse events.
• Harm: Risk of anaphylaxis.
• Cost: ILIT might be associated with reduced costs relative to SCIT (reduced 
time, reduced financial burden for patients and healthcare provider). Application 
requires training.
• Benefits-Harm Assessment: Balance of benefit over harm for ILIT relative to 
SCIT.
• Value Judgments: ILIT appears to be efficacious in the treatment of AR. 
Preliminary data indicates that, relative to SCIT, the burden of treatment on the 
patient and on the healthcare system is lower.
• Policy Level: Option, pending additional studies.
• Intervention: While the research is promising, further studies are needed before 
ILIT can be translated into routine clinical practice.
IX.D.7. Alternative forms of immunotherapy—Oral, nasal, and inhaled 
(intrabronchial) AIT represent alternate options for the treatment of AR, with primarily 
historical significance.1623 While alternative forms of AIT have been evaluated in an effort 
to avoid the local discomfort and resource utilization associated with SCIT, the adoption of 
SLIT has largely replaced these methods.1623
Non-injectable, alternative immunotherapies involve the topical absorption of allergen 
extracts via oral/gastrointestinal, nasal, or inhalational exposures. SLIT, intralymphatic, and 
epicutaneous routes are reviewed separately in this document. Double-blind, placebo-
controlled studies have evaluated oral/gastrointestinal immunotherapy for the treatment of 
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birch,1723 cat,1724 and ragweed1725 sensitivity, without a significant decline in nasal 
symptoms, improvements in provocation testing, or reductions in medication utilization. 
Additionally, oral/gastrointestinal allergen administration requires extract concentrations 
approaching 200 times greater than SCIT, and is associated with adverse gastrointestinal 
side effects.1623,1724 However, the efficacy of oral/gastrointestinal immunotherapy has been 
demonstrated for the treatment of food hypersensitivity, where this approach remains 
investigational.1726
Oral mucosal immunotherapy (OMIT) is an alternative form of AIT that is distinctly 
different from SLIT and oral/gastrointestinal strategies. OMIT utilizes a glycerin based 
toothpaste vehicle to introduce antigen to high-density antigen processing oral Langerhans 
cells in the oral vestibular and buccal mucosa.1727 Theoretical benefits include induction of 
immune tolerance with lower antigen concentrations, decreased local side effects and higher 
adherence vs SLIT.1728 A recently completed pilot study of OMIT vs SLIT identified 
clinically meaningful improvements in disease-specific QOL measures with a significant 
rise in specific IgG4 over the first 6 months of treatment.1729 No adverse events were 
reported, and there were no significant differences between outcome measures for both 
treatment arms.1729 Additional study is needed to define the role of OMIT in the treatment 
of AR.
Local nasal immunotherapy has been established as an effective approach for the treatment 
of pollen and HDM sensitivity.1730 However, high rates of local adverse reactions limit 
patient compliance, with 1 prior study finding that 43.9% of treated children abandoned this 
treatment option within the first year of therapy.1731 High-quality studies of inhaled/
intrabronchial immunotherapy for the treatment of AR have not yet been completed, with 
current studies limited to the treatment of allergic asthma.1732 In light of these findings, 
including poor compliance and limited efficacy, oral/gastrointestinal, nasal, and inhaled 
immunotherapies have limited utility in the current treatment of AR, while OMIT represents 
an emerging alternative to SCIT and SLIT.
IX.D.8. Combination omalizumab and SCIT—In consideration of combination 
therapy with concurrent biological omalizumab and AIT, each intervention targets different 
mechanisms in the allergic cascade. AIT desensitizes the body’s response to a specific 
antigen, with alteration of the Th1/Th2 balance and induction of T-cell anergy.1623 
Omalizumab indiscriminately targets the humoral effector of allergic inflammation, with use 
of a humanized monoclonal antibody to block unbound IgE.1623 While both modalities have 
independently demonstrated efficacy as treatment options, improved strategies are needed, 
especially in patients with multiple sensitizations.1733
Two benefits of combination therapy have been described: decreased incidence of AIT-
associated systemic allergic reactions and improved control of AR symptoms.
1400-1402,1734-1736 Anaphylaxis is a persistent concern with AIT, with incidence of reported 
systemic reactions as high as 65% following rush protocols.1737,1738 Omalizumab 
pretreatment has therefore been evaluated as a strategy to improve AIT tolerance, with 
positive findings. Two multicenter, randomized, placebo-controlled studies have evaluated 
the incidence of AIT-induced systemic allergic reactions following pretreatment with 
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omalizumab1402,1736 (Table IX.D.8VIII.E.4.a-1VIII.E.4.a-2). Massanari et al.1736 evaluated 
248 patients with moderate persistent asthma receiving omalizumab pretreatment or placebo 
prior to cluster AIT, an accelerated AIT buildup schedule. A significantly lower incidence of 
systemic and respiratory-related reactions was reported among the omalizumab group, with 
an improved likelihood of reaching maintenance therapy compared to the group without 
preventive treatment with this biological. Casale et al.1402 evaluated 123 adult patients with 
ragweed-induced AR receiving omalizumab prior to 1-day rush AIT, finding a 5-fold 
decreased risk of systemic allergic reactions with omalizumab pretreatment (OR, 0.17). 
Further outcomes included significant improvement in daily symptom scores among patients 
receiving combination therapy (continued omalizumab + AIT) vs AIT alone. Additional 
study of AIT for the treatment of food1739 or insect venom1740,1741 hypersensitivity has also 
demonstrated improved safety with omalizumab pretreatment.
The efficacy of combination therapy for the treatment of AR has been further evaluated by 
several iterative analyses of a single RCT.1400,1401,1735 Kuehr et al.1400 evaluated 221 
adolescents (6 to 17 years) with moderate to severe AR and sensitization to birch and grass 
pollen. Using a randomized, controlled design, the effectiveness of combination therapy was 
evaluated during sequential birch and grass pollen seasons, with comparison of AIT +/− 
concurrent omalizumab. Significant findings included superiority of combination therapies 
vs AIT alone, with 48% reduction in symptom load (sum of mean daily symptom severity 
score plus mean daily rescue medication use) during an entire pollen season and 80% 
reduction in median rescue medication score. Two additional studies report unique findings 
generated by this trial.1401,1735 Rolinck-Werninghaus et al.1401 completed a subgroup 
analysis of study patients receiving specific AIT +/− concurrent omalizumab during the 
matched grass season. Results included decreased symptoms scores and rescue medication 
usage for patients receiving combination vs either therapy alone. Kopp et al.1735 evaluated a 
subgroup of 92 children, with findings of decreased leukotriene (LTC4, LTD4, and LTE4) 
release among patients receiving combination therapies following in vitro antigen 
stimulation of collected blood cells. An unrelated study by Klunker et al.1734 provides 
further evidence for the efficacy of combination therapy, with in vitro demonstration of 
inhibition of allergen-specific IgE binding for 42 weeks after discontinuation of combination 
therapy (vs 30 weeks with omalizumab alone).
While a prior study has estimated the cost of omalizumab (1,253 EUR/patient/month) and 
AIT therapies (425 EUR/patient/year), evaluation of economic and productivity outcomes 
has not been completed for patients undergoing combination therapy.1401 Finally, 
omalizumab has been associated with anaphylactic reactions in 0.09% to 0.2% of patients, 
with current recommendations to monitor patients for 30 minutes following administration.
1742,1743
• Aggregate Grade of Evidence: B (Level 1b: 4 studies, plus 2 additional iterative 
analyses of a parent study; Table IX.D.8).
• Benefit: Improved safety of accelerated cluster and rush AIT protocols, with 
decreased symptom and rescue medication scores among a carefully selected 
population.
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• Harm: Financial cost and risk of anaphylactic reactions.
• Cost: Moderate to high.
• Benefits-Harm Assessment: Preponderance of benefit over harm.
• Value Judgments: Combination therapy increases the safety of AIT, with 
decreased systemic reactions following cluster and rush protocols. Associated 
treatment costs and likelihood of systemic reactions must be considered, with 
greater consideration for omalizumab pretreatment prior to higher-risk AIT 
protocols. While 2 high-quality RCTs have demonstrated improved symptom 
control with combination therapy over AIT or omalizumab alone, not all patients 
will require this approach. Rather, an individualized approach to patient 
management must be considered, with evaluation of alternative causes for 
persistent symptoms, such as unidentified allergen sensitivity. The current 
evidence does not support the utilization of combination therapy for all patients 
failing to benefit from AIT alone.
• Policy Level: Option, based on current evidence. However, it is important to note 
that omalizumab is not currently approved by the FDA for the treatment of AR.
• Intervention: Omalizumab may be offered as a premedication prior to induction 
of cluster or rush AIT protocols. Combination therapy is an option for a carefully 
selected patient with persistent symptomatic AR following AIT. An 
individualized approach to patient management must be considered. In addition, 
as omalizumab is not currently approved by the FDA for AR treatment, in the 
United States this treatment approach would likely not be performed in routine 
clinical practice presently.
X. Associated conditions
Several medical conditions have been associated with AR, with varying prevalence 
dependent upon the specific comorbidity. In contrast, certain conditions are often associated 
with allergy or AR by conjecture, yet the available literature fails to identify a close 
association. This section examines various medical conditions that have a potential 
association with AR, specifically examining the evidence that supports or refutes the 
association
X.A. Asthma
X.A.1. Asthma definition—Asthma is a heterogeneous and complex disease, perhaps 
better characterized as a syndrome with overlapping phenotypes. The definition of asthma 
has evolved over the past several decades, combining clinical symptoms, examination 
findings, and functional parameters. When analyzing current international or national asthma 
guidelines,1744-1747 all include respiratory symptoms such as cough, shortness of breath, 
wheezing or chest tightness, and the presence of a variable expiratory airflow limitation that 
needs to be documented from bronchodilator reversibility testing or bronchial 
hyperreactivity tests (eg, methacholine test or other tests such as inhaled histamine, 
mannitol, exercise, or eucapnic hyperventilation). All guidelines also include the statement 
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that symptoms and airflow limitation characteristically vary over time and in intensity and 
may resolve spontaneously or in response to medication. Discussion of chronic airway 
inflammation is included in all guideline documents. This has been characterized by several 
important cellular elements including mast cells, eosinophils, T-cells, macrophages, and 
neutrophils, but none of the guidelines require demonstration of inflammation by invasive or 
noninvasive methods. The Global Initiative of Asthma guidelines1744 specify that asthma is 
usually associated with bronchial hyperresponsiveness but highlight that demonstration of 
airway hyperresponsiveness and inflammation are not necessary or sufficient to make the 
diagnosis. Asthma is also classified by severity (ie, mild, moderate, severe) and by 
persistence (ie, intermittent vs persistent); however, the specific definitions of these 
categories vary dependent upon the specific guideline. Since asthma is defined as a 
heterogeneous disease, or rather as a syndrome, there appear to exist significant and variable 
etiologies that may manifest in similar phenotypes. Consequently, in the last decade, the 
definition of asthma has sought to include recognizable clusters of clinical and/or 
pathophysiological characteristics to more accurately characterize endotypes that exist.
1748,1749
X.A.2. Asthma association with allergic and non-allergic rhinitis—Most 
patients with asthma (both allergic and non-allergic) also have rhinitis, whereas 10% to 40% 
of patients with AR have comorbid asthma.101,1167 Asthma and allergy may have similar 
underlying pathogenesis and immunologic mechanisms. IgE-mediated inflammation can 
involve both the upper and lower airways, suggesting an integration of the involved areas of 
the airway. This pattern of similarities gave rise to the concept of the unified airway model, 
which considers the entire respiratory system to represent a functional unit that consists of 
the nose, paranasal sinuses, larynx, trachea, and distal lung.1750
Some, but not all, studies suggest that asthma is more common in patients with moderate-to-
severe persistent rhinitis than in those with mild rhinitis.25,1751-1753 Other large studies 
found a link between the severity and/or control of both diseases in children and adults.
1754-1758 Adults and children with asthma and documented concomitant AR experience 
more asthma-related hospitalizations and doctors’ visits and also incur higher asthma drug 
costs than adults with asthma alone1759-1764 (Table X.A.2). Concerning changes in 
prevalence of rhinitis and asthma, some studies have demonstrated a parallel increasing 
prevalence of asthma and rhinitis,1765,1766 whereas others have not.1767-1775 It appears that 
in regions of highest prevalence, the proportion of subjects suffering from asthma or rhinitis 
may be reaching a plateau.
Rhinitis and asthma are closely associated and thus AR should be evaluated in asthmatic 
patients, and likewise, the possibility of a diagnosis of asthma should be evaluated in 
patients with AR.
• Aggregate Grade of Evidence: C (Level 3b: 7 studies; Table X.A.2).
X.A.3. Allergic rhinitis as a risk factor for asthma
AR and NAR are risk factors for developing asthma. This has been demonstrated in several 
large epidemiological studies (Table X.A.3). The Children’s Respiratory Study597 showed 
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that physician-diagnosed AR during infancy is independently associated with a doubling of 
the risk of developing asthma at age 11 years. In children and adults, AR is a risk factor for 
asthma according to a 23-year follow-up of college students.1776 These studies were 
confirmed by other studies.458,1764,1777-1786 Some of these studies showed that rhinitis is a 
significant risk factor for adult-onset asthma in both atopic and nonatopic subjects.
1779,1780,1783 Therefore, rhinitis is a risk factor independent of allergy for developing asthma 
in both adults1779,1780,1783 and children.597 In adulthood, the development of asthma in 
patients with rhinitis is often independent of allergy, whereas in childhood, it is frequently 
associated with allergy,597,1785 as almost all asthma in children is allergic.
Asthma and AR also share common risk factors. Sensitization to allergens is probably the 
most important. Most inhaled allergens are associated with nasal1787 and bronchial 
symptoms, but in epidemiologic studies, differences have been observed (eg, in pollen 
allergy). Some genetic polymorphisms are different in the case of AR and asthma. Other risk 
factors for asthma such as gender, obesity, viral infections in infancy, exposure to tobacco 
smoke (passive smoking or active smoking), diet, or stress are not found as common risk 
factors for AR. Outdoor or indoor air pollution is still a matter of debate as risk factor for 
AR or NAR.101 In summary, AR and NAR are risk factors for developing asthma.
• Aggregate Grade of Evidence: C (Level 2a: 2 studies; Level 3b: 11 studies; Table 
X.A.3).
X.A.4. Treatment of allergic rhinitis and its effect on asthma
The 2015 AR clinical practice guideline from the AAO-HNS has highlighted the overlap of 
AR and asthma, specifically recommending that clinicians should assess for and document 
associated medical comorbid conditions including asthma.761 The guidelines also review 
and consider the impact of comorbid asthma on treatment decisions for AR, though the 
action statements may not apply to AR with comorbid asthma. However, there is a body of 
evidence to suggest that AR therapies, including INCS,1296,1788-1790 oral antihistamines,
1791,1792 LTRAs,7,1793,1794 and AIT1672,1788,1795,1796 may benefit both conditions. Some of 
the most promising results in altering the course of allergic inflammation common to AR 
and asthma have been seen with AIT.1678,1797,1798 Given this increased understanding of the 
relationship between AR and asthma as similar inflammatory processes affecting the upper 
and lower airways, respectively, the importance of understanding the overlap of AR 
treatment with the treatment of asthma is increasingly evident. The studies reviewed in this 
section are limited to prospective randomized trials to minimize inherent biases and 
weaknesses of retrospective studies.1794
Allergen avoidance.
Allergen avoidance is often advocated for allergy treatment, specifically for AR and allergic 
asthma.7 Despite the intuitive acceptance of this and reasonable biological plausibility, the 
evidence for benefit of avoidance and environmental control measures in AR with associated 
asthma is limited. A Cochrane review examining randomized trials of subjects with asthma 
who underwent chemical or physical methods to reduce HDM allergen found no benefit with 
these methods.1799 Single allergen avoidance or elimination plans such as removing or 
washing pets, mattress coverings, removing carpeting, and use of HEPA filters have shown 
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limited evidence-based clinical benefit for reducing asthma and/or AR symptoms.
101,1799,1800 However, there is theoretical benefit of reducing allergen exposure, a paucity of 
data on multimodality approaches to reduce allergen load, and minimal negatives to 
attempting these various techniques; therefore, allergen avoidance could be considered as 
part of a multifactorial approach in the management of asthma associated with comorbid 
AR.1801,1802 (See section IX.A. Management – Allergen avoidance for additional 
information on this topic.)
Pharmacotherapy: oral H1 antihistamines.—We identified 6 RCTs which specifically 
evaluated oral H1 antihistamines for the treatment of asthma in the context of coexistent AR 
(Table X.A.4-1). There are many oral H1 antihistamine medications, but cetirizine and 
loratadine are the 2 most highly studied second-generation antihistamines used 
concomitantly in AR and asthma. There is biologic plausibility for a role of antihistamines 
in the treatment of allergic asthma, as elevated histamine levels after allergen challenge are 
associated with bronchoconstriction responses in acute asthma episodes. Cetirizine also has 
bronchodilatory effects which are significant both as monotherapy as well as in combination 
with albuterol.1803 Despite improvement in asthma symptoms, objective measures using 
pulmonary function testing and peak expiratory flow have failed to demonstrate significant 
improvements.1804-1806 Alternatively, there is growing evidence that antihistamines may 
have a preventive effect on the development of asthma in atopic patients, as shown in the 
Early Treatment of the Atopic Child trial.1807 Briefly, atopic infants were treated with 18 
months of cetirizine and followed for the development of asthma. While analysis of the 
entire group found no significant difference between cetirizine-treated and placebo-treated 
patients, subgroup analysis revealed approximately 50% reduced risk of developing asthma 
among certizine-treated patients with grass pollen and HDM sensitivities. The authors 
hypothesize that variation in key genes related to histamine regulation may explain these 
differences.1807,1808 (See section IX.B.1.a. Management – Pharmacotherapy – 
Antihistamines – Oral H1 antihistamines for additional information on this topic.)
Pharmacotherapy: oral corticosteroids.—Oral corticosteroids are an effective 
component of the asthma treatment algorithm, particularly for cases which are inadequately 
controlled with bronchodilators and inhaled corticosteroids.1809 They are also effective for 
symptoms of rhinitis.1247 However, oral corticosteroids have significant side effects, 
especially with increasing duration of use.7 Because of the side effect profile associated with 
these medications, they are not recommended for the routine treatment of AR, and 
utilization is only recommended for select cases after thorough discussion of the associated 
risks and benefits. (See section IX.B.2.a. Management - Pharmacotherapy - Corticosteroids - 
Oral corticosteroids for additional information on this topic.)
Pharmacotherapy: intranasal corticosteroids.—In the 1980s, topical INCSs were 
reported to improve asthma symptoms in patients with coexistent AR and asthma.1364,1810 
Since then, it has been shown that very little intranasally administered corticosteroid reaches 
the lung (approximately 2%), suggesting this effect on the lower airway may be related to its 
intranasal effects.1788,1811 We have identified 2 meta-analyses and 12 RCTs that address this 
potential “unified airway” effect of INCS on asthma (Table X.A.4-2). A 2003 Cochrane 
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review evaluated the efficacy of INCS on asthma outcomes in patients with coexistent 
rhinitis, finding no significant improvement in asthma outcomes with the use of INCS.1295 
Heterogeneity in study designs may have limited the findings of this meta-analysis and 
explain the discrepancy of the results compared to high-quality RCTs. Alternatively, a 2013 
systematic review and meta-analysis of the efficacy of INCS for asthmatics with 
concomitant AR demonstrated improvements in asthma outcomes with the use of INCS 
compared to placebo, but a lack of further improvement with INCS as an addition to inhaled 
corticosteroids.1296 Interestingly, patients with concomitant AR and asthma who received 
training on the proper use of INCS and education on the relationship of AR and asthma 
demonstrated significant reductions in asthma symptoms and albuterol use compared to 
patients receiving INCS without additional education.1812 This demonstrates the importance 
of patient instruction for both therapy evaluation and future trial design. (See section 
IX.B.2.a. Management – Pharmacotherapy – Corticosteroids – Intranasal corticosteroids 
(INCSs) for additional information on this topic.)
Pharmacotherapy: leukotriene receptor antagonists.—LTRAs (montelukast and 
zafirlukast) have demonstrated benefit for the treatment of both asthma and AR, consistent 
with efficacy in addressing inflammation in the “unified airway”1813 (Table X.A.4-3). In 
2008, the ARIA group reviewed the evidence for effectiveness of montelukast in treating 
patients with asthma and AR, finding improvement of both nasal and bronchial symptoms as 
well as reduction of β-agonist use.101 In fact, the LTRAs are the only class of medications 
specifically described in the 2008 AR management guide for primary care physicians, and in 
the full ARIA report, as effective for both asthma and AR.101,1814 The 2010 ARIA update 
further supports the recommendation of LTRAs for both AR and asthma, but specifies that 
LTRAs are not recommended over other first-line therapies for the respective conditions (ie, 
it is better to treat asthma and AR with both a nasal and inhaled steroid, than try to treat both 
with an LTRA). A more recent review in 2015 also identified some utility of LTRAs for 
patients with concomitant AR and asthma.1802 Despite this evidence, the limited additional 
benefit and added cost leads to a strong recommendation (based on moderate quality 
evidence) for inhaled glucocorticoids over LTRAs for single-modality treatment of asthma 
in patients with comorbid AR.1167 Based on the summarized RCTs, an evidence-based 
recommendation is made for LTRAs not to be used as monotherapy for AR, but LTRAs may 
be considered as part of the treatment of comorbid asthma and AR (See section IX.B.4. 
Management – Pharmacotherapy – Leukotriene receptor antagonists (LTRAs) for additional 
information on this topic) (Table X.A.4-3).
Pharmacotherapy recommendations for the treatment of AR with coexisting asthma.
• Aggregate Grade of Evidence: A (Level 1a: 2 studies; Level 1b: 23 studies). 
Antihistamines (Level 1b: 6 studies; Table X.A.4-1). INCS (Level 1a: 2 studies; 
Level 1b: 12 studies; Table X.A.4-2). LTRAs (Level 1b: 5 studies; Table 
X.A.4-3).
• Benefit: Pharmacotherapy improves subjective and objective severity of asthma 
in patients with coexistent AR. Patient education and training on medication use 
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improves compliance and benefits for INCS, and likely all patient-administered 
pharmacotherapy.
• Harm: Pharmacotherapy other than systemic steroids—minimal harm with rare 
mild adverse events such as drowsiness. No serious adverse events reported in 
the studies reviewed. Systemic corticosteroids have significant side effects.
• Cost: Generally low cost for pharmacotherapy.
• Benefits-Harm Assessment: There is a benefit over placebo for asthma treatment, 
though no significant benefit is seen over standard asthma pharmacotherapy. 
Risks of routine use of systemic corticosteroids generally outweighs the benefits, 
though short courses for acute indications (eg, asthma exacerbation) have a 
favorable likelihood of benefit relative to harm.
• Value Judgments: Pharmacotherapy for AR may also benefit asthma symptoms 
and objective parameters of pulmonary function in patients with coexisting 
asthma and AR, however, the benefit for asthma should be considered a positive 
side effect rather than an indication for use as there appears to be limited benefit 
compared to standard asthma therapy.
• Policy Level: Use of pharmacotherapy other than systemic steroids: 
Recommended use for optimal control of AR, with potential additional benefit 
for coexistent asthma, though not recommended for primary intent of asthma 
treatment. Use of systemic corticosteroid: Not recommended for routine use in 
AR with comorbid asthma due to unfavorable risk-benefit profile, though certain 
situations may indicate a short course (eg, acute asthma exacerbation).
Biologics: omalizumab.—Omalizumab is an anti-IgE mAb that binds free IgE, 
preventing interactions with high-affinity IgE receptors and resulting in receptor down-
regulation on inflammatory cells.1815 Omalizumab has demonstrated effectiveness 
separately for asthma as well as AR.1393,1815-1818 Despite a number of studies evaluating 
omalizumab in AR or asthma,1815,1819 there is only 1 double-blind RCT which specifically 
evaluates the efficacy of omalizumab in patients with concomitant moderate-to-severe 
asthma and persistent AR.1820 Additionally, another study evaluates omalizumab as an 
adjunct to SCIT,1403 with both studies showing a reduction in symptoms as well as an 
improvement in QOL measures (Table X.A.4-4). The 2010 ARIA update makes a 
conditional recommendation of using a mAb against IgE, such as omalizumab for treatment 
of asthma in patients with both AR and asthma, where there is a clear IgE-dependent allergic 
component and failure of other maximal therapy.1167 Additional biologics, including anti-
IL5, anti-IL4, and IL-4 receptor mAbs, are currently in varying stages of development/
emergence with positive findings for the treatment of asthma and other atopic diseases. 
Additional evaluation is needed to further evaluate their role for the treatment of coexistent 
AR and asthma. (See section IX.B.7. Management – Pharmacotherapy – Biologics for 
additional information on this topic.)
Biologics recommendations for the treatment of AR with coexisting asthma.
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• Aggregate Grade of Evidence: B (Level 1b: 2 studies; Table X.A.4-4). Grade A 
evidence with multiple 1b RCTs and 1a reviews exist for asthma and AR 
individually, but only 1 double-blind RCT specifically evaluating omalizumab vs 
placebo in patients with concurrent conditions.
• Benefit: Decreased asthma exacerbations, decreased symptom scores, and 
improvement in disease-specific QOL in patients with coexisting asthma and 
AR.
• Harm: There is evidence for acceptable safety for use up to 52 weeks.1821 
Potential longer-term harm unknown. Minor events such as mild injection site 
reactions are reported. Possibility of anaphylaxis.
• Cost: Substantially higher cost than conventional therapy for asthma and AR.
• Benefits-Harm Assessment: Benefits appear to outweigh potential harm for the 
treatment of more severe/persistent coexistent AR and asthma.
• Value Judgments: Added benefit of omalizumab as therapy for patients with AR 
and asthma that is uncontrolled despite maximal conventional interventions. 
However, given the significant increased cost associated with omalizumab, the 
value of this therapy is likely greatest for patients with severe asthma and 
symptoms that persist despite usual therapies.
• Policy Level: Omalizumab is recommended for those patients with clear IgE-
mediated allergic asthma with coexistent AR who fail conventional therapy. The 
significant additional cost of this therapy should be considered in evaluating its 
value.
Allergen immunotherapy.—Both SCIT and SLIT have been shown to improve the 
control of comorbid AR conditions, such as asthma1618,1788,1822 (Table X.A.4-5). AIT also 
appears to prevent the development of asthma.1678,1797,1798 The efficacy of SLIT for AR has 
been confirmed by several systematic reviews.1694,1695,1823 Both SCIT and SLIT have been 
shown to be efficacious for AR, though there is ongoing debate as to whether 1 form is 
superior.1697,1703 AIT is also thought to help halt the progression of allergic disease, 
including prevention of new allergic sensitivities and the development of asthma.
1624,1626,1678,1797,1798,1824-1826 AIT also appears to have long-lasting effects even after 
discontinuing treatment, unlike pharmacotherapy. Such promising results have led to a 2010 
ARIA update statement recommending both SCIT and SLIT for the treatment of asthma in 
patients with AR and asthma.1167 Recent systematic reviews demonstrate that SCIT and 
SLIT reduce both asthma and rhinitis symptoms, as well as medication use.1694,1822 These 
evidence-based reviews also demonstrate strong evidence for the utility of SCIT and SLIT in 
the treatment of asthma alone in studies that did not specifically address the condition of 
combined asthma and AR.1694,1822 Evidence for AIT (SCIT and SLIT) for asthma in context 
of comorbid asthma and AR, is reviewed in Table X.A.4-5. (See section IX.D. Management 
– Allergen immunotherapy (AIT) for additional information on this topic.)
Allergen immunotherapy recommendations for the treatment of AR with coexisting asthma.
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• Aggregate Grade of Evidence: A (Level 1a: 2 studies; Level 1b: 4 studies; Level 
2b: 1 study; Table X.A.4-5).
• Benefit: AIT (both SCIT and SLIT) has demonstrated benefit in concomitant AR 
and asthma, with decreased symptoms, rescue medication use, and bronchial 
hyperresponsiveness, as well as reduced development of asthma in patients with 
AR only.
• Harm: Local site reactions are common and there is potential for anaphylactic 
events with any form of AIT.
• Cost: Increased cost compared to standard therapy for AR and asthma, though 
the potential to treat the underlying disease process and prevent progression of 
disease could reduce long-term costs.
• Benefits-Harm Assessment: Significant evidence to support the use of AIT for 
patients with AR and asthma, as well as the potential utility of AIT for 
preventing progression of allergic disease from AR to the development of 
allergic asthma. Harms are generally limited to minor local reactions, though 
there is a potential risk of anaphylaxis. Benefits appear to outweigh potential 
harm, given that anaphylaxis is rare.
• Value Judgments: There appears to be unique value in AIT, as this therapy treats 
the underlying pathology of AR and asthma, with potential to halt the 
progression of allergic disease. The unique benefits of this therapy are of value, 
despite some uncertainty of their true magnitude.
• Policy Level: AIT (SCIT and SLIT) is recommended for treatment of AR with 
asthma in patients following an appropriate trial of medical therapy, and may 
also be considered for the benefit of preventing progression of AR to asthma in 
patients with AR only, and for whom AIT is otherwise indicated.
X.B. Rhinosinusitis
AR may be associated with rhinosinusitis in several clinical settings. In general, AR is 
regarded as a disease-modifying factor for rhinosinusitis.1 Rhinosinusitis may be broadly 
divided into ARS, RARS, CRSwNP, or CRSsNP. The association between each of these 
forms of rhinosinusitis with AR will be discussed individually below. Of note, many of these 
studies used SPT or in vitro testing for confirmation of allergic disease. While positive 
testing does indicate evidence of sensitization, this does not necessarily correlate with 
allergic nasal disease.1843 Given the paucity of literature exclusively discussing AR and 
rhinosinusitis (vs allergy and rhinosinusitis), this literature will be included.
AR is thought to be a potential risk factor for the development of rhinosinusitis in general. 
Exposure to allergens in allergic patients has been associated with increased eosinophilia in 
the maxillary sinus.1844,1845 In addition, the majority of ragweed allergic patients (60%) 
display abnormal opacification of CT scans of the paranasal sinuses in peak allergic seasons.
1846 These CT findings persist despite symptom resolution outside the allergic season.1846 
These studies do not always delineate whether ARS, RARS, or CRS is the form of 
rhinosinusitis associated with AR.
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Allergic rhinitis and acute rhinosinusitis—In addition to these more general studies, 
evidence exists to support the concept of an increased risk of ARS with AR. There is a 
significantly higher incidence of ARS in both children and adult patients with a history of 
AR.1847,1848 Children with AR are also more likely to experience orbital complications of 
ARS compared to those without AR, especially in pollinating seasons.1849 A mouse model 
has also shown that ongoing nasal allergy is associated with worsened episodes of ARS.
1850,1851 Available data supports an association between AR and ARS. However, AR is 
thought to be a disease-modifying or risk-modifying factor rather than a causative one. 
There are no studies examining the effects of treating AR on the risk of developing an 
episode of ARS. For example, it is unclear whether treating AR decreases the incidence of 
ARS. Future study may help clarify the interaction between AR and ARS (Table X.B-1).
• Aggregate Grade of Evidence: C (Level 2a: 2 studies; Level 2b: 1 study; Level 
3a: 1 study; Level 3b: 1 study; Table X.B-1).
Allergic rhinitis and recurrent acute rhinosinusitis—The potential link between AR 
and RARS is an extension of the link between AR and ARS. The increase in sinonasal 
inflammation associated with AR is proposed to increase mucosal edema, sinus ostium 
obstruction, and the retention of sinus secretions.1 This environment may support secondary 
bacterial overgrowth and subsequent ARS or RARS.1 Two studies have specifically 
examined the association between RARS and AR, with a focus on potentially altered innate 
immunity. The results of these 2 studies are conflicting. One study suggests there is a 
decrease in the antimicrobial properties of sinonasal secretions in patients with RARS and 
AR compared to AR only patients as well as control patients.1852 The second study 
identified an upregulation in toll-like receptor 9 expression, suggesting increased resistance 
to bacterial infection rather than susceptibility.1853 Further study is required to define the 
association between AR and RARS (Table X.B-2).
• Aggregate Grade of Evidence: D (Level 2b: 2 studies; conflicting evidence; 
Table X.B-2).
Allergic rhinitis and chronic rhinosinusitis without nasal polyposis—CRS is a 
condition of the sinonasal cavity characterized by persistent inflammation. The cause of the 
inflammation varies from patient to patient. As AR is a cause of sinonasal inflammation, 
many have suspected there may be an association with the pathogenesis of CRS. However, 
there are no controlled studies examining the role of AR in the development of CRSsNP. 
Additionally, there are no studies showing that the treatment or control of allergic disease 
alters the progression of CRSsNP, or vice versa.1 Given the varied pathophysiology of 
CRSsNP, it is challenging to determine the association between allergy and CRSsNP. Wilson 
et al.1854 performed a systematic review of allergy and CRS, excluding studies that did not 
differentiate between CRSsNP and CRSwNP. Their review found 4 studies that supported an 
association between allergy and CRSsNP and 5 that did not.1854 Because the relationship 
remains unclear, allergy testing is listed as an option in CRSsNP patients based on the 
theoretical benefit of identifying and treating comorbid allergic disease1,1854 (Table X.B-3).
• Aggregate Grade of Evidence: D (Level 1b: 1 study; Level 3a: 1 study; Level 3b: 
8 studies; conflicting evidence; Table X.B-3). Adapted from Wilson et al.1854
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Allergic rhinitis and chronic rhinosinusitis with nasal polyposis—The 
pathogenesis of CRSwNP is strongly associated with Th2-mediated inflammation.1 
Additionally, nasal polyps in CRSwNP have high levels of tissue eosinophilia, as well as 
mast cells and basophils.1 AR follows a similar inflammatory pathway and this suggests 
there may be a pathophysiologic similarity between CRSwNP and AR. Wilson et al.1854 
examined the association between allergic disease and CRSwNP. Again, the evidence was 
conflicting. Ten studies supported an association while 7 did not. One study had equivocal 
findings.1854 Since this review, Li et al.1855 examined the association between atopy and 
CRSwNP and concluded that there was no correlation between atopic status and disease 
severity. They did note that atopy-positive patients were younger than atopy-negative 
patients.1855 Despite some overlapping pathophysiologic features between allergic disease 
and CRSwNP, conflicting evidence exists and there is no clear association between AR and 
CRSwNP. Allergy testing is once again an option in CRSwNP patients based on the 
theoretical benefit of identifying and treating comorbid allergic disease1,1854 (Table X.B-4).
• Aggregate Grade of Evidence: D (Level 2b: 1 study; Level 3a: 1 study; Level 3b: 
15 studies; Level 4: 4 studies; conflicting evidence; Table X.B-4). Adapted from 
Wilson et al.1854
In summary, AR has a moderate level of evidence supporting an association with ARS 
(Level C). Regarding RARS, CRSsNP and CRSwNP, the preponderance of evidence does 
not support an association, though the evidence is highly conflicting. The available literature 
is also limited as it often assumes patients who test positive on allergy testing have nasal 
allergic disease and may not differentiate between systemic allergy and nasal allergy. Further 
study is needed to determine the association between AR and rhinosinusitis, as well as the 
impact treating 1 process has on the progression of the other. However, the diagnosis and 
treatment of comorbid allergic disease is an option in rhinosinusitis patients balancing the 
cost and low evidence with the low risk of allergic rhinosinusitis treatment and the 
theoretical benefits of reducing allergic sinonasal inflammation.1
X.C. Conjunctivitis
Although the burden of illness (impaired QOL) associated with allergic conjunctivitis (AC) 
is well established, this condition is often under recognized and consequently undertreated 
except when it is most severe.1882 Its frequent association with AR contributes to the 
substantial burden associated with AR. Although this association is well recognized 
clinically, its extent remains poorly defined due to methodologic differences and deficiencies 
of the studies which have examined this association in the literature. Further compounding 
this problem is the phenotypic diversity of both AR and AC, and the observation that very 
few studies have adequately characterized the phenotypes of their study populations. 
Additionally, many epidemiologic studies are limited by being based solely on questionnaire 
results rather than on objective clinical evidence of allergic sensitization.
The largest data source regarding the AR-AC association derives from the ISAAC study, a 
worldwide study established in 1991 with the aim of investigating the epidemiology and 
etiology of asthma, rhinitis, and atopic dermatitis in each country, using standard 
methodology including questionnaire and SPT. ISAAC has reported the prevalence of AC 
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symptoms in 257,800 children aged 6 to 7 years in 91 centers in 38 countries and 463,801 
children aged 13 to 14 years in 155 centers in 56 countries. Although the ISAAC survey was 
not validated for the diagnosis of AC, ISAAC studies support the frequent association of AR 
with itchy-watery eyes, reporting that ocular symptoms affect approximately 33% to 50% of 
children with AR1883 (Table X.C).
The best evidence of disease-association derives from studies of AR patients assessed for the 
prevalence of AC as a comorbidity.1884-1890 The evidence suggests that AR is associated 
with 35% to 74% prevalence of AC and that among patients with AC, the prevalence of AR 
may be as high as 97%.
To summarize, there is a substantial body of evidence which supports AC as a frequently 
occurring comorbidity of AR, particularly in children. Not only is this disease-association 
common, but ocular allergy symptoms also contribute significantly to the QOL impairment 
associated with AR. It is not surprising, therefore, that ocular symptoms of allergic 
rhinoconjunctivitis are among the most common symptoms which cause patients to seek 
allergy treatment.1891 It is advisable, when assessing patients with AR, to also assess for 
ocular symptoms and to consider treatment specific to providing relief of AC.
• Aggregate Grade of Evidence: C (Level 2b: 2 studies; Level 3a: 2 studies; Level 
3b: 3 studies; Table X.C).
X.D. Atopic dermatitis (AD)
AD is a chronic and/or relapsing skin disorder characterized by pruritus, scratching, and 
eczematous lesions.1892 Its burden of illness, impact on QOL, and complications are 
substantial.1893 AD commonly presents as the first manifestation of atopy in infants and 
children who later develop AR and/or asthma, a pattern that has been referred to as “the 
atopic march.”1894
Although the association between AR and AD has long been clinically recognized, the 
extent of this association remains poorly defined due to methodologic differences and 
limitations of the studies that have examined this association537,556,636,1895-1912 (Table 
X.D). Further compounding this problem is the phenotypic diversity of both AR and AD, 
and the observation that very few studies have adequately characterized the phenotypes of 
their study populations. Additionally, many epidemiologic studies are limited by being based 
purely on questionnaire results rather than objective evidence of allergic sensitization, such 
as SPT or in vitro testing.
The largest data source regarding AR-AD association comes from the ISAAC study, 
investigating the epidemiology and etiology of asthma, rhinitis, and AD using standard 
methodology including questionnaires, SPT, and flexural dermatitis examination.1895 
ISAAC reported the prevalence of AD symptoms in 256,410 children aged 6 to 7 years in 90 
centers from 37 countries, and 458,623 children aged 13 to 14 years in 153 centers from 56 
countries. These studies indicate that AD is a major public health problem worldwide, 
affecting approximately 5% to 20% of children aged 6 to 7 and 13 to 14 years.1896 While 
longitudinal studies demonstrate improvement or resolution of AD with age,1897 increasing 
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severity of AD has been shown to correlate with an increased risk of developing AR, with 
prevalence of AR among people with AD ranging from 15% to 61%.1898-1900
The best evidence of disease association derives from studies which compare the incidence 
and/or prevalence of AR in populations with and without AD. In this regard, the limited 
evidence available suggests that AD is associated with a 2-fold increase in AR among 
people with AD compared with the normal population.1901 In this study, among those 
children with present or past AD, 60.8% reported AR compared to 31% in subjects without 
AD.
• Aggregate Grade of Evidence: C (Level 2b: 4 studies;, Level 3b: 15 studies; 
Level 4: 1 study; Table X.D).
X.E. Food allergy and pollen-food allergy syndrome (PFAS)
Approximately 5% to 8% of patients with pollen allergy will develop food allergy and 
pollen-food allergy syndrome (PFAS).1916 Patients with pollen allergies may have allergy-
related manifestations after consuming specific fruits, vegetables, nuts, or spices. The 
prevalence of pollen-food allergies varies with the type of pollen. As many as 70% of 
patients with birch allergy will manifest a food-related sensitivity.1917 PFAS is an IgE-
mediated reactivity, which occurs in the oral mucosa, leading to itching, stinging pain, 
angioedema, and rarely systemic symptoms. The term, “oral allergy syndrome” (OAS), has 
also been frequently used and refers to a pollen-food allergy that occurs only at the level of 
the oral mucosa. OAS is, therefore, a specific manifestation of the broader PFAS. The 
symptoms of OAS manifest because of IgE specific for the offending pollen cross-reacting 
with highly homologous proteins found in a variety of fruits, vegetables, and nuts. The most 
common example of this cross-reactivity in western populations is birch pollen and apples. 
Table X.E-1 lists common pollen allergens with plant-derived foods that may demonstrate 
cross-reactivity. These pollen-food relationships have been observed clinically and are also 
demonstrated at a molecular level through identification of the homologous amino acids, 
cross-reactive carbohydrate determinants, and lipid transfer proteins. The birch-apple 
syndrome is due to the high homology of the major birch allergen Bet v 1 and the apple 
allergen Mal d 1.1918
The diagnosis of PFAS is typically established by a detailed history and physical exam. The 
history should be guided by an understanding of the patient’s underlying pollen allergy and 
foods that share highly homologous proteins. The clinician should elicit a detailed history of 
the allergic response including any systemic symptoms and history of anaphylaxis. The 
estimated rate of systemic reaction from a pollen-food allergy is 10% and the estimated rate 
of anaphylaxis is 1.7% to 10%.1742,1919,1920 Systemic symptoms are the manifestation of an 
allergic response by organ systems that have not come into direct contact with the ingested 
food and include: urticaria, nasal congestion, sneezing, flushing, wheezing, cough, diarrhea, 
and hypotension. The gold standard for establishing a diagnosis of PFAS is a double-blind 
food challenge. However, this is difficult to perform because of the bias inherent to the 
appearance, texture, and taste of foods.1921 Oral food challenge, SPT, and food-specific IgE 
levels have also been used to establish the diagnosis. The diagnostic approach should be 
guided by the patient’s history and severity of allergic response.
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The standard recommendation for the treatment of PFAS has been elimination of the 
offending food. Patients should be counseled on the risk for systemic and anaphylactic 
reactions. Patients with a history of systemic or anaphylactic reactions should be provided 
with an epinephrine autoinjector. The proteins responsible for PFAS are often labile and may 
be denatured by heat. The denatured proteins are typically not cross-reactive with the pollen 
IgE. Therefore, pollen-associated foods may become edible when heated. In 1 study, food 
challenges were performed with cooked apple, carrot, or celery in patients with atopic 
dermatitis and birch pollen allergy who had OAS and dermatologic symptoms upon 
ingestion of the raw foods. Cooked versions of the offending foods did not cause oral allergy 
symptoms.1922 However, some patients did manifest a late eczematous skin reaction, which 
was likely T-cell–mediated (Table X.E-2).
There is also 1 RCT in a group of 30 patients evaluating the use of an antihistamine to 
reduce PFAS symptoms, which demonstrated a clinically significant reduction in allergy 
symptoms compared to placebo when ingesting offending foods.1923 The antihistamine used 
in this study, astemizole, has been removed from the market due to QT interval prolongation 
on electrocardiogram.
There have been several studies evaluating the effect of targeted immunotherapy for pollen 
allergy at reducing PFAS symptoms. The results are mixed. Several small cohort studies and 
RCTs have shown an increased tolerance to the offending food when patients are treated 
with pollen specific immunotherapy.1916,1924-1926 However, 1 RCT failed to demonstrate 
any improved tolerance to apple in birch allergic patients treated with birch specific 
immunotherapy compared to placebo.1921 One study evaluating the persistence of tolerance 
for apple after birch immunotherapy demonstrated that some patients had an increased apple 
tolerance for up to 30 months after immunotherapy. However, there was no statistically 
significant difference between the immunotherapy and control groups.1927 Immunotherapy 
is not currently recommended for the sole purpose of treating PFAS. Patients receiving 
immunotherapy for the treatment of pollen allergies should be counseled on the potential but 
unsubstantiated benefit for improved food tolerance.
• Aggregate Grade of Evidence: B (Level 2b: 8 studies; Level 4: 1 study; Table 
X.E-2).
X.F. Adenoid hypertrophy
In children, adenoid hypertrophy (AH) and AR may exhibit similar symptoms including 
nasal obstruction and rhinorrhea. The potential relationship between AR and AH is explored 
in this section. Adenoid enlargement most commonly begins during infancy; it continues 
through the first 5 to 6 years of life and involutes with puberty.1930,1931 Symptomatic AH 
affects an unknown percentage of children and may contribute to a range of symptoms 
including nasal obstruction, nasal drainage, sleep disturbance, increased episodes of 
rhinosinusitis, increased lower respiratory tract infections, worsened asthma, and Eustachian 
tube dysfunction.1930,1932
Case series evaluating the relationship between AH and allergic sensitization fall into 2 main 
categories: (1) cohorts of children with allergic conditions assessed for AH; or (2) children 
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identified with AH assessed for allergy sensitization. These may not represent the same 
populations.
Three studies assessing allergic children found a higher rate of AH than controls (when 
present). In 2015, 1322 children (mean age 5.9 ± 3.3 years) treated for “allergic conditions” 
were compared to 100 age-matched children with no allergic disease for AH. They found 
AH was more prevalent in the allergic group (12.4%) than controls (3%) (p < 0.0001). AH 
was statistically associated with AR and cigarette smoke exposure (p = 0.004).1933 Similarly, 
Dogru et al.1934 found that among 566 children with AR the prevalence of AH was 21.2% 
(no control group). Additionally, they reported that children with both AH and AR had a 
higher frequency of persistent rhinitis (p < 0.05), moderate/severe rhinitis (p = 0.005), and 
nasal congestion (p = 0.001) than those with AR alone. The AR-only group had a higher 
prevalence of asthma (p = 0.037) and “itchy nose” (0.017). In another study, adenoid size in 
seasonally allergic children was assessed by Modrynski and Zawisza,1935 concluding that 
seasonal adenoid enlargement was observed in birch pollen–allergic children more than 
controls not allergic during the tree-pollen season. The increased adenoid size resolved after 
pollen season in the study group, and the seasonal increase in adenoid size was not observed 
in birch-allergic children treated co-seasonally with topical nasal steroid and antihistamines. 
The study was small (n = 67 among 4 groups) and did not state whether it was blinded 
(Table X.F).
Exposure and sensitization to mold and AH has been specifically examined. Atan Sahin et 
al.1936 compared 242 children living in a less humid environment to 142 children living on 
the more humid Turkish Mediterranean coast. Mite-sensitive children in the coastal group 
had an increase in AH (p = 0.01). Those living in the more humid coastal location 
demonstrated increased mold and pollen sensitization but no significant correlation with 
adenoid hypertrophy was found. In contrast, Huang and Giannoni1937 compared 315 
children with AH and AR to age-matched controls with AR-alone. There was a higher 
prevalence of positive skin tests to molds in the AH group (p = 0.013 to <0.0001). Dogru et 
al.1934 also reported an increased sensitization to Alternaria in children with both AH and 
AR compared to AR alone (p = 0.032), although a statistical correction for multiple 
variables was not described.
In studies where children were recruited by nasal obstruction, the degree of AH sometimes 
showed either no relationship or an inverse relationship with the prevalence of allergy 
sensitization. Cassano et al.1931 reported that the prevalence of specific inhalant IgE 
sensitization decreased as the AH increased: AH first degree (37% sensitized), AH second 
degree (35% sensitized), and AH third degree (19% sensitized). Karaca et al.1938 did SPT on 
82 children who presented with upper airway obstruction to an otolaryngology clinic and 
compared allergy sensitization to radiographic adenoid size and clinically assessed tonsil 
size. They concluded that there was not a statistically significant association with adenoid 
size (p = 0.195) and a negative correlation with tonsil size (p = 0.045). The methods are 
vague on how the correlation was performed with tables showing percentages of “negative” 
SPT and the text incongruently stating “all of the cases were positive for at least 1 of the 14 
allergens.”1938 Ameli et al.1939 assessed 205 children (mean age 6.7 years) with nasal 
endoscopy and SPT and found an association between negative SPT and adenoid volume (p 
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< 0.0001). In an exception to the previously noted studies, Sadeghi-Shabestari et al.1940 
compared 117 children aged 1 to 14 years with adenotonsillar hypertrophy to 100 controls of 
similar age for allergen SPT, total IgE, and smoking parents. They reported 70.3% of the 
adenotonsillar hypertrophy group had a positive SPT compared to 10% of the control group 
(p = 0.04); however, they included SPTs for foods (highest positive allergen subgroup) and 
latex.
In a study that is difficult to categorize by recruitment, 155 children (mean age 8.7 years) 
referred from Pediatric Allergy to Otolaryngology were assessed by rigid nasal endoscopy 
and SPT. Children on allergy medication were excluded. They observed a negative 
correlation between AH and allergen positivity (r = −0.208, p = 0.009).1941
Immunologic evidence of allergy in adenoid tissue is limited in the literature. Ni et al.1942 
found a higher Th17/Treg ratio in adenoid tissue from children with AR than controls. 
Masieri et al.1943 reported Th1 gene expression in non-allergic adenoid tissue, Th1 and Th2 
gene expression in adenoid tissue in those with AR treated with antihistamines, and a down 
regulation in Th1 and Th2 gene expression in adenoid tissue from children treated with 
SLIT. Both studies were small.
Treatment studies are also limited. One retrospective, uncontrolled study (n = 47) reported 
improvement in rhinitis symptoms in similar percentages for both AR (86%) and NAR 
(76%) after adenoidectomy.1944 The effect of INCS on reducing nasal obstruction in the 
setting of AH, independent of allergy, has been demonstrated in systematic reviews,1932,1945 
but whether this is due to decrease in adenoid size is less clear and blinded studies are 
uncommon. 1946
In conclusion, there is a trend among allergic children who are assessed for AH to have 
increased prevalence AH compared to non-allergic controls. However, when children are 
selected for upper airway obstruction and then assessed for inhalant allergy sensitivity, a 
consistently increased prevalence of allergic sensitivity is not found. One potential 
explanation for this discrepancy is that symptomatic AH peaks in younger children than 
pediatric AR, with the allergic cohorts having a higher average age. This is supported in the 
literature by Pagella et al.1947 who retrospectively reviewed records of children referred to 
Otolaryngology for nasal symptoms (n = 795). They found an association between allergy 
and AH in children aged 8 to 14 years (p = 0.0043), but not for children aged 1 to 7 years (p 
= 0.34).
• Aggregate Grade of Evidence: C (Level 4: 11 studies; Table X.F).
X.G. Otologic conditions Eustachian tube dysfunction
Ear symptoms are commonly experienced by patients with AR. Ear fullness and pressure, 
otalgia, popping or other sounds during swallowing, and transient hearing loss can all be 
manifestations of Eustachian tube dysfunction. The Eustachian tube opens into the 
nasopharynx and is in direct continuity with the upper respiratory tract. Inflammation of the 
nasal mucosa may involve the torus tubarius or Eustachian tube mucosa, resulting in 
obstruction that leads to negative pressure as middle ear gases are resorbed. Frequent 
sniffing or swallowing during nasal obstruction may transmit negative pressure to the middle 
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ear space. The frequently observed clinical association of Eustachian tube symptoms and 
AR is corroborated by high-level evidence that demonstrates that in AR patients, nasal 
challenge with histamine or relevant aeroallergens results in transient Eustachian tube 
obstruction.1948-1950 These studies used the 9-step inflation-deflation swallow test of 
Eustachian tube function developed by Bluestone and Cantekin.1951 The development of 
negative middle ear pressure after allergen challenge corresponds with increases in nasal 
airway resistance.1952 AR appears to increase the incidence of Eustachian tube dysfunction 
relative to control populations,1953 and natural pollen exposure has been associated with 
negative middle ear pressures1954 and defects in Eustachian tube opening.1955 This body of 
evidence supports a direct causal role for AR in some cases of Eustachian tube dysfunction 
(Table X.G-1).
• Aggregate Grade of Evidence: C (Level 1b: 3 studies; Level 2b: 1 study; Level 
3b: 1 study; Level 4: 2 studies; Table X.G-1).
Otitis media—The role of allergy as a causative factor in otitis media has not been clearly 
demonstrated. Historically, allergy was considered an important etiologic factor in otitis 
media. However, as clinical definitions have become more stringent and evidence 
expectations have evolved, it has become apparent that a clear etiopathogenic connection 
between AR and otitis media is yet to be demonstrated. Investigations into the connection 
between these 2 conditions have examined the evidence for type 1 IgE-mediated 
inflammation in the middle ear space, epidemiologic associations between the 2 conditions, 
and the effect of allergy treatment on otitis outcomes. The middle ear mucosa may behave in 
a manner similar to nasal mucosa and be a site of local IgE-mediated inflammatory 
reactions.1956-1958 However, direct intranasal allergen challenge in allergic subjects does not 
appear to cause otitis media.1948-1950 Studies of the epidemiologic association of AR or 
atopy and otitis media with effusion (OME) are widely discordant. Some studies have found 
no significant difference in allergic sensitization or clinical allergy in OME patients 
compared to control groups,1959,1960 while others have shown a dramatically increased 
prevalence of IgE sensitization or clinical allergy in OME patients,1961-1964 or that AR is an 
independent risk factor for the development of OME.1965 Finally, some studies suggest a 
nearly universal association of OME and allergic disease.1966-1970 These inconsistencies in 
the literature are likely related to highly selected patient populations in specialty practices, 
variability in allergy test methods, and the problems incumbent in identifying appropriate 
control groups. Thus, the relationship of allergy and OME remains unclear (Table X.G-2).
In general, randomized placebo-controlled trials have shown that INCS do not improve 
OME outcomes.1971-1973 Also, a Cochrane systematic review found no benefit of 
antihistamines and/or decongestants in the treatment of OME. Thus, traditional medical 
treatments for AR do not appear to be an effective option for OME and recent otitis media 
CPGs recommend against the use of these agents.1974 Additional investigation is needed to 
discern the effect of allergy on the incidence or natural history of OME and to determine if 
AIT has beneficial effects.
• Aggregate Grade of Evidence: C (Level 2b: 2 studies; Level 3b: 3 studies; Level 
4: 11 studies; Table X.G-2).
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Inner ear disease—Meniere’s disease is characterized by recurring episodes of tinnitus, 
hearing loss, aural fullness, and vertigo. The basic pathophysiologic defect in Meniere’s 
disease appears to be a dysregulation of endolymph in the inner ear (endolymphatic 
hydrops).1975 An immunologically-mediated disturbance in fluid handling by the 
endolymphatic sac has been postulated as 1 cause for the disease.1976 The notion that 
“allergy” of the inner ear is a cause of Meniere’s disease predates our modern understanding 
of type 1 IgE-mediated hypersensitivity, and is still evoked as a possible causative or 
contributing factor for the disease in some individuals. Indeed, AR has been postulated as a 
cause of inner ear dysfunction,1977 and a connection between allergy and inner ear disorders 
such as Meniere’s disease is plausible based on compiled circumstantial evidence. Derebery 
and colleagues have published studies suggesting that inhalant and food allergies are more 
common in Meniere’s patients,1978 and that allergy treatment including AIT results in 
improved Meniere’s disease symptoms.1979,1980 However, these studies generally provide 
low grade evidence, and aside from 1 small study that also found a higher prevalence of IgE-
mediated hypersensitivity in Meniere’s patients,1981 these findings have not been duplicated 
by others. Case-control studies examining total serum IgE levels have provided conflicting 
results.1981,1982 A few small studies have shown changes in objective parameters such as the 
electrocochleographic summating potential/action potential (SP/AP) ratio in response to 
aeroallergen or food challenge in Meniere’s patients.1983,1984 Overall, the evidence 
supporting a connection between type 1 IgE-mediated hypersensitivity and Meniere’s 
disease is of low grade, with substantial defects in study design (Table X.G-3).
• Aggregate Grade of Evidence: C (Level 3b: 4 studies; Level 4: 4 studies; Table 
X.G-3).
X.H. Cough—Cough is a sudden reflex used to clear the breathing passage of any foreign 
particles or irritants. There is evidence that vagal afferent nerves regulate an involuntary 
cough; yet, there is also cortical control of this overall visceral reflex.1985 Cough is often 
considered a comorbidity of AR. The rhinobronchial reflex is 1 of the mechanisms that may 
explain the ability of stimuli on the nasal mucosa, such as an allergen, to result in direct 
bronchospasm.1986 The role of descending secretions (postnasal drip) from the upper to 
lower airways is a second theory. While many practitioners link postnasal drainage to cough, 
there is very little evidence to support this. When functioning normally, the vocal folds 
protect the lower airways from upper airway secretions and foreign bodies. Third, a direct 
mechanism due to diffuse inflammation and activation of eosinophils may be responsible for 
the common upper and lower airway manifestations. The American College of Chest 
Physicians evidence-based clinical practice guidelines on cough suggest the term upper 
airway cough syndrome, rather than postnasal drip syndrome, when discussing a cough 
originating from the upper airway due to the varying possible causes.1985
AR and asthma may coexist and may indeed produce a continuum of the same airway 
disease.1167 Associations with cough in AR patients can relate to their underlying asthma or 
a seasonal asthma during peak pollen season. The Asia Pacific Burden of Respiratory 
Diseases study, a 1000-person cross-sectional observational study, revealed that cough was 
the primary reason for a visit to the physician for patients with asthma and or COPD. 
However, AR patients were more likely to present with classic watery, sneezing, runny nose. 
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The study however did find that 33.5% of patients were diagnosed with combinations of 
respiratory disease; the most frequent was asthma and AR1987,1988 (Table X.H).
While patients with AR that have concomitant chest symptoms such as cough often do have 
asthma, seasonal asthma, and/or a nonspecific bronchial hyperreactivity, many studies show 
generalized inflammation of the upper airways extending to the lower airways. There is a 
complex interplay between cells and inflammatory cytokines and hence one should consider 
the upper and lower airways as a single unique functional unit.1986 The key pathogenic 
mechanism is the inflammation of the upper airways with extension to the lower airways and 
the induction of a systemic dysregulation via a complex interaction between cells and 
inflammatory cytokines.1986
Many patients with AR and cough do not have the diagnostic airflow obstruction or the 
reversibility of forced expiratory volume in 1 second (FEV1) following bronchodilator 
administration to make a diagnosis of asthma.1167 Krzych-Falta et al.1989 performed a nasal 
challenge in 30 patients with AR. Extranasal symptoms were noted, including a cough and 
breathlessness, especially in those with PAR. In 2000, Chakir et al.1990 performed 
histochemical tests on bronchial biopsies of patients with AR but without current or history 
of asthma. They demonstrated increased numbers of lymphocytes, eosinophil recruitment 
and IL-5 expression in the bronchial mucosa after exposure with natural pollen.1990 This 
2000 study followed a prior investigation of deposition of type I and III collagens and 
fibronectin by bronchial myofibroblasts in AR patients.1991 This is suggestive of an active 
structural remodeling of the lower airways in AR patients that is similar to asthma patients 
but less severe. In addition, Buday et al.1992 demonstrated that guinea pigs sensitized to 
HDM had a significantly enhanced cough response compared to those that were not 
sensitized; however, airway resistances did not change. This study is relevant to humans, 
since the neurophysiology of the vagus nerve in the guinea pig is thought to be closest to 
humans. These studies demonstrate that AR, unrelated to asthma, can indeed result in 
bronchial inflammation, possible lower airway remodeling and ultimately a symptom of 
cough.
A large-scale cross-sectional, multinational observational study set out to determine the 
symptom of cough as it relates to respiratory diseases in the Asia-Pacific region. With over 
5250 patients enrolled, the study found that 47% of patients with AR frequently reported 
cough as a symptom; however, only 11% of these patients had cough as the main reason for 
seeking medical care.1993 The numbers were 61% and 33%, respectively, for patients with 
asthma and cough. In a prospective study with 2713 AR patients, He et al.1994 found the 
occurrence of comorbidities, including cough, to gradually increase from mild intermittent, 
to mild persistent, to moderate-severe intermittent, and moderate-severe persistent AR.
There is low level evidence that associates AR with cough or, more commonly, cough as a 
comorbidity of AR.1990-1992 The severity of AR may affect its manifestation toward upper 
airway cough syndrome.1994 AR is often a comorbidity with asthma which also has an 
increased correlation with cough. The exact pathways and mechanisms by which the unified 
airway functions continue to unfold.
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• Aggregate Grade of Evidence: C (Level 2b: 2 studies; Level 3b: 2 studies; Level 
4: 4 studies; Level 5: 1 study; Table X.H).
X.I. Laryngeal disease
AR has been implicated as a cause of laryngeal disease. However, further understanding of 
its precise role has been limited. While previous research has provided anecdotal evidence of 
a relationship between the 2, establishing a causal relationship between AR and laryngeal 
dysfunction had proven difficult due to a lack of safe and effective models for studying the 
larynx.1995 Findings of laryngeal inflammation have largely been attributed to 
laryngopharyngeal reflux (LPR), but various etiologies may contribute to laryngeal 
dysfunction.
Vocal dysfunction can have a significant psychosocial impact on patients, including those 
with AR. Several studies have reported higher Voice Handicap Index (VHI) scores in 
patients with AR compared to control subjects.1996-1999 Dysphonia is particularly disturbing 
for professional voice users. Singers with self-perceived voice issues were 15% more likely 
to have AR than singers without vocal complaints.2000 The likelihood of AR increased as the 
number of vocal symptoms increased.2000 When comparing patients with AR and NAR to 
control patients, Turley et al.2001 found that dysphonia was more prevalent in patients with 
asthma. A prior study had similar overall findings in patients with AR while controlling for 
asthma.2002 Studies have reported the adverse effects of AR on voice-related QOL, and 
Turley et al.2001 validated this by showing that patients who reported poor rhinitis-related 
QOL on questionnaires also had poor voice-related QOL and more severe chronic laryngeal 
symptoms.1996,1998 The greater the degree of allergen load, the greater severity of vocal 
symptoms.1999 Overall, patients with vocal dysfunction have a higher than anticipated 
incidence of AR and vice versa1999,2001,2002 (Table X.I).
Allergic laryngitis can be difficult to distinguish from other laryngeal inflammatory 
disorders, including LPR, due to the limitations of current diagnostic methods, which overall 
have poor specificity and interrater reliability. In a study of patients presenting with voice 
complaints, Randhawa et al.2003 noted that two-thirds of patients were diagnosed with 
allergies whereas only one-third were diagnosed with LPR. However, allergy testing may be 
positive in up to 46% of the general population.2004 Laryngeal findings in AR and LPR can 
be indistinguishable and include laryngeal edema, excessive mucus, vocal fold erythema, 
and arytenoid erythema.1995,2005 A study by Eren et al.2005 supported this diagnostic 
challenge in demonstrating no significant difference in the appearance of the larynx between 
allergy-positive and LPR-positive subjects; however, thick endolaryngeal mucus has been 
shown to be a predictor of allergy. Belafsky et al.2006 and Mouadeb et al.2007 examined the 
effects of Dermatophagoides on the laryngeal mucosa of guinea pigs and found an increase 
in eosinophilia compared to those exposed to saline, which provides some support for 
etiologies other than reflux contributing to laryngeal disease. In contrast, Krouse et al.1998 
were unable to demonstrate a difference in acoustic and speech aerodynamic testing or 
videostroboscopic evaluation between allergic patients compared to control subjects.
Despite anecdotal evidence implicating the role of allergic laryngitis in laryngeal 
dysfunction, there have been limited studies demonstrating a direct causal relationship 
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between the 2. Three studies with similar design evaluated the symptoms and laryngeal 
appearance and function in patients with proven allergies exposed to direct laryngeal 
stimulationship by the nebulized allergen D. pteronyssinus.2008-2010 Initially, Reidy et al.
2009 were unable to find any significant difference between antigen-challenged and placebo-
challenged subjects on any of the evaluated measures, including VHI, Sinus Symptoms 
Questionnaire, laryngoscopic findings, and acoustic and speech aerodynamic testing. In a 
subsequent study, Dworkin et al.2010 increased the concentration of allergen in the antigenic 
suspension and noted an increase in endolaryngeal mucus in addition to coughing and throat 
clearing. The study was terminated prematurely due to adverse pulmonary reactions 
attributed to the higher antigen concentration, and it is possible that the lower airway 
reactivity contributed to the visualized endolaryngeal mucus.2010 Roth et al.2008 then 
performed a study using similar methods but isolated the larynx by utilizing a nose clip to 
ensure oral inhalation and by eliminating patients with reactive airways based on 
methacholine challenge testing. They demonstrate an apparent causal relationship between 
allergen stimulation and impaired vocal function.2008
There is mounting evidence suggesting a relationship between AR and laryngeal 
dysfunction. There have not been consistently reported laryngeal findings specific to allergic 
laryngitis, though thick endolaryngeal mucous should raise suspicion for allergy as a cause. 
Although its exact role in the pathophysiology of laryngitis has yet to be fully elucidated, 
AR should be considered in the differential diagnosis of patients with vocal complaints as it 
may have implications on treatment of laryngeal disease.
• Aggregate Grade of Evidence: C (Level 2b: 8 studies; Level 3a: 1 study; Level 
3b: 4 studies; Level 4: 5 studies; Table X.I).
X.J. Eosinophilic esophagitis (EoE)
Eosinophilic esophagitis is an allergic inflammatory condition of the esophagus with 
infiltration of eosinophils. Symptoms include dysphagia, heartburn, and vomiting. Several 
studies have examined the prevalence of clinician-diagnosed AR and aeroallergen 
sensitization in patients with eosinophilic esophagitis (EoE) (Table X.J). Among both 
pediatric and adult patients with EoE, it has consistently been found that 50% to 75% have 
AR.2013-2020 Although many of these studies were case series, the consistency of the 
findings strongly suggests that most patients with EoE have comorbid AR.
The evidence for an association between environmental allergies and EoE pathogenesis is 
less clear. A few case series, among both children and adults, have observed seasonal peaks 
of EoE diagnosis in the spring and summer.2021-2023 One of these studies found that EoE 
diagnosis was correlated with grass pollen counts.2021 Another showed that esophageal 
eosinophilia on biopsies was least intense in the winter.2023 There is 1 reported case of a 
pediatric EoE patient whose symptoms flared seasonally, in whom biopsies revealed 
moderate to severe esophageal eosinophilia during pollen seasons with no or mild 
inflammation in winter months, with no change in diet.2024 Another case report described 
resolution of esophageal eosinophilia in a pediatric patient with EoE and dust mite 
sensitization after a course of high-dose dust mite immunotherapy.2025 Therefore, there is 
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very limited observational data suggesting a potential association between aeroallergens and 
EoE pathogenesis, but more study is needed.
• Aggregate Grade of Evidence: C (Level 3a: 1 study; Level 4: 12 studies; Table 
X.J).
X.K. Sleep disturbance and obstructive sleep apnea (OSA)
Nasal congestion is reported by as many as 90% of AR patients.2026 Nocturnal nasal 
congestion can significantly affect sleep quality. Nasal obstruction due to AR has been well 
established as a cause of sleep disruption.707,714,2026 One population-based survey study of 
children with AR identified sleep disturbance due to AR as a significant factor affecting 
health-related QOL.2027 Diminished sleep quality resulting from AR has been shown to 
negatively impact work performance and productivity.2028 Another population-based study 
found that patients with AR were more likely to report suffering from insomnia, snoring and 
sleep apnea than control groups.727 The severity of AR symptoms was also shown to affect 
the duration of sleep, frequency of daytime somnolence, and sleep latency. The influence of 
AR on sleep is multifactorial. Upper airway resistance, biochemical and hormonal effects, 
and pharmacologic interventions all play a role in altering sleep. A large population-based 
survey of AR patients demonstrated a strong correlation between AR disease severity and 
sleep disturbance.679 The study showed that increasing severity of AR symptoms caused 
worse sleep quality.
When establishing a diagnosis of AR, the impact of allergy symptoms on sleep should be 
assessed by detailed history. There are several different instruments, which have been used 
to assess the impact of AR on sleep. These include: the ESS, Stanford Sleepiness Score, 
Jenkins Questionnaire, Pittsburgh Sleep Quality Index, University of Pennsylvania 
Functional Outcomes of Sleep, Sleep scale from the Medical Outcome Study, Sleep 
Disorders Questionnaire, The Pediatric Sleep Questionnaire, and The Pediatric Daytime 
Sleepiness Scale. These metrics may be useful in establishing baseline symptoms and 
monitoring a response to treatment.
There have been several studies that have investigated the relationship between AR and 
sleep-disordered breathing (SDB) (Table X.K). SDB refers to a spectrum of conditions 
including primary snoring, upper airway resistance syndrome, and obstructive sleep apnea. 
In a population-based analysis, Young et al.714 found that moderate-to-severe SDB were 1.8 
times more frequent in participants with nasal congestion due to allergy. In a small case 
series of patients with SAR who underwent repeat PSG, patients with symptomatic AR had 
an average 1.7 occurrences of obstructive apnea per hour of sleep that decreased to 0.7 per 
hour when patients were symptom free.718 A 2011 case-control study assessing differences 
in polysomnography between persistent AR sufferers and healthy controls found no 
statistically significant difference in apnea-hypopnea index (AHI) between the 2 groups.720 
There were modest differences in sleep efficiency, arousal index, and snoring time.
A standard approach to the treatment of AR should help to decrease or alleviate the 
symptoms that adversely impact sleep. Medications that act to treat nasal congestion are 
typically effective at improving sleep quality. INCS have been shown to improve nasal 
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congestion, daytime somnolence, and sleep quality.2029 INCS are also thought to improve 
sleep quality by reducing proinflammatory cytokines, which have been shown to negatively 
impact sleep.2030 There have been 5 RCTs assessing the efficacy of INCSs on nasal 
congestion and sleep.673,706,707,1275,1276 The results of all 5 studies demonstrated an 
improvement in sleep quality and sleep-related QOL metrics. A meta-analysis by Weiner et 
al.1297 found that INCSs were more effective than oral antihistamines at treating nasal 
blockage, although there was no significant differences between treatments on nasal 
resistance.
The pharmacologic interventions used in the treatment of AR may also have consequences 
on sleep. The first-generation H1 antagonists are known to cause sedation due to the 
capability of crossing the blood-brain barrier and acting as a depressant on the central 
nervous system leading to drowsiness.2031 While this may be a desirable side effect at 
bedtime, it is an undesirable consequence for daytime symptom management. The second-
generation H1 antagonists have less propensity for crossing the blood-brain barrier and are 
therefore less sedating. Fexofenadine and loratadine are reported as the least sedating oral 
antihistamine treatment options.2032,2033 Patients should be counseled regarding the 
potential for sedation when taking oral H1 antihistamines. There has been 1 RCT study 
looking at pseudoephedrine (taken in the morning) and the impact on sleep quality, daytime 
somnolence, and fatigue. The study found no significant negative or positive impact on all 
measures compared to placebo.2030 There was a statistically significant beneficial effect on 
nasal congestion.
The impact of AR on sleep should be assessed by history, sleep and QOL questionnaires, 
and careful physical examination. A standard treatment algorithm for symptomatic 
management of AR should be effective at improving the symptoms which adversely affect 
sleep. INCSs are the most effective pharmacologic therapy for alleviating nasal congestion. 
Patients treated with oral antihistamines should be mindful of the potential for sedation.
• Aggregate Grade of Evidence: B (Level 1b: 5 studies; Level 2b: 1 study; Level 
2c: 5 studies; Level 3b: 7 studies; Level 4: 2 studies; Table X.K).
XI. Knowledge gaps and research opportunities
The existing literature related to AR is quite deep in certain areas but notably lacking in 
others (Table XI). We continue to see more and more citations related to AR every year, yet 
the process undertaken to produce this ICAR:AR document has identified some important 
knowledge gaps. The sections below highlight the need for future research related to specific 
aspects of AR.
XI.A. Epidemiology and risk factors
Studies have previously been undertaken to determine the prevalence of AR in various parts 
of the world. While the data from these studies is often quoted, it is limited by its 
methodology relating primarily to surveys (sometimes complemented by allergen sensitivity 
testing). Our world is better connected by technology today than it had been previously. We 
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should leverage these capabilities to better understand the epidemiology of AR. Research 
opportunities include:
• Improved understanding of the incidence and prevalence of AR and its 
phenotypes (ie, SAR, PAR, IAR, PER) worldwide.
• Improved understanding of AR variation by geographic region, patient age, and 
sex.
• Evaluation of climate change and its effect on the pattern and degree of allergen 
exposure.
Our understanding of the risk factors for the development of AR should also be improved. 
While certain areas (ie, early childhood exposure to pets as a risk factor vs protective factor) 
have seen numerous articles published, the data is highly conflicting. In other areas, such as 
early exposure to pollens and mites, the data is more limited. Genetic studies provide some 
notable evidence for potential AR risk but functional data needs to be expanded. Research 
opportunities include:
• Understanding the role of candidate gene alterations in the pathophysiology of 
AR via functional characterization.
• Investigation of epigenetic mechanisms to provide a functional explanation 
between gene-environment interactions and AR disease development.
• Improved understanding of environmental exposures as a risk/protective factor 
for AR disease development, especially in diverse geographic locations.
• Further study of the role of pollutants and tobacco smoke in the development of 
AR and in the severity of allergic rhinitis symptoms.
• Greater elucidation of the environmental risk factors and protective factors for 
AR, particularly exposure to pets, HDM, and breastfeeding.
• Longitudinal study evaluating risk factor reduction and its effect on the incidence 
of AR.
XI.B. Evaluation and diagnosis
Evaluation of the patient with suspected AR classically relies on a thorough history, often 
reinforced by findings on physical examination. The diagnosis is further supported with skin 
or in vitro testing methods. These techniques have been rather dependable, provided 
objective testing is correlated to the patient’s clinical symptoms and not used in isolation to 
determine a treatment plan, as there are distinct differences between sensitization and 
clinical allergy. As newer testing methods gain their footing, we have the opportunity to 
bring them to widespread clinical practice with solid supporting evidence. Research 
opportunities include:
• Improved characterization of newer testing techniques (ie, nasal sIgE, BAT) in 
larger populations to provide standardization for incorporation into mainstream 
clinical practice.
• Need for comparative studies for IDT and single-dilution intradermal testing.
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• Further study of the role of single intradermal testing after a negative prick test.
• Development of standardized testing and interpretation of testing for LAR, as 
well as further defining the clinical utility of testing.
• Further elucidation of clinical uses for CRD in patient management.
• Need for international consensus on allergen units in antigen standardization.
XI.C. Management
There are several options for management of the AR patient. Allergen avoidance and EC 
strategies are often discussed, yet high-level evidence is frequently lacking, especially as it 
relates to AR symptom control. Many pharmacotherapy options have very high LOEs, which 
is helpful as we strive to choose the best drug options to control patient symptoms. SCIT and 
SLIT also have very high LOEs in general, yet specific issues related to AIT management 
could be bolstered with additional evidence. Research opportunities include:
• Improved understanding of the impact of EC strategies on AR symptom control 
and rescue medication use, especially for cockroach, pet, and pollen allergens.
• Improved understanding of the polyallergic AR patient and appropriate AIT 
regimens in this population.
• Improved understanding and characterization of ILIT for possible routine clinical 
application.
• Further study of comparative efficacy/effectiveness of SLIT vs SCIT.
• Further study of AIT with multiple allergens.
• Improved understanding of cost effective management for optimal AR control 
and the use of multimodality therapy, including combinations of 
pharmacotherapy and AIT.
• Further study of the comparative effectiveness of various AR treatments.
XI.D. Associated conditions
The evidence supporting an association between AR and numerous other conditions is weak 
or conflicting. There is clearly a need to better define the relationship between AR and 
several of the comorbidities identified in this document (especially rhinosinusitis, otitis 
media with effusion, cough, laryngeal disease, and eosinophilic esophagitis), and to further 
delineate the role that AR treatment has for potential improvement of associated conditions.
XII. Conclusion
In summary, the authors of ICAR:AR have worked to collate the best external evidence for 
various aspects of AR, providing evidence grades and recommendations where appropriate. 
From this evidence, knowledge gaps and research opportunities have been identified. It is 
our sincere hope that the ICAR:AR document will be a reference for understanding the 
current AR evidence and a springboard for future investigation.
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List of abbreviations
AAAAI American Academy of Allergy Asthma&Immunology
AAO-HNS American Academy ofOtolaryngology-Head and Neck Surgery
AC allergic conjunctivitis
ACC allergen challenge chamber
ACE-I angiotensin converting enzyme inhibitor
ACTH adrenal corticotropic hormone
AD atopic dermatitis





ANCA anti-nuclear cytoplasmic antibody
APC antigen presenting cell
AR allergic rhinitis
ARIA Allergic Rhinitis and its Impact on Asthma
ARS acute rhinosinusitis
BAFF B-cell activating factor
BAT basophil activation test
BDNF brain-derived neurotrophic factor
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CARAT10 Control of Allergic Rhinitis and Asthma Test
CCAAPS Cincinnati Childhood Allergen and Air Pollution Study
CCAD central compartment atopic disease
cGMP cyclic guanosine monophosphate
CI confidence interval
CNS central nervous system
CO carbon monoxide
COX cyclooxygenase
CPAP continuous positive airway pressure
CPG clinical practice guideline
CPT conjunctival provocation test
CRD component resolved diagnosis
CRS chronic rhinosinusitis
CRSsNP chronic rhinosinusitis without nasal polyposis




DBP diastolic blood pressure
DCS Daily Combined Score
DEP diesel exhaust particles
DSCG disodium cromoglycate
EAACI European Academy of Allergy&Clinical Immunology
EAN European Aeroallergen Network
EBR evidence-based review (without recommendations)
EBRR evidence-based review with recommendations
EC environmental control
ECP eosinophil cationic protein
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ECRHS European Community Respiratory Health Survey
EEC environmental exposure chamber
EGPA eosinophilic granulomatosis with polyangiitis
ENS empty nose syndrome
EoE eosinophilic esophagitis
EPOS European Position Paper on Rhinosinusitis and Nasal Polyps
ESS Epworth Sleepiness Scale
EU European Union
FDA U.S. Food and Drug Administratio
FEV1 forced expiratory volume in 1 second
FoxP3 forkhead box P3
GA2LEN Global Allergy and Asthma Network of Excellence
GM-CSF granulocyte-macrophage colony stimulating factor
GPA granulomatosis with polyangiitis
GWAS genome-wide association study
HD-42 Sleep Disorders Questionnaire
HDM house dust mite
HEPA high-efficiency particulate air
HFA hydrofluoroalkane
HMW high molecular weight
HR heart rate
IAR intermittent allergic rhinitis
ICAR International Consensus Statement on Allergy and Rhinology
ICAR:AR International Consensus Statement on Allergy and Rhinology: 
Allergic Rhinitis
ICAR:RS International Consensus Statement on Allergy and Rhinology: 
Rhinosinusitis
IDT intradermal dilutional testing
IFN interferon
IgE immunoglobulin E
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ISAAC International Study of Asthma and Allergies in Childhood
JSQ The Jenkins Questionnaire
LAR local allergic rhinitis
LMW low molecular weight
LOE level of evidence
LPR laryngopharyngeal reflux
LRRC32 leucine-rich repeat-containing protein 32
LT leukotriene
LTRA leukotriene receptor antagonist
mAb monoclonal antibody
MAS Multicentre Allergy Study
MCC mucociliary clearance
MCP macrophage/monocyte chemoattractant protein
MD molecular diagnosis
MDC macrophage-derived chemokine
MIF macrophage migration inhibitory factor
MIP macrophage inflammatory protein
MQT Modified Quantitative Testing
NAR non-allergic rhinitis
NARES non-allergic rhinitis with eosinophilia syndrome
NARESMA non-allergic rhinitis with eosinophils and mast cells
NARMA non-allergic rhinitis with mast cells
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NARNE non-allergic rhinitis with neutrophils
NC nasal cytology
NGF nerve growth factor
NHANES National Health and Nutrition Examination Survey
NO nitric oxide
NO2 nitrogen dioxide
NPT nasal provocation test
NSAID nonsteroidal anti-inflammatory drug
O3 ozone
OAS oral allergy syndrome
OME otitis media with effusion
OMIT oral mucosal immunotherapy
OR odds ratio
OSA obstructive sleep apnea
OTC over the counter
PAR perennial allergic rhinitis
PARIS Pollution and Asthma Risk: An Infant Study
PDE phosphodiesterase
PER persistent allergic rhinitis
PFAS pollen food allergy syndrome
PM10 particulate matter <10 μm
PM2.5 particulate matter <2.5 μm
PNU protein nitrogen unit
ppm parts per million
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-analyses
PROM patient-reported outcome measure
PSG polysomnogram
QOL quality of life
RANTES regulated on activation, normal T-cell expressed and secreted
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RAP Respiratory Allergy Prediction test
RARS recurrent acute rhinosinusitis
RAST radioallergosorbent test
RC-ACS Rhinoconjunctivitis-Allergy Control Score
RCT randomized controlled trial
RFA radiofrequency ablation
RM rhinitis medicamentosa
RMS Rescue Medication Score
RQLQ Rhinoconjunctivitis Quality of Life Questionnaire
rTNSS Reflective Total Nasal Symptom Score
RTSS Rhinitis Total Symptom Score
RUDS reactive upper airway dysfunction syndrome
SAPALDIA Swiss Study of Air Pollution and Lung Disease in Adults
SAR seasonal allergic rhinitis




sIgE antigen-specific immunoglobulin E
SLE systemic lupus erythematosus
SLIT sublingual immunotherapy
SMD standardized mean difference
SNP single nucleotide polymorphism
SO2 sulfur dioxide
SPT skin-prick test
SQ-U standardized quality units
SSRI selective serotonin reuptake inhibitor
SSS Stanford Sleepiness Score
TARC thymus and activation regulated chemokine
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TCRS Total Combined Rhinitis Score
TDI threshold, discrimination, identification
TGF-β transforming growth factor beta
Th T-helper cell
Th0 naive T-helper cell
tIgE total immunoglobulin E
TLR toll-like receptor
TNF tumor necrosis factor
TNSS Total Nasal Symptom Score
TOSS Total Ocular Symptom Score
TOTALL TOTal Costs of ALLergic Rhinitis in Sweden
Treg T-regulatory cell
TSLP thymic stromal lymphoprotein
VAS Visual Analog Scale
VHI Voice Handicap Index
WHO World Health Organization
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Topic development. AAP = American Academy of Pediatrics; EBRR = evidence-based 
review with recommendation; PE = principal editor; 10 = primary; PRISMA = Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses.
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Topic EBRR iterative review. 10 = primary; 20 = secondary; 30 = tertiary; EBRR = evidence-
based review with recommendation; PE = principal editor.
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ICAR: Allergic Rhinitis statement iterative review. ICAR:AR = International Consensus 
Statement on Allergy and Rhinology: Allergic Rhinitis; PE = principal editor.
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Classification of work-related rhinitis.84 Adapted from Moscato et al. Allergy. 
2008;63:969-980.
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TABLE II.A-1.
Aggregate grade of evidence6
Grade Research quality
A Well-designed RCTs
B RCTs with minor limitations; Overwhelming consistent evidence from observational studies
C Observational studies (case control and cohort design)
D Expert opinion; Case reports; Reasoning from first principles
RCT = randomized controlled trial.
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TABLE III.C.









• Rhinitis of pregnancy and hormonally-induced rhinitis
• Food- and alcohol-induced rhinitis
• NARES
• Vasomotor rhinitis (nonallergic rhinopathy)
• Age-related rhinitis (ie, elderly)
• Empty nose syndrome
• Atrophic rhinitis
• Autoimmune, granulomatous, and vasculitic rhinitis
• Rhinosinusitis
*
For each of these conditions, the similarities and differences to allergic rhinitis are discussed within each content section.
a
This table is specific to various etiologies of rhinitis. Structural sinonasal conditions (ie, deviated septum), tumors, and cerebrospinal fluid leak are 
not listed here. NARES = nonallergic rhinitis with eosinophilia syndrome.
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TABLE III.C.2.
Intranasal decongestants associated with rhinitis medicamentosa26,61
Sympathomimetic amines Phenylephrine, pseudoephedrine, ephedrine, amphetamine, Benzedrine, caffeine, mescaline
Imidazoline derivatives Oxymetazoline, xylometazoline, naphazoline, clonidine
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TABLE III.C.3.
Examples of high-risk occupations for occupational rhinitis and causal agents
Occupation Agent
 High molecular weight agents
 Bakers, food industry Cereal flours87
 Laboratory workers Laboratory animals (rat, mouse)88
 Health care workers Latex89
 Farmers Animal-derived allergens, plant allergens, molds90
 Seafood workers Shellfish, bony fish91
 Pharmaceutical & detergent industries Biological enzymes92
 Low molecular weight agents
 Hairdressers Persulphates93
 Carpentry, furniture making Wood dust94,95
 Pharmaceutics, health care workers Drugs96
 Chemical factories Mixture of irritants96
 Cleaners Mixture of irritants97,98


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Wise et al. Page 411
TABLE IX.D.2-1.






 Alum salts (SQ)
 Allergoids/polymerized allergens
Adjuvant constructs (SQ; IM)
 DNA vaccines
 TLR-9 (CpG oligonucleotides) (SQ)
  Linked to allergen; co-combined
  Nanoparticle-based VLPs
 TLR-4 (MPL) (SQ)
*Modified and used with permission; from: Creticos PS. Allergen immunotherapy: vaccine modification. Immunol Allergy Clin North Am. 
2016;36:103-124.
CpG = cytosine phosphorylated to guanine; ID = intradermal; IM = intramuscular; MPL = monophosphoryl lipid A; SQ = subcutaneous; TLR = 
toll-like receptor; VLP = viral-like particles.











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Birch Apple, pear, sweet cherry, peach, plum, apricot, almond, celery, carrot, potato, kiwifruit, hazelnut, mango
Japanese cedar Tomato
Mugwort Celery, carrot, mango, spice
Grass Melon, watermelon, tomato, potato, kiwifruit, orange, peanut
Ragweed Melon, watermelon, cantaloupe, zucchini, cucumber, banana
Plane Hazelnut, apple, lettuce, corn, peanut, chickpea
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
